"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2008/0293380 A1,106-898-650-913-408,2008-11-27,2008,US 95726007 A,2007-12-14,US 95726007 A;;US 93994507 P;;US 94805407 P,2007-05-24,MESSEAGING SERVICE,"Messages are processed by receiving, from a first user on a wireless phone, a first message addressed to a second user. An extended header that is related to the first user and is for the first message is accessed. An alert is generated in response. A response to the alert from the second user is received. If the response includes an instruction from the second user to validate the message, a validation request is generated. The validation request is processed using a certificate authority. Based on a validation decision by the certificate authority for the validation request, a report for the second user with one or more processing options is generated. An instruction is received from the second user with a selection from among processing options. The first message is delivered to the second user if the instruction from the second user indicates that the message should be delivered.",ANDERSON JIM,ANDERSON JIM,,https://lens.org/106-898-650-913-408,Patent Application,yes,2,1,3,3,0,G06Q20/40;;H04L63/126;;H04M1/7243;;H04W12/106;;H04L51/58;;G06Q20/40;;H04L63/126;;H04M1/7243;;H04W12/106;;H04L51/58,H04M3/16;;H04M1/66;;H04W12/10,455/411,0,0,,,,DISCONTINUED
2,US,B2,US 6616834 B2,178-210-488-463-675,2003-09-09,2003,US 97752301 A,2001-10-14,US 97752301 A,2001-10-14,Wastewater processor,"
    A wastewater treatment apparatus comprised of a water inlet  10,  a filter component comprised of a series of filters  20, 30, 40  and settling ing areas  12, 22, 32  over a grade, and a series of separator tanks,  42, 52  connected by a lift tube  54  for removal of hydrocarbons, particulate material and other impurities and a water outlet for discharge into either a general wastewater system or a gray water reclamation system. 
",ANDERSON JIM,ANDERSON JIM,,https://lens.org/178-210-488-463-675,Granted Patent,yes,13,22,2,2,0,B01D21/0012;;B01D21/0012;;B01D21/0006;;B01D21/0006;;B01D21/0018;;B01D21/0018;;B01D21/0024;;B01D21/0024;;B01D21/0033;;B01D21/0033;;B01D24/007;;B01D24/007;;B01D24/04;;B01D24/04;;C02F2103/001;;C02F2103/001;;C02F2103/002;;C02F2103/002,B01D21/00;;B01D24/00,210/155;;210/162;;210/170;;210/299;;210/300;;210/301;;210/335,0,0,,,,EXPIRED
3,SE,C2,SE 509666 C2,066-839-601-252-456,1999-02-22,1999,SE 9504261 A,1995-11-28,SE 9504261 A,1995-11-28,Sätt och anordning för att tillföra luft till en brännkammare,,ABB CARBON AB,ANDERSON JIM,,https://lens.org/066-839-601-252-456,Granted Patent,no,0,0,8,8,0,F02C9/16;;F02C9/16;;F02C3/36;;F23L5/02;;Y02E20/16;;Y02E20/18,F02C3/28;;F02C3/36;;F02C9/16;;F23C10/16;;F23L5/02,,0,0,,,,EXPIRED
4,US,S,US D0278634 S,194-669-685-329-925,1985-04-30,1985,US 41687682 F,1982-09-13,US 41687682 F,1982-09-13,Double tipped drumstick,,ANDERSON JIM,ANDERSON JIM,,https://lens.org/194-669-685-329-925,Design Right,yes,4,6,1,1,0,,,D17/22,1,0,,,"Targ & Dinner 1970 Catalog, p. 287, Item #'s 9838 & 9839.",EXPIRED
5,WO,A1,WO 2008/147993 A1,140-028-137-661-725,2008-12-04,2008,US 2008/0064702 W,2008-05-23,US 93994507 P;;US 94805407 P;;US 95726007 A,2007-05-24,MESSAGING SERVICE,"Messages are processed by receiving, from a first user on a wireless phone, a first message addressed to a second user. An extended header that is related to the first user and is for the first message is accessed. An alert is generated in response. A response to the alert from the second user is received. If the response includes an instruction from the second user to validate the message, a validation request is generated. The validation request is processed using a certificate authority. Based on a validation decision by the certificate authority for the validation request, a report for the second user with one or more processing options is generated. An instruction is received from the second user with a selection from among processing options. The first message is delivered to the second user if the instruction from the second user indicates that the message should be delivered.",ANDERSON JIM,ANDERSON JIM,,https://lens.org/140-028-137-661-725,Patent Application,yes,5,0,3,3,0,G06Q20/40;;H04L63/126;;H04M1/7243;;H04W12/106;;H04L51/58;;G06Q20/40;;H04L63/126;;H04M1/7243;;H04W12/106;;H04L51/58,H04W12/10,,0,0,,,,PENDING
6,US,A1,US 2008/0313167 A1,047-015-075-942-009,2008-12-18,2008,US 76387107 A,2007-06-15,US 76387107 A,2007-06-15,System And Method For Intelligently Indexing Internet Resources,"The present invention is a system and method for building an intelligent index of Internet web pages. A populator retrieves a web page, divides words within the web page into categories, and determines a relevancy rating for the words in each category, the relevancy rating based on the number of appearances of the word in the corresponding category. The populator then weights each relevancy rating by a weighting factor corresponding to the category, and sums the weighted relevancy ratings to determine a web page relevancy rating for each unique word. The categories include a header, hidden words, non-sentences, repetitive words, non-nouns, and nouns. Each category is further subdivided into subcategories of commonly used words and uncommonly used words. A relevancy rating is determined for each subcategory.",ANDERSON JIM,ANDERSON JIM,,https://lens.org/047-015-075-942-009,Patent Application,yes,9,16,3,3,0,G06F16/951;;G06F16/951,G06F17/30,707/5;;X707E17108,0,0,,,,DISCONTINUED
7,US,A1,US 2011/0152917 A1,094-791-251-470-642,2011-06-23,2011,US 64433809 A,2009-12-22,US 64433809 A,2009-12-22,INTRAVASCULAR FILTER RESTRAINING DEVICE,"A filtering device includes a filter that captures embolic material, a plurality of biased support struts that expand outwardly to deploy the filter, and a restraining mechanism. The restraining mechanism applies a restraining force that prevents the plurality of biased support struts from expanding outwardly to deploy the filter and includes a sleeve with one or more sleeve support bands biased to expand from a first position to a second position. An actuating member cooperates with a portion of the restraining mechanism to allow the sleeve support band to expand and release the restraining force.",BOSTON SCIENT SCIMED INC,ANDERSON JIM,BOSTON SCIENTIFIC SCIMED INC (2009-12-18),https://lens.org/094-791-251-470-642,Patent Application,yes,15,0,1,1,0,A61F2002/018;;A61F2/011;;A61F2002/018;;A61F2/011,A61M29/00,606/200,0,0,,,,DISCONTINUED
8,US,A1,US 2008/0294556 A1,159-461-758-400-429,2008-11-27,2008,US 95726207 A,2007-12-14,US 95726207 A;;US 93994507 P;;US 94805407 P,2007-05-24,MOBILE COMMERCE SERVICE,"A payment system processes payments so that vendors and consumer may have an increased degree of confidence as to the security of the transaction. More precisely, a consumer enters a messaging address through which the user may receive communications on a wireless device using a vendor point of sale system. The consumer identifies goods for purchase and the vendor generates a transaction total for the identified goods. The consumer's messaging address is received and a transaction request is received at an intermediary server operated by a wireless carrier. The transaction request is presented to the consumer in a display on the wireless device. The consumer uses the wireless device to authorize the transaction request and transmits the authorization to the intermediary server. The intermediary server receives the authorization and transfers, based on receiving the authorization, resources to the vendor to pay the transaction amount.",ANDERSON JIM,ANDERSON JIM,,https://lens.org/159-461-758-400-429,Patent Application,yes,4,167,3,3,0,G06Q20/40;;H04L63/126;;H04M1/7243;;H04W12/106;;H04L51/58;;G06Q20/40;;H04L63/126;;H04M1/7243;;H04W12/106;;H04L51/58,H04W12/10;;G06Q20/00,705/44;;455/466,0,0,,,,DISCONTINUED
9,WO,A2,WO 2008/157385 A2,056-131-286-854-345,2008-12-24,2008,US 2008/0066963 W,2008-06-13,US 76387107 A,2007-06-15,SYSTEM AND METHOD FOR INTELLIGENTLY INDEXING INTERNET RESOURCES,"The present invention is a system and method for building an intelligent index of Internet web pages. A populator retrieves a web page, divides words within the web page into categories, and determines a relevancy rating for the words in each category, the relevancy rating based on the number of appearances of the word in the corresponding category. The populator then weights each relevancy rating by a weighting factor corresponding to the category, and sums the weighted relevancy ratings to determine a web page relevancy rating for each unique word. The categories include a header, hidden words, non-sentences, repetitive words, non-nouns, and nouns. Each category is further subdivided into subcategories of commonly used words and uncommonly used words. A relevancy rating is determined for each subcategory.",ANDERSON JIM,ANDERSON JIM,,https://lens.org/056-131-286-854-345,Patent Application,yes,0,0,3,3,0,G06F16/951;;G06F16/951,G06F17/30;;G06F17/00,,0,0,,,,PENDING
10,US,A1,US 2003/0070977 A1,102-134-668-599-44X,2003-04-17,2003,US 97752301 A,2001-10-14,US 97752301 A,2001-10-14,Wastewater processor,"
    A wastewater treatment apparatus comprised of a water inlet 10,  a filter component comprised of a series of filters 20, 30, 40  and settling ing areas 12, 22, 32  over a grade, and a series of separator tanks, 42, 52  connected by a lift tube 54  for removal of hydrocarbons, particulate material and other impurities and a water outlet for discharge into either a general wastewater system or a gray water reclamation system. 
",ANDERSON JIM,ANDERSON JIM,,https://lens.org/102-134-668-599-44X,Patent Application,yes,0,18,2,2,0,B01D21/0012;;B01D21/0012;;B01D21/0006;;B01D21/0006;;B01D21/0018;;B01D21/0018;;B01D21/0024;;B01D21/0024;;B01D21/0033;;B01D21/0033;;B01D24/007;;B01D24/007;;B01D24/04;;B01D24/04;;C02F2103/001;;C02F2103/001;;C02F2103/002;;C02F2103/002,B01D21/00;;B01D24/00,210/301,0,0,,,,EXPIRED
11,WO,A1,WO 1997/020135 A1,152-974-780-980-975,1997-06-05,1997,SE 9601475 W,1996-11-14,SE 9504261 A,1995-11-28,A METHOD AND A DEVICE FOR SUPPLYING AIR TO A COMBUSTOR,"A method and a device for supplying air to a pressurized combustor (BK) in a gas turbine plant which for pressurization of the combustor (BK) comprises a compressor (C) driven by a gas turbine (GT), which in turn is driven by gases formed during combustion of a fuel in the combustor (BK). The invention is characterized in that the air is supplied to the low-pressure side of the compressor (C) via a pressurization device (F) in which the air is compressed such that air with a predetermined density is supplied to the compressor (C).",ABB CARBON AB;;ANDERSON JIM,ANDERSON JIM,,https://lens.org/152-974-780-980-975,Patent Application,yes,4,2,8,8,0,F02C9/16;;F02C9/16;;F02C3/36;;F23L5/02;;Y02E20/16;;Y02E20/18,F02C3/28;;F02C3/36;;F02C9/16;;F23C10/16;;F23L5/02,,0,0,,,,PENDING
12,SE,L,SE 9504261 L,174-303-662-600-338,1997-05-29,1997,SE 9504261 A,1995-11-28,SE 9504261 A,1995-11-28,Sätt och anordning för att tillföra luft till en brännkammare,,ABB CARBON AB,ANDERSON JIM,,https://lens.org/174-303-662-600-338,Abstract,no,0,0,8,8,0,F02C9/16;;F02C9/16;;F02C3/36;;F23L5/02;;Y02E20/16;;Y02E20/18,F02C3/28;;F02C3/36;;F02C9/16;;F23C10/16;;F23L5/02,,0,0,,,,EXPIRED
13,WO,A3,WO 2008/157385 A3,188-998-843-344-347,2009-02-12,2009,US 2008/0066963 W,2008-06-13,US 76387107 A,2007-06-15,SYSTEM AND METHOD FOR INTELLIGENTLY INDEXING INTERNET RESOURCES,"The present invention is a system and method for building an intelligent index of Internet web pages. A populator retrieves a web page, divides words within the web page into categories, and determines a relevancy rating for the words in each category, the relevancy rating based on the number of appearances of the word in the corresponding category. The populator then weights each relevancy rating by a weighting factor corresponding to the category, and sums the weighted relevancy ratings to determine a web page relevancy rating for each unique word. The categories include a header, hidden words, non-sentences, repetitive words, non-nouns, and nouns. Each category is further subdivided into subcategories of commonly used words and uncommonly used words. A relevancy rating is determined for each subcategory.",ANDERSON JIM,ANDERSON JIM,,https://lens.org/188-998-843-344-347,Search Report,yes,4,0,3,3,0,G06F16/951;;G06F16/951,G06F17/30;;G06F17/00,,0,0,,,,PENDING
14,EP,A1,EP 0864036 A1,025-896-176-507-393,1998-09-16,1998,EP 96941243 A,1996-11-14,SE 9601475 W;;SE 9504261 A,1995-11-28,A METHOD AND A DEVICE FOR SUPPLYING AIR TO A COMBUSTOR,,ABB CARBON AB,ANDERSON JIM,,https://lens.org/025-896-176-507-393,Patent Application,yes,0,0,8,8,0,F02C9/16;;F02C9/16;;F02C3/36;;F23L5/02;;Y02E20/16;;Y02E20/18,F02C3/28;;F02C3/36;;F02C9/16;;F23C10/16;;F23L5/02,,1,0,,,See references of WO 9720135A1,DISCONTINUED
15,US,A,US 4936716 A,115-966-592-533-367,1990-06-26,1990,US 38202089 A,1989-07-18,SE 8605199 A,1986-12-03,Transport device for pneumatically transporting particulate material from a container under high pressure to a container under low pressure,"A transport device for pneumatically transporting particulate material from a container which is under pressure to a container which is under a lower pressure, in which successive pressure reduction is achieved by repeated deceleration and acceleration of the particulate material in the gas-particle flow and by diversion of the gas-particle flow. The transport device includes a number of rectilinearly arranged nozzles and cup-shaped containers placed downstream of the nozzles and alternating with the nozzles. The cup-shaped containers receive material flowing out of the nozzles. The containers are arranged such that a channel is formed around the outside walls of the containers through which the particulate material flows to a downstream nozzle.",ABB STAL AB,ANDERSON JIM S,ABB STAL AB (1989-11-15),https://lens.org/115-966-592-533-367,Granted Patent,yes,4,4,6,6,0,F23J3/06;;F23J3/06;;F23C10/16;;F23C10/16,F23C10/16;;F23J3/06,406/168;;406/83;;138/42,0,0,,,,EXPIRED
16,ES,A6,ES 2005717 A6,062-735-216-939-92X,1989-03-16,1989,ES 8703458 A,1987-12-02,SE 8605199 A,1986-12-03,Transport device for pneumatically transporting particulate material from a container under high pressure to a container under low pressure,"A transport device for pneumatically transporting particulate material from a container which is under pressure to a container which is under a lower pressure, in which successive pressure reduction is achieved by repeated deceleration and acceleration of the particulate material in the gas-particle flow and by diversion of the gas-particle flow. The transport device includes a number of rectilinearly arranged nozzles and cup-shaped containers placed downstream of the nozzles and alternating with the nozzles. The cup-shaped containers receive material flowing out of the nozzles. The containers are arranged such that a channel is formed around the outside walls of the containers through which the particulate material flows to a downstream nozzle.",ASEA STAL AB,ANDERSON JIM S,,https://lens.org/062-735-216-939-92X,Granted Patent,no,0,0,6,6,0,F23J3/06;;F23J3/06;;F23C10/16;;F23C10/16,F23C10/16;;F23J3/06,,0,0,,,,EXPIRED
17,US,A1,US 2010/0188770 A1,125-594-588-450-33X,2010-07-29,2010,US 36243209 A,2009-01-29,US 36243209 A,2009-01-29,DATA TRANSFER APPARATUS,"A data transfer apparatus comprises drive apparatus to move a received tape along a path in a longitudinal direction of the tape, a transducer head to transfer data to and/or from the tape, a tape lifter to contact the tape; and control apparatus operable, in response to a tape speed related condition or event, to cause relative movement between the tape lifter and the tape into mutual contact, thereby biasing the tape away from surface to surface contact with the transducer head.",ANDERSON JIM;;MCALISTER JEFF,ANDERSON JIM;;MCALISTER JEFF,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27),https://lens.org/125-594-588-450-33X,Patent Application,yes,13,3,2,2,0,G11B15/43;;G11B15/43;;G11B15/62;;G11B15/62,G11B15/18,360/71;;XG9B 15021,0,0,,,,ACTIVE
18,US,B2,US 6568976 B2,020-288-898-107-147,2003-05-27,2003,US 77041401 A,2001-01-29,US 77041401 A,2001-01-29,Water floatation cushion with deployable tether,"
    The flotation cushion with deployable tether is generally the contour shape of a cushion without tether. A pocket is formed in the flotation cushion to conform to existing cushion structures. The tether is stored in the pocket in a manner to minimize bulging. With the tether attached at one end to the flotation cushion interior to the pocket, the flotation cushion may be thrown to a person in need of rescue while the user is grasping the tether at its free end. When the person to be rescued grabs the flotation cushion the tether may be used to retrieve the person and cushion. 
",ANDERSON DON;;WAY JIM,ANDERSON DON;;WAY JIM,,https://lens.org/020-288-898-107-147,Granted Patent,yes,19,19,2,2,0,B63C9/30;;B63C9/30;;B63B2205/02;;B63B2205/02;;B63C9/26;;B63C9/26,B63C9/26;;B63C9/30,441/80,0,0,,,,EXPIRED
19,US,B2,US 9058836 B2,064-713-005-353-465,2015-06-16,2015,US 36243209 A,2009-01-29,US 36243209 A,2009-01-29,Data transfer apparatus,"A data transfer apparatus comprises drive apparatus to move a received tape along a path in a longitudinal direction of the tape, a transducer head to transfer data to and/or from the tape, a tape lifter to contact the tape; and control apparatus operable, in response to a tape speed related condition or event, to cause relative movement between the tape lifter and the tape into mutual contact, thereby biasing the tape away from surface to surface contact with the transducer head.",ANDERSON JIM;;MCALLISTER JEFF;;HEWLETT PACKARD DEVELOPMENT CO,ANDERSON JIM;;MCALLISTER JEFF,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27),https://lens.org/064-713-005-353-465,Granted Patent,yes,13,2,2,2,0,G11B15/43;;G11B15/43;;G11B15/62;;G11B15/62,G11B15/46;;G11B15/43;;G11B15/62,,0,0,,,,ACTIVE
20,US,A1,US 2022/0123560 A1,062-050-805-142-116,2022-04-21,2022,US 202017072699 A,2020-10-16,US 202017072699 A,2020-10-16,Scalable Power System for Vehicles,"The technology relates to a scalable power system. A scalable power system includes battery modules connected in parallel, a network of diodes, a battery management system that may be localized or centralized, a localized battery management system configured to control an individual battery module, a centralized battery management system configured to control all of the battery modules in the scalable power system. In a system with localized battery control, a parallelizing circuit board may connect battery modules to a system bus in parallel. The battery modules can be charged and discharged by the system bus. A method of adding a battery module to a scalable power system includes discharging a highest-charged battery module, then discharging a next highest-charged battery module until there are no remaining charged battery modules, then adding an additional battery module in parallel, and charging the connected battery modules in parallel.",LOON LLC,ANDERSON KEVIN;;MORASH JIM,LOON LLC (2020-10-13),https://lens.org/062-050-805-142-116,Patent Application,yes,0,1,1,1,0,H02J7/0063;;H02J7/0025;;H02J7/0048;;Y02E60/10;;Y02T10/70;;Y02T10/7072;;Y02T90/14;;B60L58/18;;B60L58/21;;B60L58/22;;B60L58/27;;B60L3/0046;;B60L58/12;;H01M2220/20;;H01M10/441;;H01M10/6571;;H01M10/4207;;H01M10/486;;H01M2010/4271;;H01M10/425;;H01M10/615;;H01M10/46;;H01M10/63;;H02J7/0013;;H02J7/0029;;H02J7/0048;;H01M10/615;;H01M10/425;;H01M10/46;;H01M2220/20;;B60L50/66;;B60L58/18;;B60L58/27;;B60L58/12;;B60L53/00;;H01M2010/4271;;H01M10/63,H02J7/00;;B60L50/60;;B60L53/00;;B60L58/12;;B60L58/18;;B60L58/27;;H01M10/42;;H01M10/46;;H01M10/615;;H01M10/63,,0,0,,,,DISCONTINUED
21,US,A1,US 2002/0102891 A1,161-123-103-741-724,2002-08-01,2002,US 77041401 A,2001-01-29,US 77041401 A,2001-01-29,Water floatation cushion with deployable tether,"
   The flotation cushion with deployable tether is generally the contour shape of a cushion without tether. A pocket is formed in the flotation cushion to conform to existing cushion structures. The tether is stored in the pocket in a manner to minimize bulging. With the tether attached at one end to the flotation cushion interior to the pocket, the flotation cushion may be thrown to a person in need of rescue while the user is grasping the tether at its free end. When the person to be rescued grabs the flotation cushion the tether may be used to retrieve the person and cushion. 
",ANDERSON DON;;WAY JIM,ANDERSON DON;;WAY JIM,,https://lens.org/161-123-103-741-724,Patent Application,yes,0,5,2,2,0,B63C9/30;;B63C9/30;;B63B2205/02;;B63B2205/02;;B63C9/26;;B63C9/26,B63C9/26;;B63C9/30,441 8,0,0,,,,EXPIRED
22,US,A1,US 2020/0279629 A1,194-533-620-711-215,2020-09-03,2020,US 202016804445 A,2020-02-28,US 202016804445 A;;US 201962812570 P,2019-03-01,SYSTEM AND METHOD FOR GATHERING AND ANALYZING HUMAN EXPERIENCE REPORTS,"A system and method for gathering and analyzing electronic records. The method comprises collecting user value statements, determining personal product differentiation (PPD) scores based on the user value statements, collecting experiences related to a user reaction to a product, analyzing the collected experiences based on the PPDs, and generating at least a recommendation of a preferred product for the user.",MEDICINE DIFFERENTIATION ANALYTICS LLC,MORRISSEY EILEEN;;ANDERSON JIM,MEDICINE DIFFERENTIATION ANALYTICS LLC (2020-02-25),https://lens.org/194-533-620-711-215,Patent Application,yes,3,4,1,1,0,G06Q30/0201;;G16H15/00;;G16H20/10;;G16H50/70;;G16H70/40;;G16H20/10;;G16H70/40;;G06Q30/0201;;G16H50/70;;G16H10/60,G16H20/10;;G06Q30/02;;G16H10/60;;G16H50/70;;G16H70/40,,0,0,,,,PENDING
23,US,A1,US 2012/0245950 A1,099-742-162-281-381,2012-09-27,2012,US 201213426935 A,2012-03-22,US 201213426935 A;;US 201161467231 P,2011-03-24,SYSTEM AND METHOD FOR DETERMINING ASSET DIFFERENTIATION IN MEDICINE DEVELOPMENT,"A computer implemented system and method of determining pharmaceutical asset market potential is disclosed. The system and method comprising: collecting asset information of a proposed pharmaceutical asset; determining a therapeutic category of the proposed pharmaceutical asset; determining an unmet need for proposed pharmaceutical asset by evaluating a plurality of Customer Value Statements (CVS) based on the therapeutic category. Also disclosed, the system and method computes a differentiation score based on the plurality of CVS and comparing a strength of the proposed pharmaceutical asset against existing competitor data in the therapeutic category and computes a Real/Win/Worth (RWW) score to determine the probability of success of the proposed pharmaceutical asset in the therapeutic category based, in part, on the differentiation score; and CVS. The disclosed system and method additionally generates an executive summary report of the proposed pharmaceutical asset market potential base, in part, on the RWW score.",MORRISSEY EILEEN;;ANDERSON JIM;;MEDICINE DIFFERENTIATION ANALYTICS LLC,MORRISSEY EILEEN;;ANDERSON JIM,MEDICINE DIFFERENTIATION ANALYTICS LLC (2012-03-21),https://lens.org/099-742-162-281-381,Patent Application,yes,6,0,1,1,0,G06Q30/02;;G06Q30/02,G06Q50/22,705/2,0,0,,,,DISCONTINUED
24,US,S,US D0727971 S,070-540-720-149-118,2015-04-28,2015,US 201429493321 F,2014-06-09,US 201429493321 F,2014-06-09,Pump,,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L (2014-07-03),https://lens.org/070-540-720-149-118,Design Right,no,0,1,1,1,0,,,1502;;D15/7,0,0,,,,ACTIVE
25,US,S,US D0768725 S,041-158-327-653-909,2016-10-11,2016,US 201529531053 F,2015-06-23,US 201529531053 F,2015-06-23,Angled pump,,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L (2015-06-29),https://lens.org/041-158-327-653-909,Design Right,no,0,3,2,2,0,,,1502;;D15/7,0,0,,,,ACTIVE
26,US,B1,US 6909431 B1,159-821-172-301-948,2005-06-21,2005,US 51692500 A,2000-03-01,US 51692500 A;;US 12220099 P,1999-03-01,Position and shape control for cloth and soft body animation,"Animation controls according to the present invention introduce a predictable level of control for animation without the need for iterating the simulation. Controls include shape controls that permit the effect of the simulation to be overridden for cloth and soft body materials. The effect of shape tacks are to control the local shape of objects such as cloth and soft body materials, the shape may be weighted and time varying. Shape tacking is relative to the reference coordinate system of the object being shaped. Position tacks provide control in absolute space and permit accurate placement of an object to be animated overriding the control of the simulation.",LUCAS DIGITAL LTD,ANDERSON JOHN R;;HOURIHAN JIM,LUCAS DIGITAL LTD (2000-05-15);;LUCASFILM ENTERTAINMENT COMPANY LTD (2004-04-30),https://lens.org/159-821-172-301-948,Granted Patent,yes,2,60,1,1,0,G06T13/20;;G06T2210/16;;G06T13/20;;G06T2210/16,G06T13/00,345/473;;345/423,0,0,,,,EXPIRED
27,US,B1,US 7980533 B1,102-752-159-400-947,2011-07-19,2011,US 7082305 A,2005-03-02,US 7082305 A;;US 54938904 P,2004-03-02,Breakaway coupling for road-side signs,"A breakaway coupling for use with a ground-installed road sign such as a stop sign typically located at the side of a road. The coupling interfaces between a conventional hollow ground stake and a hollow sign post. The coupling can be used with newly installed stop signs, as well as with currently installed stop signs, without modification to either the post of the ground stake. When the sign post is struck by an automobile, the coupling shears along a preformed score section generally aligned with the bottom of the post such that the post and sign break completely from the ground stake and are propelled away from the automobile.",DESIGNORATIONS INC,ANDERSON JIM;;TRAVIS HARRY M,DESIGNOVATIONS INC (2005-03-02),https://lens.org/102-752-159-400-947,Granted Patent,yes,15,23,1,1,0,Y10S256/05;;E01F9/635;;E01F9/635;;Y10S256/05,E01F9/018;;E01F15/00,256/13.1;;404/10;;40/607.04;;X256DIG 5,0,0,,,,ACTIVE
28,US,S,US D0882795 S,122-708-695-250-126,2020-04-28,2020,US 201829646654 F,2018-05-07,US 201829646654 F,2018-05-07,Inoculator marker,,ANDERSON MARK L,WAIT JIM;;ANDERSON MARK L,ANDERSON MARK L (2018-05-10),https://lens.org/122-708-695-250-126,Design Right,no,14,3,3,3,0,,,2402;;D24/146;;D15/7,0,0,,,,ACTIVE
29,US,S,US D0727364 S,007-841-804-795-226,2015-04-21,2015,US 201429494862 F,2014-06-25,US 201429494862 F,2014-06-25,Dual pump,,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L (2014-07-03),https://lens.org/007-841-804-795-226,Design Right,no,0,0,1,1,0,,,1502;;D15/7,0,0,,,,ACTIVE
30,US,S,US D0745967 S,119-091-974-677-784,2015-12-22,2015,US 201429493326 F,2014-06-09,US 201429493326 F,2014-06-09,Dental hammer,,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L;;WAIT JIM,ANDERSON MARK L (2014-07-03),https://lens.org/119-091-974-677-784,Design Right,no,0,3,1,1,0,,,2402;;D24/152,0,0,,,,ACTIVE
31,WO,A2,WO 2007/090099 A2,019-887-557-689-707,2007-08-09,2007,US 2007/0061248 W,2007-01-29,US 76333106 P,2006-01-30,METHODS FOR OIL EXTRACTION,"The present invention relates to methods for the extraction of heavy oils and oil sands from oil reservoirs and methods for the extraction of bitumen from oil sands and oil shale. The methods comprise an injection of a solvent comprising sodium silicate, the use of thermal technology, and/or the use of gas injection into an oil reservoir to enhance the extraction of oil from the oil reservoir. Further, methods of extracting bitumen from oils sands using a solvent comprising sodium silicate are also provided.",GGT WASTE INC;;VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,,https://lens.org/019-887-557-689-707,Patent Application,yes,0,4,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10C1/18,,0,0,,,,PENDING
32,AU,A1,AU 2007/211109 A1,043-929-531-476-634,2007-08-09,2007,AU 2007/211109 A,2007-01-29,US 76333106 P;;US 2007/0061248 W,2006-01-30,Methods for oil extraction,,GGT WASTE INC,BALLEW JIM;;VRIESINGA MARK;;ANDERSON WILLIAM,,https://lens.org/043-929-531-476-634,Patent Application,no,0,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,DISCONTINUED
33,CN,A,CN 1168955 A,061-691-282-415-149,1997-12-31,1997,CN 97109565 A,1997-03-08,SE 9601394 A,1996-04-12,Combustion plant,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS,,https://lens.org/061-691-282-415-149,Patent Application,no,0,1,6,6,0,F23C10/10;;F23C10/16,F23C10/10;;F23C10/16,,0,0,,,,DISCONTINUED
34,US,A1,US 2004/0237497 A1,195-557-478-989-242,2004-12-02,2004,US 44905403 A,2003-05-30,US 44905403 A,2003-05-30,Method to provide precision draw dimension of links,"
   A method of punching chain links for a power transmission chain from metal sheet material to ensure precise location of the apertures relative to the outer link contour of the link being created comprising the steps of piercing the metal sheet material to form the apertures and the back contour of the link at a first station. Piercing the metal sheet material to form link flanks at a second station. Shaving the apertures, the link flanks, and the back contour sequentially at a third same station as the metal sheet material is held stationary. Blanking the outer link contour to separate the link from the metal sheet material at fourth station. 
",BORGWARNER INC,ANDERSON DAVE;;BENJAMIN JIM;;YOSHIMORI TAKAHARU,BORGWARNER INC (2003-08-07),https://lens.org/195-557-478-989-242,Patent Application,yes,5,1,1,1,0,B21L9/04;;B21L9/04,B21L9/04,59/8,0,0,,,,DISCONTINUED
35,WO,A3,WO 2007/090099 A3,156-433-105-289-180,2008-01-24,2008,US 2007/0061248 W,2007-01-29,US 76333106 P,2006-01-30,METHODS FOR OIL EXTRACTION,"The present invention relates to methods for the extraction of heavy oils and oil sands from oil reservoirs and methods for the extraction of bitumen from oil sands and oil shale. The methods comprise an injection of a solvent comprising sodium silicate, the use of thermal technology, and/or the use of gas injection into an oil reservoir to enhance the extraction of oil from the oil reservoir. Further, methods of extracting bitumen from oils sands using a solvent comprising sodium silicate are also provided.",GGT WASTE INC;;VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,,https://lens.org/156-433-105-289-180,Search Report,yes,3,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,PENDING
36,BR,A2,BR PI0706789 A2,162-636-532-731-372,2011-04-05,2011,BR PI0706789 A,2007-01-29,US 76333106 P;;US 2007/0061248 W,2006-01-30,processos para extração de óleo,"PROCESSOS PARA EXTRAçãO DE óLEO A presente invenção refere-se a processos para a extração de óleos pesados e areias oleiferas de reservatórios de óleo e processos para a extração de betume de areias oleíferas e xisto petrolífero. Os processos compreendem uma injeção de um solvente que compreende silicato de só-dio, o uso de tecnologia térmica, e/ou o uso de injeção de gás em um reservatório de óleo para aumentar a extração de óleo do reservatório de óleo. Além disso, processos de extrair betume de areias oleiferas usando um solvente que compreende silicato de sódio também são fornecidos.",GGT WASTE INC,VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,,https://lens.org/162-636-532-731-372,Patent Application,no,0,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,DISCONTINUED
37,US,S,US D0915579 S,170-016-197-542-859,2021-04-06,2021,US 201829649932 F,2018-06-04,US 201829649932 F,2018-06-04,Double barrel doser,,ANDERSON MARK L,ANDERSON MARK L;;WAIT JIM L,ANDERSON MARK L (2018-06-08),https://lens.org/170-016-197-542-859,Design Right,no,25,2,1,1,0,,,2402;;D24/113;;D24/114,2,0,,,"Syringe pump with double-barreled, publication date Aug. 27, 2018, [online][site visited Oct. 22, 2020] URL: http://www.livestocktool.com/product/veterinary-instruments1/automatic-continuous-syringe/syringe-pump-with-double-barreled.html (Year: 2018).;;Double-Barreled Continuous Syringe, publication date Apr. 5, 2019, [online][site visited Oct. 22, 2020] URL: http://www.levah.com/Agriculture/Veterinary-Continuous-Syringe/Double-Barreled-Continuous-Syringe-VC290128.html (Year: 2019).",ACTIVE
38,US,B2,US 8388645 B2,072-247-754-002-106,2013-03-05,2013,US 64302909 A,2009-12-21,US 64302909 A,2009-12-21,Intravascular filter restraining device,"A filtering device includes a filter that captures embolic material, a plurality of biased support struts that expand outwardly to deploy the filter, and a restraining mechanism. The restraining mechanism applies a restraining force that prevents the plurality of biased support struts from expanding outwardly to deploy the filter. An actuating member cooperates with a portion of the restraining mechanism to release the restraining force and allow the filter to deploy.",TRIPP GRACE;;ZOROMSKI MICHELE;;ANDERSON JIM;;BOSTON SCIENT SCIMED INC,TRIPP GRACE;;ZOROMSKI MICHELE;;ANDERSON JIM,BOSTON SCIENTIFIC SCIMED INC (2009-12-18),https://lens.org/072-247-754-002-106,Granted Patent,yes,15,0,2,2,0,A61F2002/018;;A61F2230/0006;;A61F2230/008;;A61F2/01;;A61F2002/018;;A61F2230/008;;A61F2230/0006;;A61F2/01,A61F2/06;;A61M29/00,606/200;;623/1.11,0,0,,,,INACTIVE
39,EP,A2,EP 1981952 A2,098-631-722-859-850,2008-10-22,2008,EP 07762662 A,2007-01-29,US 2007/0061248 W;;US 76333106 P,2006-01-30,METHODS FOR OIL EXTRACTION,,GGT WASTE INC,VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,,https://lens.org/098-631-722-859-850,Patent Application,yes,0,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,DISCONTINUED
40,AU,A4,AU 2004/100553 A4,056-335-211-689-95X,2004-08-12,2004,AU 2004/100553 A,2004-07-06,AU 2004/100553 A,2004-07-06,Ladder access standard,,PCH GROUP LTD,GREGORY PAUL;;RUDD PAUL;;ANDERSON JIM,,https://lens.org/056-335-211-689-95X,Limited Patent,no,0,1,1,1,0,,E04G1/00;;E04G3/00;;E04G5/00;;E04G21/32,,0,0,,,,INACTIVE
41,MX,A,MX 2008009707 A,016-568-151-946-454,2008-12-17,2008,MX 2008009707 A,2007-01-29,US 76333106 P;;US 2007/0061248 W,2006-01-30,METHODS FOR OIL EXTRACTION.,"The present invention relates to methods for the extraction of heavy oils and oil sands from oil reservoirs and methods for the extraction of bitumen from oil sands and oil shale. The methods comprise an injection of a solvent comprising sodium silicate, the use of thermal technology, and/or the use of gas injection into an oil reservoir to enhance the extraction of oil from the oil reservoir. Further, methods of extracting bitumen from oils sands using a solvent comprising sodium silicate are also provided.",GGT WASTE INC,ANDERSON WILLIAM;;BALLEW JIM;;VRIESINGA MARK,,https://lens.org/016-568-151-946-454,Patent Application,no,0,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,PENDING
42,CA,A1,CA 2640005 A1,070-356-996-714-069,2007-08-09,2007,CA 2640005 A,2007-01-29,US 76333106 P;;US 2007/0061248 W,2006-01-30,METHODS FOR OIL EXTRACTION,"The present invention relates to methods for the extraction of heavy oils an d oil sands from oil reservoirs and methods for the extraction of bitumen from oil sands and oil shale. The methods comprise an injection of a solvent comprising sodium silicate, the use of thermal technology, and/or the use of gas injection into an oil reservoir to enhance the extraction of oil from th e oil reservoir. Further, methods of extracting bitumen from oils sands using a solvent comprising sodium silicate are also provided.",GGT WASTE INC,VRIESINGA MARK;;BALLEW JIM;;ANDERSON WILLIAM,,https://lens.org/070-356-996-714-069,Patent Application,no,0,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,DISCONTINUED
43,US,A,US 5145030 A,059-738-561-666-198,1992-09-08,1992,US 75771991 A,1991-09-11,US 75771991 A,1991-09-11,Guard rail post,"This invention provides a guard rail post for use on scaffolding of the type used in the construction of buildings. The guard rail post comprises an elongated member having securing means for securing the guard rail post to a vertical support member of the scaffold, positioning means for mounting the guard rail post in fixed relationship to a scaffold work platform and means for connecting guard rails to the post at a fixed distance above the work platform.",WACO INTERNATIONAL CORP,PAVLESCAK JIM J;;ANDERSON GARY V,WACO INTERNATIONAL CORPORATION (1991-09-03),https://lens.org/059-738-561-666-198,Granted Patent,yes,17,40,1,1,0,E04G5/14;;E04G5/14,E04G5/14,182/113;;182/178,0,0,,,,EXPIRED
44,CN,A,CN 1182182 A,117-837-028-522-415,1998-05-20,1998,CN 97110946 A,1997-03-07,SE 9601390 A,1996-04-12,Combustion plant and method of combustion,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSSON HANS;;ANDERSON JIM,ABB ALSTOM POWER GARBON AG (2012-12-05);;ALSTOM SWITZERLAND LTD. (2012-11-02);;ABB ALSTOM POWER SWISS AG (2012-11-02),https://lens.org/117-837-028-522-415,Patent Application,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,EXPIRED
45,US,A1,US 2011/0152916 A1,052-484-193-511-43X,2011-06-23,2011,US 64302909 A,2009-12-21,US 64302909 A,2009-12-21,INTRAVASCULAR FILTER RESTRAINING DEVICE,"A filtering device includes a filter that captures embolic material, a plurality of biased support struts that expand outwardly to deploy the filter, and a restraining mechanism. The restraining mechanism applies a restraining force that prevents the plurality of biased support struts from expanding outwardly to deploy the filter. An actuating member cooperates with a portion of the restraining mechanism to release the restraining force and allow the filter to deploy.",BOSTON SCIENT SCIMED INC,TRIPP GRACE;;ZOROMSKI MICHELE;;ANDERSON JIM,BOSTON SCIENTIFIC SCIMED INC (2009-12-18),https://lens.org/052-484-193-511-43X,Patent Application,yes,15,6,2,2,0,A61F2002/018;;A61F2230/0006;;A61F2230/008;;A61F2/01;;A61F2002/018;;A61F2230/008;;A61F2230/0006;;A61F2/01,A61F2/01,606/200,0,0,,,,INACTIVE
46,CN,A,CN 101454422 A,049-001-962-725-882,2009-06-10,2009,CN 200780008514 A,2007-01-29,US 76333106 P,2006-01-30,Methods for oil extraction,"The present invention relates to methods for the extraction of heavy oils and oil sands from oil reservoirs and methods for the extraction of bitumen from oil sands and oil shale. The methods comprise an injection of a solvent comprising sodium silicate, the use of thermal technology, and/or the use of gas injection into an oil reservoir to enhance the extraction of oil from the oil reservoir. Further, methods of extracting bitumen from oils sands using a solvent comprising sodium silicate are also provided.",GGT WASTE INC,MARK VRIESINGA;;JIM BALLEW;;WILLIAM ANDERSON,,https://lens.org/049-001-962-725-882,Patent Application,no,0,1,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10G1/04,,0,0,,,,DISCONTINUED
47,CN,A,CN 1168459 A,014-316-259-823-321,1997-12-24,1997,CN 97110041 A,1997-03-07,SE 9601391 A,1996-04-12,Method of combustion and combustion plant,,A BB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C,,https://lens.org/014-316-259-823-321,Patent Application,no,0,1,4,4,0,F01K23/062;;F23C10/10,F01K23/06;;F23C10/10,,0,0,,,,DISCONTINUED
48,EC,A,EC SP088705 A,123-840-186-527-54X,2009-01-30,2009,EC SP088705 A,2008-08-28,US 76333106 P,2006-01-30,MÉTODO PARA LA EXTRACCIÓN DE PETRÓLEO,"La presente invención se relaciona con métodos para la extracción de petróleos pesados y arenas petrolíferas de depósitos de petróleo y métodos para la extracción de bitumen de arenas petrolíferas o esquisto bituminoso. Los métodos comprenden una inyección de un solvente que comprende silicato de sodio, la utilización de tecnología térmica, y/o la utilización de inyección de gas en el interior de un depósito de petróleo para mejorar la extracción de petróleo del depósito de petróleo. Además, se proporcionan métodos para la extracción del bitumen de las arenas petrolíferas utilizando un solvente que comprende silicato de sodio.",GGT WASTE INC,ANDERSON WILLIAM H;;VRIESINGA MARK;;BALLEW JIM,,https://lens.org/123-840-186-527-54X,Patent Application,no,0,0,10,10,0,C09K8/592;;C09K8/594;;C10G1/04;;C10G1/045;;E21B43/24;;E21B43/34;;E21B43/34;;E21B43/24,C10C1/18,,0,0,,,,PENDING
49,CN,A,CN 1180152 A,026-636-853-426-503,1998-04-29,1998,CN 97110931 A,1997-03-08,SE 9601392 A,1996-04-12,Method of combustion and combustion plant,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C,ABB ALSTOM POWER GARBON AG (2012-12-05);;ALSTOM SWITZERLAND LTD. (2012-11-01);;ABB ALSTOM POWER SWISS AG (2012-11-01),https://lens.org/026-636-853-426-503,Patent Application,no,0,2,7,7,0,F23J7/00;;F23J7/00;;F01K23/062;;F01K23/062;;F23C6/047;;F23C6/047;;F23C10/10;;F23C10/10;;F23C10/16;;F23C10/16,F23C10/22;;F01K23/06;;F23C6/04;;F23C10/10;;F23C10/16;;F23J7/00,,0,0,,,,EXPIRED
50,CN,A,CN 1177079 A,021-144-968-524-979,1998-03-25,1998,CN 97110945 A,1997-03-08,SE 9601393 A,1996-04-12,Method of combustion and combustion plant,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C,,https://lens.org/021-144-968-524-979,Patent Application,no,0,0,6,6,0,B01D53/34;;F23C10/10;;Y02E20/34;;F23C10/10;;B01D53/34,F23C10/18;;B01D53/34;;F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,DISCONTINUED
51,WO,A1,WO 1998/048711 A1,044-688-876-124-687,1998-11-05,1998,US 9808933 W,1998-05-01,US 4526897 P,1997-05-01,ULTRASOUND CATHETER,A catheter for use in a vessel of a body is disclosed. The catheter includes an elongated body and a plurality of ultrasound elements coupled to the elongated body. Each of the plurality of ultrasound elements is separated from an adjacent ultrasound element.,EKOS CORP,TACHIBANA KATSURO;;HANSMANN DOUGLAS R;;ANDERSON JIM,,https://lens.org/044-688-876-124-687,Patent Application,yes,8,34,2,2,0,A61B17/22012;;A61B2017/22021;;A61B2017/22084;;A61M25/007;;A61M37/0092;;A61M2205/058;;A61M25/007;;A61M37/0092;;A61B17/22012;;A61B2017/22021;;A61M2205/058;;A61B2017/22084,A61B17/22;;A61M25/00;;A61M37/00,,0,0,,,,PENDING
52,US,S,US D0634428 S,009-653-221-104-774,2011-03-15,2011,US 35243809 F,2009-12-21,US 35243809 F,2009-12-21,Equine dental light,,ANDERSON MARK L;;WAIT JIM;;TOYCEN MARK,ANDERSON MARK L;;WAIT JIM;;TOYCEN MARK,ANDERSON MARK L (2010-01-22),https://lens.org/009-653-221-104-774,Design Right,no,0,6,1,1,0,,,2402;;D24/152,0,0,,,,ACTIVE
53,US,B2,US 8266071 B2,121-751-889-716-569,2012-09-11,2012,US 201113007036 A,2011-01-14,US 201113007036 A;;US 74546803 A,2003-12-22,Manifest generation and download systems and methods,"The present invention is directed to systems and methods to generate a manifest of work that is to be performed by a driver. Specifically, systems and methods are described in the context of a package delivery system to generate a manifest of deliveries and pickups to be performed by a driver and to download the generated manifest to a portable computing device used by the driver to service the route.",HOLSEN JIM;;ANDERSON DUANE;;PEREZ JUAN;;DAVIDSON MARK;;UNITED PARCEL SERVICE INC,HOLSEN JIM;;ANDERSON DUANE;;PEREZ JUAN;;DAVIDSON MARK,,https://lens.org/121-751-889-716-569,Granted Patent,yes,25,2,5,5,0,G06Q10/08;;G06Q10/08;;G06Q10/08355;;G06Q10/08355,G06Q30/00;;G01C1/00;;G01C21/00;;G06F9/06;;G06Q10/00;;G08G1/00;;G08G1/123,705/338;;705/1.1;;705/7.11;;705/330;;340/904;;340/988;;340/994;;701/200;;701/207;;701/208;;701/212,1,0,,,"Gooley, Toby B., ""When There's No Time To Waste . . . "" Jun. 1997, Logistics Management, pp. 35-37.",EXPIRED
54,WO,A2,WO 2000/057334 A2,064-994-418-130-634,2000-09-28,2000,US 0007803 W,2000-03-24,US 12608199 P;;US 49344800 A,1999-03-25,METHODS AND APPARATUSES FOR INTERACTING WITH MEMBERS OF A MEMBERSHIP ORGANIZATION,"L'invention concerne un dispositif et un procédé qui permettent de payer en liquide ou d'une manière équivalente les membres d'une association désirant participer aux activités de ladite association. Dans l'un des modes de réalisation, l'association indemnise les membres pour le temps qu'ils passent à naviguer sur le Web. Elle paie également en liquide ou d'une manière équivalente un premier membre pour le temps que passe un second membre à naviguer sur le Web quand ledit second membre a été mentionné, directement ou indirectement, par le premier.",ALL ADVANTAGE COM INC,ANDERSON CARL;;BROCK OLIVER;;JORGENSEN JIM;;POHLE JOHANNES,,https://lens.org/064-994-418-130-634,Patent Application,yes,0,0,3,6,0,G06Q30/02,G06Q30/00,,0,0,,,,PENDING
55,US,A1,US 2011/0112979 A1,116-969-287-003-829,2011-05-12,2011,US 201113007036 A,2011-01-14,US 201113007036 A;;US 74546803 A,2003-12-22,MANIFEST GENERATION AND DOWNLOAD SYSTEMS AND METHODS,"The present invention is directed to systems and methods to generate a manifest of work that is to be performed by a driver. Specifically, systems and methods are described in the context of a package delivery system to generate a manifest of deliveries and pickups to be performed by a driver and to download the generated manifest to a portable computing device used by the driver to service the route.",UNITED PARCEL SERVICE INC,HOLSEN JIM;;ANDERSON DUANE;;PEREZ JUAN;;DAVIDSON MARK,,https://lens.org/116-969-287-003-829,Patent Application,yes,24,9,5,5,0,G06Q10/08;;G06Q10/08;;G06Q10/08355;;G06Q10/08355,G06Q10/00;;G06F9/06,705/338,0,0,,,,EXPIRED
56,US,B2,US 7895132 B2,164-357-606-686-481,2011-02-22,2011,US 74546803 A,2003-12-22,US 74546803 A,2003-12-22,Manifest generation and download systems and methods,"The present invention is directed to systems and methods to generate a manifest of work that is to be performed by a driver. Specifically, systems and methods are described in the context of a package delivery system to generate a manifest of deliveries and pickups to be performed by a driver and to download the generated manifest to a portable computing device used by the driver to service the route.",UNITED PARCEL SERVICE INC,HOLSEN JIM;;ANDERSON DUANE;;PEREZ JUAN;;DAVIDSON MARK,UNITED PARCEL SERVICE OF AMERICA INC (2004-04-21),https://lens.org/164-357-606-686-481,Granted Patent,yes,25,2,5,5,0,G06Q10/08;;G06Q10/08;;G06Q10/08355;;G06Q10/08355,G06Q30/00;;G01C21/00;;G01C21/30;;G06F9/06;;G06F9/46;;G06F11/34;;G06F17/50;;G06Q10/00;;G08G1/00;;G08G1/123,705/338;;705/1.1;;705/7;;705/9;;705/11;;701/200;;701/207;;701/208;;701/212;;340/904;;340/988;;340/994,1,0,,,"Gooley, Toby, ""When There's No Time To Waste . . ."", Jun. 1997, Logistics Management, pp. 35.",ACTIVE
57,WO,A8,WO 2000/057334 A8,198-700-718-087-415,2001-10-25,2001,US 0007803 W,2000-03-24,US 12608199 P;;US 49344800 A,1999-03-25,METHODS AND APPARATUSES FOR INTERACTING WITH MEMBERS OF A MEMBERSHIP ORGANIZATION,"L'invention concerne un dispositif et un procédé qui permettent de payer en liquide ou d'une manière équivalente les membres d'une association désirant participer aux activités de ladite association. Dans l'un des modes de réalisation, l'association indemnise les membres pour le temps qu'ils passent à naviguer sur le Web. Elle paie également en liquide ou d'une manière équivalente un premier membre pour le temps que passe un second membre à naviguer sur le Web quand ledit second membre a été mentionné, directement ou indirectement, par le premier.",ALL ADVANTAGE COM INC,ANDERSON CARL;;BROCK OLIVER;;JORGENSEN JIM;;POHLE JOHANNES,,https://lens.org/198-700-718-087-415,Patent Application,no,0,0,3,6,0,G06Q30/02,G06Q30/00,,0,0,,,,PENDING
58,EP,A1,EP 2384387 A1,175-129-373-082-269,2011-11-09,2011,EP 10736459 A,2010-01-29,US 2010/0022540 W;;US 14869509 P,2009-01-30,"METHODS, SYSTEMS, AND TOOL ASSEMBLIES FOR DISTRIBUTING WEIGHT-ON-BIT BETWEEN A PILOT EARTH-BORING ROTARY DRILL BIT AND A REAMER DEVICE",,BAKER HUGHES INC,RADFORD STEVEN;;ANDERSON MARK;;THOMPSON WILLIAM;;POWERS JIM,,https://lens.org/175-129-373-082-269,Patent Application,yes,0,0,6,6,0,E21B10/32;;E21B10/32,E21B10/46;;E21B10/26;;E21B10/54,,0,0,,,,DISCONTINUED
59,WO,A3,WO 2013/043106 A3,169-437-612-789-200,2013-07-11,2013,SE 2012050972 W,2012-09-14,EP 11182531 A;;US 201161539227 P,2011-09-23,MIXER UNIT,"A mixer unit (30) for frequency translating, based on an LO signal, an input signal having one or more input signal components is disclosed. The mixer unit has a signal processing path (50a-d, 60a-d) from each Input terminal (32+, 32-) to each output terminal (34_I+, 34_ I-, 34_Q+,34_Q—) of the mixer unit (30), The LO signal has an associated LO signal component (LO_Ia-d, LO_Qa-d) for each signal processing path. The mixer unit (30) comprises a plurality of mixer switches (70a- N ) and a control unit (90). The control unit (90) is adapted to, for each signal processing path (50a-d, 60a-d), dynamically select an associated subset, in the following denoted active switch subset, of the plurality of mixer switches (70a- N ) for operation in the signal processing path (50a-d, 60a~d) such that which of the plurality of mixer switches (70a-N) belong to said active switch subset varies in time. At any instant in time, the union of all the active switch subsets is a strict subset, denoted combined active subset, of the plurality of mixer switches (70a- N ). The control unit (90) is further adapted to activate only the mixer switches (70a- N ) in said combined active subset by, for each mixer switch (70a- N ) in the combined active subset, supplying the corresponding LO signal component to the mixer switch. A related radio receiver circuit (10), a related radio communication apparatus (1, 2), and a related method are also disclosed.",ERICSSON TELEFON AB L M;;SJOELAND HENRIK;;SUNDSTROEM LARS;;ANDERSON MARTIN;;SVENSSON JIM,SJOELAND HENRIK;;SUNDSTROEM LARS;;ANDERSON MARTIN;;SVENSSON JIM,,https://lens.org/169-437-612-789-200,Search Report,yes,5,0,6,6,0,H03D7/165;;H03D7/18;;H03D7/1458;;H03D7/1466;;H03D7/165;;H03D7/18;;H04B1/405;;H04L27/12,H03D7/14,,1,1,095-791-506-242-593,10.1109/4.890307,"BAUTISTA, E.E. ET AL.: ""A High P2 Downconversion Mixer Using Dynamic Matching"", IEEE JOURNAL OF SOLID-STATE CIRCUITS, vol. 35, 12 December 2000 (2000-12-12), XP011450389, DOI: doi:10.1109/4.890307",PENDING
60,BR,A2,BR PI1008353 A2,048-691-566-967-147,2016-02-23,2016,BR PI1008353 A,2010-01-29,US 2010/0022540 W;;US 14869509 P,2009-01-30,"métodos, sistemas e conjuntos de ferramentas para distribuição de peso aplicado à broca entre a broca de perfuração rotativa perfuração da terra e o dispositivo escareador",,BAKER HUGHES INC,POWERS JIM;;ANDERSON MARK;;RADFORD STEVEN;;THOMPSON WILLIAM,,https://lens.org/048-691-566-967-147,Patent Application,no,0,0,6,6,0,E21B10/32;;E21B10/32,E21B10/46;;E21B10/54,,0,0,,,,DISCONTINUED
61,US,S,US D0708682 S,080-957-721-470-567,2014-07-08,2014,US 201329444184 F,2013-01-28,US 201329444184 F,2013-01-28,Device for varying range of motion for barbell exercise,,JAMES MADISON INNOVATIONS;;JAMES MADISON INNOVATIONS INC,JONES JUSTIN SCOTT;;ANDERSON COREY MARC;;DURNING JIM,ANDERSON COREY (2023-05-04);;JAMES MADISON INNOVATIONS (2013-01-16),https://lens.org/080-957-721-470-567,Design Right,no,0,11,1,1,0,,,2102;;D21/680,0,0,,,,ACTIVE
62,US,A,US 5785012 A,102-642-807-011-804,1998-07-28,1998,US 45425696 A,1996-03-11,US 45425696 A;;US 9210843 W,1992-12-15,Acoustically enhanced combustion method and apparatus,"A method and apparatus are provided for enhancing the efficiency of combustion in a combustion chamber with the use of acoustic energy. A means for generating acoustic energy (34) is located in relation to a combustion chamber (12) such that acoustic energy is transmitted into the combustion chamber (12) resulting in excitation of particulate and gases flowing therein and increased combustion efficiency. In the preferred embodiment, increased combustion efficiency is accomplished by operation of a horn (34) located at substantially the top of the combustion chamber (12) for generating acoustic energy into the chamber (12).",BHA GROUP HOLDINGS INC,PARSONS JIM;;SCHWAB JAMES JOSEPH;;ANDERSON MARLIN H,BHA ALTAIR LLC (2013-12-16);;BHA GROUP HOLDINGS INC (2004-11-18),https://lens.org/102-642-807-011-804,Granted Patent,yes,16,9,1,1,0,F23B7/00;;F23B7/00;;F23B5/02;;F23B5/02;;F23G2202/703;;F23G2202/703;;F23G2203/10;;F23G2203/10;;F23G2203/101;;F23G2203/101;;F23G2209/281;;F23G2209/281,F22B15/00;;F22B25/00;;F22B31/00;;F22B37/10,122/235.11;;X122  6 A;;431/1;;431/2,0,0,,,,EXPIRED
63,AU,A,AU 2000/037716 A,120-769-865-334-290,2000-10-09,2000,AU 2000/037716 A,2000-03-24,US 12608199 P;;US 49344800 A;;US 0007803 W,1999-03-25,Methods and apparatuses for interacting with members of a membership organization,,ALL ADVANTAGE COM INC,ANDERSON CARL;;BROCK OLIVER;;JORGENSEN JIM;;POHLE JOHANNES,,https://lens.org/120-769-865-334-290,Patent Application,no,0,0,3,6,0,G06Q30/02,G06Q30/00,,0,0,,,,DISCONTINUED
64,US,B2,US 9264091 B2,003-071-813-864-971,2016-02-16,2016,US 201214346103 A,2012-09-14,US 201214346103 A;;EP 11182531 A;;US 201161539227 P;;SE 2012050972 W,2011-09-23,Mixer unit,"A mixer unit ( 30 ) for frequency translating, based on an LO signal, an input signal having one or more input signal components is disclosed. The mixer unit has a signal processing path ( 50 a - d, 60 a - d ) from each Input terminal ( 32+, 32 −) to each output terminal ( 34 _I+, 34 _I−, 34 _Q+, 34 _Q−) of the mixer unit ( 30 ), The LO signal has an associated LO signal component (LO_Ia-d, LO_Qa-d) for each signal processing path. The mixer unit ( 30 ) comprises a plurality of mixer switches ( 70 a -N) and a control unit ( 90 ). The control unit ( 90 ) is adapted to, for each signal processing path ( 50 a - d, 60 a - d ), dynamically select an associated subset, in the following denoted active switch subset, of the plurality of mixer switches ( 70 a -N) for operation in the signal processing path ( 50 a - d, 60 a˜d ) such that which of the plurality of mixer switches ( 70 a -N) belong to said active switch subset varies in time. At any instant in time, the union of all the active switch subsets is a strict subset, denoted combined active subset, of the plurality of mixer switches ( 70 a -N). The control unit ( 90 ) is further adapted to activate only the mixer switches ( 70 a -N) in said combined active subset by, for each mixer switch ( 70 a -N) in the combined active subset, supplying the corresponding LO signal component to the mixer switch. A related radio receiver circuit ( 10 ), a related radio communication apparatus ( 1, 2 ), and a related method are also disclosed.",ANDERSON MARTIN;;SJÖLAND HENRIK;;SUNDSTRÖM LARS;;SVENSSON JIM;;ERICSSON TELEFON AB L M,ANDERSON MARTIN;;SJÖLAND HENRIK;;SUNDSTRÖM LARS;;SVENSSON JIM,TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) (2014-03-24),https://lens.org/003-071-813-864-971,Granted Patent,yes,26,0,6,6,0,H03D7/165;;H03D7/18;;H03D7/1458;;H03D7/1466;;H03D7/165;;H03D7/18;;H04B1/405;;H04L27/12,H04B1/26;;H03D7/16;;H03D7/18;;H04B1/405;;H04L27/12,,1,1,095-791-506-242-593,10.1109/4.890307,"Bautista, E. E. et al., ""A High IIP2 Downconversion Mixer Using Dynamic Matching,"" IEEE Journal of Solid-State Circuits. Dec. 2000. pp. 1934-1941. vol. 35, No. 12.",ACTIVE
65,US,A1,US 2015/0110161 A1,004-137-449-502-75X,2015-04-23,2015,US 201214346103 A,2012-09-14,US 201214346103 A;;EP 11182531 A;;US 201161539227 P;;SE 2012050972 W,2011-09-23,Mixer Unit,"A mixer unit ( 30 ) for frequency translating, based on an LO signal, an input signal having one or more input signal components is disclosed. The mixer unit has a signal processing path ( 50 a - d, 60 a - d ) from each Input terminal ( 32+, 32 −) to each output terminal ( 34 _I+, 34 _I−, 34 _Q+, 34 _Q−) of the mixer unit ( 30 ), The LO signal has an associated LO signal component (LO_Ia-d, LO_Qa-d) for each signal processing path. The mixer unit ( 30 ) comprises a plurality of mixer switches ( 70 a -N) and a control unit ( 90 ). The control unit ( 90 ) is adapted to, for each signal processing path ( 50 a - d, 60 a - d ), dynamically select an associated subset, in the following denoted active switch subset, of the plurality of mixer switches ( 70 a -N) for operation in the signal processing path ( 50 a - d, 60 a˜d ) such that which of the plurality of mixer switches ( 70 a -N) belong to said active switch subset varies in time. At any instant in time, the union of all the active switch subsets is a strict subset, denoted combined active subset, of the plurality of mixer switches ( 70 a -N). The control unit ( 90 ) is further adapted to activate only the mixer switches ( 70 a -N) in said combined active subset by, for each mixer switch ( 70 a -N) in the combined active subset, supplying the corresponding LO signal component to the mixer switch. A related radio receiver circuit ( 10 ), a related radio communication apparatus ( 1, 2 ), and a related method are also disclosed.",ANDERSON MARTIN;;SJÖLAND HENRIK;;SUNDSTRÖM LARS;;SVENSSON JIM;;ERICSSON TELEFON AB L M,ANDERSON MARTIN;;SJÖLAND HENRIK;;SUNDSTRÖM LARS;;SVENSSON JIM,TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) (2014-03-24),https://lens.org/004-137-449-502-75X,Patent Application,yes,18,2,6,6,0,H03D7/165;;H03D7/18;;H03D7/1458;;H03D7/1466;;H03D7/165;;H03D7/18;;H04B1/405;;H04L27/12,H04B1/405;;H04L27/12,375/219,0,0,,,,ACTIVE
66,EP,A4,EP 2384387 A4,118-253-186-166-054,2015-03-25,2015,EP 10736459 A,2010-01-29,US 2010/0022540 W;;US 14869509 P,2009-01-30,"METHODS, SYSTEMS, AND TOOL ASSEMBLIES FOR DISTRIBUTING WEIGHT-ON-BIT BETWEEN A PILOT EARTH-BORING ROTARY DRILL BIT AND A REAMER DEVICE",,BAKER HUGHES INC,RADFORD STEVEN;;ANDERSON MARK;;THOMPSON WILLIAM;;POWERS JIM,,https://lens.org/118-253-186-166-054,Search Report,no,2,0,6,6,0,E21B10/32;;E21B10/32,E21B10/46;;E21B10/26;;E21B10/54,,2,1,057-732-169-505-816,10.2118/112647-ms,"IAN THOMSON ET AL: ""IADC/SPE 112647 A Systematic Approach to a Better Understanding of the Concentric Hole- Opening Process Utilizing Drilling Mechanics and Drilling Dynamics Measurements Recorded Above and Below the Reamer"", 4 March 2008 (2008-03-04), XP055168692, Retrieved from the Internet <URL:https://www.onepetro.org/download/conference-paper/SPE-112647-MS?id=conference-paper/SPE-112647-MS> [retrieved on 20150210];;See also references of WO 2010088489A1",DISCONTINUED
67,WO,A1,WO 2019/117900 A1,116-355-308-330-663,2019-06-20,2019,US 2017/0066209 W,2017-12-13,US 2017/0066209 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A flow distribution may be monitored to one or more clusters of perforations. Plugging criteria may be identified based on the flow distribution and characteristics associated with perforation plugs to be dropped into a wellbore associated with the subsurface formation may be determined based on the flow distribution, characteristics of the one or more clusters, and the plugging objective. The perforation plugs may be dropped into the wellbore. The perforation plugs may have tracers which indicate whether the perforation plugs reached a location associated with the one or more clusters.",HALLIBURTON ENERGY SERVICES INC,INYANG UBONG;;CAMP JOSHUA;;ANDERSON TYLER;;SURJAATMADJA JIM,,https://lens.org/116-355-308-330-663,Patent Application,yes,5,0,6,6,0,E21B33/13;;E21B47/10;;E21B47/11;;E21B47/11;;E21B33/13;;E21B47/10,E21B33/13;;E21B33/12;;E21B47/10,,0,0,,,,PENDING
68,IN,A,IN 2085DEN2014 A,141-380-786-720-472,2015-05-15,2015,IN 2085DEN2014 A,2014-03-20,EP 11182531 A;;US 201161539227 P;;SE 2012050972 W,2011-09-23,MIXER UNIT,A mixer unit (30) for frequency translating based on an LO signal an input signal having one or more input signal components is disclosed. The mixer unit has a signal processing path (50a d 60a d) from each Input terminal (32+ 32 ) to each output terminal (34_I+ 34_ I 34_Q+ 34_Q ) of the mixer unit (30) The LO signal has an associated LO signal component (LO_Ia d LO_Qa d) for each signal processing path. The mixer unit (30) comprises a plurality of mixer switches (70a ) and a control unit (90). The control unit (90) is adapted to for each signal processing path (50a d 60a d) dynamically select an associated subset in the following denoted active switch subset of the plurality of mixer switches (70a ) for operation in the signal processing path (50a d 60a~d) such that which of the plurality of mixer switches (70a N) belong to said active switch subset varies in time. At any instant in time the union of all the active switch subsets is a strict subset denoted combined active subset of the plurality of mixer switches (70a ). The control unit (90) is further adapted to activate only the mixer switches (70a ) in said combined active subset by for each mixer switch (70a ) in the combined active subset supplying the corresponding LO signal component to the mixer switch. A related radio receiver circuit (10) a related radio communication apparatus (1 2) and a related method are also disclosed.,ERICSSON TELEFON AB L M,SJÖLAND HENRIK;;SUNDSTRÖM LARS;;ANDERSON MARTIN;;SVENSSON JIM,,https://lens.org/141-380-786-720-472,Patent Application,no,0,0,6,6,0,H03D7/165;;H03D7/18;;H03D7/1458;;H03D7/1466;;H03D7/165;;H03D7/18;;H04B1/405;;H04L27/12,H03D7/14,,0,0,,,,PENDING
69,US,A1,US 2005/0137933 A1,021-701-553-273-281,2005-06-23,2005,US 74546803 A,2003-12-22,US 74546803 A,2003-12-22,Manifest generation and download systems and methods,"The present invention is directed to systems and methods to generate a manifest of work that is to be performed by a driver. Specifically, systems and methods are described in the context of a package delivery system to generate a manifest of deliveries and pickups to be performed by a driver and to download the generated manifest to a portable computing device used by the driver to service the route.",UNITED PARCEL SERVICE INC,HOLSEN JIM;;ANDERSON DUANE;;PEREZ JUAN;;DAVIDSON MARK,UNITED PARCEL SERVICE OF AMERICA INC (2004-04-21),https://lens.org/021-701-553-273-281,Patent Application,yes,24,59,5,5,0,G06Q10/08;;G06Q10/08;;G06Q10/08355;;G06Q10/08355,G06F9/06,705/10,0,0,,,,EXPIRED
70,WO,A1,WO 2010/088489 A1,108-062-014-017-998,2010-08-05,2010,US 2010/0022540 W,2010-01-29,US 14869509 P,2009-01-30,"METHODS, SYSTEMS, AND TOOL ASSEMBLIES FOR DISTRIBUTING WEIGHT-ON-BIT BETWEEN A PILOT EARTH-BORING ROTARY DRILL BIT AND A REAMER DEVICE","Methods, systems, and tool assemblies for distributing weight between a bit and a reamer device are disclosed. For example, at least one of the drill bit and the reamer may be configured to selectively distribute a weight-on-bit between the drill bit and the reamer, such as within a predetermined range. Additionally, methods of drilling wellbores may include selectively distributing a weight-on-bit applied to a bottom hole assembly between a drill bit and a reamer of the bottom hole assembly. Also, a reamer may be configured to exhibit a first maximum rate-of-penetration into a relatively hard formation, and a drill bit may be configured to exhibit a second maximum rate-of-penetration into a relatively soft formation that is less than the first maximum rate-of-penetration.",BAKER HUGHES INC;;RADFORD STEVEN;;ANDERSON MARK;;THOMPSON WILLIAM;;POWERS JIM,RADFORD STEVEN;;ANDERSON MARK;;THOMPSON WILLIAM;;POWERS JIM,,https://lens.org/108-062-014-017-998,Patent Application,yes,4,0,6,6,0,E21B10/32;;E21B10/32,E21B10/46;;E21B10/54,,1,0,,,See also references of EP 2384387A4,PENDING
71,WO,A2,WO 2013/043106 A2,096-156-970-960-015,2013-03-28,2013,SE 2012050972 W,2012-09-14,EP 11182531 A;;US 201161539227 P,2011-09-23,MIXER UNIT,"A mixer unit (30) for frequency translating, based on an LO signal, an input signal having one or more input signal components is disclosed. The mixer unit has a signal processing path (50a-d, 60a-d) from each Input terminal (32+, 32-) to each output terminal (34_I+, 34_ I-, 34_Q+,34_Q—) of the mixer unit (30), The LO signal has an associated LO signal component (LO_Ia-d, LO_Qa-d) for each signal processing path. The mixer unit (30) comprises a plurality of mixer switches (70a- N ) and a control unit (90). The control unit (90) is adapted to, for each signal processing path (50a-d, 60a-d), dynamically select an associated subset, in the following denoted active switch subset, of the plurality of mixer switches (70a- N ) for operation in the signal processing path (50a-d, 60a~d) such that which of the plurality of mixer switches (70a-N) belong to said active switch subset varies in time. At any instant in time, the union of all the active switch subsets is a strict subset, denoted combined active subset, of the plurality of mixer switches (70a- N ). The control unit (90) is further adapted to activate only the mixer switches (70a- N ) in said combined active subset by, for each mixer switch (70a- N ) in the combined active subset, supplying the corresponding LO signal component to the mixer switch. A related radio receiver circuit (10), a related radio communication apparatus (1, 2), and a related method are also disclosed.",ERICSSON TELEFON AB L M;;SJOELAND HENRIK;;SUNDSTROEM LARS;;ANDERSON MARTIN;;SVENSSON JIM,SJOELAND HENRIK;;SUNDSTROEM LARS;;ANDERSON MARTIN;;SVENSSON JIM,,https://lens.org/096-156-970-960-015,Patent Application,yes,0,0,6,6,0,H03D7/165;;H03D7/18;;H03D7/1458;;H03D7/1466;;H03D7/165;;H03D7/18;;H04B1/405;;H04L27/12,H04B1/04,,0,0,,,,PENDING
72,US,A,US 5628814 A,045-481-618-792-189,1997-05-13,1997,US 56167195 A,1995-11-22,US 56167195 A;;US 36563194 A,1994-12-28,Coated nickel-base superalloy article and powder and method useful in its preparation,"A nickel-base superalloy article has a coating having a composition, in weight percent, of from about 10 to about 20 percent cobalt, from about 14 to about 25 percent chromium, from about 2 to about 12 percent aluminum, from 0 to about 0.2 percent yttrium, from about 0.001 to about 3 percent boron, from about 1 to about 10 percent silicon, balance nickel and incidental impurities. The coating is preferably applied by mixing together two powders, one with a higher solidus temperature and one with a lower solidus temperature, whose net composition is that of the coating. The powder mixture is compacted with a binder, applied to a surface of the article, and heated to a temperature above the lower solidus temperature.",GEN ELECTRIC,REEVES JIM D;;BUDINGER DAVID E;;ANDERSON ROBERT A,,https://lens.org/045-481-618-792-189,Granted Patent,yes,8,51,3,3,0,B22F7/062;;B23K35/0244;;B23K35/025;;B23K35/304;;C23C24/10;;C23C24/106;;C23C26/02;;C23C30/00;;Y10T428/12028;;Y10T428/12063;;B22F1/09;;Y10T428/12028;;Y10T428/12063;;C23C24/106;;B22F7/062;;B23K35/304;;C23C24/10;;C23C30/00;;B23K35/0244;;B23K35/025;;C23C26/02;;B22F1/09,B22F1/00;;B22F7/06;;B23K35/02;;B23K35/30;;C23C24/10;;C23C26/02;;C23C30/00,75/255;;420/443;;420/445;;420/460,0,0,,,,EXPIRED
73,US,A,US 5010807 A,031-052-017-038-611,1991-04-30,1991,US 55349090 A,1990-07-17,US 55349090 A,1990-07-17,Ravioli machine,A ravioli machine having improved means for feeding and dispensing filling material is disclosed. The machine includes a reciprocating slide bar dispenser mounted adjacent a die roll for accurately depositing metered amounts of filling material into dough-lined mold cavities in the die roll. A flighted screw conveyor is provided for the transfer of filling material from a storage hopper to the slide bar dispenser.,NESTEC SA,ANDERSON JIM L;;BELTZ TERRY W;;TAYLOR RAYMOND E,NESTEC S.A. A CORP. OF THE SWISS CONFEDERATION (1990-07-03),https://lens.org/031-052-017-038-611,Granted Patent,yes,10,13,1,1,0,A21C9/066;;A21C9/066,A21C9/06,99/450.6;;99/450.2;;99/450.7,0,0,,,,EXPIRED
74,US,A,US 5705281 A,180-723-594-114-386,1998-01-06,1998,US 56167095 A,1995-11-22,US 56167095 A;;US 36563194 A,1994-12-28,Coated nickel-base superalloy article and powder and method useful in its preparation,"A nickel-base superalloy article has a coating having a composition, in weight percent, of from about 10 to about 20 percent cobalt, from about 14 to about 25 percent chromium, from about 2 to about 12 percent aluminum, from 0 to about 0.2 percent yttrium, from about 0.001 to about 3 percent boron, from about 1 to about 10 percent silicon, balance nickel and incidental impurities. The coating is preferably applied by mixing together two powders, one with a higher solidus temperature and one with a lower solidus temperature, whose net composition is that of the coating. The powder mixture is compacted with a binder, applied to a surface of the article, and heated to a temperature above the lower solidus temperature.",GEN ELECTRIC,REEVES JIM D;;BUDINGER DAVID E;;ANDERSON ROBERT A,,https://lens.org/180-723-594-114-386,Granted Patent,yes,7,26,3,3,0,B22F7/062;;B23K35/0244;;B23K35/025;;B23K35/304;;C23C24/10;;C23C24/106;;C23C26/02;;C23C30/00;;Y10T428/12028;;Y10T428/12063;;B22F1/09;;Y10T428/12028;;Y10T428/12063;;C23C24/106;;B22F7/062;;B23K35/304;;C23C24/10;;C23C30/00;;B23K35/0244;;B23K35/025;;C23C26/02;;B22F1/09,B22F1/00;;B22F7/06;;B23K35/02;;B23K35/30;;C23C24/10;;C23C26/02;;C23C30/00,428/553;;428/548,0,0,,,,EXPIRED
75,US,A,US 5523170 A,071-962-589-564-223,1996-06-04,1996,US 36491594 A,1994-12-28,US 36491594 A,1994-12-28,Repaired article and material and method for making,"An article with a high temperature superalloy body having a directionally oriented microsuucture and a structural discontinuity, such as a crack, or surface erosion or wear portion, is repaired, to provide a repaired article, using a mixture of Ni base ahoy powders. One powder includes a careful balance of the temperature depressants Si and B. In the one powder, Si is included in the range of about 0.05-2.2 wt. % to provide about 0.02-1.3 wt. % Si in a repaired portion as bonded with the article. In that same powder, B is include in the range of about 0.2-1.2 wt. % to provide about 0.08-0.7 wt. % in that repaired portion. In the repair method, the repaired portion can be provided, when shorter brazing times are used, with improved mechanical properties by diffusing the brazed alloy and aging the repaired structure in the range of about 1600.degree.-1700.degree. F. for a time in the range of about 1-16 hours.",GEN ELECTRIC,BUDINGER DAVID E;;REEVES JIM D;;ANDERSON ROBERT A,GENERAL ELECTRIC COMPANY (1994-12-21),https://lens.org/071-962-589-564-223,Granted Patent,yes,10,63,1,1,0,B23K35/0244;;B23K35/3033;;B32B15/01;;C22C1/0433;;C22C19/056;;C22C19/057;;Y10T428/12139;;Y10T428/12049;;Y10T428/12056;;Y10T428/12063;;Y10T428/12139;;Y10T428/12049;;Y10T428/12056;;Y10T428/12063;;B32B15/01;;C22C19/056;;C22C1/0433;;B23K35/3033;;C22C19/057;;B23K35/0244,B23K35/02;;B23K35/30;;C22C1/04,428/551;;75/255;;419/54;;419/8;;419/9;;419/60;;428/552;;428/553;;428/564,0,0,,,,EXPIRED
76,US,S,US D0866604 S,120-593-546-506-87X,2019-11-12,2019,US 201829654846 F,2018-06-28,US 201829654846 F,2018-06-28,Adjustable pump,,ANDERSON MARK L,WAIT JIM;;HARMON JOHN;;ANDERSON MARK L;;ROBBINS CLENT,ANDERSON MARK L (2018-07-09),https://lens.org/120-593-546-506-87X,Design Right,no,7,3,3,3,0,,,1502;;D15/7;;D23/231,0,0,,,,ACTIVE
77,US,A,US 5561827 A,191-119-270-022-504,1996-10-01,1996,US 36563194 A,1994-12-28,US 36563194 A,1994-12-28,Coated nickel-base superalloy article and powder and method useful in its preparation,"A nickel-base superalloy article has a coating having a composition, in weight percent, of from about 10 to about 20 percent cobalt, from about 14 to about 25 percent chromium, from about 2 to about 12 percent aluminum, from 0 to about 0.2 percent yttrium, from about 0.001 to about 3 percent boron, from about 1 to about 10 percent silicon, balance nickel and incidental impurities. The coating is preferably applied by mixing together two powders, one with a higher solidus temperature and one with a lower solidus temperature, whose net composition is that of the coating. The powder mixture is compacted with a binder, applied to a surface of the article, and heated to a temperature above the lower solidus temperature.",GEN ELECTRIC,REEVES JIM D;;BUDINGER DAVID E;;ANDERSON ROBERT A,GENERAL ELECTRIC COMPANY (1994-12-21),https://lens.org/191-119-270-022-504,Granted Patent,yes,5,67,3,3,0,B22F7/062;;B23K35/0244;;B23K35/025;;B23K35/304;;C23C24/10;;C23C24/106;;C23C26/02;;C23C30/00;;Y10T428/12028;;Y10T428/12063;;B22F1/09;;Y10T428/12028;;Y10T428/12063;;C23C24/106;;B22F7/062;;B23K35/304;;C23C24/10;;C23C30/00;;B23K35/0244;;B23K35/025;;C23C26/02;;B22F1/09,B22F1/00;;B22F7/06;;B23K35/02;;B23K35/30;;C23C24/10;;C23C26/02;;C23C30/00,419/5;;419/8;;419/9;;419/10;;419/11;;419/12;;419/32;;419/39,0,0,,,,EXPIRED
78,US,S,US D0904485 S,157-977-224-030-675,2020-12-08,2020,US 201829647196 F,2018-05-10,US 201829647196 F,2018-05-10,Mobile device camera adapter,,ANDERSON MARK L,ROBBINS CLENT;;BATTLE BOB;;WAIT JIM;;ANDERSON MARK L,ANDERSON MARK L (2018-05-25),https://lens.org/157-977-224-030-675,Design Right,no,13,0,3,3,0,,,1601;;D16/208,0,0,,,,ACTIVE
79,WO,A1,WO 1997/039280 A1,060-385-918-783-763,1997-10-23,1997,SE 9700597 W,1997-04-10,SE 9601392 A,1996-04-12,A METHOD OF COMBUSTION AND A COMBUSTION PLANT FOR BURNING A COMPLEMENTARY FUEL IN THE FREE-BOARD OF A PRESSURIZED FLUIDIZED BED,"The invention relates to a method of combustion and a combustion plant. During the combustion in a combustion chamber (1) enclosing a pressurized fluidized bed and a space (7) located above the bed, an oxygen-containing gas is fed into the bed (4), a particulate fuel is supplied to the bed (4) and the combustion gases formed in said space during the combustion are collected. These are discharged from the combustion chamber (1) and solid material is separated from said combustion gases by means of a separating member (9). The separated solid material is recirculated (23) to the combustion chamber and a complementary fuel is supplied to said space (7) via a fuel supply member (40) for the combustion thereof in said collected combustion gases.",ABB CARBON AB;;ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/060-385-918-783-763,Patent Application,yes,6,2,7,7,0,F23J7/00;;F23J7/00;;F01K23/062;;F01K23/062;;F23C6/047;;F23C6/047;;F23C10/10;;F23C10/10;;F23C10/16;;F23C10/16,F23C10/22;;F01K23/06;;F23C6/04;;F23C10/10;;F23C10/16;;F23J7/00,,0,0,,,,PENDING
80,US,B1,US 6260492 B1,140-206-296-384-330,2001-07-17,2001,US 17101298 A,1998-12-22,SE 9601392 A;;SE 9700597 W,1996-04-12,Method and apparatus for burning fuel in the free board of a pressurized fluidized bed with solids recirculation,"A method of combustion in a pressurized, fluidized bed and in the freeboard thereof. The combustion method is further characterized by the recirculation of solid sulfur absorbing materials. A gas channel, designed so as to prevent fluidizing gas from entering the channel from below, is provided such that it opens to the freeboard and to a separating member which separates particulate matter from the combustion gasses.",ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,ALSTOM POWER CARBON AB (2000-07-13);;GENERAL ELECTRIC TECHNOLOGY GMBH (2012-08-02);;ALSTOM POWER SWEDEN AB (2008-02-20),https://lens.org/140-206-296-384-330,Granted Patent,yes,15,4,7,7,0,F23J7/00;;F23J7/00;;F01K23/062;;F01K23/062;;F23C6/047;;F23C6/047;;F23C10/10;;F23C10/10;;F23C10/16;;F23C10/16,F23C10/22;;F01K23/06;;F23C6/04;;F23C10/10;;F23C10/16;;F23J7/00,110/348;;110/212;;110/245;;110/262;;110/347;;110/344;;431/7;;422/139;;422/234;;422/145,0,0,,,,EXPIRED
81,US,B1,US 6557639 B1,030-108-834-365-034,2003-05-06,2003,US 68456600 A,2000-10-07,CA 2286823 A,1999-10-18,Apparatus and method for pumping fluids for use with a downhole rotary pump,"
    An apparatus and method for pumping fluids in a wellbore. The apparatus includes a pipe string in the wellbore extending between a wellhead end and a production end, the pipe string defining an interior fluid path. A swivel device is connected into the pipe string so that an upper portion of the pipe string rotates relative to a lower portion thereof. A lower connector connects the lower portion with a stator of a rotary pump such that a fluid pumped by the pump is conducted through the interior fluid path of the pipe string. An upper connector connects the upper portion with a rotor of the rotary pump such that rotation of the upper portion rotates the rotor and thus pumps the fluid. The method includes rotatably supporting the upper portion in the wellbore at the wellhead end, connecting the lower portion with the stator, connecting the upper portion with the rotor, positioning the pump in the wellbore and rotating the upper portion in order to rotate the rotor to pump the fluid. 
",INNOVATIVE PRODUCTION TECHNOLO,MATTHEWS ED;;ANDERSON GARY;;DEUGO SHAWN;;ANAKA JIM;;PATON MEL,INNOVATIVE PRODUCTION TECHNOLOGIES LTD (2000-10-02),https://lens.org/030-108-834-365-034,Granted Patent,yes,12,23,3,3,0,F04C13/008;;E21B43/126;;F04C13/008;;E21B43/126,E21B43/12;;F04C13/00,166/369;;166/68.5;;166/73;;166/105;;417/374,0,0,,,,EXPIRED
82,WO,A1,WO 1997/039282 A1,044-748-504-084-225,1997-10-23,1997,SE 9700599 W,1997-04-10,SE 9601394 A,1996-04-12,"A FLUIDIZED BED COMBUSTION PLANT, EQUIPPED WITH MEANS FOR DISTRIBUTING RECIRCULATED MATERIAL IN THE BED","A combustion plant comprises a combustion chamber (1) which is provided to enclose a fluidized bed (4) and in which a combustion of a fuel is intended to be performed while forming combustion gases. Furthermore, the plant comprises a purification device (9, 10, 11) for purifying said combustion gases. The purification device comprises a separating member (9), arranged to separate particulate material from said combustion gases, and a channel (23) connecting the separating member and the combustion chamber (1) and being arranged to recirculate the separated material to the combustion chamber (1) in which at least one distributing member (4) is provided above the orifice of the recirculating channel (23) and is arranged to provide a distribution of the recirculated separated material in the bed (4).",ABB CARBON AB;;ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/044-748-504-084-225,Patent Application,yes,2,2,6,6,0,F23C10/10;;F23C10/16,F23C10/10;;F23C10/16,,0,0,,,,PENDING
83,US,A1,US 2011/0237271 A1,048-803-000-760-976,2011-09-29,2011,US 201113156075 A,2011-06-08,US 201113156075 A;;US 40577809 A;;US 19038305 A,2005-07-26,MULTI-MVNO WIRELESS SERVICE,"Systems and methods for determining an optimal range of frequencies of electromagnetic waves are described. In some embodiments, mobile voice communications devices measure average power received from certain ranges of such frequencies, each range associated with a communications service provider. A cost may be associated with each range. An optimal range of frequencies may be determined based on these factors. Each device may also receive a set of data identifying the location of the device. Each device may transmit one or more communications signals to a CIP with such measurements and location information, and some of this information may be stored in a database.",QWEST COMM INT INC,STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW,QWEST COMMUNICATIONS INTERNATIONAL INC (2005-08-28),https://lens.org/048-803-000-760-976,Patent Application,yes,61,0,6,6,0,H04W16/18;;H04W24/02;;H04W24/02;;H04W16/18,H04W4/24;;H04W72/00;;H04W16/18;;H04W24/02,455/450;;455/62,0,0,,,,ACTIVE
84,CA,A1,CA 2286823 A1,169-000-777-303-553,2001-04-18,2001,CA 2286823 A,1999-10-18,CA 2286823 A,1999-10-18,APPARATUS AND METHOD FOR PUMPING FLUIDS FOR USE WITH A DOWNHOLE ROTARY PUMP,"An apparatus and method for pumping fluids in a wellbore. The apparatus includes a pipe string in the wellbore extending between a wellhea d end and a production end, the pipe string defining an interior fluid path. A swivel device is connected into the pipe string so that an upper portion of the pipe string rotates relative to a lower portion thereof. A lower connector connects the lower portion wit h a stator of a rotary pump such that a fluid pumped by the pump is conducted through t he interior fluid path of the pipe string. An upper connector connects the uppe r portion with a rotor of the rotary pump such that rotation of the upper portion rotates the rotor and thus pumps the fluid. The method includes rotatably supporting the upper portion in the wellbore at the wellhead end, connecting the lower portion with the stator, connecting the upper portion with the rotor, positioning the pump in the wellbore and rotating the upper portion in order to rotate the rotor to pump the fluid.</ SDOAB>",MATTHEWS ED;;DEUGO SHAWN;;ANDERSON GARY;;PATON MEL;;ANAKA JIM,MATTHEWS ED;;DEUGO SHAWN;;ANDERSON GARY;;PATON MEL;;ANAKA JIM,,https://lens.org/169-000-777-303-553,Patent Application,no,0,1,3,3,0,F04C13/008;;E21B43/126;;F04C13/008;;E21B43/126,E21B43/12;;F04C13/00,,0,0,,,,EXPIRED
85,CA,C,CA 2286823 C,138-610-175-093-863,2002-05-07,2002,CA 2286823 A,1999-10-18,CA 2286823 A,1999-10-18,APPARATUS AND METHOD FOR PUMPING FLUIDS FOR USE WITH A DOWNHOLE ROTARY PUMP,"An apparatus and method for pumping fluids in a wellbore. The apparatus includes a pipe string in the wellbore extending between a wellhea d end and a production end, the pipe string defining an interior fluid path. A swivel device is connected into the pipe string so that an upper portion of the pipe string rotates relative to a lower portion thereof. A lower connector connects the lower portion wit h a stator of a rotary pump such that a fluid pumped by the pump is conducted through t he interior fluid path of the pipe string. An upper connector connects the uppe r portion with a rotor of the rotary pump such that rotation of the upper portion rotates the rotor and thus pumps the fluid. The method includes rotatably supporting the upper portion in the wellbore at the wellhead end, connecting the lower portion with the stator, connecting the upper portion with the rotor, positioning the pump in the wellbore and rotating the upper portion in order to rotate the rotor to pump the fluid.</ SDOAB>",ANAKA JIM;;PATON MEL;;DEUGO SHAWN;;MATTHEWS ED;;ANDERSON GARY,ANAKA JIM;;PATON MEL;;DEUGO SHAWN;;MATTHEWS ED;;ANDERSON GARY,,https://lens.org/138-610-175-093-863,Granted Patent,no,0,0,3,3,0,F04C13/008;;E21B43/126;;F04C13/008;;E21B43/126,E21B43/12;;F04C13/00,,0,0,,,,EXPIRED
86,US,B1,US 9958307 B1,021-416-229-279-961,2018-05-01,2018,US 201615143106 A,2016-04-29,US 201615143106 A;;US 201662277386 P,2016-01-11,Chemical dosing system,"A liquid dosing device for use with a liquid dispenser that includes a container for holding liquid in communication with a dispenser base, an outlet port for dispensing the liquid. The liquid dosing device includes a valve housing, a reservoir and a dosing cup. The valve housing is mounted to the dispenser base and includes an open top, an outlet port and a blocking region. The reservoir is mounted within the valve housing and includes at least one inlet port in communication with the dispenser base outlet port and at least one outlet port. The dosing cup is movably mounted within the valve housing in fluid communication with the reservoir and includes at least one inlet port in fluid communication with the reservoir outlet port, a blocking region, at least one outlet port and mechanism for moving the dosing cup between a fill position and a dose position to prevent spillage of the liquid being dispensed, or to dispense the liquid in defined quantities.",ANDERSON CHEMICAL COMPANY,ANDERSON LEIF;;ALSLEBEN JIM;;BREKKE JAMIE;;CARLSON ALEX;;REGENBRECHT KURT,ANDERSON CHEMICAL COMPANY (2016-04-22),https://lens.org/021-416-229-279-961,Granted Patent,yes,39,1,3,3,0,G01F11/22;;G01F11/22;;B08B3/08;;B67C11/04;;G01F11/44;;G01F15/005,G01F11/28;;B08B3/08;;B67C11/04;;G01F11/44;;G01F15/00,,0,0,,,,ACTIVE
87,WO,A8,WO 2019/117901 A8,044-884-136-498-163,2020-04-23,2020,US 2017/0066224 W,2017-12-13,US 2017/0066224 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria.",HALLIBURTON ENERGY SERVICES INC,MONTALVO JANETTE;;INYANG UBONG;;CAMP JOSHUA;;ANDERSON TYLER;;SURJAATMADJA JIM,,https://lens.org/044-884-136-498-163,Amended Application,yes,0,0,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,E21B43/25;;E21B47/10,,0,0,,,,PENDING
88,WO,A1,WO 2019/117901 A1,195-625-971-035-647,2019-06-20,2019,US 2017/0066224 W,2017-12-13,US 2017/0066224 W,2017-12-13,REEL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria.",HALLIBURTON ENERGY SERVICES INC,MONTALVO JANETTE;;INYANG UBONG;;CAMP JOSHUA;;ANDERSON TYLER;;SURJAATMADJA JIM,,https://lens.org/195-625-971-035-647,Patent Application,yes,5,1,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,E21B43/25;;E21B47/10,,0,0,,,,PENDING
89,US,B1,US 6389995 B1,011-114-918-142-067,2002-05-21,2002,US 17101198 A,1998-12-21,SE 9601393 A;;SE 9700598 W,1996-04-12,Method of combustion and a combustion plant in which absorbent is regenerated,"
    A method of combustion and a combustion plant in which absorbent is regenerated is described herein. During the combustion of a fuel in a combustion chamber enclosing a fluidized bed, a fuel and an absorbent are supplied to the fluidized bed. The combustion gases generated during the combustion are collected and purified in a separating member by separation of solid material from the combustion gases. The separated solid material is recirculated to the fluidized bed through a channel, and a gaseous medium is supplied in a controlled manner to the separated solid material present in the channel in order to displace the combustion gases and provide a chemical reaction. 
",ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,ALSTOM POWER CARBON AB (2000-07-13);;GENERAL ELECTRIC TECHNOLOGY GMBH (2012-08-02);;ALSTOM POWER SWEDEN AB (2008-02-20),https://lens.org/011-114-918-142-067,Granted Patent,yes,17,11,6,6,0,B01D53/34;;F23C10/10;;Y02E20/34;;F23C10/10;;B01D53/34,F23C10/18;;B01D53/34;;F23C10/02;;F23C10/10;;F23C10/16,110/245;;110/188;;110/204;;110/203;;110/248;;X122  4 D;;422/146;;422/147;;422/143,0,0,,,,EXPIRED
90,US,B2,US 8165584 B2,023-871-724-490-729,2012-04-24,2012,US 201113156075 A,2011-06-08,US 201113156075 A;;US 40577809 A;;US 19038305 A,2005-07-26,Multi-MVNO wireless service,"Systems and methods for determining an optimal range of frequencies of electromagnetic waves are described. In some embodiments, mobile voice communications devices measure average power received from certain ranges of such frequencies, each range associated with a communications service provider. A cost may be associated with each range. An optimal range of frequencies may be determined based on these factors. Each device may also receive a set of data identifying the location of the device. Each device may transmit one or more communications signals to a CIP with such measurements and location information, and some of this information may be stored in a database.",STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW;;QWEST COMMUNIATIONS INTERNATIONAL INC,STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW,QWEST COMMUNICATIONS INTERNATIONAL INC (2005-08-28),https://lens.org/023-871-724-490-729,Granted Patent,yes,61,0,6,6,0,H04W16/18;;H04W24/02;;H04W24/02;;H04W16/18,H04W4/24;;H04W4/00;;H04W16/18;;H04W24/02,455/435.2;;455/434;;455/552.1,6,0,,,"U.S. Appl. No. 11/190,383, Issue Notification dated Mar. 25, 2009; 1 page.;;U.S. Appl. No. 11/190,383, Notice of Allowance dated Sep. 10, 2008; 8 pages.;;U.S. Appl. No. 11/190,383, Office Action dated Mar. 18, 2008; 19 pages.;;U.S. Appl. No. 12/405,778, Issue Notification dated Jun. 15, 2011; 1 page.;;U.S. Appl. No. 12/405,778; Notice of Allowance dated Feb. 28, 2011; 17 pages.;;U.S. Appl. No. 12/405,778; Notice of Publication dated Jul. 16, 2009; 1 page.",ACTIVE
91,US,B2,US 7519353 B2,142-335-775-341-462,2009-04-14,2009,US 19038305 A,2005-07-26,US 19038305 A,2005-07-26,Multi-MVNO wireless service,"Systems and methods for determining an optimal range of frequencies of electromagnetic waves are described. In some embodiments, mobile voice communications devices measure average power received from certain ranges of such frequencies, each range associated with a communications service provider. A cost may be associated with each range. An optimal range of frequencies may be determined based on these factors. Each device may also receive a set of data identifying the location of the device. Each device may transmit one or more communications signals to a CIP with such measurements and location information, and some of this information may be stored in a database.",QWEST COMM INT INC,STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW,QWEST COMMUNICATIONS INTERNATIONAL INC (2005-08-28),https://lens.org/142-335-775-341-462,Granted Patent,yes,44,23,6,6,0,H04W16/18;;H04W24/02;;H04W24/02;;H04W16/18,H04M11/00;;H04W4/24;;H04W16/18;;H04W24/02,455/407;;455/405;;455/406;;455/408;;455/445;;455/552.1;;379/114.01,0,0,,,,ACTIVE
92,US,B2,US 7974601 B2,023-547-192-817-094,2011-07-05,2011,US 40577809 A,2009-03-17,US 40577809 A;;US 19038305 A,2005-07-26,Multi-MVNO wireless service,"Systems and methods for determining an optimal range of frequencies of electromagnetic waves are described. In some embodiments, mobile voice communications devices measure average power received from certain ranges of such frequencies, each range associated with a communications service provider. A cost may be associated with each range. An optimal range of frequencies may be determined based on these factors. Each device may also receive a set of data identifying the location of the device. Each device may transmit one or more communications signals to a CIP with such measurements and location information, and some of this information may be stored in a database.",QWEST COMM INT INC,STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW,QWEST COMMUNICATIONS INTERNATIONAL INC (2005-08-28),https://lens.org/023-547-192-817-094,Granted Patent,yes,50,1,6,6,0,H04W16/18;;H04W24/02;;H04W24/02;;H04W16/18,H04M11/00;;H04W4/24;;H04W16/18;;H04W24/02,455/406;;455/552.1;;455/456.2;;455/407;;379/114.01,2,0,,,"U.S. Appl. No. 11/190,383, Notice of Allowance dated Sep. 10, 2008, 8 pages.;;U.S. Appl. No. 11/190,383, Office Action dated Mar. 18, 2008, 19 pages.",ACTIVE
93,WO,A1,WO 1997/039279 A1,058-067-393-565-425,1997-10-23,1997,SE 9700596 W,1997-04-10,SE 9601391 A,1996-04-12,A METHOD OF COMBUSTION AND A COMBUSTION PLANT,"A fuel is combusted in a combustion plant having a combustion chamber (1) enclosing a bubbling fluidized bed (4) in which the combustion of a fuel is arranged to be performed while forming combustion gases. Furthermore, the plant comprises members (5) for feeding of a oxygen-containing gas from beneath to the bed (4), a tube arrangement (22) provided in the combustion chamber (1) and arranged to receive heat generated at the combustion, and a purification device (9, 10, 11) for purifying said combustion gases. The purification device comprises a separating member (9) arranged to separate particulate solid material from said combustion gases and a device (23) arranged to recirculate the separated material to the combustion chamber (1). Furthermore, means (41, 51, 47) are arranged to regulate the quantity of separated solid material supplied to the combustion chamber (1) in such a manner that the heat transfer to said tube arrangement (22) is controlled.",ABB CARBON AB;;ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/058-067-393-565-425,Patent Application,yes,7,1,4,4,0,F01K23/062;;F23C10/10,F01K23/06;;F23C10/10,,1,0,,,"PATENT ABSTRACTS OF JAPAN, Vol. 14, No. 447, M-1029; & JP,A,02 176 304, (MITSUI ENG & SHIPBUILD CO LTD), 9 July 1990.",PENDING
94,CA,C,CA 2928480 C,125-050-186-656-786,2019-03-05,2019,CA 2928480 A,2016-04-29,US 201662277386 P,2016-01-11,CHEMICAL DOSING SYSTEM,"A liquid dosing device including a container for holding liquid with an outlet port for dispensing the liquid, a valve housing, a reservoir and a dosing cup. The valve housing is mounted to a dispenser, having an open top, an outlet port and a blocking region. The reservoir is mounted within the valve housing and includes at least one outlet port and at least one inlet port in communication with the dispenser outlet port. The dosing cup is movably mounted within the valve housing in fluid communication with the reservoir and includes at least one inlet port in fluid communication with the reservoir outlet port, a blocking region, at least one outlet port and mechanism for moving the dosing cup between a fill position and a dose position to prevent spillage of the liquid being dispensed, or to dispense the liquid in defined quantities.",ANDERSON CHEMICAL COMPANY,ANDERSON LEIF;;ALSLEBEN JIM;;BREKKE JAMIE;;CARLSON ALEX;;REGENBRECHT KURT,,https://lens.org/125-050-186-656-786,Granted Patent,no,0,0,3,3,0,G01F11/22;;G01F11/22;;B08B3/08;;B67C11/04;;G01F11/44;;G01F15/005,G01F11/22,,0,0,,,,ACTIVE
95,WO,A1,WO 1997/039281 A1,197-219-397-914-813,1997-10-23,1997,SE 9700598 W,1997-04-10,SE 9601393 A,1996-04-12,A METHOD OF COMBUSTION AND A COMBUSTION PLANT IN WHICH ABSORBENT IS REGENERATED,This invention relates to a method of combustion and a combustion plant in which absorbent is regenerated. During the combustion of a fuel in a combustion chamber (1) enclosing a fluidized bed (4) a fuel and an absorbent are supplied to the bed (4). The combustion gases generated during the combustion are collected and purified in a separating member (9) by separation of solid material from said gases. The separated solid material is recirculated to the bed through a channel (23) and a gaseous medium is supplied in a controlled manner to the separated solid material (24) present in the channel (23) in order to displace the combustion gases and provide a chemical reaction.,ABB CARBON AB;;ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/197-219-397-914-813,Patent Application,yes,7,0,6,6,0,B01D53/34;;F23C10/10;;Y02E20/34;;F23C10/10;;B01D53/34,F23C10/18;;B01D53/34;;F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,PENDING
96,CA,A1,CA 2928480 A1,109-375-450-811-251,2017-07-11,2017,CA 2928480 A,2016-04-29,US 201662277386 P,2016-01-11,CHEMICAL DOSING SYSTEM,"The present invention relates to liquid dispensers and particularly, to dispensers of liquid chemical in defined quantities.",ANDERSON CHEMICAL COMPANY,ANDERSON LEIF;;ALSLEBEN JIM;;BREKKE JAMIE;;CARLSON ALEX;;REGENBRECHT KURT,,https://lens.org/109-375-450-811-251,Patent Application,no,0,1,3,3,0,G01F11/22;;G01F11/22;;B08B3/08;;B67C11/04;;G01F11/44;;G01F15/005,G01F11/22,,0,0,,,,ACTIVE
97,US,A1,US 2009/0182768 A1,112-000-564-554-270,2009-07-16,2009,US 40577809 A,2009-03-17,US 40577809 A;;US 19038305 A,2005-07-26,MULTI-MVNO WIRELESS SERVICE,"Systems and methods for determining an optimal range of frequencies of electromagnetic waves are described. In some embodiments, mobile voice communications devices measure average power received from certain ranges of such frequencies, each range associated with a communications service provider. A cost may be associated with each range. An optimal range of frequencies may be determined based on these factors. Each device may also receive a set of data identifying the location of the device. Each device may transmit one or more communications signals to a CIP with such measurements and location information, and some of this information may be stored in a database.",QWEST COMM INT INC,STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW,QWEST COMMUNICATIONS INTERNATIONAL INC (2005-08-28),https://lens.org/112-000-564-554-270,Patent Application,yes,7,15,6,6,0,H04W16/18;;H04W24/02;;H04W24/02;;H04W16/18,G06F17/30;;H04W4/00;;H04W4/24;;H04W16/18;;H04W24/02,707/102;;455/407;;370/328;;X707E17005,0,0,,,,ACTIVE
98,US,A1,US 2007/0026853 A1,177-045-663-314-165,2007-02-01,2007,US 19038305 A,2005-07-26,US 19038305 A,2005-07-26,Multi-MVNO wireless service,"Systems and methods for determining an optimal range of frequencies of electromagnetic waves are described. In some embodiments, mobile voice communications devices measure average power received from certain ranges of such frequencies, each range associated with a communications service provider. A cost may be associated with each range. An optimal range of frequencies may be determined based on these factors. Each device may also receive a set of data identifying the location of the device. Each device may transmit one or more communications signals to a CIP with such measurements and location information, and some of this information may be stored in a database.",QWEST COMM INT INC,STEVENS GILMAN;;GIBSON MICHAEL;;ANDERSON JIM;;CERAMI RICH;;WHITE ANDREW,QWEST COMMUNICATIONS INTERNATIONAL INC (2005-08-28),https://lens.org/177-045-663-314-165,Patent Application,yes,44,9,6,6,0,H04W16/18;;H04W24/02;;H04W24/02;;H04W16/18,H04W4/24;;H04W16/18;;H04W24/02,455/423,0,0,,,,ACTIVE
99,SA,B1,SA 520411600 B1,009-420-571-899-645,2023-02-19,2023,SA 520411600 A,2020-03-24,US 2017/0066209 W,2017-12-13,Real-Time Perforation Plug Deployment and Stimulation in A Subsurface Formation,"A flow distribution may be monitored to one or more clusters of perforations. Plugging criteria may be identified based on the flow distribution and characteristics associated with perforation plugs to be dropped into a wellbore associated with the subsurface formation may be determined based on the flow distribution, characteristics of the one or more clusters, and the plugging objective. The perforation plugs may be dropped into the wellbore. The perforation plugs may have tracers which indicate whether the perforation plugs reached a location associated with the one or more clusters. Fig 3.",HALLIBURTON ENERGY SERVICES INC,TYLER AUSTEN ANDERSON;;JOSHUA LANE CAMP;;JIM BASUKI SURJAATMADJA;;UBONG INYANG,,https://lens.org/009-420-571-899-645,Granted Patent,no,0,0,6,6,0,E21B33/13;;E21B47/10;;E21B47/11;;E21B47/11;;E21B33/13;;E21B47/10,,,0,0,,,,ACTIVE
100,CA,C,CA 2642098 C,127-115-862-894-577,2014-04-08,2014,CA 2642098 A,2007-02-16,US 74331806 P;;US 74749606 P;;US 82888806 P;;US 2007/0004062 W,2006-02-17,PROVIDING ALTERNATIVE PERSISTENT STATE RECOVERY TECHNIQUES,"This document discusses, among other things, systems and methods for alternative persistent state recovery methods. A method comprises detecting persistent state recovery information from one of two or more persistent state recovery techniques, wherein the persistent state recovery information identifies a persistent state in a wagering game; and restoring the persistent state of the wagering game from the detected persistent state recovery information.",WMS GAMING INC,ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,,https://lens.org/127-115-862-894-577,Granted Patent,no,0,0,6,7,0,G07F17/32;;G07F17/32,A63F9/24;;A63F3/06;;G06Q50/34,,0,0,,,,INACTIVE
101,SE,D0,SE 9601394 D0,137-303-803-420-516,1996-04-12,1996,SE 9601394 A,1996-04-12,SE 9601394 A,1996-04-12,Förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/137-303-803-420-516,Patent Application,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/10;;F23C10/16,,0,0,,,,EXPIRED
102,SE,L,SE 9601393 L,156-917-648-864-525,1997-10-13,1997,SE 9601393 A,1996-04-12,SE 9601393 A,1996-04-12,Förfarande för förbränning och förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/156-917-648-864-525,Abstract,no,0,0,6,6,0,B01D53/34;;F23C10/10;;Y02E20/34;;F23C10/10;;B01D53/34,F23C10/18;;B01D53/34;;F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,PENDING
103,US,A,US 5349730 A,152-589-439-489-591,1994-09-27,1994,US 2879193 A,1993-03-09,US 2879193 A,1993-03-09,Mehtod and apparatus for assembling blinds,"A method and apparatus for assembling blinds includes a punching and cutting station, an outfeed station and a lacing stating having a plurality of lacing towers. A guide cable extends between adjacent lacing towers for guiding transported slats. A pivoted backstop at a downstream end of the lacing station yieldingly arrests the motion of incoming slats. The outfeed station of the apparatus includes a continuously driven outfeed drive roller and an opposed pinch roller which may be selectively urged against the drive roller so as to drive a slat out of the outfeed station. Each lacing tower of the apparatus includes a spring-biased spreader which provides longitudinal tension to a tape ladder while preventing longitudinal stringers of the ladder from converging upon each other. The method of the present invention includes operating the apparatus to automatically learn the selected length and arrangement of the blind and to subsequently automatically manufacture a blind to those specifications.",HUNTER DOUGLAS,ANDERSON RICHARD N;;HURT DAN;;BURTNETT DAVE;;GASKINS JAY;;WALL JIM,HUNTER DOUGLAS INC (1993-04-27),https://lens.org/152-589-439-489-591,Granted Patent,yes,23,66,1,1,0,E06B9/266;;Y10T29/53009;;Y10T29/39;;Y10T83/178;;Y10T29/53009;;Y10T29/39;;Y10T83/178;;E06B9/266,E06B9/266,29/24.5;;29/702;;83/76.8,0,0,,,,EXPIRED
104,SE,L,SE 9601391 L,131-142-767-107-959,1997-10-13,1997,SE 9601391 A,1996-04-12,SE 9601391 A,1996-04-12,Förfarande för förbränning och förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/131-142-767-107-959,Abstract,no,0,0,4,4,0,F01K23/062;;F23C10/10,F01K23/06;;F23C10/10,,0,0,,,,PENDING
105,US,A1,US 2010/0240442 A1,146-187-613-573-248,2010-09-23,2010,US 27983407 A,2007-02-16,US 27983407 A;;US 74331806 P;;US 74749606 P;;US 82888806 P;;US 2007/0004062 W,2006-02-17,PROVIDING ALTERNATIVE PERSISTENT STATE RECOVERY TECHNIQUES,"This document discusses, among other things, systems and methods for alternative persistent state recovery methods. A method comprises detecting persistent state recovery information from one of two or more persistent state recovery techniques, wherein the persistent state recovery information identifies a persistent state in a wagering game; and restoring the persistent state of the wagering game from the detected persistent state recovery information.",WMS GAMING INC,ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,SG GAMING INC (2015-06-29);;WMS GAMING INC (2009-03-17),https://lens.org/146-187-613-573-248,Patent Application,yes,27,17,6,7,0,G07F17/32;;G07F17/32,A63F9/24,463/24;;463/43,0,0,,,,INACTIVE
106,CA,A1,CA 2642098 A1,024-313-828-827-728,2007-08-30,2007,CA 2642098 A,2007-02-16,US 74331806 P;;US 74749606 P;;US 82888806 P;;US 2007/0004062 W,2006-02-17,PROVIDING ALTERNATIVE PERSISTENT STATE RECOVERY TECHNIQUES,,WMS GAMING INC,WARD MATTHEW J;;JAFFE JOEL R;;ANDERSON PETER R;;MOTYL JIM,,https://lens.org/024-313-828-827-728,Patent Application,no,0,0,6,7,0,G07F17/32;;G07F17/32,A63F9/24;;A63F13/00;;G06Q40/00,,0,0,,,,INACTIVE
107,WO,A3,WO 2008/005298 A3,077-625-203-449-806,2008-11-27,2008,US 2007/0015053 W,2007-06-28,US 80638806 P;;US 85196506 P;;US 91636507 P,2006-06-30,SYSTEMS AND METHODS FOR MANAGING MEMORY IN WAGERING GAME MACHINES,"Systems and methods manage memory in a wagering game machine. The systems and methods determine one or more quantities of various types of memory that are required by a wagering game application. The systems and methods determine if the wagering game machine has enough available memory to perform a requested operation such as downloading the wagering game, activating a component of the wagering game, or installing content for the wagering game.",WMS GAMING INC;;ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM,ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM,,https://lens.org/077-625-203-449-806,Search Report,yes,7,0,2,4,0,G07F17/323;;G07F17/32,A63F9/24;;A63F13/00,,0,0,,,,PENDING
108,ZA,B,ZA 200806979 B,161-256-738-136-906,2009-10-28,2009,ZA 200806979 A,2008-08-13,US 74331806 P,2006-02-17,Providing alternative persistent state recovery techniques,,WMS GAMING INC,ANDERSON PETER R;;JAFFE JOEL R;;JIM MOTYL;;WARD MATTHEW J,,https://lens.org/161-256-738-136-906,Granted Patent,no,0,0,1,7,0,,G06F/,,0,0,,,,ACTIVE
109,WO,A2,WO 2007/098017 A2,177-664-841-736-532,2007-08-30,2007,US 2007/0004062 W,2007-02-16,US 74331806 P;;US 74749606 P;;US 82888806 P,2006-02-17,PROVIDING ALTERNATIVE PERSISTENT STATE RECOVERY TECHNIQUES,"This document discusses, among other things, systems and methods for alternative persistent state recovery methods. A method comprises detecting persistent state recovery information from one of two or more persistent state recovery techniques, wherein the persistent state recovery information identifies a persistent state in a wagering game; and restoring the persistent state of the wagering game from the detected persistent state recovery information.",WMS GAMING INC;;ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,,https://lens.org/177-664-841-736-532,Patent Application,yes,0,7,6,7,0,G07F17/32;;G07F17/32,G06F19/00,,0,0,,,,PENDING
110,CA,A1,CA 3074009 A1,182-450-914-682-473,2019-06-20,2019,CA 3074009 A,2017-12-13,US 2017/0066209 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A flow distribution may be monitored to one or more clusters of perforations. Plugging criteria may be identified based on the flow distribution and characteristics associated with perforation plugs to be dropped into a wellbore associated with the subsurface formation may be determined based on the flow distribution, characteristics of the one or more clusters, and the plugging objective. The perforation plugs may be dropped into the wellbore. The perforation plugs may have tracers which indicate whether the perforation plugs reached a location associated with the one or more clusters.",HALLIBURTON ENERGY SERVICES INC,INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,,https://lens.org/182-450-914-682-473,Patent Application,no,0,0,6,6,0,E21B33/13;;E21B47/10;;E21B47/11;;E21B47/11;;E21B33/13;;E21B47/10,E21B33/13;;E21B33/12;;E21B47/10,,0,0,,,,PENDING
111,US,B2,US 8202168 B2,124-389-131-089-16X,2012-06-19,2012,US 30551707 A,2007-06-28,US 30551707 A;;US 80636806 P;;US 85196506 P;;US 91636507 P;;US 80638806 P;;US 2007/0015053 W,2006-06-30,Systems and methods for managing memory in wagering game machines,"Systems and methods manage memory in a wagering game machine. The systems and methods determine one or more quantities of various types of memory that are required by a wagering game application. The systems and methods determine if the wagering game machine has enough available memory to perform a requested operation such as downloading the wagering game, activating a component of the wagering game, or installing content for the wagering game.",ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM;;WMS GAMING INC,ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM,SG GAMING INC (2015-06-29);;WMS GAMING INC (2010-01-26),https://lens.org/124-389-131-089-16X,Granted Patent,yes,18,0,2,4,0,G07F17/323;;G07F17/323;;G07F17/32;;G07F17/32,A63F9/24;;A63F13/00;;G06F17/00;;G06F19/00,463/43;;463/16;;360/131;;711/170,2,0,,,"""International Application Serial No. PCT/US2008/15053, Search Report mailed Jun. 13, 2008"", 4 pgs.;;""International Application Serial No. PCT/US2008/15053, Written Opinion mailed Jun. 13, 2008"", 5 pgs.",INACTIVE
112,WO,A3,WO 2007/098017 A3,048-613-062-763-817,2008-11-13,2008,US 2007/0004062 W,2007-02-16,US 74331806 P;;US 74749606 P;;US 82888806 P,2006-02-17,PROVIDING ALTERNATIVE PERSISTENT STATE RECOVERY TECHNIQUES,"This document discusses, among other things, systems and methods for alternative persistent state recovery methods. A method comprises detecting persistent state recovery information from one of two or more persistent state recovery techniques, wherein the persistent state recovery information identifies a persistent state in a wagering game; and restoring the persistent state of the wagering game from the detected persistent state recovery information.",WMS GAMING INC;;ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,,https://lens.org/048-613-062-763-817,Search Report,yes,1,0,6,7,0,G07F17/32;;G07F17/32,A63F13/00;;A63F9/24;;G06Q40/00,,0,0,,,,PENDING
113,US,A1,US 2010/0029389 A1,156-187-682-420-539,2010-02-04,2010,US 30551707 A,2007-06-28,US 30551707 A;;US 80636806 P;;US 85196506 P;;US 91636507 P;;US 80638806 P;;US 2007/0015053 W,2006-06-30,SYSTEMS AND METHODS FOR MANAGING MEMORY IN WAGERING GAME MACHINES,"Systems and methods manage memory in a wagering game machine. The systems and methods determine one or more quantities of various types of memory that are required by a wagering game application. The systems and methods determine if the wagering game machine has enough available memory to perform a requested operation such as downloading the wagering game, activating a component of the wagering game, or installing content for the wagering game.",WMS GAMING INC,ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM,SG GAMING INC (2015-06-29);;WMS GAMING INC (2010-01-26),https://lens.org/156-187-682-420-539,Patent Application,yes,18,2,2,4,0,G07F17/323;;G07F17/323;;G07F17/32;;G07F17/32,A63F9/24,463/43;;463/25,0,0,,,,INACTIVE
114,SE,C3,SE 506356 C3,092-763-104-338-261,1998-01-19,1998,SE 9601394 A,1996-04-12,SE 9601394 A,1996-04-12,Foerbraenningsanlaeggning med fluidiserad baedd foersedd med anordningar foer spridning av aatermatat material,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/092-763-104-338-261,Amended Patent,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/10;;F23C10/16,,0,0,,,,EXPIRED
115,SE,D0,SE 9601393 D0,199-922-890-465-860,1996-04-12,1996,SE 9601393 A,1996-04-12,SE 9601393 A,1996-04-12,Förfarande för förbränning och förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/199-922-890-465-860,Patent Application,no,0,0,6,6,0,B01D53/34;;F23C10/10;;Y02E20/34;;F23C10/10;;B01D53/34,F23C10/18;;B01D53/34;;F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,PENDING
116,WO,A2,WO 2008/005298 A2,053-103-276-541-006,2008-01-10,2008,US 2007/0015053 W,2007-06-28,US 80638806 P;;US 85196506 P;;US 91636507 P,2006-06-30,SYSTEMS AND METHODS FOR MANAGING MEMORY IN WAGERING GAME MACHINES,"Systems and methods manage memory in a wagering game machine. The systems and methods determine one or more quantities of various types of memory that are required by a wagering game application. The systems and methods determine if the wagering game machine has enough available memory to perform a requested operation such as downloading the wagering game, activating a component of the wagering game, or installing content for the wagering game.",WMS GAMING INC;;ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM,ADIRAJU SRINIVYASA M;;ANDERSON PETER R;;MAK RYAN S;;MOTYL JIM,,https://lens.org/053-103-276-541-006,Patent Application,yes,0,4,2,4,0,G07F17/323;;G07F17/32,G06F19/00,,0,0,,,,PENDING
117,SE,L,SE 9601394 L,163-103-523-414-214,1997-10-13,1997,SE 9601394 A,1996-04-12,SE 9601394 A,1996-04-12,"Förbränningsanläggning med fluidiserad bädd, försedd med anordningar för spridning av återmatat material",,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/163-103-523-414-214,Abstract,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/10;;F23C10/16,,0,0,,,,EXPIRED
118,CA,C,CA 3074009 C,184-079-753-874-157,2022-05-24,2022,CA 3074009 A,2017-12-13,US 2017/0066209 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A flow distribution may be monitored to one or more clusters of perforations. Plugging criteria may be identified based on the flow distribution and characteristics associated with perforation plugs to be dropped into a wellbore associated with the subsurface formation may be determined based on the flow distribution, characteristics of the one or more clusters, and the plugging objective. The perforation plugs may be dropped into the wellbore. The perforation plugs may have tracers which indicate whether the perforation plugs reached a location associated with the one or more clusters.",HALLIBURTON ENERGY SERVICES INC,INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,,https://lens.org/184-079-753-874-157,Granted Patent,no,0,0,6,6,0,E21B33/13;;E21B47/10;;E21B47/11;;E21B47/11;;E21B33/13;;E21B47/10,E21B33/13;;E21B33/12;;E21B47/10,,0,0,,,,PENDING
119,US,A1,US 2021/0040813 A1,030-928-382-303-978,2021-02-11,2021,US 201716644652 A,2017-12-13,US 2017/0066209 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A flow distribution may be monitored to one or more clusters of perforations. Plugging criteria may be identified based on the flow distribution and characteristics associated with perforation plugs to be dropped into a wellbore associated with the subsurface formation may be determined based on the flow distribution, characteristics of the one or more clusters, and the plugging objective. The perforation plugs may be dropped into the wellbore. The perforation plugs may have tracers which indicate whether the perforation plugs reached a location associated with the one or more clusters.",HALLIBURTON ENERGY SERVICES INC,INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,HALLIBURTON ENERGY SERVICES INC (2017-12-05),https://lens.org/030-928-382-303-978,Patent Application,yes,0,4,6,6,0,E21B33/13;;E21B47/10;;E21B47/11;;E21B47/11;;E21B33/13;;E21B47/10,E21B33/13;;E21B47/11,,0,0,,,,ACTIVE
120,SE,D0,SE 9601391 D0,123-209-496-692-685,1996-04-12,1996,SE 9601391 A,1996-04-12,SE 9601391 A,1996-04-12,Förfarande för förbränning och förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/123-209-496-692-685,Patent Application,no,0,0,4,4,0,F01K23/062;;F23C10/10,F01K23/06;;F23C10/10,,0,0,,,,PENDING
121,SE,C2,SE 506356 C2,129-127-645-693-753,1997-12-08,1997,SE 9601394 A,1996-04-12,SE 9601394 A,1996-04-12,"Förbränningsanläggning med fluidiserad bädd, försedd med anordningar för spridning av återmatat material",,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/129-127-645-693-753,Granted Patent,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/10;;F23C10/16,,0,0,,,,EXPIRED
122,SE,D0,SE 9601392 D0,133-682-566-589-429,1996-04-12,1996,SE 9601392 A,1996-04-12,SE 9601392 A,1996-04-12,Förfarande för förbränning och förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/133-682-566-589-429,Patent Application,no,0,0,7,7,0,F23J7/00;;F23J7/00;;F01K23/062;;F01K23/062;;F23C6/047;;F23C6/047;;F23C10/10;;F23C10/10;;F23C10/16;;F23C10/16,F23C10/22;;F01K23/06;;F23C6/04;;F23C10/10;;F23C10/16;;F23J7/00,,0,0,,,,PENDING
123,US,B2,US 8216058 B2,132-711-174-847-63X,2012-07-10,2012,US 27983407 A,2007-02-16,US 27983407 A;;US 74331806 P;;US 74749606 P;;US 82888806 P;;US 2007/0004062 W,2006-02-17,Providing alternative persistent state recovery techniques,"This document discusses, among other things, systems and methods for alternative persistent state recovery methods. A method comprises detecting persistent state recovery information from one of two or more persistent state recovery techniques, wherein the persistent state recovery information identifies a persistent state in a wagering game; and restoring the persistent state of the wagering game from the detected persistent state recovery information.",ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J;;WMS GAMING INC,ANDERSON PETER R;;JAFFE JOEL R;;MOTYL JIM;;WARD MATTHEW J,SG GAMING INC (2015-06-29);;WMS GAMING INC (2009-03-17),https://lens.org/132-711-174-847-63X,Granted Patent,yes,39,1,6,7,0,G07F17/32;;G07F17/32,A63F9/24,463/24;;463/25;;463/42,8,0,,,"""European Application Serial No. 06839061.6, Extended European Search Report mailed Feb. 2, 2011"", 11 pgs.;;""International Application Serial No. PCT/US2007/04062, International Search Report and Written Opinion mailed Aug. 20, 2008"", 9 pgs.;;""U.S. Appl. No. 12/158,855 , Response filed Jul. 19, 2011 to Non Final Office Action mailed Apr. 19, 2011"", 16 pgs.;;""U.S. Appl. No. 12/158,855, Non Final Office Action mailed Apr. 19, 2011"", 18 pgs.;;Brandon, Alexander, ""Audio for Games: Planning, Process and Production"", New Riders, (Oct. 7, 2004), 42-44.;;Evry, Harry J, ""Beginning Game Graphics"", Course Technology PTR, (Jan. 1, 2005), 26-29,38-42,44.;;Morrison, Michael, ""Beginning Game Programming"", Sams, (Jul. 19, 2004), 203-205,264-266.;;Mueller, Scott, ""Upgrading and Repairing PCs"", Que, Sixteenth Edition, (Aug. 27, 2004), 881-883,917-918,932-933.",INACTIVE
124,SE,L,SE 9601392 L,074-431-252-324-802,1997-10-13,1997,SE 9601392 A,1996-04-12,SE 9601392 A,1996-04-12,Förfarande för förbränning och förbränningsanläggning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSON JIM;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;WEATHERBY JOHN,,https://lens.org/074-431-252-324-802,Abstract,no,0,0,7,7,0,F23J7/00;;F23J7/00;;F01K23/062;;F01K23/062;;F23C6/047;;F23C6/047;;F23C10/10;;F23C10/10;;F23C10/16;;F23C10/16,F23C10/22;;F01K23/06;;F23C6/04;;F23C10/10;;F23C10/16;;F23J7/00,,0,0,,,,PENDING
125,US,B2,US 11199068 B2,164-688-971-658-469,2021-12-14,2021,US 201716644652 A,2017-12-13,US 2017/0066209 W,2017-12-13,Real-time perforation plug deployment and stimulation in a subsurface formation,"A flow distribution may be monitored to one or more clusters of perforations. Plugging criteria may be identified based on the flow distribution and characteristics associated with perforation plugs to be dropped into a wellbore associated with the subsurface formation may be determined based on the flow distribution, characteristics of the one or more clusters, and the plugging objective. The perforation plugs may be dropped into the wellbore. The perforation plugs may have tracers which indicate whether the perforation plugs reached a location associated with the one or more clusters.",HALLIBURTON ENERGY SERVICES INC,INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,HALLIBURTON ENERGY SERVICES INC (2017-12-05),https://lens.org/164-688-971-658-469,Granted Patent,yes,19,1,6,6,0,E21B33/13;;E21B47/10;;E21B47/11;;E21B47/11;;E21B33/13;;E21B47/10,E21B47/11;;E21B33/13,,11,3,067-047-330-195-568;;073-496-803-047-217;;048-150-824-257-681,10.2118/553-pa;;10.2118/8401-pa;;10.2118/13085-ms,"PCT Application Serial No. PCT/US2017/066209, International Search Report, dated Sep. 6, 2018, 3 pages.;;PCT Application Serial No. PCT/US2017/066209, International Written Opinion, dated Sep. 6, 2018, 8 pages.;;PCT Application Serial No. PCT/US2017/066224, International Search Report, dated Sep. 11, 2018, 4 pages.;;PCT Application Serial No. PCT/US2017/066224, International Written Opinion, dated Sep. 11, 2018, 12 pages.;;U.S. Appl. No. 16/644,794, Restriction Requirement, dated Feb. 23, 2021, pages.;;“Diversion in Matrix-Acidizing Treatments”, [online] retrieved on Mar. 10, 2021 from https://www.halliburton.com/content/dam/ps/public/pe/contents/Best_Practices/web/A_through_G/F3354.pdf, Oct. 21, 2008, 20 pages.;;Brown, et al., “Factors Influencing Optimum Ball Sealer Performance”, Society of Petroleum Engineers, Journal of Petroleum Technology 15 (04): pp. 450-454, Paper No. SPE-553-PA, Apr. 1, 1963.;;Erbstoesser, “Improved Ball Sealer Diversion”, Society of Petroleum Engineers, Journal of Petroleum Technology 32 (11): pp. 1903-1910; Paper No. SPE-8401-PA, Nov. 1980.;;Gabriel, et al., “The Design of Buoyant Ball Sealer Treatments”, Society of Petroleum Engineers, SPE Annual Technical Conference and Exhibition, Houston, Texas, Sep. 1984, Paper No. SPE-13085-MS, 12 pages.;;CA Application No. 3074010, First Office Action, dated Apr. 20, 2021, 5 pages.;;U.S. Appl. No. 16/644,794, Non-Final Office Action, dated May 7, 2021, 13 pages.",ACTIVE
126,JP,A,JP 2005216385 A,014-317-519-478-54X,2005-08-11,2005,JP 2004022119 A,2004-01-29,JP 2004022119 A,2004-01-29,MAGNETIC HEAD DEVICE AND LINEAR TAPE DRIVE DEVICE,"<P>PROBLEM TO BE SOLVED: To increase a resonance frequency of a magnetic head chip, to decrease a Q-value of the resonance point, and to increase a servo band, in a magnetic head device for performing tracking servo of a magnetic head chip to a data track. <P>SOLUTION: The device includes a multi channel type magnetic head chip 61 in which a plurality of magnetic head elements are arranged, a tracking mechanism, and a damping mechanism 68. The tracking mechanism 67 has a twin bimorph type actuator configuration in which a pair of bimorph elements 65 are disposed. The magnetic head chip 61 is mechanically coupled and disposed between displacement ends of the bimorph elements, and the magnetic head chip 61 is displaced in the arrangement direction of the multi-channel, by a tracking signal. The damping mechanism 68 includes a holding part into which a viscoelastic member is filled, wherein a damping body mechanically coupled to the magnetic head chip 61 is inserted into the viscoelastic member. Accordingly, the damping effect is enhanced, the resonance frequency is increased, the Q-value is decreased, and the band and the servo band are enlarged. <P>COPYRIGHT: (C)2005,JPO&NCIPI",SONY CORP;;IMATION CORP,ITO SETSUHIKO;;KOGA HIROHISA;;ABE TAKASHI;;JIM S ANDERSON;;LANGLOIS DENIS J,,https://lens.org/014-317-519-478-54X,Patent Application,no,2,1,4,4,0,G11B5/0083;;G11B5/584;;G11B5/584;;G11B5/0083,G11B5/584;;G11B5/008;;G11B5/29;;G11B5/56,,0,0,,,,EXPIRED
127,ES,T3,ES 2652187 T3,040-172-458-595-758,2018-01-31,2018,ES 10759442 T,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,Fenilacetato de l-ornitina y métodos para elaborar el mismo,"Una composición que comprende una forma cristalina de fenilacetato de L-ornitina, donde dicha forma cristalina exhibe un patrón de difracción en polvo de rayos-X que comprende al menos tres picos característicos, en donde los picos característicos se seleccionan del grupo que consiste de 6,0°±0,2° 2θ, 13,9°±0,2° 2θ, 14,8°±0,2° 2θ, 17,1°±0,2° 2θ, 17,8°±0,2° 2θ y 24,1°±0,2° 2θ; y opcionalmente donde: (i) dicha forma cristalina exhibe un análisis cristalográfico de rayos X de monocristal con parámetros de cristal aproximadamente iguales a los siguientes: Dimensiones de celda unidad: a>=6,594(2) Å, b>=6,5448(18) Å, c>=31,632(8) Å, α>=90°, β>=91,12(3)°, γ>=90°; Sistema cristalino: monoclínico; y Grupo espacial: P21; y/o (ii) dicha forma cristalina está representado por la fórmula [C5H13N2O2][C8H7O2].",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE;;WATT STEPHEN;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/040-172-458-595-758,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
128,WO,A3,WO 2005/015344 A3,088-838-226-466-148,2005-09-22,2005,US 2004/0020636 W,2004-06-28,US 63167703 A,2003-07-31,SYSTEM AND METHOD FOR ROUTING AND MANAGING SERVICE REQUESTS,"A system is provided for routing and managing service requests. A service request is received from a service requestor (100), and a determination (160) is made as to which of a plurality of service-providing nodes the service request should be transmitted. The service request is transmitted to the determined service-providing node. The service request may comprise one or more attributes describing the service request, and the determination as to which of the service-providing nodes the service request is transmitted may be based on the value of the one or more service request attributes (120). The service request may be divided into portions, each portion transmitted to a service-providing node. Information received from a service-providing node may enable an evaluation of whether and why a service request was not fulfilled.",EXULT INC;;ANDERSON GREG;;CLARKE PETER;;GROENESTIJN BERRY;;JONES RICHARD;;MONTGOMERY JIM;;UNTERBERGER STEVE,ANDERSON GREG;;CLARKE PETER;;GROENESTIJN BERRY;;JONES RICHARD;;MONTGOMERY JIM;;UNTERBERGER STEVE,,https://lens.org/088-838-226-466-148,Search Report,yes,3,0,3,3,0,G06Q10/10;;H04L41/5054;;H04L41/5054;;G06Q10/10,G06F/,,0,0,,,,PENDING
129,EP,A2,EP 1948370 A2,013-464-576-900-659,2008-07-30,2008,EP 06839518 A,2006-10-24,US 2006/0060186 W;;US 73004805 P;;US 73893405 P,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS,,GGT WASTE INC,BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,,https://lens.org/013-464-576-900-659,Patent Application,yes,0,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00,,0,0,,,,DISCONTINUED
130,US,A1,US 2006/0118496 A1,018-146-042-681-592,2006-06-08,2006,US 24860605 A,2005-10-12,US 24860605 A;;US 61794504 P,2004-10-12,Water treatment using metal porphyrin,Water treatment method involves contacting water containing a dissolved contaminant or unwanted reducible species or a recoverable species and metal porphyrin as a reductive catalyst in the presence of an electron donor in a reactor under conditions to reduce the reducible species. The reduction of the contaminant or unwanted or recoverable species can be catalyzed by light or electrical activation of the metal porphyrin.,UNIV NEW MEXICO,NUTTALL H E;;SHELNUTT JOHN A;;ANDERSON WILLIAM L;;STUDER JIM E,SANDIA CORPORATION OPERATOR OF SANDIA NATIONAL LABORATORIES (2006-08-09),https://lens.org/018-146-042-681-592,Patent Application,yes,4,5,1,1,0,C02F1/70;;C02F2101/12;;C02F2101/20;;C02F2101/308;;C02F2101/36;;C02F2101/38;;C02F2305/10;;C02F1/70;;C02F2101/12;;C02F2101/36;;C02F2101/38;;C02F2101/20;;C02F2101/308;;C02F2305/10,C02F1/70,210/748;;210/757,0,0,,,,DISCONTINUED
131,US,A1,US 2010/0193248 A1,018-549-208-807-906,2010-08-05,2010,US 69673510 A,2010-01-29,US 69673510 A;;US 14869509 P,2009-01-30,"METHODS, SYSTEMS, AND TOOL ASSEMBLIES FOR DISTRIBUTING WEIGHT BETWEEN AN EARTH-BORING ROTARY DRILL BIT AND A REAMER DEVICE","Methods, systems, and tool assemblies for distributing weight between a bit and a reamer device are disclosed. For example, at least one of the drill bit and the reamer may be configured to selectively distribute a weight-on-bit between the drill bit and the reamer, such as within a predetermined range. Additionally, methods of drilling wellbores may include selectively distributing a weight-on-bit applied to a bottom hole assembly between a drill bit and a reamer of the bottom hole assembly. Also, a reamer may be configured to exhibit a first maximum rate-of-penetration into a relatively hard formation, and a drill bit may be configured to exhibit a second maximum rate-of-penetration into a relatively soft formation that is less than the first maximum rate-of-penetration.",BAKER HUGHES INC,RADFORD STEVEN R;;ANDERSON MARK E;;THOMPSON WILLIAM C;;POWERS JIM R,BAKER HUGHES INCORPORATED (2010-02-11),https://lens.org/018-549-208-807-906,Patent Application,yes,60,23,6,6,0,E21B10/32;;E21B10/32,E21B7/00;;E21B10/26,175/57;;175/385,2,1,023-405-520-875-442,10.2118/27978-ms,"Warren et al. ""PDC Bits: What's Needed To Meet Tomorrow's Challenge"" 1994, Society of Petroleum Engineers, SPE 27978;;Okewunmi et al. ""BHA Selection and Drilling Practices to Successfully Drill and Underream Difficult Deepwater GOM Salt Section, a Case History"" 2007, American Association of Drilling Engineers, AADE-07-NTCE-11",ACTIVE
132,US,A1,US 2006/0195171 A1,081-965-945-414-501,2006-08-31,2006,US 39907806 A,2006-04-06,US 39907806 A;;US 46551703 A,2003-06-19,Stabilizing apparatus for use with implantable leads,A method of placing an implantable device in a cardiac vessel involves positioning the implantable device so that a distal end of the implantable device is positioned in the cardiac vessel. A stylet having an enlarged distal portion is positioned within a lumen of the implantable device so that the enlarged distal portion of the stylet is located at a distal portion of the implantable device. A sleeve is positioned within the implantable device and in proximity to the enlarged distal portion of the stylet. The implantable device is stabilized by selective engagement and disengagement between the enlarged distal portion of the stylet and the sleeve.,CARDIAC PACEMAKERS INC,GREENLAND JOHN;;BLANKENSHIP DREW;;ANDERSON DAVID;;HALDEMAN PAUL;;NIEDERECKER JIM;;QUILES NATHALIE,,https://lens.org/081-965-945-414-501,Patent Application,yes,15,0,2,2,0,A61N1/05;;A61N1/05,A61N1/05,607/119;;607/9,0,0,,,,DISCONTINUED
133,CN,A,CN 101321594 A,151-636-082-483-180,2008-12-10,2008,CN 200680045490 A,2006-10-24,US 73004805 P,2005-10-25,Remediation with hydroexcavation and solvents,"The present invention describes methods of contaminant removal and remediation utilizing hydroexcavation in combination with solvents and/or beneficial microbes, for primary scrubbing and high pressure mixing of the soil. Various embodiments of the present invention are useful for cleaning soil with contaminants, including but not limited to hydrocarbon based materials. The solvent used in conjunction with various embodiments of the present invention comprise a degreasing composition, which may comprise sodium silicate.",GGT WASTE INC,JIM BALLEW;;MARK YEAGER;;WILLIAM ANDERSON;;DANIEL STARNES LEE;;SOO CHO JONG,,https://lens.org/151-636-082-483-180,Patent Application,no,0,2,1,11,0,,B09C1/00,,0,0,,,,DISCONTINUED
134,WO,A3,WO 2007/051102 A3,175-788-021-406-548,2008-03-06,2008,US 2006/0060186 W,2006-10-24,US 73004805 P;;US 73893405 P,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS,"The present invention describes methods of contaminant removal and remediation utilizing hydroexcavation in combination with solvents and/or beneficial microbes, for primary scrubbing and high pressure mixing of the soil. Various embodiments of the present invention are useful for cleaning soil with contaminants, including but not limited to hydrocarbon based materials. The solvent used in conjunction with various embodiments of the present invention comprise a degreasing composition, which may comprise sodium silicate.",GGT WASTE INC;;BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,,https://lens.org/175-788-021-406-548,Search Report,yes,4,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00,,0,0,,,,PENDING
135,CA,A1,CA 2628016 A1,038-135-169-561-055,2007-05-03,2007,CA 2628016 A,2006-10-24,US 73004805 P;;US 73893405 P;;US 2006/0060186 W,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS,,GGT WASTE INC,CHO JONG SOO;;STARNES LEE DANIEL;;YEAGER MARK;;ANDERSON WILLIAM;;BALLEW JIM,,https://lens.org/038-135-169-561-055,Patent Application,no,0,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00,,0,0,,,,DISCONTINUED
136,WO,A3,WO 2006/042296 A3,188-285-569-390-438,2006-11-23,2006,US 2005/0036754 W,2005-10-12,US 96340904 A,2004-10-12,AUTOMATIC FRYING APPARATUS FOR FOODSTUFFS,"An automated apparatus and method for sequentially slicing potatoes into slices, for cooking the slices into chips in a circular oil bath, and for separating the cooked chips from the bath. The apparatus includes a potato slicer (32), a circular frying trough (51) with oil circulating means and controlled heating means, a rotating and angle changing plurality of circularly arranged paddles (78) for positioning chips in and along the trough (51) during their cooking, a carousel (99) for lifting and separating cooked chips from the trough, and a conveyor belt (130) for delivering the chips from the carousel to a collection point. The method utilizes the apparatus.",JIMINY EQUIPMENT LLC;;VADEVOULIS JIM;;FITCH CLIFFORD E JR;;FITCH CLIFFORD E III;;ANDERSON MICHAEL,VADEVOULIS JIM;;FITCH CLIFFORD E JR;;FITCH CLIFFORD E III;;ANDERSON MICHAEL,,https://lens.org/188-285-569-390-438,Search Report,yes,3,0,4,5,0,A47J37/1214;;A47J37/1214,A47J37/12;;A23L1/00,,0,0,,,,PENDING
137,US,B2,US 8584776 B2,054-583-915-321-512,2013-11-19,2013,US 69673510 A,2010-01-29,US 69673510 A;;US 14869509 P,2009-01-30,"Methods, systems, and tool assemblies for distributing weight between an earth-boring rotary drill bit and a reamer device","Methods, systems, and tool assemblies for distributing weight between a bit and a reamer device are disclosed. For example, at least one of the drill bit and the reamer may be configured to selectively distribute a weight-on-bit between the drill bit and the reamer, such as within a predetermined range. Additionally, methods of drilling wellbores may include selectively distributing a weight-on-bit applied to a bottom hole assembly between a drill bit and a reamer of the bottom hole assembly. Also, a reamer may be configured to exhibit a first maximum rate-of-penetration into a relatively hard formation, and a drill bit may be configured to exhibit a second maximum rate-of-penetration into a relatively soft formation that is less than the first maximum rate-of-penetration.",RADFORD STEVEN R;;ANDERSON MARK E;;THOMPSON WILLIAM C;;POWERS JIM R;;BAKER HUGHES INC,RADFORD STEVEN R;;ANDERSON MARK E;;THOMPSON WILLIAM C;;POWERS JIM R,BAKER HUGHES INCORPORATED (2010-02-11),https://lens.org/054-583-915-321-512,Granted Patent,yes,60,10,6,6,0,E21B10/32;;E21B10/32,E21B10/26,175/385;;175/57;;175/344;;175/334,8,3,023-405-520-875-442;;115-106-137-033-782;;057-732-169-505-816,10.2118/27978-ms;;10.2118/119534-ms;;10.2118/112647-ms,"Warren et al. ""PDC Bits: What's Needed to Meet Tomorrow's Challenge"" 1994, Society of Petroleum Engineers, SPE 27978.;;Okewunmi et al. ""BHA Selection and Drilling Practices to Successfully Drill and Underream Difficult Deepwater GOM Salt Section, a Case History"" 2007, American Association of Drilling Engineers, AADE-07-NTCE-11.;;Radford et al., Novel Concentric Expandable Stabilizer Results in Increased Penetration Rates and Drilling Efficiency with Reduced Vibration, International Association of Drilling Contractors, SPE/IADC 119534, Drilling Conference and Exhibition held in Amsterdam, The Netherlands, Mar. 17-19, 2009 (13 pages).;;Thomson et al., A Systematic Approach to a Better Understanding of the Concentric Hole-Opening Process Utilizing Drilling Mechanics and Drilling Dynamics Measurements Recorded Above and Below the Reamer, IADC/SPE 112647 Drilling Conference held in Orlando, Florida, Mar. 4-6, 2008 (20 pages).;;Written Opinion of the International Searching Authority for International Application No. PCT/US2009/041526 dated Jan. 19, 2010, 6 pages.;;International Search Report for International Application No. PCT/US2009/041526 dated Jan. 19, 2010, 4 pages.;;Written Opinion of the International Searching Authority for International Application No. PCT/US2010/022540 dated Jun. 16, 2010, 3 pages.;;International Search Report for International Application No. PCT/US2010/022540 dated Jun. 16, 2010, 3 pages.",ACTIVE
138,US,A1,US 2006/0075904 A1,081-793-920-716-29X,2006-04-13,2006,US 96340904 A,2004-10-12,US 96340904 A,2004-10-12,Automatic frying apparatus for foodstuffs,"An automated apparatus and method for sequentially slicing potatoes into slices, for cooking the slices into chips in a circular oil bath, and for separating the cooked chips from the bath. The apparatus includes a potato slicer, a circular frying trough with oil circulating means and controlled heating means, a rotating and angle changing plurality of circularly arranged paddles for positioning chips in and along the trough during their cooking, a carousel for lifting and separating cooked chips from the trough, and a conveyor belt for delivering the chips from the carousel to a collection point. The method utilizes the apparatus.",VADEVOULIS JIM;;FITCH CLIFFORD E JR;;FITCH CLIFFORD E III;;ANDERSON MICHAEL,VADEVOULIS JIM;;FITCH CLIFFORD E JR;;FITCH CLIFFORD E III;;ANDERSON MICHAEL,,https://lens.org/081-793-920-716-29X,Patent Application,yes,15,9,4,5,0,A47J37/1214;;A47J37/1214,A47J37/12,99/403,0,0,,,,DISCONTINUED
139,HU,T2,HU E035921 T2,004-766-859-861-562,2018-05-28,2018,HU E10759442 A,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE;;WATT STEPHEN;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/004-766-859-861-562,Amended Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,PENDING
140,WO,A2,WO 2007/051102 A2,156-617-687-283-235,2007-05-03,2007,US 2006/0060186 W,2006-10-24,US 73004805 P;;US 73893405 P,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS,"The present invention describes methods of contaminant removal and remediation utilizing hydroexcavation in combination with solvents and/or beneficial microbes, for primary scrubbing and high pressure mixing of the soil. Various embodiments of the present invention are useful for cleaning soil with contaminants, including but not limited to hydrocarbon based materials. The solvent used in conjunction with various embodiments of the present invention comprise a degreasing composition, which may comprise sodium silicate.",GGT WASTE INC;;BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,,https://lens.org/156-617-687-283-235,Patent Application,yes,0,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/02,,0,0,,,,PENDING
141,US,A1,US 2005/0108021 A1,019-704-689-942-650,2005-05-19,2005,US 63167703 A,2003-07-31,US 63167703 A,2003-07-31,System and method for routing and managing service requests,"The disclosure presents a method for routing and managing service requests. A service request is received from a service requester, and a determination is made as to which of a plurality of service-providing nodes the service request should be transmitted. The service request is transmitted to the determined service-providing node. The service request may comprise one or more attributes describing the service request, and the determination as to which of the service-providing nodes the service request is transmitted may be based on the value of the one or more service request attributes. The service request may be divided into portions, each portion transmitted to a service-providing node. Information received from a service-providing node may enable an evaluation of whether and why a service request was not fulfilled.",ANDERSON GREG;;CLARKE PETER;;GROENESTIJN BERRY;;JONES RICHARD;;MONTGOMERY JIM;;UNTERBERGER STEVE,ANDERSON GREG;;CLARKE PETER;;GROENESTIJN BERRY;;JONES RICHARD;;MONTGOMERY JIM;;UNTERBERGER STEVE,EXULT INC (2003-09-25);;HEWITT ASSOCIATES INC (2004-10-29);;HEWITT ASSOCIATES LLC (2004-10-29),https://lens.org/019-704-689-942-650,Patent Application,yes,99,13,3,3,0,G06Q10/10;;H04L41/5054;;H04L41/5054;;G06Q10/10,G06F/,705/1,0,0,,,,DISCONTINUED
142,WO,A2,WO 2005/015344 A2,114-217-359-172-142,2005-02-17,2005,US 2004/0020636 W,2004-06-28,US 63167703 A,2003-07-31,SYSTEM AND METHOD FOR ROUTING AND MANAGING SERVICE REQUESTS,"A system is provided for routing and managing service requests. A service request is received from a service requestor (100), and a determination (160) is made as to which of a plurality of service-providing nodes the service request should be transmitted. The service request is transmitted to the determined service-providing node. The service request may comprise one or more attributes describing the service request, and the determination as to which of the service-providing nodes the service request is transmitted may be based on the value of the one or more service request attributes (120). The service request may be divided into portions, each portion transmitted to a service-providing node. Information received from a service-providing node may enable an evaluation of whether and why a service request was not fulfilled.",EXULT INC;;ANDERSON GREG;;CLARKE PETER;;GROENESTIJN BERRY;;JONES RICHARD;;MONTGOMERY JIM;;UNTERBERGER STEVE,ANDERSON GREG;;CLARKE PETER;;GROENESTIJN BERRY;;JONES RICHARD;;MONTGOMERY JIM;;UNTERBERGER STEVE,,https://lens.org/114-217-359-172-142,Patent Application,yes,0,1,3,3,0,G06Q10/10;;H04L41/5054;;H04L41/5054;;G06Q10/10,G06F/,,0,0,,,,PENDING
143,BR,A2,BR PI0617819 A2,198-641-574-810-194,2011-08-09,2011,BR PI0617819 A,2006-10-24,US 73004805 P;;US 73893405 P;;US 2006/0060186 W,2005-10-25,remediação com hidroescavação e solventes,"<B>REMEDIAçãO COM HIDROESCAVAçãO E SOLVENTES<D>A presente invenção refere-se a métodos de remoção de contaminante e remediação utilizando hidroescavação em combinação com sol- ventes e/ou micróbios benéficos, para esfregação primária e mistura em alta pressão do solo. Várias modalidades da presente invenção são úteis para limpeza do solo com contaminantes, incluindo, mas não limitado a, materiais baseados em hidrocarbono. O solvente usado em conjunto com várias modalidades da presente invenção compreende uma composição desengordurante, que pode compreender silicato de sódio.",GGT WASTE INC,BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,,https://lens.org/198-641-574-810-194,Patent Application,no,0,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00,,0,0,,,,DISCONTINUED
144,SG,A,SG 10202010988W A,121-269-979-477-99X,2020-12-30,2020,SG 10202010988W A,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE;;WATT STEPHEN;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/121-269-979-477-99X,Unknown,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,,,0,0,,,,PENDING
145,MX,A,MX 2008005449 A,135-772-969-857-469,2008-09-11,2008,MX 2008005449 A,2006-10-24,US 73004805 P;;US 73893405 P;;US 2006/0060186 W,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS.,"The present invention describes methods of contaminant removal and remediation utilizing hydroexcavation in combination with solvents and/or beneficial microbes, for primary scrubbing and high pressure mixing of the soil. Various embodiments of the present invention are useful for cleaning soil with contaminants, including but not limited to hydrocarbon based materials. The solvent used in conjunction with various embodiments of the present invention comprise a degreasing composition, which may comprise sodium silicate.",GGT WASTE INC,ANDERSON WILLIAM;;BALLEW JIM;;YEAGER MARK;;STARNES LEE DANIEL;;CHO JONG SOO,,https://lens.org/135-772-969-857-469,Patent Application,no,0,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00,,0,0,,,,PENDING
146,US,A1,US 2011/0054514 A1,133-826-779-154-840,2011-03-03,2011,US 54855809 A,2009-08-27,US 54855809 A,2009-08-27,EMBOLIC PROTECTION DEVICES WITH AN IMPROVED FILTER MEMBRANE,Embolic protection filtering devices and methods for making and using the same. An example embolic protection filter device may include an elongate shaft. A filter may be coupled to the shaft. The filter may include a filter frame and a filter membrane having a plurality of apertures formed therein attached to the filter frame. The filter may be configured to shift between a first collapsed configuration and a second expanded configuration. The apertures may have a first shape when the filter is in the first configuration and a second shape when the filter is in the second configuration.,BOSTON SCIENT SCIMED INC,ARCAND BEN;;DALLMAN GREG;;ANDERSON JIM;;GUEST ERIN;;HENDRIKSON KYLE;;UTKE AL,BOSTON SCIENTIFIC SCIMED INC (2009-08-03),https://lens.org/133-826-779-154-840,Patent Application,yes,13,68,2,2,0,A61F2/0105;;A61F2/0105;;A61F2/013;;A61F2/013;;A61F2002/018;;A61F2002/018;;A61F2230/0006;;A61F2230/0006;;A61F2230/0067;;A61F2230/0067;;A61F2230/008;;A61F2230/008;;Y10T29/49826;;Y10T29/49826,A61F2/01,606/200;;29/428,0,0,,,,ACTIVE
147,US,B2,US 9452040 B2,186-833-671-315-09X,2016-09-27,2016,US 54855809 A,2009-08-27,US 54855809 A,2009-08-27,Embolic protection devices with an improved filter membrane,Embolic protection filtering devices and methods for making and using the same. An example embolic protection filter device may include an elongate shaft. A filter may be coupled to the shaft. The filter may include a filter frame and a filter membrane having a plurality of apertures formed therein attached to the filter frame. The filter may be configured to shift between a first collapsed configuration and a second expanded configuration. The apertures may have a first shape when the filter is in the first configuration and a second shape when the filter is in the second configuration.,ARCAND BEN;;DALLMAN GREG;;ANDERSON JIM;;GUEST ERIN;;HENDRIKSON KYLE;;UTKE AL;;BOSTON SCIENT SCIMED INC,ARCAND BEN;;DALLMAN GREG;;ANDERSON JIM;;GUEST ERIN;;HENDRIKSON KYLE;;UTKE AL,BOSTON SCIENTIFIC SCIMED INC (2009-08-03),https://lens.org/186-833-671-315-09X,Granted Patent,yes,13,1,2,2,0,A61F2/0105;;A61F2/0105;;A61F2/013;;A61F2/013;;A61F2002/018;;A61F2002/018;;A61F2230/0006;;A61F2230/0006;;A61F2230/0067;;A61F2230/0067;;A61F2230/008;;A61F2230/008;;Y10T29/49826;;Y10T29/49826,A61M29/00;;A61F2/01,,0,0,,,,ACTIVE
148,WO,A2,WO 2006/042296 A2,183-545-047-689-316,2006-04-20,2006,US 2005/0036754 W,2005-10-12,US 96340904 A,2004-10-12,AUTOMATIC FRYING APPARATUS FOR FOODSTUFFS,"An automated apparatus and method for sequentially slicing potatoes into slices, for cooking the slices into chips in a circular oil bath, and for separating the cooked chips from the bath. The apparatus includes a potato slicer (32), a circular frying trough (51) with oil circulating means and controlled heating means, a rotating and angle changing plurality of circularly arranged paddles (78) for positioning chips in and along the trough (51) during their cooking, a carousel (99) for lifting and separating cooked chips from the trough, and a conveyor belt (130) for delivering the chips from the carousel to a collection point. The method utilizes the apparatus.",JIMINY EQUIPMENT LLC;;VADEVOULIS JIM;;FITCH CLIFFORD E JR;;FITCH CLIFFORD E III;;ANDERSON MICHAEL,VADEVOULIS JIM;;FITCH CLIFFORD E JR;;FITCH CLIFFORD E III;;ANDERSON MICHAEL,,https://lens.org/183-545-047-689-316,Patent Application,yes,0,6,4,5,0,A47J37/1214;;A47J37/1214,A47J37/12,,0,0,,,,PENDING
149,KR,A,KR 20080074135 A,020-600-974-217-57X,2008-08-12,2008,KR 20087012349 A,2008-05-23,US 73004805 P;;US 73893405 P,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS,"The present invention describes methods of contaminant removal and remediation utilizing hydroexcavation in combination with solvents and/or beneficial microbes, for primary scrubbing and high pressure mixing of the soil. Various embodiments of the present invention are useful for cleaning soil with contaminants, including but not limited to hydrocarbon based materials. The solvent used in conjunction with various embodiments of the present invention comprise a degreasing composition, which may comprise sodium silicate.",GGT WASTE INC,BALLEW JIM;;YEAGER MARK;;ANDERSON WILLIAM;;STARNES LEE DANIEL;;CHO JONG SOO,,https://lens.org/020-600-974-217-57X,Patent Application,no,0,0,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00;;B09C1/02;;B09C1/08,,0,0,,,,DISCONTINUED
150,JP,A,JP 2005216460 A,012-549-601-469-028,2005-08-11,2005,JP 2004026008 A,2004-02-02,JP 2004026008 A,2004-02-02,MAGNETIC HEAD APPARATUS AND LINEAR TAPE DRIVE APPARATUS,"<P>PROBLEM TO BE SOLVED: To make track width and track pitch narrower and achieve higher recording density by contriving: accurate minute movement by a minute following mechanism performing minute movement in the direction of track width of a magnetic head in a magnetic head apparatus and a linear tape drive apparatus using a linear tape; a higher frequency band of the resonance frequency; and a higher frequency and a wider band of a servo band by the above means. <P>SOLUTION: A magnetic head chip 61 itself having a plurality of magnetic head elements ID is made one part of the constitution of a minute following mechanism 67 making the magnetic head element ID track the data track of a linear magnetic tape 51. That is, the movable part of the minute following mechanism 67 is lightened by making the magnetic head chip 61 also serve as a rigid member constituting the minute following mechanism 67, thereby attaining higher frequency and wider band of the servo band, accurate minute tracking, and higher density of the data track, and improving recording density and increasing the capacity of recording. <P>COPYRIGHT: (C)2005,JPO&NCIPI",SONY CORP;;IMATION CORP,KOGA HIROHISA;;ABE TAKASHI;;ITO SETSUHIKO;;JIM S ANDERSON;;LANGLOIS DENIS J,,https://lens.org/012-549-601-469-028,Patent Application,no,0,1,4,4,0,G11B5/584;;G11B5/584;;G11B5/00826;;G11B5/00826;;G11B5/5504;;G11B5/5504,G11B5/584;;G11B5/187;;G11B5/265;;G11B5/29;;G11B5/56,,0,0,,,,EXPIRED
151,ES,T3,ES 2720148 T3,081-895-998-640-819,2019-07-18,2019,ES 11831546 T,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,Métodos de fabricación de fenilacetato de L-ornitina,Un proceso de fabricación de sal de fenilacetato de L-ornitina que comprende: preparar una solución de sal de fenilacetato mezclando un ácido fenil acético y una base en un disolvente; intermezclar benzoato de L-ornitina con la solución de sal de fenilacetato; y aislar una composición que comprende fenilacetato de L-ornitina.,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE;;WATT STEPHEN;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/081-895-998-640-819,Granted Patent,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C51/41;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
152,US,A1,US 2009/0220304 A1,080-450-217-337-414,2009-09-03,2009,US 9169806 A,2006-10-24,US 9169806 A;;US 73004805 P;;US 73893405 P;;US 2006/0060186 W,2005-10-25,REMEDIATION WITH HYDROEXCAVATION AND SOLVENTS,"The present invention describes methods of contaminant removal and remediation utilizing hydroexcavation in Hydroexcavation of the soil combination with solvents and/or beneficial microbes, for primary scrubbing and high pressure mixing of the soil. Various embodiments of the present invention are useful for cleaning soil with contaminants, including but not limited to hydrocarbon based materials. The solvent used in conjunction with various embodiments of the present invention comprise a degreasing composition, which may comprise sodium silicate.",GGT WASTE INC,BALLEW JIM;;ANDERSON WILLIAM;;CHO JONG SOO;;YEAGER MARK;;STARNES LEE DANIEL,GGT WASTE INC (2008-07-22),https://lens.org/080-450-217-337-414,Patent Application,yes,1,3,10,11,0,B09C1/00;;B09C1/02;;B09C1/10;;B09C1/00;;B09C1/08;;B09C1/02;;B09C1/02;;B09C1/10;;B09C1/00,B09C1/00,405/128.1,0,0,,,,DISCONTINUED
153,MX,A,MX 9706098 A,186-894-735-768-688,1997-10-31,1997,MX 9706098 A,1996-02-08,US 9601790 W;;US 38657695 A,1995-02-10,PRODUCT AND METHOD FOR PREVENTING RESPIRATORY VIRUS INFECTION.,"A method of treating pneumonia or other respiratory disease caused by respiratory syncytial virus, adenovirus, parainfluenza virus, or influenza virus by orally administering a liquid, preferably an infant formula, containing a virus neutralizing antibody.",ABBOTT LAB,HILTY MILO DUANE;;ANDERSON STEVEN NEAL;;SCHALLER JOSEPH PAUL;;LIU JIM-ZHOU,,https://lens.org/186-894-735-768-688,Patent Application,no,0,0,15,15,0,C07K16/1027;;A61P11/00;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/20;;C07K16/1027,A61K35/20;;A61K39/395;;A61P11/00;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/20;;C07K16/10,,0,0,,,,EXPIRED
154,US,A1,US 2004/0260371 A1,068-623-938-068-558,2004-12-23,2004,US 46551703 A,2003-06-19,US 46551703 A,2003-06-19,Stabilizing apparatus for use with implantable leads,"
   A stabilizing apparatus for implantable leads includes an elongated stylet and a sleeve slidable disposed along the stylet. The stylet includes an enlarged distal end, and the sleeve is movable onto the enlarged distal end to create an interference in a lumen of the implantable lead. The interference allows the stylet and sleeve to be used to stabilize the implantable lead during procedures that may dislodge the lead. The stabilizing apparatus also includes a proximal device that allows controllable, relative motion between the sleeve and stylet. 
",GREENLAND JOHN;;BLANKENSHIP DREW;;ANDERSON DAVID;;HALDEMAN PAUL;;NIEDERECKER JIM;;QUILES NATHALIE,GREENLAND JOHN;;BLANKENSHIP DREW;;ANDERSON DAVID;;HALDEMAN PAUL;;NIEDERECKER JIM;;QUILES NATHALIE,CARDIAC PACEMAKERS INC (2003-11-10),https://lens.org/068-623-938-068-558,Patent Application,yes,19,32,2,2,0,A61N1/05;;A61N1/05,A61N1/05,607/116;;607/119,0,0,,,,DISCONTINUED
155,CA,A1,CA 2998434 A1,020-033-134-643-48X,2010-10-07,2010,CA 2998434 A,2010-04-01,US 16667609 P;;CA 2757373 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/020-033-134-643-48X,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P3/00;;A61P7/00;;C07C57/32;;C07C229/30,,0,0,,,,ACTIVE
156,KR,A,KR 20180033313 A,029-803-117-688-809,2018-04-02,2018,KR 20187008530 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,- L-ornithine phenyl acetate and methods of making thereof,"본 발명은 L-오르니틴 페닐 아세테이트의 결정 형태 및 이의 제조방법에 관한 것이다. 본 발명에 따른 L-오르니틴 페닐 아세테이트의 결정 형태는 형태 I, II, III, 및 V, 또는 이의 조합이다. 상기 결정 형태는 간성뇌증과 같은 간질환을 나타내는 환자를 치료하기 위하여 제조될 수 있다. 또한 본 발명은 L-오르니틴 페닐 아세테이트의 제제화 방법 또는 투여 방법에 관한 것이다.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/029-803-117-688-809,Patent Application,no,2,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;A61K31/198;;C07C57/46;;C07C229/26,,1,0,,,MX PA03009902호(2005.05.03.) 1부.,ACTIVE
157,EP,B1,EP 3686183 B1,087-587-725-504-866,2022-08-03,2022,EP 20161306 A,2010-04-01,US 16667609 P;;EP 17185173 A;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/087-587-725-504-866,Granted Patent,yes,1,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,ACTIVE
158,US,A1,US 2012/0208885 A1,111-730-451-348-380,2012-08-16,2012,US 201213436642 A,2012-03-30,US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/111-730-451-348-380,Patent Application,yes,0,27,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/195;;A61P1/02;;A61P1/16;;C07C229/26,514/564;;562/561,0,0,,,,ACTIVE
159,KR,A,KR 20190068561 A,012-024-732-035-762,2019-06-18,2019,KR 20197012203 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,- L-ornithine phenyl acetate and methods of making thereof,"본 발명은 L-오르니틴 페닐 아세테이트의 결정 형태 및 이의 제조방법에 관한 것이다. 본 발명에 따른 L-오르니틴 페닐 아세테이트의 결정 형태는 형태 I, II, III, 및 V, 또는 이의 조합이다. 상기 결정 형태는 간성뇌증과 같은 간질환을 나타내는 환자를 치료하기 위하여 제조될 수 있다. 또한 본 발명은 L-오르니틴 페닐 아세테이트의 제제화 방법 또는 투여 방법에 관한 것이다.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/012-024-732-035-762,Patent Application,no,1,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;A61K31/198;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
160,JP,A,JP 2020100624 A,090-917-518-164-894,2020-07-02,2020,JP 2020003346 A,2020-01-14,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"To provide crystalline forms of L-ornithine phenyl acetate and methods of making the same.SOLUTION: A crystalline form of L-ornithine phenyl acetate may be Forms I, II, III and V, or mixtures thereof. The crystalline form may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.SELECTED DRAWING: None",OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/090-917-518-164-894,Patent Application,no,3,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K9/08;;A61K31/198;;A61P7/00;;A61P11/16;;A61P25/00;;C07C227/18;;C07C227/42,,1,0,,,"メキシコ公開特許０３００９９０２号公報, JPN7014001418, 3 May 2005 (2005-05-03), ISSN: 0004650230",ACTIVE
161,US,A1,US 2021/0040832 A1,121-925-108-635-852,2021-02-11,2021,US 201716644794 A,2017-12-13,US 2017/0066224 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria.",HALLIBURTON ENERGY SERVICES INC,MONTALVO JANETTE CORTEZ;;INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,HALLIBURTON ENERGY SERVICES INC (2017-12-05),https://lens.org/121-925-108-635-852,Patent Application,yes,0,2,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,E21B43/267;;E21B47/11,,0,0,,,,ACTIVE
162,US,A1,US 2015/0251990 A1,157-204-433-701-346,2015-09-10,2015,US 201514715481 A,2015-05-18,US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/157-204-433-701-346,Patent Application,yes,0,23,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;C07C51/42,,0,0,,,,ACTIVE
163,KR,A,KR 20200070438 A,185-425-331-932-236,2020-06-17,2020,KR 20207016586 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,- L-ornithine phenyl acetate and methods of making thereof,"본 발명은 L-오르니틴 페닐아세테이트의 결정 형태 및 이의 제조방법에 관한 것이다. 본 발명에 따른 L-오르니틴 페닐아세테이트의 결정 형태는 형태 I, II, III, 및 V, 또는 이의 조합이다. 상기 결정 형태는 간성뇌증과 같은 간질환을 나타내는 환자를 치료하기 위하여 제조될 수 있다. 또한 본 발명은 L-오르니틴 페닐아세테이트의 제제화 방법 또는 투여 방법에 관한 것이다.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/185-425-331-932-236,Patent Application,no,1,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;A61K31/198;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
164,EP,B1,EP 3263100 B1,038-029-637-208-377,2020-04-01,2020,EP 17185173 A,2010-04-01,US 16667609 P;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2020-03-25)",https://lens.org/038-029-637-208-377,Granted Patent,yes,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,6,3,146-807-588-852-994;;076-996-633-264-525;;178-262-138-140-918,10.1021/op900169b;;10.1016/j.ajps.2014.05.002;;10.1021/ar00052a005,"MICHAEL B. HURSTHOUSE ET AL: ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why Is Crystallisation Nevertheless Such a Good Purification Technique? +"", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, vol. 13, no. 6, 20 November 2009 (2009-11-20), US, pages 1231 - 1240, XP055576610, ISSN: 1083-6160, DOI: 10.1021/op900169b;;EUN HEE LEE: ""A practical guide to pharmaceutical polymorph screening & selection"", ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 9, no. 4, 16 March 2014 (2014-03-16), NL, pages 163 - 175, XP055260946, ISSN: 1818-0876, DOI: 10.1016/j.ajps.2014.05.002;;DUNITZ J D ET AL: ""DISAPPEARING POLYMORPHS"", ACCOUNTS OF CHEMICAL RESEARCH, ACS, WASHINGTON, DC, US, vol. 28, no. 4, 1 January 1995 (1995-01-01), pages 193 - 200, XP000916646, ISSN: 0001-4842, DOI: 10.1021/AR00052A005;;KAISAR RAZA ET AL.: ""Polymophism: The Phenomenon Affecting the Performance of Drugs"", S.O.J. PHARM. PHARM. SCIENCE, 2014, pages 1 - 10;;BRAGA ET AL., STRUC. BOND., 2009, pages 25 - 50;;ALFONSO R. GENNARO: ""Remington: The Science and Practice of Pharmacy"", 2000",ACTIVE
165,AU,A1,AU 2017/202081 A1,055-471-215-080-48X,2017-04-20,2017,AU 2017/202081 A,2017-03-29,AU 2017/202081 A;;AU 2015/221466 A;;AU 2010/232521 A,2010-04-01,L-ornithine phenyl acetate and methods of making thereof,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/055-471-215-080-48X,Patent Application,no,0,0,6,6,0,,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
166,EP,A4,EP 2413924 A4,082-637-161-457-662,2013-01-02,2013,EP 10759442 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2017-08-30)",https://lens.org/082-637-161-457-662,Search Report,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,1,0,,,No further relevant documents disclosed,ACTIVE
167,US,A1,US 2014/0288327 A1,156-720-788-521-058,2014-09-25,2014,US 201414299940 A,2014-06-09,US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/156-720-788-521-058,Patent Application,yes,0,24,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/32;;C07C227/40,562/494,0,0,,,,ACTIVE
168,PT,T,PT 2413924 T,051-427-249-011-059,2018-01-04,2018,PT 10759442 T,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/051-427-249-011-059,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
169,DK,T3,DK 3686183 T3,074-511-296-952-384,2022-10-03,2022,DK 20161306 T,2010-04-01,US 16667609 P;;EP 17185173 A,2009-04-03,L-ORNITHINPHENYLACETAT OG FREMGANGSMÅDER TIL FREMSTILLING DERAF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/074-511-296-952-384,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,ACTIVE
170,JP,A,JP 2017081940 A,086-226-462-601-751,2017-05-18,2017,JP 2016237164 A,2016-12-07,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"PROBLEM TO BE SOLVED: To provide methods of producing L-ornithine phenyl acetate salts that can avoid the side effects, such as ascites, plethora and electrolyte imbalance, associated with ingestion of a particular salt of L-ornithine (e.g., sodium) as an active ingredient, in the treatment of hepatic encephalopathy and the like associated with plethora and electrolyte imbalance, and to provide pharmaceutical compositions containing the salts.SOLUTION: A composition contains L-ornithine phenylacetate of a crystalline form. The L-ornithine phenylacetate is a L-ornithine phenyl acetate salt, and preferably shows a powder X-ray diffraction pattern comprising at least three characteristic peaks selected from the group consisting of about 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2θ.SELECTED DRAWING: Figure 1",OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/086-226-462-601-751,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P7/00;;A61P43/00;;C07C57/32,,4,0,,,"メキシコ公開特許０３００９９０２号公報, JPN7014001418, 3 May 2005 (2005-05-03), ISSN: 0003629832;;小嶌隆史: ""医薬品開発における結晶性選択の効率化を目指して"", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0003629833;;松岡正邦: ""有機物の結晶化技術の高度化−粒径,形態,多形,純度の制御−"", PHARM TECH JAPAN, vol. 第19巻, 第6号, JPN6009053754, 1 May 2003 (2003-05-01), pages 91 - 101, ISSN: 0003629834;;平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0003629835",ACTIVE
171,MX,A,MX 2011010262 A,109-400-122-817-445,2012-01-25,2012,MX 2011010262 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF.,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/109-400-122-817-445,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
172,CY,T1,CY 1119843 T1,150-606-787-482-803,2018-06-27,2018,CY 171101334 T,2017-12-20,US 2010/0029708 W;;US 16667609 P,2009-04-03,ΦΑΙΝΥΛΟΞΙΚΗ L-ΟΡΝΙΘΙΝΗ ΚΑΙ ΜΕΘΟΔΟΙ ΠΑΡΑΣΚΕΥΗΣ ΑΥΤΗΣ,"Αποκαλύπτονται στο παρόν κρυσταλλικές μορφές φαινυλοξικής L-ορνιθίνης και μέθοδοι παρασκευής αυτών. Η κρυσταλλική μορφή μπορεί, σε κάποιες υλοποιήσεις, να είναι οι Μορφές I, II, III και V ή μείγματα αυτών. Οι κρυσταλλικές μορφές μπορούν να μορφοποιηθούν για τη θεραπεία υποκειμένων με ηπατικές διαταραχές, όπως ηπατική εγκεφαλοπάθεια. Επομένως, κάποιες υλοποιήσεις περιλαμβάνουν σκευάσματα και μεθόδους χορήγησης της φαινυλοξικής L-ορνιθίνης.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/150-606-787-482-803,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
173,DK,T3,DK 3263100 T3,015-949-563-331-440,2020-05-11,2020,DK 17185173 T,2010-04-01,US 16667609 P;;EP 10759442 A,2009-04-03,L-ORNITHINPHENYLACETAT OG FREMGANGSMÅDER TIL FREMSTILLING DERAF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/015-949-563-331-440,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
174,MX,A,MX 2020009699 A,047-276-893-658-304,2021-12-17,2021,MX 2020009699 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF.,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;WATT STEPHEN WILLIAM;;FIGINI ATTILIA;;MANINI PETER;;HENDERSON DOUGAN CHRISTINE,,https://lens.org/047-276-893-658-304,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
175,HR,T8,HR P20221232 T8,073-560-109-947-358,2023-02-03,2023,HR P20221232 T,2010-04-01,US 16667609 P;;EP 20161306 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/073-560-109-947-358,Amended Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,ACTIVE
176,ES,T3,ES 2928586 T3,094-169-368-793-250,2022-11-21,2022,ES 20161306 T,2010-04-01,US 16667609 P,2009-04-03,Fenilacetato de L-ornitina y métodos para elaborar el mismo,"En el presente documento se describen formas cristalinas de acetato de L - ornitina fenilo y métodos para prepararlas. La forma cristalina puede, en algunas realizaciones, ser las Formas I, II, III y V, o mezclas de las mismas. Las formas cristalinas pueden formularse para tratar sujetos con trastornos hepáticos, como encefalopatía hepática. Por consiguiente, algunas realizaciones incluyen formulaciones y métodos de administración de fenilacetato de L-ornitina. (Traducción automática con Google Translate, sin valor legal)",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/094-169-368-793-250,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,ACTIVE
177,SG,A1,SG 174982 A1,154-611-403-029-826,2011-11-28,2011,SG 2011071164 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/154-611-403-029-826,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,,,0,0,,,,PENDING
178,PL,T3,PL 2413924 T3,002-450-921-884-973,2018-02-28,2018,PL 10759442 T,2010-04-01,US 16667609 P;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/002-450-921-884-973,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
179,US,B2,US 8173706 B2,068-810-427-338-257,2012-05-08,2012,US 75376310 A,2010-04-02,US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/068-810-427-338-257,Granted Patent,yes,48,32,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/185;;C07C53/134,514/576;;562/496,99,81,109-586-006-962-328;;067-100-980-739-280;;006-389-848-693-948;;013-381-039-504-948;;178-262-138-140-918;;012-776-602-401-260;;146-807-588-852-994;;107-486-946-957-376;;052-684-471-190-493;;052-067-038-116-555;;064-055-337-562-368;;069-739-648-979-821;;054-995-005-467-222;;046-328-577-402-919;;029-419-591-846-994;;038-642-776-927-940;;172-105-260-241-360;;021-594-673-656-876;;012-247-665-964-294;;033-842-245-951-890;;036-013-168-609-901;;184-275-615-368-06X;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;085-339-541-354-722;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;007-364-858-655-289;;043-146-150-003-306;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;144-424-389-607-020;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;009-191-521-945-483;;073-092-236-316-538;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;004-568-483-555-796;;063-040-386-072-391;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;032-748-625-290-265;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;008-274-826-287-829;;093-200-165-594-194,10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10551405;;10.1016/s0168-8278(99)80361-4;;10.1007/s005350200006;;11871762;;10051463;;10.1002/hep.510290309;;10.1021/ar00052a005;;10.1038/ajg.2009.191;;19455106;;10.1021/op900169b;;10.1016/j.mehy.2006.12.061;;17467190;;10.1055/s-2003-42645;;14523680;;19409290;;10.1053/j.gastro.2009.04.016;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1016/s0026-0495(03)00089-1;;12870174;;3965666;;10.1093/jn/115.1.146;;10.1002/hep.1840200109;;8020904;;10.1016/0270-9139(94)90133-3;;12848729;;10.1046/j.1469-0691.2003.00691.x;;10.1152/ajpendo.1981.241.4.e310;;10.1097/01.ccm.0000287592.94554.5f;;17901832;;10.1097/00019616-200203000-00008;;10.1055/s-2004-826885;;15213875;;10.1016/s0899-9007(98)00191-9;;10198918;;8941257;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1067/mpd.2001.109792;;11148526;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;9612237;;10.1152/ajpendo.1998.274.5.e801;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;4403084;;10.1098/rspb.1972.0064;;15176533;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1111/j.1530-0277.2006.00074.x;;16573581;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;3058448;;10.1055/s-2008-1067908;;10.1007/bf01477666;;225605,"Bighley, L.D., et al.. ""Salt Forms of Drugs and Absorption"" in Encyclopedia of Pharmaceutical Technology, Eds. J. Swarbrick and J.C. Boylan, vol. 13, Marcel Dekker, Inc., New York, (1996), pp. 453-499.;;Shriner, et al., ""Recrystallization,"" in The Systematic Identification of Organic Compounds, John Wiley & Sons, Inc., New York, (1998), pp. 78-81.;;Als-Nielsen, Bodil, et al., Non-Absorbable Disaccharides for Hepatic Encephyalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Dunitz, et al., ""Disappearing Polymorphs,"" Acc. Chem. Res. 28:193-200, 1995.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Hursthouse, et al., ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why . . . ,"" Organic Process Research & Development, 13:1231-1240, 2009.;;Jalan, et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses, 2007, p. 1064-1069, vol. 69, Elsevier Ltd.;;Jalan, M.D., Rajiv, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publishers, Inc., New York, NY, USA.;;Jalan, R., et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Cirpofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, p. 935-938, vol. 52, No. 7, Elsevier Inc.;;Rogers, Q. R. et al., Deficiency of Pyrroline-5-Carboxylate Synthase in the Intestinal Mucosa of the Cat, The Journal of Nutrition, 1985, pp. 146-150, vol. 115, No. 1, American Institution of Nutrition.;;Sanyal et al., Portosystemic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Results of a Prospective Controlled Study, Hepatology, 1994, p. 46-55, vol. 20, No. 1, Pt. 1, The American Association for the Study of Liver Diseases.;;Sanyal, A. J., Prediction of Variceal Hemorrhage in Patients with Cirrhosis, UpToDate, Inc., Website (www.uptodate.com), Jan. 2010, UpToDate®.;;Singh, et al., Changing Epidemiology and Predictors of Mortality in Patients With Spontaneous Bacterial Peritonitis at a Liver Transplant Unit, Clinical Microbiology and Infection, Jun. 2003, p. 531-537, vol. 9, No. 6., European Society of Clinical Microbiology and Infectious Diseases.;;Stewart, P. M., et al., Effects of Arginine-Free Meals on Ureagenesis in Cats, American Journal of Physiological, 1981, p. E310-E315, vol. 241, No. 4, The American Physiological Society.;;Stravitz, MD, et al., Intensive Care of Patients with Acute Liver Failure: Recommendations of the U.S. Acute Liver Failure Study Group, Critical Care Medicine, 2007, p. 2498-2508, vol. 35, No. 11, Lippincott Williams & Wilkins.;;TDRdata.com, results from query of ""Spontaneous Bacterial Peritonitis"" in the epidemiological and references databases at www.tdrdata.com, retrieved on Jul. 27, 2010, p. 1-7.;;Tuchman, M., et al., Management of Inherited Disorders of Ureagenesis, The Endocrinologist, 2002, p. 99-109, vol. 12, No. 2.;;Demand with Article 34 amendments, filed Feb. 3, 2011, in International Application No. PCT/US2010/029708.;;Demand with Article 34 amendments, filed May 16, 2011, in International Application No. PCT/US2010/029708.;;Written Opinion of the International Preliminary Examining Authority, mailed Mar. 17, 2011, for International Application No. PCT/ US2010/029708.;;Written Opinion of the International Preliminary Examining Authority, mailed Jun. 2, 2011, for International Application No. PCT/ US2010/029708.;;Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, pp. 1430-1433, vol. 129 (in German).;;Mizock, MD, FACP, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;""Sodium phenylbutyrate for urea cycle enzyme deficiencies."" [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Aggarwal et al., ""Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted tothe Medical ICU"", Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., ""Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate"", Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., ""Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy"", Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., ""The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia"", J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Anadiotis et al., ""Ornithine transcarbamylase deficiency and pancreatitis"", J Pediatr, 2001, vol. 138, pp. 123-124.;;Bachmann et al., ""Ammonia toxicity to the brain and creatine"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., ""Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,"", Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., ""Alternative pathway therapy for urea cycle disorders: twenty years later"", J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., ""Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse"", Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., ""Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,"", Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berge et al., J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., ""Long-term management of patients with urea cycle disorders"", J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bleichner, et al., ""Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage"", British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., ""Exogenous glutamine: the clinical evidence,"", Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., Biochem J, 1976, vol. 160, pp. 205-209.;;Brunquell et al., ""Electroencephalographic findings in ornithine transcarbamylase deficiency"", J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., ""Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis"", Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., ""Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis"", The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., ""Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients"", Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, ""Pathophysiology of hepatic encephalopathy: a new look at ammonia"", Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Cavarec et al., ""Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor"", Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., ""Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease"", Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chen et al., ""Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency"", Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Darmaun et al., ""Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism"", Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;Database WPI, Section Ch, Week 200331, Derwent Publications Ltd., London, GB; XP002364873 & CN 1383815 A (LIU W), Dec. 11, 2002 (Abstract Only).;;Dejong et al., ""Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia"", Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al. , ""Hyperammonemic encephalopathy"", J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Desjardins et al., ""Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle"", Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Enns et al., ""Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,"", N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;EPO Examination Report dated Nov. 5, 2008 from EP patent application No. 05808837.8.;;EPO-Extended European Search Report for EP 09013613.6, dated Jan. 15, 2010.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garden et al., ""Prediction of outcome following acute variceal haemorrhage"", Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., ""Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels"", J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., ""Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,"", Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, ""Ornithine transcarbamylase deficiency: a urea cycle defect"", European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., ""Prevention of initial variceal hemorrhage"", Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Greensteine et al., Arch Biochem Biophys, 1956, vol. 64, pp. 342-354.;;Grossi et al., ""Amino acids mixtures in prevention of acute ammonia intoxication in dogs"", Arch Surg, 1967, vol. 94, pp. 261-266.;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urca Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., ""Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)"", Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., ""Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?"", J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., ""The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy"", Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., ""Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy"", Biol. Pharm. Bull., [no date], vol. 25, Issue 9, pp. 1244-1246.;;Igarashi et al., ""Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography"", Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., ""Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria"", Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;Intellectual Property Office of Singapore (IPOS) Search Report and Written Opinion, dated Apr. 23, 2010, Singapore Patent Application No. 200907712-4.;;International Preliminary Report on Patentability issued May 30, 2007 during the prosecution of the International Application No. PCT/GB2005/004539.;;International Search Report and Written Opinion received in PCT/US2010/029708 dated Jun. 3, 2010., Jun. 3, 2010.;;International Search Report issued Feb. 8, 2006 during the prosecution of the International Application No. PCT/GB2005/004539.;;IPONZ Examination Report dated Apr. 8, 2008 from NZ patent application No. 555870.;;Iyer et al., ""Mouse model for human arginase deficiency"", Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., ""Acute-on-chronic liver failure: pathophysiological basis of therapeutic options"", Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., ""Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,"", Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., ""The molecular pathogenesis of hepatic encephalopathy"", The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;James et al., ""The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species"", Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., ""New secondary metabolites of phenylbutyrate in humans and rats"", Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, ""Ammonia metabolism and hepatic encephalopathy"", Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Kircheis et al., ""Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,"", Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Linderoth et al., ""Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,"", Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;MacArthur et al., ""Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., ""Long-term treatment of girls with ornithine transcarbamylase deficiency"", N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., ""Prospective treatment of urea cycle disorders"", J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maier, ""Therapie der hepatischen Enzephalopathie"", Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Maier, K. P. et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.",ACTIVE
180,US,A1,US 2022/0162155 A1,063-285-298-529-975,2022-05-26,2022,US 202117516591 A,2021-11-01,US 202117516591 A;;US 202016778696 A;;US 201816037655 A;;US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/063-285-298-529-975,Patent Application,yes,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C57/32;;C07C227/42;;C07C229/26,,0,0,,,,PENDING
181,LT,T,LT 3686183 T,089-734-386-089-564,2022-11-10,2022,LT 20161306 T,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/089-734-386-089-564,Unknown,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61K31/205;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/00;;A61P7/00;;A61P25/00;;A61P43/00;;C07C57/32;;C07C57/46,,0,0,,,,PENDING
182,CA,C,CA 2998344 C,109-225-910-951-957,2020-06-02,2020,CA 2998344 A,2010-04-01,US 16667609 P;;CA 2757373 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/109-225-910-951-957,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P3/00;;A61P7/00;;C07C57/32;;C07C229/30,,0,0,,,,ACTIVE
183,DK,T3,DK 2413924 T3,150-416-380-339-514,2017-12-11,2017,DK 10759442 T,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINPHENYLACETAT OG FREMGANGSMÅDER TIL FREMSTILLING HERAF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;WATT STEPHEN WILLIAM;;DOUGAN CHRISTINE HENDERSON;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/150-416-380-339-514,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
184,EP,A1,EP 4101838 A1,017-395-017-884-356,2022-12-14,2022,EP 22185562 A,2010-04-01,US 16667609 P;;EP 20161306 A;;EP 17185173 A;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"A process for making L-ornithine phenylacetate, comprising: 
forming a solution of L-ornithine, wherein the solution comprises water; 
adding a pH modifier to the solution; 
adding phenylacetic acid to the solution ; and 
isolating L-ornithine phenylacetate from the solution.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/017-395-017-884-356,Patent Application,yes,6,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/18;;C07C51/41;;C07C51/43;;C07C57/32;;C07C227/42;;C07C229/26,,2,0,,,"BIGHLEY L.D. ET AL.: ""Encyclopedia of pharmaceutical technology"", vol. 12, MARCEL DEKKER, INC., article ""Salt forms of drugs and absorption"", pages: 452 - 499;;FINGL ET AL.: ""The Pharmacological Basis of Therapeutics"", 1975, pages: 1",PENDING
185,BR,A2,BR PI1013657 A2,056-933-460-083-537,2016-04-26,2016,BR PI1013657 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,"composições, processos de produção ade sal de acetato de fenil l-ornitina, método de compressão de acetato de fenil l-ornitina e uso de quantidade terapeuticamente efetiva de forma cristalina do sal de acetato de fenil l-ornitina",,OCERA THERAPEUTICS INC,FIGINI ATTILIA;;DOUGAN CHRISTINE HENDERSON;;BEHLING JIM;;ANDERSON KEITH;;MANINI PETER;;WATT STEPHEN WILLIAM,,https://lens.org/056-933-460-083-537,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,DISCONTINUED
186,CA,C,CA 2757373 C,091-384-781-385-480,2018-05-08,2018,CA 2757373 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/091-384-781-385-480,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
187,EP,B1,EP 2413924 B1,096-446-843-496-93X,2017-09-27,2017,EP 10759442 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2017-08-30)",https://lens.org/096-446-843-496-93X,Granted Patent,yes,0,11,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,3,2,178-262-138-140-918;;146-807-588-852-994,10.1021/ar00052a005;;10.1021/op900169b,"DAVID L. BISH ET AL.: ""Accuracy in Quantitative X-Ray Powder Diffraction Analyses"", 1995, Retrieved from the Internet <URL:http://www.doitpoms.ac.uk/tlpplib/xray-diffraction/phase_identification.php>;;JACK D. DUNITY ET AL.: ""Disappearing Polymorphs"", ACC. CHEM. RES., vol. 28, 1995 - 1995, pages 193 - 200;;MICHAEL B. HURSTHOUSE ET AL.: ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?"", ORG. PROG. RES. DEV., vol. 13, 2009 - 2009, pages 1231 - 1240",ACTIVE
188,EP,A1,EP 2413924 A1,190-419-296-691-755,2012-02-08,2012,EP 10759442 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2017-08-30)",https://lens.org/190-419-296-691-755,Patent Application,yes,0,1,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
189,JP,A,JP 2015145372 A,195-128-533-092-388,2015-08-13,2015,JP 2015031199 A,2015-02-20,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THE SAME,"PROBLEM TO BE SOLVED: To provide compositions formulated for treating subjects with liver disorders such as hepatic encephalopathy caused by hyperammonemia, and methods of making salts included in the compositions.SOLUTION: A composition comprises at least about 50 wt.% of a crystalline form of an L-ornithine phenyl acetate salt and at least about 0.01 wt.% of benzoic acid or a salt thereof. A method for making the L-ornithine phenyl acetate salt comprises: intermixing an L-ornithine salt, a benzoate salt and a solvent to form an intermediate solution; intermixing phenyl acetate with the intermediate solution; and isolating a composition comprising at least 70 wt.% of crystalline L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/195-128-533-092-388,Patent Application,no,1,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/32;;C07C51/41;;C07C51/43;;C07C63/06;;C07C63/08;;C07C227/14;;C07C227/42;;C07C229/26,,1,0,,,"メキシコ公開特許０３００９９０２号公報, JPN7014001418, 3 May 2005 (2005-05-03), ISSN: 0003209057",ACTIVE
190,AU,A1,AU 2015/221466 A1,043-316-735-651-252,2015-09-24,2015,AU 2015/221466 A,2015-09-02,AU 2010/232521 A;;AU 2015/221466 A,2010-04-01,L-ornithine phenyl acetate and methods of making thereof,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, I and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/043-316-735-651-252,Patent Application,no,0,14,6,6,0,,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
191,CA,A1,CA 3074010 A1,067-115-620-080-955,2019-06-20,2019,CA 3074010 A,2017-12-13,US 2017/0066224 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria.",HALLIBURTON ENERGY SERVICES INC,MONTALVO JANETTE CORTEZ;;INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,,https://lens.org/067-115-620-080-955,Patent Application,no,0,0,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,E21B43/25;;E21B47/10,,0,0,,,,PENDING
192,US,B2,US 8492439 B2,077-010-051-224-307,2013-07-23,2013,US 201213436642 A,2012-03-30,US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/077-010-051-224-307,Granted Patent,yes,48,28,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/32;;A61K31/205;;C07C227/42;;C07C229/26,514/576;;562/496,99,85,184-275-615-368-06X;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;109-586-006-962-328;;085-339-541-354-722;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-684-471-190-493;;052-067-038-116-555;;004-568-483-555-796;;063-040-386-072-391;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;008-274-826-287-829;;093-200-165-594-194;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901;;031-758-280-989-128;;064-981-485-159-530;;049-796-115-905-999;;105-624-360-809-755;;060-965-237-325-653;;106-478-902-619-715;;020-191-827-595-592,8941257;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;10.1055/s-2003-42645;;14523680;;19409290;;10.1053/j.gastro.2009.04.016;;4403084;;10.1098/rspb.1972.0064;;15176533;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;3058448;;10.1055/s-2008-1067908;;10.1007/bf01477666;;225605;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918;;10.1016/s0387-7604(83)80059-x;;6670711;;10.1042/cs1020287;;10.1042/cs20010162;;11869169;;10.1002/hep.21737;;17680644;;10.1152/ajpgi.00445.2003;;15064231;;4997833;;10604106;;10.1016/s0955-2863(99)00022-4;;15539305,"""Sodium phenylbutyrate for urea cycle enzyme deficiencies."" [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Aggarwal et al., ""Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU"", Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., ""Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate"", Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., ""Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy"", Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., ""The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia"", J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Als-Nielsen, Bodil, et al., Non-Absorbable Disaccharides for Hepatic Encephyalopathy: Systematic Review of Randomised Trials, Bmj, 2004, p. 1-6.;;Anadiotis et al., ""Ornithine transcarbamylase deficiency and pancreatitis"", J Pediatr, 2001, vol. 138, pp. 123-124.;;Bachmann et al., ""Ammonia toxicity to the brain and creatine"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., ""Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,"", Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., ""Alternative pathway therapy for urea cycle disorders: twenty years later"", J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., ""Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse"", Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., ""Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,"", Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berge et al., J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., ""Long-term management of patients with urea cycle disorders"", J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley, L.D., et al.. ""Salt Forms of Drugs and Absorption"" in Encyclopedia of Pharmaceutical Technology, Eds. J. Swarbrick and J.C. Boylan, vol. 13, Marcel Dekker, Inc., New York, (1996), pp. 453-499.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., ""Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage"", British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., ""Exogenous glutamine: the clinical evidence,"", Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., Biochem J, 1976, vol. 160, pp. 205-209.;;Brunquell et al., ""Electroencephalographic findings in ornithine transcarbamylase deficiency"", J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., ""Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis"", Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., ""Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis"", The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., ""Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients"", Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, ""Pathophysiology of hepatic encephalopathy: a new look at ammonia"", Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., ""Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor"", Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., ""Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease"", Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chen et al., ""Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency"", Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Darmaun et al., ""Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism"", Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;Database WPI, Section Ch, Week 200331, Derwent Publications Ltd., London, GB; XP002364873 & CN 1383815 A (Liu W), Dec. 11, 2002 (Abstract Only).;;Dejong et al., ""Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia"", Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al. , Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011, in International Application No. PCT/US2010/029708.;;Demand with Article 34 amendments, filed May 16, 2011, in International Application No. PCT/US2010/029708.;;Desjardins et al., ""Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle"", Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz, et al., ""Disappearing Polymorphs,"" Acc. Chem. Res. 28:193-200, 1995.;;Enns et al., ""Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,"", N. Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;EPO Examination Report dated Nov. 5, 2008 from EP patent application No. 05808837.8.;;EPO-Extended European Search Report for EP 09013613.6, dated Jan. 15, 2010.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., ""Prediction of outcome following acute variceal haemorrhage"", Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., ""Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels"", J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., ""Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,"", Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, ""Ornithine transcarbamylase deficiency: a urea cycle defect"", European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., ""Prevention of initial variceal hemorrhage"", Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Greensteine et al., Arch Biochem Biophys, 1956, vol. 64, pp. 342-354.;;Grossi et al., ""Amino acids mixtures in prevention of acute ammonia intoxication in dogs"", Arch Surg, 1967, vol. 94, pp. 261-266.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, pp. 1430-1433, vol. 129 (in German).;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urca Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., ""Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)"", Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., ""Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?"", J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., ""The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy"", Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., ""Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy"", Biol. Pharm. Bull., [no date], vol. 25, Issue 9, pp. 1244-1246.;;Hursthouse, et al., ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why . . . ,"" Organic Process Research & Development, 13:1231-1240, 2009.;;Igarashi et al., ""Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography"", Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., ""Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria"", Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;Intellectual Property Office of Singapore (IPOS) Search Report and Written Opinion, dated Apr. 23, 2010, Singapore Patent Application No. 200907712-4.;;International Preliminary Report on Patentability issued May 30, 2007 during the prosecution of the International Application No. PCT/GB2005/004539.;;International Search Report and Written Opinion received in PCT/US2010/029708 dated Jun. 3, 2010.;;International Search Report issued Feb. 8, 2006 during the prosecution of the International Application No. PCT/GB2005/004539.;;IPONZ Examination Report dated Apr. 8, 2008 from NZ patent application No. 555870.;;Iyer et al., ""Mouse model for human arginase deficiency"", Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., ""Acute-on-chronic liver failure: pathophysiological basis of therapeutic options"", Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., ""Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,"", Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., ""The molecular pathogenesis of hepatic encephalopathy"", The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan, et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses, 2007, p. 1064-1069, vol. 69, Elsevier Ltd.;;Jalan, M.D., Rajiv, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, pp. 271-282, vol. 23, No. 3, Thieme Medical Publishers, Inc., New York, NY, USA.;;Jalan, R., et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;James et al., ""The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species"", Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., ""New secondary metabolites of phenylbutyrate in humans and rats"", Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, ""Ammonia metabolism and hepatic encephalopathy"", Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Cirpofloxacin in its Treatment, Gomel Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., ""Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,"", Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., ""Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,"", Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, p. 935-938, vol. 52, No. 7, Elsevier Inc.;;MacArthur et al., ""Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., ""Long-term treatment of girls with ornithine transcarbamylase deficiency"", N. Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., ""Prospective treatment of urea cycle disorders"", J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maier, ""Therapie der hepatischen Enzephalopathie"", Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Maier, K. P. et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Meijer, Alfred J. et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., ""A new therapy for portal systemic encephalopathy"", The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mihm et al., ""Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)"", Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., ""Septic Encephalopathy-Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy"", Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock, MD, FACP, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;Mizutani et al., ""Hyperargininemia: Clinical course and treatment with sodium benzoate and phenylacetic acid"", Brain Dev., 1983, vol. 5, Issue 6, pp. 555-563.;;Moinard et al., ""Effects of Ornithine 2-Oxoglutarateon Neutrophils in Stressed Rates: Evidence for the Involvement of Nitric Oxide and Polyamines"", Clin Sci, 2002, vol. 102, Issue 3, pp. 287-295, London, England.;;Mookerjee et al., ""Neutrophil dysfunction in alcoholilc hepatitis superimposed on cirrhosis is reversible and predicts the outcome,"", Hepatology, 2007, vol. 3, Issue 46, pp. 831-840.;;Mouille et al., Am J Gasteroenterol, 2004, vol. 287, pp. 344-351.;;Nance et al., ""Ammonia production in germ-free Eck fistula dogs"", Surgery, 1971, vol. 70, Issue 2, pp. 169-174.;;Navasa et al., ""Bacterial infections in liver cirrhosis,"", Ital J Gastroenterol Hepatol., 1999, vol. 7, Issue 31, pp. 616-625.;;Newsholme et al., ""Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease,"", J Nutr Biochem., 1999, vol. 6, Issue 10, pp. 316-324.",ACTIVE
193,AU,A1,AU 2010/232521 A1,090-312-276-873-898,2011-11-17,2011,AU 2010/232521 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;HENDERSON DOUGAN CHRISTINE;;WILLIAM WATT STEPHEN;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/090-312-276-873-898,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
194,CA,A1,CA 2998344 A1,114-680-408-981-187,2010-10-07,2010,CA 2998344 A,2010-04-01,US 16667609 P;;CA 2757373 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/114-680-408-981-187,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P3/00;;A61P7/00;;C07C57/32;;C07C229/30,,0,0,,,,ACTIVE
195,PL,T3,PL 3686183 T3,124-371-046-922-959,2022-11-28,2022,PL 20161306 T,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/124-371-046-922-959,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,PENDING
196,AU,B2,AU 2019/202311 B2,121-199-533-515-145,2021-02-04,2021,AU 2019/202311 A,2019-04-03,AU 2019/202311 A;;AU 2017/202081 A;;AU 2015/221466 A;;AU 2010/232521 A,2010-04-01,L-ornithine phenyl acetate and methods of making thereof,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Abstract Disclosed herein are crystalline forms of L-omithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I,II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/121-199-533-515-145,Granted Patent,no,0,0,6,6,0,,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
197,US,A1,US 2013/0296429 A1,149-515-518-598-868,2013-11-07,2013,US 201313937107 A,2013-07-08,US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/149-515-518-598-868,Patent Application,yes,0,26,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198,514/561;;562/493,0,0,,,,ACTIVE
198,US,B2,US 9034925 B2,162-229-510-457-829,2015-05-19,2015,US 201414299940 A,2014-06-09,US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/162-229-510-457-829,Granted Patent,yes,60,26,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/205;;A61K31/192;;A61K31/198;;C07C57/32;;C07C227/40;;C07C227/42;;C07C229/26,514/576;;562/496,99,94,005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;109-586-006-962-328;;085-339-541-354-722;;184-275-615-368-06X;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;023-591-152-002-307;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;005-411-405-905-202;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-067-038-116-555;;052-684-471-190-493;;004-568-483-555-796;;063-040-386-072-391;;001-333-743-768-03X;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;062-099-863-837-757;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901;;031-758-280-989-128;;064-981-485-159-530;;049-796-115-905-999;;105-624-360-809-755;;060-965-237-325-653;;106-478-902-619-715;;020-191-827-595-592;;026-684-980-375-813;;155-746-121-945-548;;014-585-057-157-928;;016-245-934-364-075;;017-040-741-145-623,10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;8941257;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;11391852;;10.1007/s002800000256;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;17101577;;10.1080/00365520600780403;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;19409290;;10.1053/j.gastro.2009.04.016;;10.1055/s-2003-42645;;14523680;;4403084;;10.1098/rspb.1972.0064;;15176533;;18823442;;10.1111/j.1440-1746.2008.05582.x;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918;;10.1016/s0387-7604(83)80059-x;;6670711;;10.1042/cs1020287;;10.1042/cs20010162;;11869169;;10.1002/hep.21737;;17680644;;10.1152/ajpgi.00445.2003;;15064231;;4997833;;10604106;;10.1016/s0955-2863(99)00022-4;;15539305;;11533304;;10.1093/jn/131.9.2515s;;10.1136/gut.40.3.418;;9135535;;pmc1027096;;12395326;;10.1053/jhep.2002.36497;;12020618;;10.1016/s0197-0186(02)00040-2;;12774005;;10.1053/jhep.2003.50221,"Aggarwal et al., ""Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU"", Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., ""Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate"", Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., ""Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy"", Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., ""The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia"", J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Als-Nielsen, Bodil, et al., Non-Absorbable Disaccharides for Hepatic Encephyalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., ""Ornithine transcarbamylase deficiency and pancreatitis"", J Pediatr, 2001, vol. 138, pp. 123-124.;;Anonymous, ""Sodium phenylbutyrate for urea cycle enzyme deficiencies."" [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Bachmann et al., ""Ammonia toxicity to the brain and creatine"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., ""Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,"", Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., ""Alternative pathway therapy for urea cycle disorders: twenty years later"", J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., ""Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse"", Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., ""Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,"", Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berg et al., ""Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the non-human primate"", Cancer Chemother Pharmacol. (May 2001) 47(5): 385-390. Abstract Only.;;Berge et al., Review Article: Pharmaceutical Salts, J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., ""Long-term management of patients with urea cycle disorders"", J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley et al., ""Salt Forms of Drugs and Absorption"" in Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. New York, (1996), pp. 453-499.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., ""Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage"", British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., ""Exogenous glutamine: the clinical evidence,"", Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes, Biochem J, 1976, vol. 160, pp. 205-209.;;Bruha et al., ""Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes"", Scand J Gastroenter. (2006) 41: 1454-1463.;;Brunquell et al., ""Electroencephalographic findings in ornithine transcarbamylase deficiency"", J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., ""Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis"", Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., ""Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis"", The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., ""Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients"", Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, ""Pathophysiology of hepatic encephalopathy: a new look at ammonia"", Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., ""Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor"", Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati, T. et al., Ornicetil on Encephalopathy Effect of Ornicetil (Ornithine Alpha-Ketoglutarate) on Encephalopathy in Patients with Acute and Chronic Liver Disease; Acta Hepato-Gastroenterol, 1977, vol. 24, pp. 434-439.;;Chen et al., ""Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency"", Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Clemmesen, et al., Cerebral Herniation in Patients with Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Darmaun et al., ""Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism"", Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;Database WPI, Section Ch, Week 200331, Derwent Publications Ltd., London, GB; XP002364873 & CN 1383815 A (Liu W), Dec. 11, 2002 (Abstract Only).;;Dejong et al., ""Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia"", Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al., Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Desjardins et al., ""Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle"", Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz et al., ""Disappearing Polymorphs"", Acc Chem Res. (1995) 28: 193-200.;;Enns et al., ""Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,"", N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., ""Prediction of outcome following acute variceal haemorrhage"", Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., ""Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels"", J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., ""Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,"", Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, ""Ornithine transcarbamylase deficiency: a urea cycle defect"", European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., ""Prevention of initial variceal hemorrhage"", Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Greenstein et al., Studies on the Metabolism of Amino Acids and Related Compounds in Vivo. III. Prevention of Ammonia Toxicity by Arginine and Related Compounds, Arch Biochem Biophys, 1956, vol. 64, Issue (2):, pp. 342-354.;;Grossi et al., ""Amino acids mixtures in prevention of acute ammonia intoxication in dogs"", Arch Surg, 1967, vol. 94, pp. 261-266.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, vol. 129; pp. 1430-1433 w/English Machine translation.;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urca Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., ""Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)"", Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., ""Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?"", J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., ""The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy"", Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., ""Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy"", Biol. Pharm. Bull., (2002), vol. 25, Issue 9, pp. 1244-1246.;;Hursthouse et al., ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?"", Organic Process Research & Development, (2009) 13:1231-1240.;;Igarashi et al., ""Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography"", Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., ""Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria"", Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;Iyer et al., ""Mouse model for human arginase deficiency"", Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., ""Acute-on-chronic liver failure: pathophysiological basis of therapeutic options"", Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., ""Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,"", Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., ""The molecular pathogenesis of hepatic encephalopathy"", The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses (2007) 69(5): 1064-1069, Elsevier Ltd.;;Jalan et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Jalan,, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publisheres, Inc., New York, NY, USA.;;James et al., ""The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species"", Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure,, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Jiang et al., ""L-Ornithine-I-aspartate in the management of hepatic encephalopathy: a meta-analysis"", J Gastroenterol Hepatol. (2009) 24(1): 9-14; available online: Sep. 28, 2008.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., ""New secondary metabolites of phenylbutyrate in humans and rats"", Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, ""Ammonia metabolism and hepatic encephalopathy"", Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Ciprofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., ""Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,"", Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., ""Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,"", Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lopez-Talavera et al., ""Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats"", Hepatology (1996) 23(6): 1616-1621.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, pp. 935-938, vol. 52, No. 7, Elsevier Inc.;;MacArthur et al., ""Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., ""Long-term treatment of girls with ornithine transcarbamylase deficiency"", N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., ""Prospective treatment of urea cycle disorders"", J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maev I.V. Primenenie preparata L-ornitin-L-aspartata v kompleksnoy terapii pechyonochnoy entsefalopatii u bolnykh tsirrozom pecheni. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2002, No. 6, pp. 60-66.;;Maier et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Maier, ""Therapie der hepatischen Enzephalopathie"", Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Meijer et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., ""A new therapy for portal systemic encephalopathy"", The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mihm et al., ""Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)"", Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., ""Septic Encephalopathy-Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy"", Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock,, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;Mizutani et al., ""Hyperargininemia: Clinical course and treatment with sodium benzoate and phenylacetic acid"", Brain Dev., 1983, vol. 5, Issue 6, pp. 555-563.;;Moinard et al., ""Effects of Ornithine 2-Oxoglutarateon Neutrophils in Stressed Rates: Evidence for the Involvement of Nitric Oxide and Polyamines"", Clin Sci, 2002, vol. 102, Issue 3, pp. 287-295, London, England.;;Mookerjee et al., ""Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome,"", Hepatology, 2007, vol. 3, Issue 46, pp. 831-840.;;Mouille et al., Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion, Am J Gasteroenterol, 2004, vol. 287, pp. 344-351.;;Nance et al., ""Ammonia production in germ-free Eck fistula dogs"", Surgery, 1971, vol. 70, Issue 2, pp. 169-174.;;Navasa et al., ""Bacterial infections in liver cirrhosis,"", Ital J Gastroenterol Hepatol., 1999, vol. 7, Issue 31, pp. 616-625.;;Newsholme et al., ""Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease,"", J Nutr Biochem., 1999, vol. 6, Issue 10, pp. 316-324.;;Newsholme, ""Why is L-glutamine metabolism important to cells of the immune system in health, post injury, surgery or infection?"", J Nutr., 2001, vol. 9 Suppl, Issue 131, pp. 2515S-2522S.;;Olde Damink et al., ""Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats"", Gut, 1997, vol. 40, pp. 418-424.;;Olde Damink et al., ""Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS"", Hepatology, 2002, vol. 36, Issue 5, pp. 1163-1171.;;Olde Damink et al., ""Interorgan ammonia metabolism in liver failure"", [not known], 2002, vol. 41, pp. 177-188.;;Olde Damink et al., ""The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis"", [not known], 2003, vol. 37, pp. 1277-1285.",ACTIVE
199,CN,A,CN 106810464 A,170-113-924-693-982,2017-06-09,2017,CN 201710053850 A,2010-04-01,US 16667609 P;;CN 201080021311 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/170-113-924-693-982,Patent Application,no,2,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61K31/205;;A61P1/16;;C07C51/41;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/40;;C07C227/42,,0,0,,,,ACTIVE
200,HR,T1,HR P20221232 T1,186-894-324-244-978,2022-12-23,2022,HR P20221232 T,2010-04-01,US 16667609 P;;EP 20161306 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/186-894-324-244-978,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;C07C229/26;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,0,0,,,,ACTIVE
201,CA,C,CA 3077846 C,122-904-777-058-195,2023-08-22,2023,CA 3077846 A,2010-04-01,US 16667609 P;;CA 2998344 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/122-904-777-058-195,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/30;;A61K31/192;;A61K31/198;;C07C51/43;;C07C57/32;;C07C227/42,,0,0,,,,PENDING
202,US,B2,US 11161802 B2,004-507-351-128-339,2021-11-02,2021,US 202016778696 A,2020-01-31,US 202016778696 A;;US 201816037655 A;;US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/004-507-351-128-339,Granted Patent,yes,91,1,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C57/32;;C07C227/42;;C07C229/26,,227,165,015-750-440-523-292;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;013-238-882-635-851;;109-586-006-962-328;;085-339-541-354-722;;184-275-615-368-06X;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;023-591-152-002-307;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;107-535-256-780-313;;087-003-294-580-08X;;005-411-405-905-202;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;037-307-523-122-787;;009-214-187-079-899;;104-949-654-022-72X;;006-389-848-693-948;;011-803-647-630-475;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;038-873-808-172-211;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;072-976-603-582-975;;178-262-138-140-918;;019-378-000-546-279;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;161-575-194-317-861;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-067-038-116-555;;052-684-471-190-493;;004-568-483-555-796;;063-040-386-072-391;;001-333-743-768-03X;;003-328-576-973-971;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;007-084-720-458-198;;064-055-337-562-368;;069-739-648-979-821;;013-841-799-915-103;;032-748-625-290-265;;062-099-863-837-757;;079-593-245-841-055;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901;;031-758-280-989-128;;064-981-485-159-530;;049-796-115-905-999;;008-841-018-283-529;;105-624-360-809-755;;060-965-237-325-653;;106-478-902-619-715;;020-191-827-595-592;;026-684-980-375-813;;155-746-121-945-548;;014-585-057-157-928;;016-245-934-364-075;;017-040-741-145-623;;022-940-770-633-516;;027-296-352-845-29X;;118-190-784-711-854;;028-094-130-639-491;;052-664-611-823-937;;041-763-726-091-611;;105-215-652-900-713;;046-377-535-715-555;;075-927-681-372-170;;073-180-972-519-149;;044-485-594-222-465;;046-328-577-402-919;;091-010-477-383-601;;028-944-494-543-501;;111-311-443-070-933;;012-261-100-493-035;;124-467-405-728-071;;010-208-513-979-628;;029-419-591-846-994;;003-526-763-484-740;;032-516-727-018-702;;094-400-537-780-40X;;084-881-256-943-396;;029-624-106-758-273;;052-308-695-243-647;;035-155-644-148-657;;093-350-008-802-15X;;001-436-299-870-282;;083-831-280-762-833;;038-642-776-927-940;;008-372-723-096-05X;;002-992-545-486-58X;;018-419-048-897-547;;172-105-260-241-360;;021-594-673-656-876;;129-174-137-700-680;;036-430-862-175-32X;;006-979-616-832-902;;004-086-526-654-013;;093-159-361-636-556;;012-247-665-964-294;;076-070-224-505-210;;016-249-747-580-90X;;022-980-060-535-387;;007-319-763-778-558;;041-883-471-681-172;;102-962-063-447-172;;034-978-591-029-435;;006-945-361-671-311;;064-348-611-021-409;;013-520-813-294-749;;121-778-149-592-003;;012-164-908-969-046;;015-634-309-364-793;;035-230-669-274-593,10.1053/jhep.2003.50133;;12668985;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;19707277;;10.2147/tcrm.s4443;;pmc2724191;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;8941257;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;11391852;;10.1007/s002800000256;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;10.1016/j.jceh.2017.01.025;;1008850;;pmc1164223;;10.1042/bj1600205;;17101577;;10.1080/00365520600780403;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s11011-007-9072-3;;17851742;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.1007/s005350200006;;11871762;;pmc6416231;;10.1007/s40265-018-1020-5;;30706422;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;10.1002/hep.22897;;19437490;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1128/aem.65.8.3287-3292.1999;;10427008;;pmc91493;;10.1021/ar00052a005;;10.1111/j.1572-0241.2000.03295.x;;11151894;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;10.1016/j.nutres.2007.04.019;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;19409290;;10.1053/j.gastro.2009.04.016;;10.1055/s-2003-42645;;14523680;;4403084;;10.1098/rspb.1972.0064;;15176533;;18823442;;10.1111/j.1440-1746.2008.05582.x;;10.1007/s11011-013-9391-5;;23456516;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.23037;;19441099;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;20382058;;pmc2905228;;10.1016/j.ymgme.2010.03.014;;10.1111/j.1530-0277.2006.00074.x;;16573581;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10831173;;10.1016/s0026-0495(00)80038-4;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918;;10.1016/s0387-7604(83)80059-x;;6670711;;10.1042/cs1020287;;10.1042/cs20010162;;11869169;;10.1002/hep.21737;;17680644;;10.1053/j.gastro.2006.12.035;;17570224;;10.1152/ajpgi.00445.2003;;15064231;;4997833;;10604106;;10.1016/s0955-2863(99)00022-4;;15539305;;11533304;;10.1093/jn/131.9.2515s;;10.1136/gut.40.3.418;;9135535;;pmc1027096;;12395326;;10.1053/jhep.2002.36497;;12020618;;10.1016/s0197-0186(02)00040-2;;12774005;;10.1053/jhep.2003.50221;;pmc508470;;9389730;;10.1172/jci119812;;10.1053/jhep.1996.v24.pm0008855179;;8855179;;10.1002/hep.510240408;;10.3109/01677068709167220;;3598771;;10.1007/s004310050985;;9877039;;9846074;;10801054;;10.1023/a:1005661631281;;2982530;;10.1042/cs0680247;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10986219;;pmc1728090;;10.1136/gut.47.4.571;;9250851;;10.1056/nejm199708143370707;;pmc4237123;;23847109;;10.1002/hep.26611;;3965666;;10.1093/jn/115.1.146;;15246207;;10.1016/j.jhep.2004.03.021;;10.1016/s1569-1993(07)60026-5;;10.1016/s0168-8278(98)80479-0;;10462368;;10.1002/hep.510300311;;4727456;;pmc333026;;10.1172/jci107410;;9698078;;10.1016/s0006-2952(98)00112-9;;10.1002/hep.1840200109;;8020904;;10.1016/0270-9139(94)90133-3;;8474573;;10.1007/bf00967259;;10.1016/j.ymgme.2003.11.017;;15050979;;3930757;;10.1002/jnr.490140210;;2507845;;10.1016/0024-3205(89)90155-0;;11465067;;10.2174/1389450003349254;;12220296;;10.1034/j.1600-0676.2002.00001.x;;10330005;;10.1152/ajpgi.1999.276.5.g1145;;10.1002/hep.22474;;18697192;;15680459;;10.1016/s0140-6736(05)70239-7;;10.1016/s0140-6736(05)17832-5;;3099249;;10.1203/00006450-198611000-00011;;12848729;;10.1046/j.1469-0691.2003.00691.x;;4411934;;7242660;;10.1038/291378a0;;7272044;;10.1152/ajpendo.1981.241.4.e310;;10.1097/01.ccm.0000287592.94554.5f;;17901832;;10.1097/00000658-198707000-00002;;pmc1492937;;3496861;;10.1016/j.jss.2007.02.002;;17574581;;10.1152/ajpendo.1996.271.4.e718;;8897860;;10.1053/gast.1997.v112.pm9024301;;9024301;;10.1002/hep.21673;;17596891;;10.1097/00019616-200203000-00008;;10.1001/archneur.1990.00530100104022;;2222247;;10.1002/hep.1840100311;;2788117;;17499398;;10.1016/j.clnu.2007.03.002;;23751856;;10.1097/mcg.0b013e318299c789;;10.1111/j.1365-2362.1982.tb00993.x;;6809468;;10.1016/j.surg.2005.04.019;;16153446;;9148009;;10.1016/s0168-8278(97)80024-4;;15664244;;10.1016/j.jhep.2004.10.019;;10.1016/s0168-8278(09)60775-3;;10.1152/ajpgi.00440.2005;;16782695;;19554542;;10.1002/hep.22917;;pmc507662;;10.1172/jci119023;;8903337;;3508233;;10.1007/bf00998474;;10.1080/07315724.1986.10720123;;3088083,"Abraldes et al., “Hemodynamic Response to Pharmacological Treatment of Portal Hypertension and Long-Term Prognosis of Cirrhosis”, Hepatol. 2003, 37:902-908.;;Aggarwal et al., “Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU”, Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., “Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate”, Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., “Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy”, Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., “The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia”, J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Al Sibae et al., “Current Trends in the Treatment of Hepatic Encephalopathy”, Ther Clin Risk Manag. Jun. 2009, 5(3): 617-626.;;Als-Nielsen et al.,, Non-Absorbable Disaccharides for Hepatic Encephalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., “Ornithine transcarbamylase deficiency and pancreatitis”, J Pediatr, 2001, vol. 138, pp. 123-124.;;Anonymous,, “Sodium phenylbutyrate for urea cycle enzyme deficiencies.” [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Australian Examination Report dated Jun. 11, 2014 from Application No. 2010232521, filed Apr. 1, 2010.;;Australian Examination Report dated Feb. 9, 2018 from Application No. 2017202081, filed Mar. 29, 2017.;;Bachmann et al., “Ammonia toxicity to the brain and creatine”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., “Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,”, Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., “Alternative pathway therapy for urea cycle disorders: twenty years later”, J Pediatr. 2001, 138(1 Suppl): S46-S55.;;Batshaw et al., “Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse”, Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., “Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,”, Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berg et al., “Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the non-human primate”, Cancer Chemother Pharmacol. May 2001, 47(5): 385-390. Abstract Only.;;Berge et al., “Pharmaceutical Salts”, J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., “Long-term management of patients with urea cycle disorders”, J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley et al., “Salt Forms of Drugs and Absorption” in Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. New York, 1996, pp. 453-499.;;Blei et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., “Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage”, British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., “Exogenous glutamine: the clinical evidence,”, Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Bosoi et al., Long term oral treatment of ornithine phenylacetate increases lean mass and attenuates brain edema in bile-duct ligated rats. Hepatology Oct. 2015, 62(Suppl 1):953A; Abstract 1523.;;Bosoi et al., “Oral Ornithine Phenylacetate Attenuates Muscle Mass Loss and Prevents Hepatic Encephalopathy in BDL Rats”, Abstract 23; J Clin Exper Hepatol. (Feb. 2017) 7:S18-S19.;;Braga et al., “Crystal Polymorphism and Multiple Crystal Forms”, Struct Bond, 2009, 132: 25-50 [pub online Feb. 25, 2009].;;Briggs et al., “Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes”, Biochem J, 1976, vol. 160, pp. 205-209.;;Bruha et al., “Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes”, Scand J Gastroenter. 2006, 41: 1454-1463.;;Brunquell et al., “Electroencephalographic findings in ornithine transcarbamylase deficiency”, J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., “Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis”, Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., “Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis”, The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., “Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients”, Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, “Pathophysiology of hepatic encephalopathy: a new look at ammonia”, Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Butterworth, “Neuronal cell death in hepatic encephalopathy”, Metab Brain Dis. Dec. 2007, 22(3-4): 309-320.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, Pharma Res. 1995, 12(7): 945-954.;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds”, Topic in Current Chemistry 1998, 198: 163-208.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Canbay et al. “L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease”, Drugs 2019, vol. 79(Suppl 1), pp. S39-S44 (first published online Jan. 31, 2019).;;Cavarec et al., “Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor”, Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., “Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease”, Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chawla et al., “Challenges in Polymorphism of Pharmaeuticals”, CRIPS Mar. 2004, 5(1): 9-12.;;Chen et al., “Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency”, Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Chinese Office Action dated Feb. 19, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 18, 2012 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 23, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Jul. 9, 2015 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Chinese Office Action dated Apr. 5, 2016 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Chinese Office Action dated Feb. 12, 2018 for Application No. 201710053850.1, filed Jan. 22, 2017.;;Chung et al., “Cirrhosis and its Complications”, Harrison's Principles of Internal Medicine (16th Edition) (2005) 289, pp. 1858-1869.;;Clément et al., “Minimal hepatic encephalopathy leads to hypotension-induced neuronal cell loss in BDL rats”, Abstract 51; Hepatology (Oct. 2015) 62(Suppl 1):233A-234A.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;ClinicalTrails.gov; William Lee, Med. Uni. S.C.; “Safety Study of Ornithine Phenylacetate to Treat Patients with Acute Liver Failure (STOP-ALF)”, ID #NCT01548690; Feb. 2012; 7 pages.;;Darmaun et al., “Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism”, Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;DERWENT 1 January 1900 Derwent World Patents Index; AN 2003-314385, XP002364873, ""Composition used for preventing and treating hepatosis and hepatic encephalopathy comprises ornithine and asparagic acid"";;Davies, et al., “L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats”, Hepatology Jul. 2009, 50(1): 155-164.;;Dejong et al., “Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia”, Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al., Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011 in International Application No. PCT/US2010/029708.;;Desjardins et al., “Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle”, Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dewhirst et al., “Phylogeny of the defined murine microbiota: Altered Schaedler Flora”, Appl. Environ Microbiol. 1999, 65(8): 3287-3292.;;Dunitz et al., “Disappearing Polymorphs”, Acc Chem Res. 1995, 28: 193-200.;;Efrati et al., “Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution”, Am J Gastroenterol. (2000) 95(12):3574-3578. (Abstract).;;Enns et al., “Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,”, N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;Eurasian Office Action dated May 24, 2016 for Application No. 201500650 filed Jul. 16, 2015.;;Eurasian Office Action dated Sep. 27, 2017 for Application No. 201500650 filed Jul. 16, 2015.;;European Extended Search Report dated Nov. 30, 2012 for Application No. 10759442.6.;;European Extended Search Report dated Nov. 9, 2017 for Application No. 17185173.6.;;Fabbri et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology 1993, 18(1): 28-35.;;Feuerstein et al., Cytokines, Inflammation, and Brain Injury: Role of Tumor Necrosis Factor-α. Cerebrovasc Brain Metab Rev. 1994, 6(4):341-360.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., “Prediction of outcome following acute variceal haemorrhage”, Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., “Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels”, J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., “Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,”, Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, “Ornithine transcarbamylase deficiency: a urea cycle defect”, European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., “Prevention of initial variceal hemorrhage”, Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Grant, D.J.W., “Theory and Origin of Polymorphism” Chapter 1 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., 1999; pp. 1-11.;;Greenstein et al., Studies on the Metabolism of Amino Acids and Related Compounds in Vivo. III. Prevention of Ammonia Toxicity by Arginine and Related Compounds, Arch Biochem Biophys, 1956, vol. 64, Issue (2):, pp. 342-354.;;Grossi et al., “Amino acids mixtures in prevention of acute ammonia intoxication in dogs”, Arch Surg, 1967, vol. 94, pp. 261-266.;;Guillory, J.K., “Generation of Polymorphs, Hydrates, Solvates, and Amorphous” Chapter 5 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., 1999, pp. 183-226.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, vol. 129; pp. 1430-1433.;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urea Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., “Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)”, Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., “Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?”, J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., “The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy”, Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Hirayama et al., [Eds], “Organic compound crystal produced handbook—Principles and know-how”, Maruzen Co., Ltd., Japan; (Jul. 2008), pp. 17-23, 37-40, 45-51 and 57-65; 31 pages.;;Honda et al., “Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy”, Biol. Pharm. Bull., Sep. 2002, 25(9): 1244-1246.;;Hopkins Medicine (http://www.hopkinsmedicine.org/gastroenterology_hepatology/_pdfs/liver/portal_hypertension.pdf; accessed Jun. 22, 2016); 13 pages.;;Hursthouse et al., “Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?”, Organic Process Research & Development, 2009, 13:1231-1240.;;Igarashi et al., “Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography”, Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;India Office Action dated Jul. 26, 2017 for Application No. 7982/DELNP/2011, filed Apr. 1, 2010.;;Inoue et al., “Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria”, Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;International Preliminary Report on Patentability dated Jun. 2, 2011 for Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;International Search Report and Written Opinion dated Jun. 3, 2010 for PCT/US2010/029708, filed Apr. 1, 2010.;;Israel Office Action dated Sep. 30, 2014 for Application No. 215449, filed Apr. 1, 2010.;;Islam et al., “Sorbitol and lactitol reduce body fat and toxic ammonia levels in rats”, Nutrition Res. (2007) 27:440-447.;;Iyer et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., “Acute-on-chronic liver failure: pathophysiological basis of therapeutic options”, Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., “Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,”, Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., “The molecular pathogenesis of hepatic encephalopathy”, The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses, 2007, 69(5): 1064-1069, Elsevier Ltd.;;Jalan et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Jalan,, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publisheres, Inc., New York, NY, USA.;;James et al., “The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species”, Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Japanese Office Action dated May 13, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Oct. 21, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Jun. 7, 2016 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Sep. 5, 2017 for Application No. 2016-237164, filed Jul. 12, 2016.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure,, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Jiang et al., “L-Ornithine-I-aspartate in the management of hepatic encephalopathy: a meta-analysis”, J Gastroenterol Hepatol. 2009, 24(1): 9-14; available online: Sep. 28, 2008.;;Jover-Cobos et al., Ornithine phenylacetate revisited; Metabolic Brain Disease 2013, 28(2): 327-331.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., “New secondary metabolites of phenylbutyrate in humans and rats”, Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, “Ammonia metabolism and hepatic encephalopathy”, Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan et al.,, Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Ciprofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., “Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,”, Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Kojima et al., “Effective Solid Form Selection for the Pharmaceutical Development”, J Pharma Science Tech. Sep. 2008, 68(5): 344-349.;;Korean Office Action dated Jun. 8, 2016 for Application No. 10-2011-7026256, filed Apr. 1, 2010.;;Korean Office Action dated Mar. 30, 2017 for Application No. 10-2011-7026256, filed Apr. 1, 2010.;;Korean Office Action dated Aug. 1, 2017 for Application No. 10-2011-7026256, filed Nov. 3, 2011.;;Larsen et al., “Alternative Pathway Therapy for Hyperammonemia in Liver Failure”; Hepatolory, Jul. 2009, 50(1): 3-5.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Lee et al., “Phase 2 Comparison of a Novel Ammonia Scavenging Agent with Sodium Phenylbutyrate in Patients with Urea Cycle Disorders: Safety, Pharmacokinetics and Ammonia Control”, Mol Genet Metab. Mar. 2010, 100(3): 221-228.;;Linderoth et al., “Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,”, Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lopez-Talavera et al., “Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats”, Hepatology, 1996, 23(6): 1616-1621.;;Lukkarinen, M. et al., Effect of Lysine Infusion on Urea Cycle in Lysinuric Protein Intolerance, Metabolism, May 2000, 49(5): 621-625.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, 52(7): 935-938.;;MacArthur et al., “Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., “Long-term treatment of girls with ornithine transcarbamylase deficiency”, N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., “Prospective treatment of urea cycle disorders”, J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maev I.V. Application of L-ornitine-L-aspartate in complex therapy of hepatic encephalopathy in liver cirrhosis patients (Engl. Title) koloproktologii, 2002, No. 6, pp. 60-66.;;Maier et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Maier, “Therapie der hepatischen Enzephalopathie”, Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Maruzen Co., Ltd., “Jikken Kagaku Guide Book (Experimental Chemistry Guide Book),” The Chemical Society of Japan, 1992, 3rd Edition, pp. 130-131.;;Maruzen Co., Ltd., “Jikken Kagaku Koza (Zoku) Experimental Chemistry Course (cont.)”, 2. Bunri to Seisei (Isolation and Purification), Jan. 25, 1967, pp. 159-162 and 184-193.;;Matsuoka et al., “Advanced Crystallization Technology of Organic Materials—Control of Size, Morphology, Polymorph and Purity”, Pharm Tech, Japan (May 2003) 19(6): 91(955)-101(965).;;Meijer et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., “A new therapy for portal systemic encephalopathy”, The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mexican Office Action dated Dec. 10, 2013 for Application No. MX/a/2012/013961, filed Nov. 30, 2012.;;Mexican Office Action dated Oct. 5, 2017 for Application No. MX/a/2014/008993, filed Jul. 24, 2014.;;Mihm et al., “Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)”, Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., “Septic Encephalopathy—Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy”, Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;Mizutani et al., “Hyperargininemia: Clinical course and treatment with sodium benzoate and phenylacetic acid”, Brain Dev., 1983, vol. 5, Issue 6, pp. 555-563.;;Moinard et al.,, “Effects of Ornithine 2-Oxoglutarate on Neutrophils in Stressed Rates: Evidence for the Involvement of Nitric Oxide and Polyamines”, Clin Sci, 2002, vol. 102, Issue 3, pp. 287-295, London, England.;;Mookerjee et al., “Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome,”, Hepatology, 2007, vol. 3, Issue 46, pp. 831-840.;;Mookerjee et al., “Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis”, Gastroenterology Jun. 2007, 132(7): 2533-2541.;;Mouille et al., “Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion”, Am J Gastrointest Liver Physiol., 2004, 287(2), G344-G351.;;Nance et al., “Ammonia production in germ-free Eck fistula dogs”, Surgery, 1971, vol. 70, Issue 2, pp. 169-174.;;Navasa et al., “Bacterial infections in liver cirrhosis,”, Ital J Gastroenterol Hepatol., 1999, vol. 7, Issue 31, pp. 616-625.;;New Zealand Office Action dated Jan. 8, 2014 for Application No. 619235, filed Dec. 20, 2013.;;Newsholme et al., “Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease,”, J Nutr Biochem., 1999, vol. 6, Issue 10, pp. 316-324.;;Newsholme, “Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?”, J Nutr., 2001, vol. 9 Suppl, Issue 131, pp. 2515S-2522S.;;Ocera Therapeutics, Inc., News Release: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy; Globe Newswire; Apr. 1, 2015, 2 pages.;;Ocera Therapeutics, Inc., News Release: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Acute Hepatic Encephalopathy; Globe Newswire; Nov. 16, 2015, 2 pages.;;Ocera Therapeutics, Inc., News Release: Ocera Completes Plasma Data from Pilot Phase 1 Study for Orally-available OCR-002 in Development for the Prevention of Acute Hepatic Encephalopathy; Globe Newswire; Jan. 8, 2016, 3 pages.;;Olde Damink et al., “Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats”, Gut, 1997, vol. 40, pp. 418-424.;;Olde Damink et al., “Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS”, Hepatology, 2002, vol. 36, Issue 5, pp. 1163-1171.;;Olde Damink et al., “Interorgan ammonia metabolism in liver failure”, Neurochemistry International, 2002, vol. 41, pp. 177-188.;;Olde Damink et al., “The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis”, Hepatology, 2003, vol. 37, pp. 1277-1285.;;Olde Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Pahan et al., Lovastatin and Phenylacetate Inhibit the Induction of Nitric Oxide Synthase and Cytokines in Rat primary Astrocytes, Microglia, and Macrophages, J Clin Invest. BMJ Group GB, 1997, 100(11):2671-2679.;;Pauwels et al., “Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection”, Hepatology, 1996, vol. 24, Issue 4, pp. 802-806.;;Petrowski et al., “Pharmacologic amino acid acylation in the acute hyperammonemia of propionic acidemia”, Journal of Neurogenetics, 1987, vol. 4, pp. 87-96.;;Plecko et al., “Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate”, Eur J Pediatr., 1998, vol. 157, pp. 996-998.;;Powell et al., “Compendium of Excipients for Parenteral Formulations”, PDA J Pharm Sci Technol. 1998, 52(5): 238-311.;;Praphanphoj et al., “Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonemia”, J Inherit Metab Dis., 2000, vol. 23, pp. 129-136.;;Rajkovic et al., “Mechanisms of abnormalities in host defences against bacterial infection in liver disease,”, Clin Sci. (Lond.), 1985, vol. 3, Issue 68, pp. 247-253, London.;;Ramaswamy et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., Jul. 2002, vol. 22, Issue 13, pp. 4491-4498.;;Rees et al., “Effect of L-Ornithine-L-Aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial”, Gut, 2000, vol. 47, pp. 571-574.;;Riordan et al., “Treatment of hepatic encephalopathy”, Curr Concepts, 1997, vol. 337, Issue 7, pp. 473-479.;;Rockey et al., “Randomized, Double-Blind, Controlled Study of Glycerol Phenylbutyrate in Hepatic Encephalopathy,” Hepatology (2014) 59(3): 1073-1083.;;Rogers, Q. R. et al., Deficiency of Pyrroline-5-Carboxylate Synthase in the Intestinal Mucosa of the Cat, J Nutrition, 1985, 115(1): 146-150.;;Romero-Gómez et al., “Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy”, J Hepatol. 2004, 41: 49-54.;;Roque et al., “32* Pro-inflammatory effects of sodium 4-phenylbutyrate in CF lung epithelial cells containing F508del-CFTR”, J Cystic Fibrosis 2007, 6: S7.;;Rose et al., “L-Ornithine-L-Aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action”, Metabolic Brain Disease, 1998, vol. 13, Issue 2, pp. 147-157.;;Rose et al., “L-Ornithine-L-Aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure”, Hepatology, 1999, vol. 30, Issue 3, pp. 636-640.;;Rudman et al., Maximal Rates of Excretion and Synthesis of Urea in Normal and Cirrhotic Subjects, The Journal of Clinical Investigation, Sep. 1973, vol. 52, pp. 2241-2249.;;Rukmini et al., “Region-specific changes in CNS muscarinic acetylcholine receptors in a rat model of hyperammonemia”, Biochem Pharmacol., 1998, vol. 56, Issue 2, pp. 237-241.;;Sanyal et al., Portosystemic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Results of a Prospective Controlled Study, Hepatology, 1994, p. 46-55, vol. 20, No. 1, Pt. 1, The American Association for the Study of Liver Diseases.;;Sanyal, A. J., Prediction of Variceal Hemorrhage in Patients with Cirrhosis, UpToDate, Inc., Website (www.uptodate.com), Jan. 2010, UpToDate.;;Sarhan et al., “Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy”, Neurochem Res., 1993, vol. 18, Issue 4, pp. 539-549.;;Scaglia et al., “Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients”, Mol Genet Metabolism, 2004, vol. 81, pp. S79-S85.;;Sears et al., “Disruption of the blood-brain barrier in hyperammonaemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine”, J Neurosci Res., 1985, vol. 14, Issue 2, pp. 255-261.;;Seiler et al., “Ornithine aminotransferase activity, liver ornithine concentration and acute ammonia intoxication”, Life Sciences, 1989, vol. 45, Issue 11, pp. 1009-1020.;;Seiler, “Ornithine aminotransferase, a potential target for the treatment of hyperammonemias”, 'Curr Drug Targets., Sep. 2000, vol. 1, Issue 2, pp. 119-153.;;Sen et al., “The pathophysiological basis of acute-on-chronic liver failure”, Liver, 2002, vol. 22, Issue Suppl. 2, pp. 5-13.;;Shangraw et al., Effect of Liver Disease and Transplantation on Urea Synthesis in Humans: Relationship to Acid-Base Status, AM J Physiol Gastrointest Liver Physiol, 1999, vol. 276, pp. 1145-1152.;;Shawcross et al., “Ammonia impairs neutrophil phagocytic function in liver disease,”, Hepatology, 2008, vol. 4, Issue 48, pp. 1202-1212.;;Shawcross et al., “Dispelling myths in the treatment of hepatic encephalopathy,”, Lancet, 2005, vol. 9457, Issue 365, pp. 431-433.;;Shawcross et al., “Hyperammonemia impairs neutrophil function”, Hepatology, 2005, vol. 42, pp. 537A.;;Shriner et al., “Recrystallization”, Chapter 3.5 Preliminary Examination in the Systematic Identification of Organic Compounds, John Wiley & Sons, Inc. New York, 1998, Chapter 3, pp. 78-81.;;Simell et al., “Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance”, Pediatric Research, 1986, vol. 20, Issue 11, pp. 1117-1121.;;Singapore Examination Report dated Sep. 27, 2013 for Application No. 201107116-4, filed Apr. 1, 2010.;;Singapore Examination Report & Written Opinion dated Mar. 8, 2018 for Application No. 10201406300Y, filed Oct. 2, 2014.;;Singh, et al., Changing Epidemiology and Predictors of Mortality in Patients With Spontaneous Bacterial Peritonitis at a Liver Transplant Unit, Clinical Microbiology and Infection, Jun. 2003, p. 531-537, vol. 9, No. 6., European Society of Clinical Microbiology and Infectious Diseases.;;Smirnov et al., “Ammonia Neutralization and Urea Synthesis in Cardiac Muscle”, Circ Res. 1974, 35(Suppl 3):58-73.;;Smith et al., “The treatment of inborn errors of the urea cycle”, Nature, 1981, vol. 291, Issue 5814, pp. 378-380.;;Soláini et al., “Variations in the plasma concentration of ornithine, citrulline and arginine in acute experimental liver failure” [Article in Italian], Boll Soc Ital Biol Sper., 1981, vol. 57, Issue 7, pp. 705-710.;;Stedman's Medical Dictionary; “Encephalopathy”, 27th Edition, 2002; 1 page.;;Stewart, P. M., et al., Effects of Arginine-Free Meals on Ureagenesis in Cats, American Journal of Physiological, 1981, pp. E310-E315, vol. 241, No. 4, The American Physiological Society.;;Stravitz, MD, et al., Intensive Care of Patients with Acute Liver Failure: Recommendations of the U.S. Acute Liver Failure Study Group, Critical Care Medicine, 2007, p. 2498-2508, vol. 35, No. 11, Lippincott Williams & Wilkins. et al.",ACTIVE
203,SI,T1,SI 2413924 T1,003-920-954-739-65X,2018-01-31,2018,SI 201031596 T,2010-04-01,US 16667609 P;;US 2010/0029708 W;;EP 10759442 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/003-920-954-739-65X,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61P1/00;;A61K31/00;;C07C57/00;;C07C229/00,,0,0,,,,ACTIVE
204,JP,A,JP 2018138575 A,002-238-471-279-101,2018-09-06,2018,JP 2018079490 A,2018-04-18,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THE SAME,"PROBLEM TO BE SOLVED: To provide compositions of L-ornithine phenyl acetate which exhibit long-term stability, can be administered intravenously at high concentrations due to low tonicity, and is expected to provide significant clinical improvements for the treatment of hepatic encephalopathy.SOLUTION: Provided are compositions including L-ornithine phenyl acetate in a crystalline form. The crystalline form is a Form I, II, III, or V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy.SELECTED DRAWING: None",OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/002-238-471-279-101,Patent Application,no,0,1,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K9/08;;A61K31/198;;A61K47/02;;A61K47/12;;A61P1/16;;A61P7/00;;A61P25/00;;C07C51/41;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42,,6,0,,,"メキシコ公開特許０３００９９０２号公報, JPN7014001418, 3 May 2005 (2005-05-03), ISSN: 0004020042;;小嶌隆史: ""医薬品開発における結晶性選択の効率化を目指して"", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0004020043;;松岡正邦: ""有機物の結晶化技術の高度化−粒径,形態,多形,純度の制御−"", PHARM TECH JAPAN, vol. 第19巻, 第6号, JPN6009053754, 1 May 2003 (2003-05-01), pages 91 - 101, ISSN: 0004020044;;平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0004020045;;社団法人日本化学会, 実験化学ガイドブック, vol. 第３刷, JPN6008055044, 1992, pages 130 - 131, ISSN: 0004020046;;実験化学講座（続）２ 分離と精製, JPN6009058003, 25 January 1967 (1967-01-25), pages 159 - 162, ISSN: 0004020047",ACTIVE
205,US,B2,US 9604909 B2,060-475-822-158-540,2017-03-28,2017,US 201514715481 A,2015-05-18,US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/060-475-822-158-540,Granted Patent,yes,69,22,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/32;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C227/40;;C07C227/42;;C07C229/26,,194,148,101-278-850-557-816;;007-084-720-458-198;;012-164-908-969-046;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;109-586-006-962-328;;085-339-541-354-722;;184-275-615-368-06X;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;023-591-152-002-307;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;005-411-405-905-202;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;009-214-187-079-899;;104-949-654-022-72X;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;038-873-808-172-211;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-067-038-116-555;;052-684-471-190-493;;004-568-483-555-796;;063-040-386-072-391;;001-333-743-768-03X;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;062-099-863-837-757;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901;;031-758-280-989-128;;064-981-485-159-530;;049-796-115-905-999;;105-624-360-809-755;;060-965-237-325-653;;106-478-902-619-715;;020-191-827-595-592;;026-684-980-375-813;;155-746-121-945-548;;014-585-057-157-928;;016-245-934-364-075;;017-040-741-145-623;;027-296-352-845-29X;;118-190-784-711-854;;028-094-130-639-491;;041-763-726-091-611;;105-215-652-900-713;;046-377-535-715-555;;075-927-681-372-170;;073-180-972-519-149;;046-328-577-402-919;;091-010-477-383-601;;111-311-443-070-933;;012-261-100-493-035;;124-467-405-728-071;;010-208-513-979-628;;029-419-591-846-994;;003-526-763-484-740;;032-516-727-018-702;;094-400-537-780-40X;;084-881-256-943-396;;029-624-106-758-273;;052-308-695-243-647;;035-155-644-148-657;;093-350-008-802-15X;;001-436-299-870-282;;083-831-280-762-833;;038-642-776-927-940;;002-992-545-486-58X;;018-419-048-897-547;;172-105-260-241-360;;021-594-673-656-876;;129-174-137-700-680;;036-430-862-175-32X;;006-979-616-832-902;;004-086-526-654-013;;093-159-361-636-556;;012-247-665-964-294;;076-070-224-505-210;;016-249-747-580-90X;;022-980-060-535-387;;041-883-471-681-172;;034-978-591-029-435;;006-945-361-671-311;;064-348-611-021-409;;013-520-813-294-749;;121-778-149-592-003;;015-634-309-364-793;;035-230-669-274-593;;015-750-440-523-292,12230130;;10.1248/bpb.25.1244;;10.1002/hep.23037;;19441099;;pmc507662;;10.1172/jci119023;;8903337;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;8941257;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;11391852;;10.1007/s002800000256;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;17101577;;10.1080/00365520600780403;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;10.1002/hep.22897;;19437490;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;19409290;;10.1053/j.gastro.2009.04.016;;10.1055/s-2003-42645;;14523680;;4403084;;10.1098/rspb.1972.0064;;15176533;;18823442;;10.1111/j.1440-1746.2008.05582.x;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918;;10.1016/s0387-7604(83)80059-x;;6670711;;10.1042/cs1020287;;10.1042/cs20010162;;11869169;;10.1002/hep.21737;;17680644;;10.1152/ajpgi.00445.2003;;15064231;;4997833;;10604106;;10.1016/s0955-2863(99)00022-4;;15539305;;11533304;;10.1093/jn/131.9.2515s;;10.1136/gut.40.3.418;;9135535;;pmc1027096;;12395326;;10.1053/jhep.2002.36497;;12020618;;10.1016/s0197-0186(02)00040-2;;12774005;;10.1053/jhep.2003.50221;;10.1053/jhep.1996.v24.pm0008855179;;8855179;;10.1002/hep.510240408;;10.3109/01677068709167220;;3598771;;10.1007/s004310050985;;9877039;;10801054;;10.1023/a:1005661631281;;2982530;;10.1042/cs0680247;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10986219;;pmc1728090;;10.1136/gut.47.4.571;;9250851;;10.1056/nejm199708143370707;;3965666;;10.1093/jn/115.1.146;;15246207;;10.1016/j.jhep.2004.03.021;;10.1016/s0168-8278(98)80479-0;;10462368;;10.1002/hep.510300311;;4727456;;pmc333026;;10.1172/jci107410;;9698078;;10.1016/s0006-2952(98)00112-9;;10.1002/hep.1840200109;;8020904;;10.1016/0270-9139(94)90133-3;;8474573;;10.1007/bf00967259;;10.1016/j.ymgme.2003.11.017;;15050979;;3930757;;10.1002/jnr.490140210;;2507845;;10.1016/0024-3205(89)90155-0;;11465067;;10.2174/1389450003349254;;12220296;;10.1034/j.1600-0676.2002.00001.x;;10330005;;10.1152/ajpgi.1999.276.5.g1145;;10.1002/hep.22474;;18697192;;15680459;;10.1016/s0140-6736(05)70239-7;;10.1016/s0140-6736(05)17832-5;;3099249;;10.1203/00006450-198611000-00011;;12848729;;10.1046/j.1469-0691.2003.00691.x;;7242660;;10.1038/291378a0;;7272044;;10.1152/ajpendo.1981.241.4.e310;;10.1097/01.ccm.0000287592.94554.5f;;17901832;;10.1097/00000658-198707000-00002;;pmc1492937;;3496861;;10.1016/j.jss.2007.02.002;;17574581;;10.1152/ajpendo.1996.271.4.e718;;8897860;;10.1053/gast.1997.v112.pm9024301;;9024301;;10.1002/hep.21673;;17596891;;10.1097/00019616-200203000-00008;;10.1001/archneur.1990.00530100104022;;2222247;;10.1002/hep.1840100311;;2788117;;17499398;;10.1016/j.clnu.2007.03.002;;10.1111/j.1365-2362.1982.tb00993.x;;6809468;;9148009;;10.1016/s0168-8278(97)80024-4;;15664244;;10.1016/j.jhep.2004.10.019;;10.1016/s0168-8278(09)60775-3;;10.1152/ajpgi.00440.2005;;16782695;;19554542;;10.1002/hep.22917;;3508233;;10.1007/bf00998474;;10.1080/07315724.1986.10720123;;3088083;;10.1053/jhep.2003.50133;;12668985,"Braga et al., “Crystal Polymorphism and Multiple Crystal Forms”, Struct Bond (2009) 132: 25-50 [pub online Feb. 25, 2009].;;ClinicalTrails.gov; William Lee, Med. Uni. S.C.; “Safety Study of Ornithine Phenylacetate to Treat Patients with Acute Liver Failure (STOP-ALF)”, ID #NCT01548690; Feb. 2012; 7 pages.;;Honda et al., “Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy”, Biol. Pharm. Bull., Sep. 2002, 25(9): 1244-1246.;;Larsen et al., “Alternative Pathway Therapy for Hyperammonemia in Liver Failure”; Hepatolory (Jul. 2009), 50(1): 3-5.;;Yudkoff et al., “In Vivo Nitrogen Metabolism in Ornithine Transcarbamylase Deficiency”; J Clin. Invest., Nov. 1996, 98(9): 2167-2173.;;Singapore Examination Report dated Sep. 27, 2013 for Application No. 201107116-4, filed Apr. 1, 2010.;;Aggarwal et al., “Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU”, Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., “Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate”, Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., “Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy”, Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., “The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia”, J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Als-Nielsen, Bodil, et al., Non-Absorbable Disaccharides for Hepatic Encephyalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., “Ornithine transcarbamylase deficiency and pancreatitis”, J Pediatr, 2001, vol. 138, pp. 123-124.;;Anonymous, “Sodium phenylbutyrate for urea cycle enzyme deficiencies.” [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Bachmann et al., “Ammonia toxicity to the brain and creatine”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., “Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,”, Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., “Alternative pathway therapy for urea cycle disorders: twenty years later”, J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., “Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse”, Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., “Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,”, Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berg et al., “Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the non-human primate”, Cancer Chemother Pharmacol. (May 2001) 47(5): 385-390. Abstract Only.;;Berge et al., Review Article: Pharmaceutical Salts, J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., “Long-term management of patients with urea cycle disorders”, J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley et al., “Salt Forms of Drugs and Absorption” in Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. New York, (1996), pp. 453-499.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., “Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage”, British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., “Exogenous glutamine: the clinical evidence,”, Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes, Biochem J, 1976, vol. 160, pp. 205-209.;;Bruha et al., “Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes”, Scand J Gastroenter. (2006) 41: 1454-1463.;;Brunquell et al., “Electroencephalographic findings in ornithine transcarbamylase deficiency”, J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., “Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis”, Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., “Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis”, The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., “Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients”, Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, “Pathophysiology of hepatic encephalopathy: a new look at ammonia”, Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, Pharma Res. (1995) 12(7): 945-954.;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds”, Topic in Current Chemistry (1998) 198: 163-208.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., “Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor”, Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati, T. et al., Ornicetil on Encephalopathy Effect of Ornicetil (Ornithine Alpha-Ketoglutarate) on Encephalopathy in Patients with Acute and Chronic Liver Disease; Acta Hepato-Gastroenterol, 1977, vol. 24, pp. 434-439.;;Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS (Mar. 2004) 5(1): 9-12.;;Chen et al., “Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency”, Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Darmaun et al., “Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism”, Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;DATABASE WPI 1 January 1900 Derwent World Patents Index; AN 2003-314385, XP002364873, ""Composition used for preventing and treating hepatosis and hepatic encephalopathy comprises ornithine and asparagic acid"";;Davies, et al., “L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats”, Hepatology (Jul. 2009) 50(1): 155-164.;;Dejong et al., “Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia”, Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al., Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Desjardins et al., “Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle”, Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz et al., “Disappearing Polymorphs”, Acc Chem Res. (1995) 28: 193-200.;;Enns et al., “Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,”, N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., “Prediction of outcome following acute variceal haemorrhage”, Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., “Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels”, J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., “Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,”, Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, “Ornithine transcarbamylase deficiency: a urea cycle defect”, European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., “Prevention of initial variceal hemorrhage”, Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Grant, D.J.W., “Theory and Origin of Polymorphism” Chapter 1 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., (1999) pp. 1-11.;;Greenstein et al., Studies on the Metabolism of Amino Acids and Related Compounds in Vivo. III. Prevention of Ammonia Toxicity by Arginine and Related Compounds, Arch Biochem Biophys, 1956, vol. 64, Issue (2):, pp. 342-354.;;Grossi et al., “Amino acids mixtures in prevention of acute ammonia intoxication in dogs”, Arch Surg, 1967, vol. 94, pp. 261-266.;;Guillory, J.K., “Generation of Polymorphs, Hydrates, Solvates, and Amorphous” Chapter 5 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., (1999) pp. 183-226.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, vol. 129; pp. 1430-1433 w/English Machine translation.;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urca Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., “Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)”, Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., “Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?”, J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., “The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy”, Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., “Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy”, Biol. Pharm. Bull., (2002), vol. 25, Issue 9, pp. 1244-1246.;;Hursthouse et al., “Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?”, Organic Process Research & Development, (2009) 13:1231-1240.;;Igarashi et al., “Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography”, Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., “Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria”, Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;Iyer et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., “Acute-on-chronic liver failure: pathophysiological basis of therapeutic options”, Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., “Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,”, Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., “The molecular pathogenesis of hepatic encephalopathy”, The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses (2007) 69(5): 1064-1069, Elsevier Ltd.;;Jalan et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Jalan,, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publisheres, Inc., New York, NY, USA.;;James et al., “The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species”, Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure,, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Jiang et al., “L-Ornithine-I-aspartate in the management of hepatic encephalopathy: a meta-analysis”, J Gastroenterol Hepatol. (2009) 24(1): 9-14; available online: Sep. 28, 2008.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., “New secondary metabolites of phenylbutyrate in humans and rats”, Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, “Ammonia metabolism and hepatic encephalopathy”, Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Ciprofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., “Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,”, Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., “Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,”, Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lopez-Talavera et al., “Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats”, Hepatology (1996) 23(6): 1616-1621.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, pp. 935-938, vol. 52, No. 7, Elsevier Inc.;;Macarthur et al., “Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., “Long-term treatment of girls with ornithine transcarbamylase deficiency”, N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., “Prospective treatment of urea cycle disorders”, J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maev I.V. Primenenie preparata L-ornitin-L-aspartata v kompleksnoy terapii pechyonochnoy entsefalopatii u bolnykh tsirrozom pecheni. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2002, No. 6, pp. 60-66.;;Maier et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Maier, “Therapie der hepatischen Enzephalopathie”, Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Meijer et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., “A new therapy for portal systemic encephalopathy”, The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mihm et al., “Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)”, Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., “Septic Encephalopathy—Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy”, Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock,, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;Mizutani et al., “Hyperargininemia: Clinical course and treatment with sodium benzoate and phenylacetic acid”, Brain Dev., 1983, vol. 5, Issue 6, pp. 555-563.;;Moinard et al., “Effects of Ornithine 2-Oxoglutarateon Neutrophils in Stressed Rates: Evidence for the Involvement of Nitric Oxide and Polyamines”, Clin Sci, 2002, vol. 102, Issue 3, pp. 287-295, London, England.;;Mookerjee et al., “Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome,”, Hepatology, 2007, vol. 3, Issue 46, pp. 831-840.;;Mouille et al., Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion, Am J Gasteroenterol, 2004, vol. 287, pp. 344-351.;;Nance et al., “Ammonia production in germ-free Eck fistula dogs”, Surgery, 1971, vol. 70, Issue 2, pp. 169-174.;;Navasa et al., “Bacterial infections in liver cirrhosis,”, Ital J Gastroenterol Hepatol., 1999, vol. 7, Issue 31, pp. 616-625.;;Newsholme et al., “Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease,”, J Nutr Biochem., 1999, vol. 6, Issue 10, pp. 316-324.;;Newsholme, “Why is L-glutamine metabolism important to cells of the immune system in health, post injury, surgery or infection?”, J Nutr., 2001, vol. 9 Suppl, Issue 131, pp. 2515S-2522S.;;Olde Damink et al., “Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats”, Gut, 1997, vol. 40, pp. 418-424.;;Olde Damink et al., “Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS”, Hepatology, 2002, vol. 36, Issue 5, pp. 1163-1171.;;Olde Damink et al., “Interorgan ammonia metabolism in liver failure”, [not known], 2002, vol. 41, pp. 177-188.;;Olde Damink et al., “The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis”, [not known], 2003, vol. 37, pp. 1277-1285.;;Olde Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Pauwels et al., “Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection”, Hepatology, 1996, vol. 24, Issue 4, pp. 802-806.;;Petrowski et al., “Pharmacologic amino acid acylation in the acute hyperammonemia of propionic acidemia”, Journal of Neurogenetics, 1987, vol. 4, pp. 87-96.;;Plecko et al., “Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate”, Eur J Pediatr., 1998, vol. 157, pp. 996-998.;;Praphanphoj et al., “Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia”, J Inherit Metab Dis., 2000, vol. 23, pp. 129-136.;;Rajkovic et al., “Mechanisms of abnormalities in host defences against bacterial infection in liver disease,”, Clin Sci. (Lond.), 1985, vol. 3, Issue 68, pp. 247-253, London.;;Ramaswamy et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., Jul. 2002, vol. 22, Issue 13, pp. 4491-4498.;;Rees et al., “Effect of L-Ornithine-L-Aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial”, Gut, 2000, vol. 47, pp. 571-574.;;Riordan et al., “Treatment of hepatic encephalopathy”, Curr Concepts, 1997, vol. 337, Issue 7, pp. 473-479.;;Rogers, Q. R. et al., Deficiency of Pyrroline-5-Carboxylate Synthase in the Intestinal Mucosa of the Cat, The Journal of Nutrition, 1985, pp. 146-150, vol. 115, No. 1, American Institution of Nutrition.;;Romero-Gómez et al., “Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy”, Journal of Hepatology, 2004, vol. 41, pp. 49-54.;;Rose et al., “L-Ornithine-L-Aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action”, Metabolic Brain Disease, 1998, vol. 13, Issue 2, pp. 147-157.;;Rose et al., “L-Ornithine-L-Aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure”, Hepatology, 1999, vol. 30, Issue 3, pp. 636-640.;;Rudman, Daniel, et al., Maximal Rates of Excretion and Synthesis of Urea in Normal and Cirrhotic Subjects, The Journal of Clinical Investigation, Sep. 1973, vol. 52, pp. 2241-2249.;;Rukmini Devi et al., “Region-specific changes in CNS muscarinic acetylcholine receptors in a rat model of hyperammonemia”, Biochem Pharmacol., 1998, vol. 56, Issue 2, pp. 237-241.;;Sanyal et al., Portosystemic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Results of a Prospective Controlled Study, Hepatology, 1994, p. 46-55, vol. 20, No. 1, Pt. 1, The American Association for the Study of Liver Diseases.;;Sanyal, A. J., Prediction of Variceal Hemorrhage in Patients with Cirrhosis, UpToDate, Inc., Website (www.uptodate.com), Jan. 2010, UpToDate.;;Sarhan et al., “Effects of inhibition of ornithine aminotransferase on thioactamide-induced hepatogenic encephalopathy”, Neurochem Res., 1993, vol. 18, Issue 4, pp. 539-549.;;Scaglia et al., “Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients”, Mol Genet Metabolism, 2004, vol. 81, pp. S79-S85.;;Sears et al., “Disruption of the blood-brain barrier in hyperammonaemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine”, J Neurosci Res., 1985, vol. 14, Issue 2, pp. 255-261.;;Seiler et al., “Ornithine aminotransferase activity, liver ornithine concentration and acute ammonia intoxication”, Life Sciences, 1989, vol. 45, Issue 11, pp. 1009-1020.;;Seiler, “Ornithine aminotransferase, a potential target for the treatment of hyperammonemias”, Curr Drug Targets., Sep. 2000, vol. 1, Issue 2, pp. 119-153.;;Sen et al., “The pathophysiological basis of acute-on-chronic liver failure”, Liver, 2002, vol. 22, Issue Suppl. 2, pp. 5-13.;;Shangraw, Robert E. et al., Effect of Liver Disease and Transplantation on Urea Synthesis in Humans: Relationship to Acid-Base Status, Am J Physiol Gastrointest Liver Physiol, 1999, vol. 276, pp. 1145-1152.;;Shawcross et al., “Ammonia impairs neutrophil phagocytic function in liver disease,”, Hepatology, 2008, vol. 4, Issue 48, pp. 1202-1212.;;Shawcross et al., “Dispelling myths in the treatment of hepatic encephalopathy,”, Lancet, 2005, vol. 9457, Issue 365, pp. 431-433.;;Shawcross et al., “Hyperammonemia impairs neutrophil function”, Hepatology, 2005, vol. 42, pp. 537A.;;Shriner et al., “Recrystallization”, Chapter 3.5 Preliminary Examination in the Systematic Identification of Organic Compounds, John Wiley & Sons, Inc. New York, (1998), Chapter 3, pp. 78-81.;;Simell et al., “Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance”, Pediatric Research, 1986, vol. 20, Issue 11, pp. 1117-1121.;;Singh, et al., Changing Epidemiology and Predictors of Mortality in Patients With Spontaneous Bacterial Peritonitis at a Liver Transplant Unit, Clinical Microbiology and Infection, Jun. 2003, p. 531-537, vol. 9, No. 6., European Society of Clinical Microbiology and Infectious Diseases.;;Smith et al., “The treatment of inborn errors of the urca cycle”, Nature, 1981, vol. 291, Issue 5814, pp. 378-380.;;Soláini et al., “Variations in the plasma concentration of ornithine, citrulline and arginine in acute experimental liver failure” [Article in Italian], Boll Soc Ital Biol Sper., 1981, vol. 57, Issue 7, pp. 705-710.;;Stedman's Medical Dictionary; “Encephalopathy”, 27th Edition (2002); 1 page.;;Stewart, P. M., et al., Effects of Arginine-Free Meals on Ureagenesis in Cats, American Journal of Physiological, 1981, pp. E310-E315, vol. 241, No. 4, The American Physiological Society.;;Stravitz, MD, et al., Intensive Care of Patients with Acute Liver Failure: Recommendations of the U.S. Acute Liver Failure Study Group, Critical Care Medicine, 2007, p. 2498-2508, vol. 35, No. 11, Lippincott Williams & Wilkins.;;Suchy et al., Clinical Manifestations and Complications—Typical Clinical Presentation;, Liver Disease in Children, 2nd Edition, 2001, pp. 74-77.;;Sugarbaker et al., “The role of the small intestine in ammonia production after gastric blood administration”, Ann Surg., 1987, vol. 206, Issue 1, pp. 5-17.;;Sukhotnik et al., “Oral glutamine prevents gut mucosal injury and improves mucosal recovery following lipopolysaccharide endotoxemia in a rat,”, J Surg Res., 2007, vol. 2, Issue 143, pp. 379-384.;;Svanberg et al., “Effects of amino acids on synthesis and degradation of skeletal muscle proteins in humans”, Am J Physiol., 1996, vol. 271, Issue 4 Pt1, pp. E718-E724.;;TDRdata.com, results from query of “Spontaneous Bacterial Peritonitis” in the epidemiological and references databases at www.tdrdata.com, retrieved on Jul. 27, 2010, pp. 1-7.;;Teran et al., “Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis”, Gastroenter., 1997, vol. 112, Issue 2, pp. 473-482.;;Trebicka et al., Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Roh-kinase and activation of endothelial nitric oxide synthase, Hapatology, (2007) 46(1): 242-253.;;Tuchman, M., et al., Management of Inherited Disorders of Ureagenesis, The Endocrinologist, 2002, p. 99-109, vol. 12, No. 2.;;Tuchman, MD et al., “Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome”, Arch Neurol., 1990, vol. 47, pp. 1134-1137.;;Van Berlo et al., “Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of isoleucine in hemoglobin? A study in pigs”, Hepatology, 1989, vol. 10, Issue 3, pp. 315-323.;;Van Den Berg et al., “The effect of glutamine-enriched enteral nutrition on intestinal microflora in very low birth weight infants: a randomized controlled trial,” Clin Nutr., 2007, vol. 4, Issue 26, pp. 430-439.;;Vilstrup, H. et al., Elimination of Infused Amino Acids From Plasma of Control Subjects and of Patients With Cirrhosis of the Liver, European Journal of Clinical Investigation, 1982, vol. 12, pp. 197-202, Blackwell Scientific Publications.;;Vogels et al., “L-ornithine vs L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats”, J Hepatology, 1997, vol. 26, Issue 1, pp. 174-182.;;Wasmuth et al., “Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis,”, J Hepatol., 2005, vol. 2, Issue 42, pp. 195-201.;;Wright et al., “Reduction in Ammonia with L-Ornithine, Phenylacetate (OP) but not Anti-TNF Prevents LPS Induced Brain Edema in Bile-duct Ligated Cirrhotic Rats”, Abstract 773; J Hepatology (2009) 50: S283.;;Ytrebø et al., “Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure,”, Am J Physiol Gastrointest Liver Physiol., 2006, vol. 3, Issue 291, pp. G373-G381.;;Ytrebø et al., “L-Ornithine Phenylacetate Attenuates Increased Arterial and Extracellular Brain Ammonia and Prevents Intracranial Hypertension in Pigs with Acute Liver Failure”, Hepatology (072009) 50(1): 165-174.;;Zetterman, Rowen K., MD, “Complications of Portal Hypertension: Hepatic Encephalopathy”, Medscape (Jun. 2011) available online at www.medscape.com/viewarticle/744392; downloaded Dec. 3, 2014; 6 pages.;;Zieve et al., “Ammonia toxicity: comparative protective effect of various arginine and ornithine derivatives, aspartate, benzoate, and carbamyl glutamate”, Metabo Brain Dis., 1986, vol. 1, Issue 1, pp. 25-35.;;Zieve et al., “Conditional deficiencies of ornithine or ornithine or arginine”, J Am Coll Nutr., 1986, vol. 5, Issue 2, pp. 167-176.;;Written Opinion of the International Search Authority issued Feb. 7, 2006 during the prosecution of the International Application No. PCT/GB2005/004539.;;International Search Report and Written Opinion dated Jun. 3, 2010 for Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;Demand with Article 34 amendments, filed Feb. 3, 2011 in International Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;International Preliminary Report on Patentability dated Jun. 2, 2011 for Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;Demand with Article 34 amendments, filed May 16, 2011 in International Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;Australian Examination Report dated Jun. 11, 2014 from Application No. 2010232521, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 18, 2012 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Feb. 19, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 23, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;EPO Extended Search Report dated Nov. 30, 2012 for Application No. 10759442.6., filed Apr. 1, 2010.;;Israel Office Action dated Sep. 30, 2014 for Application No. 215449, filed Apr. 1, 2010.;;Japanese Office Action dated May 13, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Oct. 21, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Mexican Office Action dated Dec. 10, 2013 for Application No. MX/a/2012/013961, filed Nov. 30, 2012.;;New Zealand Examination Report dated Apr. 8, 2008 for Application No. 555870, filed Apr. 1, 2010.;;New Zealand Office Action dated Jan. 8, 2014 for Application No. 619235, filed Dec. 20, 2013.;;UK Search Report dated Apr. 8, 2005 from GB patent application No. 0426142.6.;;Abraldes et al., “Hemodynamic Response to Pharmacological Treatment of Portal Hypertension and Long-Term Prognosis of Cirrhosis”, Hepatol. (2003) 37:902-908.;;Hirayama et al., [Eds], “Organic compound crystal produced handbook—Principles and know-how”, Maruzen Co., Ltd., Japan; (Jul. 2008), pp. 17-23, 37-40, 45-51 and 57-65; 31 pages.;;Hopkins Medicine (http://www.hopkinsmedicine.org/gastroenterology—hepatology/—pdfs/liver/portal—hypertension.pdf; accessed Jun. 22, 2016); 13 pages.;;Kojima et al., “Effective Solid Form Selection for the Pharmaceutical Development”, J Pharma Science Tech. (Sep. 2008) 68(5): 344-349.;;Matsuoka et al., “Advanced Crystallization Technology of Organic Materials—Control of Size, Morphology, Polymorph and Purity”, Pharm Tech, Japan (May 2003) 19(6): 91(955)-101(965).;;Chinese Office Action dated Jul. 9, 2015 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Chinese Office Action dated Apr. 5, 2016 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Eurasian Office Action dated May 24, 2016 for Application No. 201500650, filed Jul. 16, 2015.;;Israel Office Action dated Mar. 30, 2016 for Application No. 215449, filed Apr. 1, 2010.;;Japanese Office Action dated Jun. 7, 2016 for Application No. 2012-503725, filed Apr. 1, 2010.;;Korean Office Action dated Jun. 8, 2016 for Application No. 10-2011-7026256, filed Apr. 1, 2010.",ACTIVE
206,HK,A1,HK 1248558 A1,080-254-170-955-734,2018-10-19,2018,HK 18108291 A,2018-06-27,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/080-254-170-955-734,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K/;;A61P/;;C07C/,,0,0,,,,PENDING
207,CN,A,CN 102421432 A,084-252-846-470-574,2012-04-18,2012,CN 201080021311 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,KEITH ANDERSON;;JIM BEHLING;;HENDERSON DOUGAN CHRISTINE;;WILLIAM WATT STEPHEN;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/084-252-846-470-574,Patent Application,no,4,8,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
208,KR,A,KR 20120006039 A,097-603-293-243-235,2012-01-17,2012,KR 20117026256 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/097-603-293-243-235,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
209,HR,T1,HR P20171962 T1,098-529-768-232-69X,2018-02-09,2018,HR P20171962 T,2017-12-19,US 16667609 P;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGEN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/098-529-768-232-69X,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
210,KR,A,KR 20220067001 A,123-239-395-465-173,2022-05-24,2022,KR 20227016294 A,2010-04-01,US 16667609 P;;KR 20217004211 A;;US 2010/0029708 W,2009-04-03,- L-ornithine phenyl acetate and methods of making thereof,"본 발명은 L-오르니틴 페닐 아세테이트의 결정 형태 및 이의 제조방법에 관한 것이다. 본 발명에 따른 L-오르니틴 페닐 아세테이트의 결정 형태는 형태 I, II, III, 및 V, 또는 이의 조합이다. 상기 결정 형태는 간성뇌증과 같은 간질환을 나타내는 환자를 치료하기 위하여 제조될 수 있다. 또한 본 발명은 L-오르니틴 페닐 아세테이트의 제제화 방법 또는 투여 방법에 관한 것이다.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/123-239-395-465-173,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61P1/16;;C07C227/16;;C07C227/42,,0,0,,,,ACTIVE
211,CA,C,CA 2998434 C,081-297-785-122-612,2020-05-12,2020,CA 2998434 A,2010-04-01,US 16667609 P;;CA 2757373 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/081-297-785-122-612,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P3/00;;A61P7/00;;C07C57/32;;C07C229/30,,0,0,,,,ACTIVE
212,AU,A1,AU 2019/202311 A1,077-868-819-157-437,2019-05-02,2019,AU 2019/202311 A,2019-04-03,AU 2019/202311 A;;AU 2017/202081 A;;AU 2015/221466 A;;AU 2010/232521 A,2010-04-01,L-ornithine phenyl acetate and methods of making thereof,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Abstract Disclosed herein are crystalline forms of L-omithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I,II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/077-868-819-157-437,Patent Application,no,0,1,6,6,0,,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
213,EA,B1,EA 023051 B1,112-534-767-349-599,2016-04-29,2016,EA 201171216 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,CRYSTALLINE FORMS OF L-ORNITHINE PHENYL ACETATE AND USE THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate which are Forms I, II and III. The crystalline forms may be formulated for treating or ameliorating hyperammonemia symptoms.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/112-534-767-349-599,Granted Patent,no,2,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
214,ES,T3,ES 2791524 T3,094-702-871-345-036,2020-11-04,2020,ES 17185173 T,2010-04-01,US 16667609 P,2009-04-03,Fenilacetato de L-ornitina y métodos de elaboración del mismo,"Una composición que comprende una forma cristalina de fenilacetato de L-ornitina, en donde dicha forma cristalina muestra un patrón de difracción de rayos X de polvo que comprende al menos tres picos característicos, en donde dichos picos característicos se seleccionan del grupo que consiste en 4,9° ± 0,2° 2θ, 13,2° ± 0,2° 2θ, 17,4° ± 0,2° 2θ, 20,8° ± 0,2° 2θ y 24,4° ± 0,2° 2θ.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/094-702-871-345-036,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
215,US,A1,US 2010/0280119 A1,109-756-962-640-889,2010-11-04,2010,US 75376310 A,2010-04-02,US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/109-756-962-640-889,Patent Application,yes,23,29,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61P1/16;;A61P25/00;;C07C229/26,514/564;;562/561,0,0,,,,ACTIVE
216,NZ,A,NZ 619235 A,127-633-005-264-458,2015-06-26,2015,NZ 61923510 A,2010-04-01,US 16667609 P;;NZ 59570610 A,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Provided are processes for preparing crystalline L-ornithine phenyl acetate salts. One method of preparation involves intermixing an L-ornithine salt, a benzoate salt and a solvent to form an intermediate solution; intermixing phenyl acetate with the solution; and isolating a composition comprising at least 70% crystalline L-ornithine phenyl acetate by weight. A second method involves increasing the pH value of a solution comprising an L-ornithine salt at least until an intermediate salt precipitates, wherein said intermediate salt is not an L-ornithine salt; isolating the intermediate salt from said solution; intermixing phenyl acetic acid with said solution; and isolating an L-ornithine phenyl acetate salt from said solution. A third method involves intermixing an L-ornithine salt, silver phenyl acetate and a solvent to form a solution, wherein the L-ornithine salt is a halide salt. Further provided are crystalline L-ornithine phenyl acetate salts which may, in some embodiments, be of Form I, II, III or V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;FIGINI ATTILIA;;WATT STEPHEN WILLIAM;;ANDERSON KEITH;;MANINI PETER,,https://lens.org/127-633-005-264-458,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
217,AU,B2,AU 2017/202081 B2,196-411-211-132-535,2019-01-17,2019,AU 2017/202081 A,2017-03-29,AU 2017/202081 A;;AU 2015/221466 A;;AU 2010/232521 A,2010-04-01,L-ornithine phenyl acetate and methods of making thereof,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;ANDERSON KEITH,,https://lens.org/196-411-211-132-535,Granted Patent,no,0,0,6,6,0,,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
218,SA,B1,SA 520411599 B1,048-448-748-499-823,2022-11-20,2022,SA 520411599 A,2020-03-24,US 2017/0066224 W,2017-12-13,Real-Time Perforation Plug Deployment and Stimulation in A Subsurface Formation,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria. Fig 7.",HALLIBURTON ENERGY SERVICES INC,TYLER AUSTEN ANDERSON;;JANETTE CORTEZ MONTALVO;;JOSHUA LANE CAMP;;JIM BASUKI SURJAATMADJA;;UBONG INYANG,,https://lens.org/048-448-748-499-823,Granted Patent,no,0,0,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,,,0,0,,,,ACTIVE
219,AU,B2,AU 2010/232521 B2,060-232-297-735-63X,2015-07-16,2015,AU 2010/232521 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/060-232-297-735-63X,Granted Patent,no,1,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
220,EP,A1,EP 3263100 A1,109-212-041-269-565,2018-01-03,2018,EP 17185173 A,2010-04-01,US 16667609 P;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2020-03-25)",https://lens.org/109-212-041-269-565,Patent Application,yes,6,12,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,2,0,,,"BIGHLEY L.D. ET AL.: ""Encyclopedia of pharmaceutical technology"", vol. 12, MARCEL DEKKER, INC., article ""Salt forms of drugs and absorption"", pages: 452 - 499;;FINGL ET AL.: ""The Pharmacological Basis of Therapeutics"", 1975, pages: 1",ACTIVE
221,CA,A1,CA 3205755 A1,097-197-062-895-526,2010-10-07,2010,CA 3205755 A,2010-04-01,US 16667609 P;;CA 3077846 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline founs of L-ornithine phenyl acetate and methods of making the same. The crystalline faun may, in some embodiments, be FOMIS I, II, III and V, or mixtures thereof. The crystalline fauns may be founulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include fonnulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/097-197-062-895-526,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,,,0,0,,,,PENDING
222,AU,B2,AU 2015/221466 B2,131-420-999-386-608,2017-02-02,2017,AU 2015/221466 A,2015-09-02,AU 2010/232521 A;;AU 2015/221466 A,2010-04-01,L-ornithine phenyl acetate and methods of making thereof,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, I and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/131-420-999-386-608,Granted Patent,no,1,0,6,6,0,,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
223,US,B2,US 11162346 B2,192-667-899-920-145,2021-11-02,2021,US 201716644794 A,2017-12-13,US 2017/0066224 W,2017-12-13,Real-time perforation plug deployment and stimulation in a subsurface formation,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria.",HALLIBURTON ENERGY SERVICES INC,MONTALVO JANETTE CORTEZ;;INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,HALLIBURTON ENERGY SERVICES INC (2017-12-05),https://lens.org/192-667-899-920-145,Granted Patent,yes,19,3,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,E21B43/267;;E21B33/13;;E21B47/11,,10,3,067-047-330-195-568;;073-496-803-047-217;;048-150-824-257-681,10.2118/553-pa;;10.2118/8401-pa;;10.2118/13085-ms,"PCT Application Serial No. PCT/US2017/066209, International Search Report, dated Sep. 6, 2018, 3 pages.;;PCT Application Serial No. PCT/US2017/066209, International Written Opinion, dated Sep. 6, 2018, 8 pages.;;PCT Application Serial No. PCT/US2017/066224, International Search Report, dated Sep. 11, 2018, 4 pages.;;PCT Application Serial No. PCT/US2017/066224, International Written Opinion, dated Sep. 11, 2018, 12 pages.;;“Diversion in Matrix-Acidizing Treatments”, [online] retrieved on Mar. 10, 2021 from https://www.halliburton.com/content/dam/ps/public/pe/contents/Best_Practices/web/A_through_G/F3354.pdf, Oct. 21, 2008, 20 pages.;;Brown, et al., “Factors Influencing Optimum Ball Sealer Performance”, Society of Petroleum Engineers, Journal of Petroleum Technology 15 (04): pp. 450-454, Paper No. SPE-553-PA, Apr. 1, 1963.;;Erbstoesser, “Improved Ball Sealer Diversion”, Society of Petroleum Engineers, Journal of Petroleum Technology 32 (11): pp. 1903-1910; Paper No. SPE-8401-PA, Nov. 1980.;;Gabriel, et al., “The Design of Buoyant Ball Sealer Treatments”, Society of Petroleum Engineers, SPE Annual Technical Conference and Exhibition, Houston, Texas, Sep. 1984, Paper No. SPE-13085-MS, 12 pages.;;CA Application No. 3074010, First Office Action, dated Apr. 20, 2021, 5 pages.;;U.S. Appl. No. 16/644,652; First Office Action; dated Jun. 1, 2021, 14 pages.",ACTIVE
224,HU,T2,HU E060371 T2,016-401-407-805-141,2023-02-28,2023,HU E20161306 A,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/016-401-407-805-141,Amended Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61P1/16;;C07C229/26;;C07C57/32;;C07C57/46,,0,0,,,,PENDING
225,CN,A,CN 104230730 A,043-001-511-219-077,2014-12-24,2014,CN 201410392027 A,2010-04-01,US 16667609 P;;CN 201080021311 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/043-001-511-219-077,Patent Application,no,6,2,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/18;;C07C51/41;;C07C57/32;;C07C229/26,,1,0,,,"R.JALAN等: ""L-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy"", 《MEDICAL HYPOTHESES》, vol. 69, 31 December 2007 (2007-12-31), pages 1064 - 1069",ACTIVE
226,CN,B,CN 102421432 B,048-316-451-648-336,2014-09-17,2014,CN 201080021311 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/048-316-451-648-336,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
227,US,B2,US 8785498 B2,103-809-025-769-635,2014-07-22,2014,US 201313937107 A,2013-07-08,US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/103-809-025-769-635,Granted Patent,yes,56,26,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/32;;A61K31/205,514/576;;562/496,99,83,005-411-405-905-202;;001-333-743-768-03X;;062-099-863-837-757;;093-159-361-636-556;;064-348-611-021-409;;184-275-615-368-06X;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;109-586-006-962-328;;085-339-541-354-722;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-684-471-190-493;;052-067-038-116-555;;004-568-483-555-796;;063-040-386-072-391;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;008-274-826-287-829;;093-200-165-594-194;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901,17101577;;10.1080/00365520600780403;;18823442;;10.1111/j.1440-1746.2008.05582.x;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10.1002/hep.21673;;17596891;;10.1016/s0168-8278(09)60775-3;;8941257;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;10.1055/s-2003-42645;;14523680;;19409290;;10.1053/j.gastro.2009.04.016;;4403084;;10.1098/rspb.1972.0064;;15176533;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;3058448;;10.1055/s-2008-1067908;;10.1007/bf01477666;;225605;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918,"Bruha et al., ""Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes"", Scand J Gastroenter. (2006) 41: 1454-1463.;;Jiang et al., ""L-Ornithine-I-aspartate in the management of hepatic encephalopathy: a meta-analysis"", J Gastroenterol Hepatol. (2009) 24(1): 9-14.;;Lopez-Talavera et al., ""Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats"", Hepatology (1996) 23(6): 1616-1621.;;Maev I.V. Primenenie preparata L-ornitin-L-aspartata v kompleksnoy terapii pechyonochnoy entsefalopatii u bolnykh tsirrozom pecheni. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2002, No. 6, pp. 60-66.;;Trebicka et al., Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Roh-kinase and activation of endothelial nitric oxide synthase, Hapatology, (2007) 46(1): 242-253.;;Wright et al., ""Reduction in Ammonia with L-Ornithine, Phenylacetate (OP) but not Anti-TNF Prevents LPS Induced Brain Edema in Bile-duct Ligated Cirrhotic Rats"", Abstract 773; J Hepatology (2009) 50: S283.;;EPO Extended Search Report dated Nov. 30, 2012 for Application No. 10759442.6.;;""Sodium phenylbutyrate for urea cycle enzyme deficiencies."" [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Aggarwal et al., ""Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU"", Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., ""Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate"", Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., ""Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy"", Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., ""The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia"", J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Als-Nielsen, Bodil, et al., Non-Absorbable Disaccharides for Hepatic Encephyalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., ""Ornithine transcarbamylase deficiency and pancreatitis"", J Pediatr, 2001, vol. 138, pp. 123-124.;;Bachmann et al., ""Ammonia toxicity to the brain and creatine"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., ""Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,"", Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., ""Alternative pathway therapy for urea cycle disorders: twenty years later"", J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., ""Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse"", Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., ""Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,"", Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berge et al., J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., ""Long-term management of patients with urea cycle disorders"", J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley, L.D., et al.. ""Salt Forms of Drugs and Absorption"" in Encyclopedia of Pharmaceutical Technology, Eds. J. Swarbrick and J.C. Boylan, vol. 13, Marcel Dekker, Inc., New York, (1996), pp. 453-499.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., ""Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage"", British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., ""Exogenous glutamine: the clinical evidence,"", Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., Biochem J, 1976, vol. 160, pp. 205-209.;;Brunquell et al., ""Electroencephalographic findings in ornithine transcarbamylase deficiency"", J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., ""Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis"", Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., ""Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis"", The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., ""Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients"", Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, ""Pathophysiology of hepatic encephalopathy: a new look at ammonia"", Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., ""Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor"", Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., ""Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease"", Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chen et al., ""Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency"", Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Darmaun et al., ""Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism"", Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;Database WPI, Section Ch, Week 200331, Derwent Publications Ltd., London, GB; XP002364873 & CN 1383815 A (LIU W), Dec. 11, 2002 (Abstract Only).;;Dejong et al., ""Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia"", Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al. , Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011, in International Application No. PCT/US2010/029708.;;Demand with Article 34 amendments, filed May 16, 2011, in International Application No. PCT/US2010/029708.;;Desjardins et al., ""Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle"", Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz, et al., ""Disappearing Polymorphs,"" Acc. Chem. Res. 28:193-200, 1995.;;Enns et al., ""Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,"", N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;EPO Examination Report dated Nov. 5, 2008 from EP patent application No. 05808837.8.;;EPO-Extended European Search Report for EP 09013613.6, dated Jan. 15, 2010.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., ""Prediction of outcome following acute variceal haemorrhage"", Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., ""Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels"", J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., ""Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,"", Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, ""Ornithine transcarbamylase deficiency: a urea cycle defect"", European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., ""Prevention of initial variceal hemorrhage"", Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Greensteine et al., Arch Biochem Biophys, 1956, vol. 64, pp. 342-354.;;Grossi et al., ""Amino acids mixtures in prevention of acute ammonia intoxication in dogs"", Arch Surg, 1967, vol. 94, pp. 261-266.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, pp. 1430-1433, vol. 129 (in German).;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urca Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., ""Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)"", Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., ""Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?"", J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., ""The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy"", Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., ""Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy"", Biol. Pharm. Bull., [no date], vol. 25, Issue 9, pp. 1244-1246.;;Hursthouse, et al., ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why . . . ,"" Organic Process Research & Development, 13:1231-1240, 2009.;;Igarashi et al., ""Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography"", Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., ""Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria"", Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;Intellectual Property Office of Singapore (IPOS) Search Report and Written Opinion, dated Apr. 23, 2010, Singapore Patent Application No. 200907712-4.;;International Preliminary Report on Patentability issued May 30, 2007 during the prosecution of the International Application No. PCT/GB2005/004539.;;International Search Report and Written Opinion received in PCT/US2010/029708 dated Jun. 3, 2010.;;International Search Report issued Feb. 8, 2006 during the prosecution of the International Application No. PCT/GB2005/004539.;;IPONZ Examination Report dated Apr. 8, 2008 from NZ patent application No. 555870.;;Iyer et al., ""Mouse model for human arginase deficiency"", Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., ""Acute-on-chronic liver failure: pathophysiological basis of therapeutic options"", Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., ""Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,"", Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., ""The molecular pathogenesis of hepatic encephalopathy"", The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan, et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses, 2007, p. 1064-1069, vol. 69, Elsevier Ltd.;;Jalan, M.D., Rajiv, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publishers, Inc., New York, NY, USA.;;Jalan, R., et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;James et al., ""The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species"", Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., ""New secondary metabolites of phenylbutyrate in humans and rats"", Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, ""Ammonia metabolism and hepatic encephalopathy"", Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Cirpofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., ""Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,"", Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., ""Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,"", Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, p. 935-938, vol. 52, No. 7, Elsevier Inc.;;MacArthur et al., ""Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., ""Long-term treatment of girls with ornithine transcarbamylase deficiency"", N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., ""Prospective treatment of urea cycle disorders"", J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maier, ""Therapie der hepatischen Enzephalopathie"", Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Maier, K. P. et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Meijer, Alfred J. et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., ""A new therapy for portal systemic encephalopathy"", The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mihm et al., ""Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)"", Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., ""Septic Encephalopathy-Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy"", Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock, MD, FACP, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.",ACTIVE
228,NZ,A,NZ 595706 A,145-090-130-612-807,2014-01-31,2014,NZ 59570610 A,2010-04-01,US 2010/0029708 W;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"595706 Provided are crystalline forms of L-ornithine phenyl acetate, as depicted in structure (V), and methods of making the same. The crystalline form may, in some embodiments, be of Form I, II, III or V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;FIGINI ATTILIA;;WATT STEPHEN WILLIAM;;ANDERSON KEITH;;MANINI PETER,"OCERA THERAPEUTICS, INC., US (2012-03-30)",https://lens.org/145-090-130-612-807,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
229,CA,A1,CA 2757373 A1,195-678-779-242-223,2010-10-07,2010,CA 2757373 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/195-678-779-242-223,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
230,CA,A1,CA 3077846 A1,006-255-401-174-064,2010-10-07,2010,CA 3077846 A,2010-04-01,US 16667609 P;;CA 2998344 A,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/006-255-401-174-064,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,,,0,0,,,,PENDING
231,SG,A,SG 10201406300Y A,022-395-458-895-692,2015-01-29,2015,SG 10201406300Y A,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, some embodiments, in be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-omithine phenyl acetate. Figure 1 -77-",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/022-395-458-895-692,Unknown,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,,,0,0,,,,PENDING
232,ZA,B,ZA 201107189 B,088-076-428-251-243,2012-12-27,2012,ZA 201107189 A,2011-09-30,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/088-076-428-251-243,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61P/;;A61K/;;C07C/,,0,0,,,,ACTIVE
233,EP,A1,EP 3686183 A1,172-103-684-922-056,2020-07-29,2020,EP 20161306 A,2010-04-01,US 16667609 P;;EP 17185173 A;;EP 10759442 A;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-omithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.
",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/172-103-684-922-056,Patent Application,yes,6,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C229/26;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46,,2,0,,,"BIGHLEY L.D. ET AL.: ""Encyclopedia of pharmaceutical technology"", vol. 12, MARCEL DEKKER, INC., article ""Salt forms of drugs and absorption"", pages: 452 - 499;;FINGL ET AL., THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1975",ACTIVE
234,NZ,A,NZ 708458 A,183-425-032-135-04X,2017-02-24,2017,NZ 70845810 A,2010-04-01,US 16667609 P;;NZ 61923510 A,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed is a process for making L-ornithine phenyl acetate salt comprising: increasing the pH value of a solution comprising an L-ornithine salt at least until an intermediate salt precipitates, wherein said intermediate salt is not an L-ornithine salt; isolating the intermediate salt from said solution; intermixing phenyl acetic acid with said solution; and isolating L-ornithine phenyl acetate salt from said solution. Also disclosed is the L-ornithine phenyl acetate salt prepared by this process. L-ornithine phenyl acetate is useful in the treatment of hyperammonemia.",OCERA THERAPEUTICS INC,BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;FIGINI ATTILIA;;WATT STEPHEN WILLIAM;;ANDERSON KEITH;;MANINI PETER,,https://lens.org/183-425-032-135-04X,Patent Application,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
235,US,A1,US 2020/0239406 A1,022-193-370-141-76X,2020-07-30,2020,US 202016778696 A,2020-01-31,US 202016778696 A;;US 201816037655 A;;US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/022-193-370-141-76X,Patent Application,yes,0,1,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C57/32;;C07C227/42;;C07C229/26,,0,0,,,,ACTIVE
236,CA,C,CA 3074010 C,054-928-779-107-933,2022-05-24,2022,CA 3074010 A,2017-12-13,US 2017/0066224 W,2017-12-13,REAL-TIME PERFORATION PLUG DEPLOYMENT AND STIMULATION IN A SUBSURFACE FORMATION,"A first flow distribution to one or more entry points into a subsurface formation may be monitored. Stimulation criteria may be identified based on the first flow distribution. At least one characteristic associated with a first treatment fluid to be injected into a wellbore associated with the subsurface formation may be determined based on the first flow distribution, where the at least one characteristic is based on the stimulation criteria. The subsurface formation may be stimulated with the first treatment fluid and a second flow distribution monitored based on the stimulation. A determination is made whether the second flow distribution meets the stimulation criteria. The subsurface formation may be stimulated with a second treatment fluid based on the determination that the second flow distribution does not meet the stimulation criteria.",HALLIBURTON ENERGY SERVICES INC,MONTALVO JANETTE CORTEZ;;INYANG UBONG;;CAMP JOSHUA LANE;;ANDERSON TYLER AUSTEN;;SURJAATMADJA JIM BASUKI,,https://lens.org/054-928-779-107-933,Granted Patent,no,0,0,7,7,0,E21B43/25;;E21B47/11;;E21B47/11;;E21B33/13;;E21B43/267,E21B43/25;;E21B47/10,,0,0,,,,PENDING
237,WO,A1,WO 2010/115055 A1,103-462-439-416-661,2010-10-07,2010,US 2010/0029708 W,2010-04-01,US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC;;ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/103-462-439-416-661,Patent Application,yes,8,41,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/46;;C07C229/26,,1,0,,,"BIGHLEY L.D. ET AL.: ""Encyclopedia of pharmaceutical technology"", vol. 12, MARCEL DEKKER, INC., article ""Salt forms of drugs and absorption"", pages: 452 - 499",PENDING
238,EA,B1,EA 034409 B1,091-585-664-245-017,2020-02-05,2020,EA 201500650 A,2010-04-01,US 16667609 P,2009-04-03,METHODS OF MAKING CRYSTALLINE L-ORNITHINE PHENYL ACETATE,"The present invention relates to the field of pharmaceutical chemistry, biochemistry and medicine. In particular, it relates to methods of making a crystalline L-ornithine phenylacetate salt.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/091-585-664-245-017,Granted Patent,no,2,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/198;;A61K31/192;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
239,KR,A,KR 20210019592 A,111-161-265-525-526,2021-02-22,2021,KR 20217004211 A,2010-04-01,US 16667609 P;;KR 20207016586 A;;US 2010/0029708 W,2009-04-03,- L-ornithine phenyl acetate and methods of making thereof,"본 발명은 L-오르니틴 페닐아세테이트의 결정 형태 및 이의 제조방법에 관한 것이다. 본 발명에 따른 L-오르니틴 페닐아세테이트의 결정 형태는 형태 I, II, III, 및 V, 또는 이의 조합이다. 상기 결정 형태는 간성뇌증과 같은 간질환을 나타내는 환자를 치료하기 위하여 제조될 수 있다. 또한 본 발명은 L-오르니틴 페닐아세테이트의 제제화 방법 또는 투여 방법에 관한 것이다.",OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/111-161-265-525-526,Patent Application,no,1,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;A61K31/198;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
240,LT,T,LT 2413924 T,161-004-534-523-41X,2018-02-12,2018,LT 10759442 T,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,,OCERA THERAPEUTICS INC,ANDERSON KEITH;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/161-004-534-523-41X,Unknown,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
241,MX,B,MX 356608 B,175-263-075-849-166,2018-06-06,2018,MX 2014008993 A,2010-04-01,US 16667609 P;;US 2010/0029708 W,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF.,"Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,PETER MANINI;;KEITH ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;ATTILIA FIGINI,,https://lens.org/175-263-075-849-166,Granted Patent,no,0,0,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;A61K31/198;;A61P1/16;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
242,US,B2,US 9260379 B2,001-141-443-953-712,2016-02-16,2016,US 201514601591 A,2015-01-21,US 201514601591 A;;US 201313878146 A;;US 2011/0054983 W;;US 39058510 P,2010-10-06,Methods of making L-ornithine phenyl acetate,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH E;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2013-05-27);;OCERA THERAPEUTICS INC (2013-05-28);;SOLID FORM SOLUTIONS LTD (2013-09-23),https://lens.org/001-141-443-953-712,Granted Patent,yes,68,23,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;C07C51/41,,99,81,005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;109-586-006-962-328;;085-339-541-354-722;;184-275-615-368-06X;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;023-591-152-002-307;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;005-411-405-905-202;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-067-038-116-555;;052-684-471-190-493;;004-568-483-555-796;;063-040-386-072-391;;001-333-743-768-03X;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;062-099-863-837-757;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630,10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;8941257;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;11391852;;10.1007/s002800000256;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;17101577;;10.1080/00365520600780403;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;19409290;;10.1053/j.gastro.2009.04.016;;10.1055/s-2003-42645;;14523680;;4403084;;10.1098/rspb.1972.0064;;15176533;;18823442;;10.1111/j.1440-1746.2008.05582.x;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443,"Aggarwal et al., ""Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted tothe Medical ICU"", Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., ""Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate"", Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., ""Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy"", Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., ""The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia"", J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Als-Nielsen et al., Non-Absorbable Disaccharides for Hepatic Encephalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., ""Ornithine transcarbamylase deficiency and pancreatitis"", J Pediatr, 2001, vol. 138, pp. 123-124.;;Anonymous ""Sodium phenylbutyrate for urea cycle enzyme deficiencies."" [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Bachmann et al., ""Ammonia toxicity to the brain and creatine"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., ""Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,"", Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., ""Alternative pathway therapy for urea cycle disorders: twenty years later"", J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., ""Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse"", Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., ""Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,"", Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berg et al., ""Pharmacokinetics and cerebrospinal fluid penetration of pheylacetate and phenylbutyrate in the non-human primate"", Cancer Chemother Pharmacol. (May 2001) 47(5): 385-390. Abstract Only.;;Berge et al., Review Article: Pharmaceutical Salts, J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., ""Long-term management of patients with urea cycle disorders"", J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley et al., ""Salt Forms of Drugs and Absorption"" in Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. New York, (1996), pp. 453-499.;;Blei et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., ""Frequency of infections in cirrhotic patients presenting with acute gastrointestinal hemorrhage"", British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., ""Exogenous glutamine: the clinical evidence,"", Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes, Biochem J, 1976, vol. 160, pp. 205-209.;;Bruha et al., ""Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes"", Scand J Gastroenter. (2006) 41: 1454-1463.;;Brunquell et al., ""Electroencephalographic findings in ornithine transcarbamylase deficiency"", J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., ""Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis"", Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., ""Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis"", The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., ""Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients"", Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, ""Pathophysiology of hepatic encephalopathy: a new look at ammonia"", Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Callado Franca, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., ""Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor"", Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., ""Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease"", Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chen et al., ""Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency"", Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Chinese Office Action dated Jul. 11, 2014 from Application No. 201180058441.1, filed Jun. 4, 2013.;;Clemmesen et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Darmaun et al., ""Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism"", Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;Database WPI, Section Ch, Week 200331, Derwent Publications Ltd., London, GB; XP002364873 & CN 1383815 A (Liu W), Dec. 11, 2002 (Abstract Only).;;Dejong et al., ""Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia"", Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al., Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011 in International Application No. PCT/US2010/029708.;;Demand with Article 34 amendments, filed May 16, 2011 in International Application No. PCT/US2010/029708.;;Desjardins et al., ""Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle"", Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz et al., ""Disappearing Polymorphs"", Acc Chem Res. (1995) 28: 193-200.;;Enns et al., ""Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,"", N. Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;Eurasian Office Action dated Mar. 21, 2014 from Application No. 201390403, filed Apr. 17, 2013.;;European Extended Search Report dated Jan. 15, 2010 for Application No. 09013613.6.;;European Office Action dated Nov. 5, 2008 from EP Application No. 05808837.8.;;Fabbri et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., ""Prediction of outcome following acute variceal haemorrhage"", Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., ""Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels"", J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., ""Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,"", Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, ""Ornithine transcarbamylase deficiency: a urea cycle defect"", European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., ""Prevention of initial variceal hemorrhage"", Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Greenstein et al., Studies on the Metabolism of Amino Acids and Related Compounds in Vivo. III. Prevention of Ammonia Toxicity by Arginine and Related Compounds, Arch Biochem Biophys, 1956, vol. 64, Issue (2):, pp. 342-354.;;Grossi et al., ""Amino acids mixtures in prevention of acute ammonia intoxication in dogs"", Arch Surg, 1967, vol. 94, pp. 261-266.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, vol. 129; pp. 1430-1433 w/English Machine translation.;;Hamberg et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urea Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pgs. 237-243, Elsevier Science Publishers B.V.;;Hass et al., ""Detection of subclinical and overt hepatic encephalopathy and treatment control after LOrnithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)"", Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., ""Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?"", J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., ""The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy"", Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., ""Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy"", Biol. Pharm. Bull., (2002), vol. 25, Issue 9, pp. 1244-1246.;;Hursthouse et al., ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?"", Organic Process Research & Development, (2009) 13:1231-1240.;;Igarashi et al., ""Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography"", Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., ""Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria"", Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;International Search Report dated Feb. 8, 2006 for International Application No. PCT/GB2005/004539.;;International Preliminary Report on Patentability dated May 30, 2007 for International Application No. PCT/GB2005/004539.;;International Search Report and Written Opinion dated Jun. 3, 2010 for Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;International Search Report and Written Opinion dated Dec. 9, 2011 for Application No. PCT/US2011/054983, filed Oct. 5, 2011.;;International Preliminary Report on Patentability dated Apr. 9, 2013 for Application No. PCT/US2011/054983, filed Oct. 5, 2011.;;IPONZ Examination Report dated Apr. 8, 2008 from NZ patent application No. 555870.;;IPOS, Examination Report dated Jan. 21, 2011 for Singapore Patent Application No. 200907712-4.;;Iyer et al., ""Mouse model for human arginase deficiency"", Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., ""Acute-on-chronic liver failure: pathophysiological basis of therapeutic options"", Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., ""Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,"", Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., ""The molecular pathogenesis of hepatic encephalopathy"", The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses (2007) 69(5): 1064-1069, Elsevier Ltd.;;Jalan et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Jalan Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publisheres, Inc., New York, NY, USA.;;James et al., ""The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species"", Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Jiang et al., ""L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis"", J Gastroenterol Hepatol. (2009) 24(1): 9-14; available online: Sep. 28, 2008.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., ""New secondary metabolites of phenylbutyrate in humans and rats"", Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, ""Ammonia metabolism and hepatic encephalopathy"", Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Ciprofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., ""Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,"", Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., ""Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,"", Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lopez-Talavera et al., ""Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats"", Hepatology (1996) 23(6): 1616-1621.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, pp. 935-938, vol. 52, No. 7, Elsevier Inc.;;MacArthur et al., ""Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., ""Long-term treatment of girls with ornithine transcarbamylase deficiency"", N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., ""Prospective treatment of urea cycle disorders"", J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maev I.V. Primenenie preparata L-ornitin-L-aspartata v kompleksnoy terapii pechyonochnoy entsefalopatii u bolnykh tsirrozom pecheni. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2002, No. 6, pp. 60-66.;;Maier et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Maier, ""Therapie der hepatischen Enzephalopathie"", Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Meijer et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., ""A new therapy for portal systemic encephalopathy"", The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mihm et al., ""Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)"", Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., ""Septic Encephalopathy-Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy"", Arch Intern Med, 1990, vol. 150, pp. 443-449.",ACTIVE
243,WO,A2,WO 2020/102424 A2,164-644-770-735-013,2020-05-22,2020,US 2019/0061280 W,2019-11-13,US 201862760457 P,2018-11-13,IMPROVED SAMPLE GRINDER,"A bead beater homogenizer (100) includes a shaft having a main body (30) extending along a main axis (32) and a distal connection body (34) extending along a connection axis (36) that is acutely angled with respect to the main axis (32), a motor (20) configured to rotate the shaft about the main axis (32), a head (60) rotatably connected to the distal connection body (34) of the shaft, and a clamp (62, 64, 66) secured to the head (60) and configured to secure a sample vial holder (70, 170, 270, 370, 470) configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis (32) is translated into motion of the head (60) in directions normal to the main axis (32). A sample vial holder (470) having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/164-644-770-735-013,Patent Application,yes,0,1,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06,,0,0,,,,PENDING
244,US,A1,US 2023/0225422 A1,155-112-691-427-529,2023-07-20,2023,US 202318125505 A,2023-03-23,US 202318125505 A;;US 202117313051 A,2021-05-06,DEVICE AND SYSTEM FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A test fixture for testing aerosol provision devices may include a housing, a plurality of testing modules disposed at the housing where each of the testing modules includes a cavity configured to receive a portion of an aerosol provision device, and processing circuitry operably coupled to the testing modules. Each of the testing modules may be configured to interface with an assembly of a respective one of the aerosol provision devices to transition the assembly between an initial state and a transitioned state during a functional test controlled by the processing circuitry. The processing circuitry may be configured to conduct the functional test of at least two of the testing modules simultaneously.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,RAI STRATEGIC HOLDINGS INC (2021-05-04),https://lens.org/155-112-691-427-529,Patent Application,yes,0,0,6,6,0,A24F40/53;;A24F40/80;;A61M15/06;;G01M99/005;;A61M2205/3306;;A61M2205/3375;;A61M2205/8206;;A61M11/042;;A61M2205/276;;A61M2205/60;;A61M2016/0024;;A61M2016/0021;;A61M2016/0027;;A61M2205/505;;A61M2205/581;;A61M2205/582;;A61M2205/583;;A61M11/005;;A61M11/06;;A61M2205/3653;;A61M15/0003;;A61M2205/75;;A61M2016/0033;;A61M2205/3553;;A61M2205/3592;;A61M2205/3561;;A61M2205/70;;A61M2205/3584;;G01M99/008;;A24F40/80;;A24F40/53;;A61M15/06;;G01M99/005;;G06F11/26,A24F40/80;;A24F40/53;;G01M99/00;;G06F11/26,,0,0,,,,PENDING
245,CA,A1,CA 3217388 A1,114-645-133-845-050,2022-11-10,2022,CA 3217388 A,2022-05-06,US 202117313051 A;;US 2022/0027981 W,2021-05-06,DEVICE AND SYSTEM FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A test fixture for testing aerosol provision devices may include a housing, a plurality of testing modules disposed at the housing where each of the testing modules includes a cavity configured to receive a portion of an aerosol provision device, and processing circuitry operably coupled to the testing modules. Each of the testing modules may be configured to interface with an assembly of a respective one of the aerosol provision devices to transition the assembly between an initial state and a transitioned state during a functional test controlled by the processing circuitry. The processing circuitry may be configured to conduct the functional test of at least two of the testing modules simultaneously.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,,https://lens.org/114-645-133-845-050,Patent Application,no,0,0,6,6,0,A24F40/53;;A24F40/80;;A61M15/06;;G01M99/005;;A61M2205/3306;;A61M2205/3375;;A61M2205/8206;;A61M11/042;;A61M2205/276;;A61M2205/60;;A61M2016/0024;;A61M2016/0021;;A61M2016/0027;;A61M2205/505;;A61M2205/581;;A61M2205/582;;A61M2205/583;;A61M11/005;;A61M11/06;;A61M2205/3653;;A61M15/0003;;A61M2205/75;;A61M2016/0033;;A61M2205/3553;;A61M2205/3592;;A61M2205/3561;;A61M2205/70;;A61M2205/3584;;G01M99/008;;A24F40/80;;A24F40/53;;A61M15/06;;G01M99/005;;G06F11/26,A24F40/53;;A24F40/80,,0,0,,,,PENDING
246,KR,A,KR 20140053807 A,142-507-232-733-492,2014-05-08,2014,KR 20137011664 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,,OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/142-507-232-733-492,Patent Application,no,1,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;C07C57/32;;C07C229/26,,3,2,107-486-946-957-376;;107-486-946-957-376,10.1016/j.mehy.2006.12.061;;17467190;;10.1016/j.mehy.2006.12.061;;17467190,"Medical Hypotheses, 2007, vol. 69, pp.1064-1069;;일본 특허공보 특허 제 3273578호(2002.04.08.) 1부.;;Medical Hypotheses, 2007, vol. 69, pp.1064-1069",ACTIVE
247,SG,A1,SG 189231 A1,011-826-227-889-861,2013-05-31,2013,SG 2013024559 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/011-826-227-889-861,Patent Application,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,,,0,0,,,,PENDING
248,US,B2,US 8946473 B2,013-490-260-967-354,2015-02-03,2015,US 201113878146 A,2011-10-05,US 201113878146 A;;US 39058510 P;;US 2011/0054983 W,2010-10-06,Methods of making L-ornithine phenyl acetate,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2013-05-27);;OCERA THERAPEUTICS INC (2013-05-28);;SOLID FORM SOLUTIONS LTD (2013-09-23),https://lens.org/013-490-260-967-354,Granted Patent,yes,58,27,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;C07C51/41;;C07C229/26,562/496,99,81,005-411-405-905-202;;001-333-743-768-03X;;062-099-863-837-757;;093-159-361-636-556;;064-348-611-021-409;;023-591-152-002-307;;184-275-615-368-06X;;005-617-134-437-163;;151-697-969-723-439;;026-294-638-279-89X;;021-575-246-585-985;;109-586-006-962-328;;085-339-541-354-722;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;107-486-946-957-376;;098-424-890-714-27X;;036-903-424-040-422;;052-684-471-190-493;;052-067-038-116-555;;004-568-483-555-796;;063-040-386-072-391;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871,17101577;;10.1080/00365520600780403;;18823442;;10.1111/j.1440-1746.2008.05582.x;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10.1002/hep.21673;;17596891;;10.1016/s0168-8278(09)60775-3;;11391852;;10.1007/s002800000256;;8941257;;10.1378/chest.119.5.1489;;11348958;;10.1023/a:1024048118294;;12872849;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;10.1016/j.mehy.2006.12.061;;17467190;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1055/s-2003-42645;;14523680;;19409290;;10.1053/j.gastro.2009.04.016;;4403084;;10.1098/rspb.1972.0064;;15176533;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701,"Bruha et al., ""Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes"", Scand J Gastroenter. (2006) 41: 1454-1463.;;Jiang et al., ""L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis"", J Gastroenterol Hepatol. (2009) 24(1): 9-14; Available online: Sep. 24, 2008.;;Lopez-Talavera et al., ""Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats"", Hepatology (1996) 23(6): 1616-1621.;;Maev I.V. Primenenie preparata L-ornitin-L-aspartata v kompleksnoy terapii pechyonochnoy entsefalopatii u bolnykh tsirrozom pecheni. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2002, No. 6, pp. 60-66.;;Trebicka et al., Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Roh-kinase and activation of endothelial nitric oxide synthase, Hapatology, (2007) 46(1): 242-253.;;Wright et al., ""Reduction in Ammonia with L-Ornithine, Phenylacetate (OP) but not Anti-TNF Prevents LPS Induced Brain Edema in Bile-duct Ligated Cirrhotic Rats"", Abstract 773; J Hepatology (2009) 50: S283.;;International Search Report and Written Opinion dated Dec. 9, 2011 for Application No. PCT/US2011/054983, filed Oct. 5, 2011.;;International Preliminary Report on Patentability dated Apr. 9, 2013 for Application No. PCT/US2011/054983, filed Oct. 5, 2011.;;Berg et al., ""Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the non-human primate"", Cancer Chemother. Pharmacol. (May 2001) 47(5): 385-390. Abstract Only.;;""Sodium phenylbutyrate for urea cycle enzyme deficiencies."" [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Aggarwal et al., ""Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted tothe Medical ICU"", Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Al-Hassnan et al., ""The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia"", J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Albrecht et al., ""Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate"", Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., ""Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy"", Neuroreport, 1994, vol. 5, Issue 6, pp. 671-673.;;Als-Nielsen, Bodil, et al., Non-Absorbable Disaccharides for Hepatic Encephyalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., ""Ornithine transcarbamylase deficiency and pancreatitis"", J Pediatr, 2001, vol. 138, pp. 123-124.;;Bachmann et al., ""Ammonia toxicity to the brain and creatine"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., ""Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,"", Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., ""Alternative pathway therapy for urea cycle disorders: twenty years later"", J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., ""Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse"", Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., ""Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,"", Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berge et al., ""Pharmaceutical Salts"", J Pharm Sci, 1977, vol. 66(1), pp. 1-19.;;Berry et al., ""Long-term management of patients with urea cycle disorders"", J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley, L.D., et al.. ""Salt Forms of Drugs and Absorption"" in Encyclopedia of Pharmaceutical Technology, Eds. J. Swarbrick and J.C. Boylan, vol. 13, Marcel Dekker, Inc., New York, (1996), pp. 453-499.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., ""Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage"", British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., ""Exogenous glutamine: the clinical evidence,"", Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Briggs et al., ""Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes"", Biochem J, 1976, vol. 160, pp. 205-209.;;Brunquell et al., ""Electroencephalographic findings in ornithine transcarbamylase deficiency"", J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., ""Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis"", Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., ""Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis"", The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., ""Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients"", Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, ""Pathophysiology of hepatic encephalopathy: a new look at ammonia"", Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2. 119-122 [Abstract Only].;;Cavarec et al., ""Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor"", Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., ""Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease"", Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chen et al., ""Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency"", Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Darmaun et al., ""Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism"", Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;Database WPI, Section Ch, Week 200331, Derwent Publications Ltd., London, GB; XP002364873 & CN 1383815 A (Liu W), Dec. 11, 2002 (Abstract Only).;;Dejong et al., ""Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia"", Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al. , Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011, in International Application No. PCT/US2010/029708.;;Demand with Article 34 amendments, filed May 16, 2011, in International Application No. PCT/US2010/029708.;;Desjardins et al., ""Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle"", Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz, et al., ""Disappearing Polymorphs,"" Acc. Chem. Res. 28:193-200, 1995.;;Enns et al., ""Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,"", N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;EPO Examination Report dated Nov. 5, 2008 from EP patent application No. 05808837.8.;;EPO Extended European Search Report for EP 09013613.6, dated Jan. 15, 2010.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., ""Prediction of outcome following acute variceal haemorrhage"", Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., ""Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels"", J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., ""Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,"", Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, ""Ornithine transcarbamylase deficiency: a urea cycle defect"", European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., ""Prevention of initial variceal hemorrhage"", Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Greensteine et al., Arch Biochem Biophys, 1956, vol. 64, pp. 342-354.;;Grossi et al., ""Amino acids mixtures in prevention of acute ammonia intoxication in dogs"", Arch Surg, 1967, vol. 94, pp. 261-266.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, pp. 1430-1433, vol. 129 (in German).;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urca Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., ""Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)"", Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., ""Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?"", J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., ""The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy"", Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Honda et al., ""Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy"", Biol. Pharm. Bull., [no date], vol. 25, Issue 9, pp. 1244-1246.;;Hursthouse, et al., ""Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why . . . ,"" Organic Process Research & Development, 13:1231-1240, 2009.;;Igarashi et al., ""Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography"", Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., ""Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria"", Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;Intellectual Property Office of Singapore (IPOS) Search Report and Written Opinion, dated Apr. 23, 2010, Singapore Patent Application No. 200907712-4.;;IPONZ Examination Report dated Apr. 8, 2008 from NZ patent application No. 555870.;;International Preliminary Report on Patentability and Written Opinion in International Application No. PCT/US2011/054983, filed Oct. 5, 2011, dated Apr. 18, 2013.;;International Preliminary Report on Patentability in International Application No. PCT/GB2005/004539, filed Nov. 28, 2005, dated May 30, 2007.;;International Search Report and Written Opinion in International Application No. PCT/US2011/054983, filed Oct. 5, 2011, dated Dec. 9, 2011.;;International Search Report and Written Opinion in International Application No. PCT/US2010/029708, filed Apr. 1, 2010, dated Jun. 3, 2010.;;International Search Report in International Application No. PCT/GB2005/004539, filed Nov. 28, 2005, issued Feb. 8, 2006.;;Iyer et al., ""Mouse model for human arginase deficiency"", Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., ""Acute-on-chronic liver failure: pathophysiological basis of therapeutic options"", Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan, et al., ""L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy"", Medical Hypotheses, 2007, p. 1064-1069, vol. 69.;;Jalan et al., ""Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,"", Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., ""The molecular pathogenesis of hepatic encephalopathy"", The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan, M.D., Rajiv, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publishers, Inc., New York, NY, USA.;;Jalan, R., et al., ""Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes"", Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;James et al., ""The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species"", Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., ""New secondary metabolites of phenylbutyrate in humans and rats"", Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, ""Ammonia metabolism and hepatic encephalopathy"", Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan, et al., Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Cirpofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., ""Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,"", Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., ""Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,"", Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, p. 935-938, vol. 52, No. 7.;;MacArthur et al., ""Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers"", Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., ""Long-term treatment of girls with ornithine transcarbamylase deficiency"", N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., ""Prospective treatment of urea cycle disorders"", J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maier, K. P. et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 57, pp. 661-665.;;Maier, K.P., ""herapie der hepatischen Enzephalopathie"", Deutsche Med. Wochenzts. 1988, vol. 113, Issue 48, pp. 1886-1889.;;Meijer, Alfred J. et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748.",ACTIVE
249,EP,A1,EP 2625162 A1,035-108-046-404-647,2013-08-14,2013,EP 11831546 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,,OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2019-02-20)",https://lens.org/035-108-046-404-647,Patent Application,yes,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
250,CN,A,CN 103502203 A,086-924-485-789-302,2014-01-08,2014,CN 201180058441 A,2011-10-05,US 2011/0054983 W;;US 39058510 P,2010-10-06,Methods of making L-ornithine phenyl acetate,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/086-924-485-789-302,Patent Application,no,3,5,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
251,WO,A1,WO 2022/235993 A1,117-984-151-665-235,2022-11-10,2022,US 2022/0027981 W,2022-05-06,US 202117313051 A,2021-05-06,DEVICE AND SYSTEM FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A test fixture for testing aerosol provision devices may include a housing, a plurality of testing modules disposed at the housing where each of the testing modules includes a cavity configured to receive a portion of an aerosol provision device, and processing circuitry operably coupled to the testing modules. Each of the testing modules may be configured to interface with an assembly of a respective one of the aerosol provision devices to transition the assembly between an initial state and a transitioned state during a functional test controlled by the processing circuitry. The processing circuitry may be configured to conduct the functional test of at least two of the testing modules simultaneously.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,,https://lens.org/117-984-151-665-235,Patent Application,yes,4,0,6,6,0,A24F40/53;;A24F40/80;;A61M15/06;;G01M99/005;;A61M2205/3306;;A61M2205/3375;;A61M2205/8206;;A61M11/042;;A61M2205/276;;A61M2205/60;;A61M2016/0024;;A61M2016/0021;;A61M2016/0027;;A61M2205/505;;A61M2205/581;;A61M2205/582;;A61M2205/583;;A61M11/005;;A61M11/06;;A61M2205/3653;;A61M15/0003;;A61M2205/75;;A61M2016/0033;;A61M2205/3553;;A61M2205/3592;;A61M2205/3561;;A61M2205/70;;A61M2205/3584;;G01M99/008;;A24F40/80;;A24F40/53;;A61M15/06;;G01M99/005;;G06F11/26,A24F40/53;;A24F40/80,,0,0,,,,PENDING
252,EP,A4,EP 2625162 A4,022-571-724-322-951,2014-06-25,2014,EP 11831546 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,,OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2019-02-20)",https://lens.org/022-571-724-322-951,Search Report,no,1,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
253,US,A1,US 2013/0211135 A1,059-188-447-055-605,2013-08-15,2013,US 201113878146 A,2011-10-05,US 201113878146 A;;US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,OCERA THERAPEUTICS INC (2013-09-20);;SOLID FORM SOLUTIONS LTD (2013-09-23),https://lens.org/059-188-447-055-605,Patent Application,yes,0,30,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;C07C51/41,562/493,0,0,,,,ACTIVE
254,CA,C,CA 2813563 C,079-239-889-584-195,2019-02-26,2019,CA 2813563 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/079-239-889-584-195,Granted Patent,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/198;;A61P1/16;;C07C229/26,,0,0,,,,ACTIVE
255,TR,T4,TR 201903978 T4,178-246-663-780-016,2019-04-22,2019,TR 201903978 T,2011-10-05,US 39058510 P,2010-10-06,L-ornitin fenil asetat yapım yöntemleri.,"Buluş, L-ornitin fenil asetat tuzu yapımı için bir proses olup, bir fenil asetik asit ve bir çözücü olarak bir bazın karıştırılması yoluyla fenil asetat tuzunun bir çözeltisinin hazırlanması, fenil asetat tuzunun bir çözeltisi ile L-ornitin benzoat'ın birbirine karıştırılması ve L-ornitin fenil asetat içeren bir bileşimin izole edilmesi işlem adımlarını içermesi ile ilgilidir.",OCERA THERAPEUTICS INC,KEITH H ANDERSON;;JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI,,https://lens.org/178-246-663-780-016,Granted Patent,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,A61K31/192;;A61K31/198;;A61P1/16;;C07C51/41;;C07C57/46;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
256,MX,B,MX 360062 B,193-215-940-404-329,2018-10-22,2018,MX 2013003764 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE.,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,JIM BEHLING;;CHRISTINE HENDERSON DOUGAN;;STEPHEN WILLIAM WATT;;PETER MANINI;;ATTILIA FIGINI;;KEITH H ANDERSON,,https://lens.org/193-215-940-404-329,Granted Patent,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C51/41;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
257,US,A1,US 2018/0237909 A1,060-494-391-015-292,2018-08-23,2018,US 201715691593 A,2017-08-30,US 201715691593 A;;US 201662381440 P,2016-08-30,MULTI-LAYER DEPOSITION SYSTEM AND PROCESS,"A modular multilayer deposition system includes a plurality of modular deposition chambers, including at least one parylene deposition chamber and at least one ALD deposition chamber. The parylene deposition chamber is connected in series with the ALD deposition chamber. Substrates are automatically moved from within the parylene deposition chamber to within the ALD deposition chamber or from within the ALD deposition chamber to the parylene deposition chamber.",HZO INC,YUN YANG;;SORENSEN MAX;;HSUEH CHIEN-LAN;;SU TINING;;DEMPSTER JIM;;ANDERSON ALEX;;BAKER LAYTON,HZO INC (2017-10-02),https://lens.org/060-494-391-015-292,Patent Application,yes,3,5,3,3,0,H01L21/67161;;H01L21/67173;;H01L21/67207;;H01L21/6776;;H01L21/022;;C23C16/54;;C23C28/00;;C23C16/26;;C23C16/52;;C23C16/45525;;H01L21/67173;;H01L21/67207;;H01L21/6776;;C23C16/44;;H01L21/67161;;C23C16/00;;C23C16/455;;H01L21/022;;C23C16/45544;;C23C16/45525;;C23C16/52,C23C16/455;;C23C16/52;;H01L21/67;;H01L21/677,,0,0,,,,ACTIVE
258,US,A1,US 2018/0044281 A1,115-329-444-431-666,2018-02-15,2018,US 201715469359 A,2017-03-24,US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH E;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/115-329-444-431-666,Patent Application,yes,0,13,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C57/32;;C07C227/42;;C07C229/26,,0,0,,,,ACTIVE
259,US,A1,US 2018/0319736 A1,015-979-090-922-255,2018-11-08,2018,US 201816037655 A,2018-07-17,US 201816037655 A;;US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH E;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC. C/O MALLINCKRODT PHARMACEUTICALS (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/015-979-090-922-255,Patent Application,yes,4,3,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,A61K31/192;;C07C227/40;;A61K31/198;;A61K31/205;;C07C51/42;;C07C57/32;;C07C227/42;;C07C229/26,,0,0,,,,ACTIVE
260,CA,A1,CA 3217412 A1,125-548-311-784-110,2022-11-10,2022,CA 3217412 A,2022-05-06,US 202117313059 A;;US 2022/0027989 W,2021-05-06,METHOD FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A method for functional testing of aerosol provision devices may include performing a functional state transition test of a power unit. The functional state transition test of the power unit may include extracting a unique identifier from the power unit of an aerosol provision device responsive to operable coupling of the power unit to a test fixture, determining a transition code based on the unique identifier, providing the transition code to the power unit via the test fixture to transition the power unit from an initial state to a transitioned state, and transitioning the power unit to the initial state.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,,https://lens.org/125-548-311-784-110,Patent Application,no,0,0,4,4,0,A24F40/80;;A61M15/06;;A61M2205/6018;;A61M2205/70;;A61M11/042;;A61M11/005;;A61M15/0085;;A61M2205/6063;;A61M2205/43;;A61M2205/44;;A61M2205/3592;;A61M2205/3553;;A61M2205/3569;;A24F40/80;;A24F40/53;;A61M2205/70;;A61M15/06;;A61M2205/6018;;G01N27/00,A24F40/80;;A24F40/49;;A24F40/50;;A24F40/53;;G06F21/31;;G06Q20/20,,0,0,,,,PENDING
261,AU,B2,AU 2011/312042 B2,110-997-373-616-496,2015-08-20,2015,AU 2011/312042 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,Methods of making L-ornithine phenyl acetate,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/110-997-373-616-496,Granted Patent,no,1,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
262,CA,A1,CA 2813563 A1,164-175-211-527-200,2012-04-12,2012,CA 2813563 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/164-175-211-527-200,Patent Application,no,0,3,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
263,US,A,US 5918010 A,022-190-559-397-650,1999-06-29,1999,US 1992498 A,1998-02-06,US 1992498 A;;US 3785297 P,1997-02-07,Collaborative internet data mining systems,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",GEN INTERNET INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA,ABOUT.COM INC (1999-10-13);;ABOUT INC (2002-01-31);;MININGCO.COM INC (1998-12-24);;GENERAL INTERNET INC (1998-07-21),https://lens.org/022-190-559-397-650,Granted Patent,yes,10,342,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,395/200.33,8,1,041-858-749-543-336,10.17487/rfc1945,"Berners Lee, T., et al.; Hypertext Transfer Protocol HTTP/1.0; University of California, Irvine; http://www.ics.uci.edu/pub/ietf/http/rfc 1945.html; May 1996.;;Burke, J.; Web Databases with Cold Fusion 3; McGraw Hill; 1997.;;Dallas, A.; Using Collabra Share 2; Que; 1995.;;Graves, S.; FrontPage 97 Web Sites; The Coriolis Group, Inc.; 1997.;;HTML; w3, http://www.w3.org/History/19921103...t/hypertext/WWW/MarkUp/MarkUp.html.;;HTML Quick Reference; The University of Kansas;http://www.cc.ukans.edu/ acs/docs/other/HTML quick.shtml.;;HTML Reference Manual; Sandia National Laboratories, http://www.sandia.gov/sci compute/html ref.html; Jan. 2, 1996.;;Miller, K., et al.; Inside Microsoft Visual InterDev; Microsoft Press; 1997.",EXPIRED
264,EP,B1,EP 2625162 B1,066-400-013-606-51X,2019-03-13,2019,EP 11831546 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,,OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,"OCERA THERAPEUTICS, INC. (2019-02-20)",https://lens.org/066-400-013-606-51X,Granted Patent,yes,1,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C51/41;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
265,EA,B1,EA 028395 B1,108-492-602-223-739,2017-11-30,2017,EA 201390403 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate, comprising preparing a solution of phenyl acetate salt by mixing a phenyl acetic acid and a base in a first solvent; intermixing L-ornithine benzoate with the solution of phenyl acetate salt; and isolating a composition comprising L-ornithine phenyl acetate. The present invention also relates to pharmaceutical compositions for treating hyperammonemia, comprising L-ornithine phenyl acetate salt obtained from said process and a pharmaceutically acceptable carrier and/or diluent, wherein said composition comprises at least about 0.10 wt.% benzoate salt.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/108-492-602-223-739,Granted Patent,no,3,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
266,US,A1,US 2022/0354185 A1,152-806-644-211-722,2022-11-10,2022,US 202117313051 A,2021-05-06,US 202117313051 A,2021-05-06,DEVICE AND SYSTEM FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A test fixture for testing aerosol provision devices may include a housing, a plurality of testing modules disposed at the housing where each of the testing modules includes a cavity configured to receive a portion of an aerosol provision device, and processing circuitry operably coupled to the testing modules. Each of the testing modules may be configured to interface with an assembly of a respective one of the aerosol provision devices to transition the assembly between an initial state and a transitioned state during a functional test controlled by the processing circuitry. The processing circuitry may be configured to conduct the functional test of at least two of the testing modules simultaneously.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,RAI STRATEGIC HOLDINGS INC (2021-05-04),https://lens.org/152-806-644-211-722,Patent Application,yes,6,2,6,6,0,A24F40/53;;A24F40/80;;A61M15/06;;G01M99/005;;A61M2205/3306;;A61M2205/3375;;A61M2205/8206;;A61M11/042;;A61M2205/276;;A61M2205/60;;A61M2016/0024;;A61M2016/0021;;A61M2016/0027;;A61M2205/505;;A61M2205/581;;A61M2205/582;;A61M2205/583;;A61M11/005;;A61M11/06;;A61M2205/3653;;A61M15/0003;;A61M2205/75;;A61M2016/0033;;A61M2205/3553;;A61M2205/3592;;A61M2205/3561;;A61M2205/70;;A61M2205/3584;;G01M99/008;;A24F40/80;;A24F40/53;;A61M15/06;;G01M99/005;;G06F11/26,A24F40/80;;A24F40/53;;G01M99/00;;G06F11/26,,0,0,,,,ACTIVE
267,US,B2,US 10669627 B2,171-776-689-219-589,2020-06-02,2020,US 201715691593 A,2017-08-30,US 201715691593 A;;US 201662381440 P,2016-08-30,Multi-layer deposition system and process,"A modular multilayer deposition system includes a plurality of modular deposition chambers, including at least one parylene deposition chamber and at least one ALD deposition chamber. The parylene deposition chamber is connected in series with the ALD deposition chamber. Substrates are automatically moved from within the parylene deposition chamber to within the ALD deposition chamber or from within the ALD deposition chamber to the parylene deposition chamber.",HZO INC,YUN YANG;;SORENSON MAX;;HSUEH CHIEN-LAN;;SU TINING;;DEMPSTER JIM;;ANDERSON ALEX;;BAKER LAYTON,HZO INC (2017-10-02),https://lens.org/171-776-689-219-589,Granted Patent,yes,6,0,3,3,0,H01L21/67161;;H01L21/67173;;H01L21/67207;;H01L21/6776;;H01L21/022;;C23C16/54;;C23C28/00;;C23C16/26;;C23C16/52;;C23C16/45525;;H01L21/67173;;H01L21/67207;;H01L21/6776;;C23C16/44;;H01L21/67161;;C23C16/00;;C23C16/455;;H01L21/022;;C23C16/45544;;C23C16/45525;;C23C16/52,C23C16/455;;C23C16/00;;C23C16/44;;C23C16/52;;H01L21/02;;H01L21/67;;H01L21/677,,2,0,,,"Copenheaver “International Search Report for PCT/US2017/049470” dated Nov. 20, 2017, 2 pages.;;Copenheaver “Written Opinion of the International Searching Authority for PCT/US2017/049470” dated Nov. 20, 2017, 6 pages.",ACTIVE
268,US,A1,US 2015/0133684 A1,066-587-299-995-014,2015-05-14,2015,US 201514601591 A,2015-01-21,US 201514601591 A;;US 201313878146 A;;US 2011/0054983 W;;US 39058510 P,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2013-05-27);;OCERA THERAPEUTICS INC (2013-05-28);;SOLID FORM SOLUTIONS LTD (2013-09-23),https://lens.org/066-587-299-995-014,Patent Application,yes,1,23,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;C07C51/41,562/496,0,0,,,,ACTIVE
269,US,B2,US 10173964 B2,082-293-270-903-573,2019-01-08,2019,US 201715469359 A,2017-03-24,US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH E;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/082-293-270-903-573,Granted Patent,yes,82,7,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C57/32;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C227/40;;C07C227/42;;C07C229/26,,206,157,015-750-440-523-292;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;109-586-006-962-328;;085-339-541-354-722;;184-275-615-368-06X;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;023-591-152-002-307;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;005-411-405-905-202;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;009-214-187-079-899;;104-949-654-022-72X;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;038-873-808-172-211;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-067-038-116-555;;052-684-471-190-493;;004-568-483-555-796;;063-040-386-072-391;;001-333-743-768-03X;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;007-084-720-458-198;;064-055-337-562-368;;069-739-648-979-821;;032-748-625-290-265;;062-099-863-837-757;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901;;031-758-280-989-128;;064-981-485-159-530;;049-796-115-905-999;;105-624-360-809-755;;060-965-237-325-653;;106-478-902-619-715;;020-191-827-595-592;;026-684-980-375-813;;155-746-121-945-548;;014-585-057-157-928;;016-245-934-364-075;;017-040-741-145-623;;027-296-352-845-29X;;118-190-784-711-854;;028-094-130-639-491;;041-763-726-091-611;;105-215-652-900-713;;046-377-535-715-555;;075-927-681-372-170;;073-180-972-519-149;;046-328-577-402-919;;091-010-477-383-601;;111-311-443-070-933;;012-261-100-493-035;;124-467-405-728-071;;010-208-513-979-628;;029-419-591-846-994;;003-526-763-484-740;;032-516-727-018-702;;094-400-537-780-40X;;084-881-256-943-396;;029-624-106-758-273;;052-308-695-243-647;;035-155-644-148-657;;093-350-008-802-15X;;001-436-299-870-282;;083-831-280-762-833;;038-642-776-927-940;;002-992-545-486-58X;;018-419-048-897-547;;172-105-260-241-360;;021-594-673-656-876;;129-174-137-700-680;;036-430-862-175-32X;;006-979-616-832-902;;004-086-526-654-013;;093-159-361-636-556;;012-247-665-964-294;;076-070-224-505-210;;016-249-747-580-90X;;022-980-060-535-387;;041-883-471-681-172;;034-978-591-029-435;;006-945-361-671-311;;064-348-611-021-409;;013-520-813-294-749;;121-778-149-592-003;;012-164-908-969-046;;015-634-309-364-793;;035-230-669-274-593;;003-328-576-973-971;;079-593-245-841-055;;044-485-594-222-465;;007-319-763-778-558;;013-238-882-635-851;;037-307-523-122-787;;072-976-603-582-975;;013-841-799-915-103;;008-841-018-283-529;;052-664-611-823-937,10.1053/jhep.2003.50133;;12668985;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;8941257;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;11391852;;10.1007/s002800000256;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;17101577;;10.1080/00365520600780403;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;10.1002/hep.22897;;19437490;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;19409290;;10.1053/j.gastro.2009.04.016;;10.1055/s-2003-42645;;14523680;;4403084;;10.1098/rspb.1972.0064;;15176533;;18823442;;10.1111/j.1440-1746.2008.05582.x;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.23037;;19441099;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;10.1111/j.1530-0277.2006.00074.x;;16573581;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918;;10.1016/s0387-7604(83)80059-x;;6670711;;10.1042/cs1020287;;10.1042/cs20010162;;11869169;;10.1002/hep.21737;;17680644;;10.1152/ajpgi.00445.2003;;15064231;;4997833;;10604106;;10.1016/s0955-2863(99)00022-4;;15539305;;11533304;;10.1093/jn/131.9.2515s;;10.1136/gut.40.3.418;;9135535;;pmc1027096;;12395326;;10.1053/jhep.2002.36497;;12020618;;10.1016/s0197-0186(02)00040-2;;12774005;;10.1053/jhep.2003.50221;;10.1053/jhep.1996.v24.pm0008855179;;8855179;;10.1002/hep.510240408;;10.3109/01677068709167220;;3598771;;10.1007/s004310050985;;9877039;;10801054;;10.1023/a:1005661631281;;2982530;;10.1042/cs0680247;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10986219;;pmc1728090;;10.1136/gut.47.4.571;;9250851;;10.1056/nejm199708143370707;;3965666;;10.1093/jn/115.1.146;;15246207;;10.1016/j.jhep.2004.03.021;;10.1016/s0168-8278(98)80479-0;;10462368;;10.1002/hep.510300311;;4727456;;pmc333026;;10.1172/jci107410;;9698078;;10.1016/s0006-2952(98)00112-9;;10.1002/hep.1840200109;;8020904;;10.1016/0270-9139(94)90133-3;;8474573;;10.1007/bf00967259;;10.1016/j.ymgme.2003.11.017;;15050979;;3930757;;10.1002/jnr.490140210;;2507845;;10.1016/0024-3205(89)90155-0;;11465067;;10.2174/1389450003349254;;12220296;;10.1034/j.1600-0676.2002.00001.x;;10330005;;10.1152/ajpgi.1999.276.5.g1145;;10.1002/hep.22474;;18697192;;15680459;;10.1016/s0140-6736(05)70239-7;;10.1016/s0140-6736(05)17832-5;;3099249;;10.1203/00006450-198611000-00011;;12848729;;10.1046/j.1469-0691.2003.00691.x;;7242660;;10.1038/291378a0;;7272044;;10.1152/ajpendo.1981.241.4.e310;;10.1097/01.ccm.0000287592.94554.5f;;17901832;;10.1097/00000658-198707000-00002;;pmc1492937;;3496861;;10.1016/j.jss.2007.02.002;;17574581;;10.1152/ajpendo.1996.271.4.e718;;8897860;;10.1053/gast.1997.v112.pm9024301;;9024301;;10.1002/hep.21673;;17596891;;10.1097/00019616-200203000-00008;;10.1001/archneur.1990.00530100104022;;2222247;;10.1002/hep.1840100311;;2788117;;17499398;;10.1016/j.clnu.2007.03.002;;10.1111/j.1365-2362.1982.tb00993.x;;6809468;;9148009;;10.1016/s0168-8278(97)80024-4;;15664244;;10.1016/j.jhep.2004.10.019;;10.1016/s0168-8278(09)60775-3;;10.1152/ajpgi.00440.2005;;16782695;;19554542;;10.1002/hep.22917;;pmc507662;;10.1172/jci119023;;8903337;;3508233;;10.1007/bf00998474;;10.1080/07315724.1986.10720123;;3088083;;10.1007/s11011-013-9391-5;;23456516;;10831173;;10.1016/s0026-0495(00)80038-4;;pmc4237123;;23847109;;10.1002/hep.26611;;23751856;;10.1097/mcg.0b013e318299c789;;19707277;;10.2147/tcrm.s4443;;pmc2724191;;10.1007/s11011-007-9072-3;;17851742;;10.1128/aem.65.8.3287-3292.1999;;10427008;;pmc91493;;20382058;;pmc2905228;;10.1016/j.ymgme.2010.03.014;;10.1053/j.gastro.2006.12.035;;17570224;;9846074,"Abraldes et al., “Hemodynamic Response to Pharmacological Treatment of Portal Hypertension and Long-Term Prognosis of Cirrhosis”, Hepatol. (2003) 37:902-908.;;Aggarwal et al., “Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU”, Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., “Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate”, Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., “Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy”, Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., “The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia”, J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Als-Nielsen et al.,, Non-Absorbable Disaccharides for Hepatic Encephalopathy: Systematic Review of Randomised Trials, BMJ, 2004, pp. 1-6.;;Anadiotis et al., “Ornithine transcarbamylase deficiency and pancreatitis”, J Pediatr, 2001, vol. 138, pp. 123-124.;;Anonymous,, “Sodium phenylbutyrate for urea cycle enzyme deficiencies.” [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Australian Examination Report dated Jun. 11, 2014 from Application No. 2010232521, filed Apr. 1, 2010.;;Bachmann et al., “Ammonia toxicity to the brain and creatine”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., “Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,”, Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., “Alternative pathway therapy for urea cycle disorders: twenty years later”, J Pediatr, 2001, vol. 138, Issue 1, pp. S46-S55.;;Batshaw et al., “Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse”, Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., “Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,”, Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berg et al., “Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the non-human primate”, Cancer Chemother Pharmacol. (May 2001) 47(5): 385-390. Abstract Only.;;Berge et al., Review Article: Pharmaceutical Salts, J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., “Long-term management of patients with urea cycle disorders”, J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley et al., “Salt Forms of Drugs and Absorption” in Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. New York, (1996), pp. 453-499.;;Blei, Andres T., et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., “Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage”, British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., “Exogenous glutamine: the clinical evidence,”. Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Braga et al., “Crystal Polymorphism and Multiple Crystal Forms”, Struct Bond (2009) 132: 25-50 [pub online Feb. 25, 2009].;;Briggs et al., Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes, Biochem J, 1976, vol. 160, pp. 205-209.;;Bruha et al., “Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes”, Scand J Gastroenter. (2006) 41: 1454-1463.;;Brunquell et al., “Electroencephalographic findings in ornithine transcarbamylase deficiency”, J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., “Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis”, Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., “Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis”, The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., “Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients”, Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, “Pathophysiology of hepatic encephalopathy: a new look at ammonia”, Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, Pharma Res. (1995) 12(7): 945-954.;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds”, Topic in Current Chemistry (1998) 198: 163-208.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., “Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor”, Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., “Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease”, Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chawla et al., “Challenges in Polymorphism of Pharmaeuticals”, CRIPS (Mar. 2004) 5(1): 9-12.;;Chen et al., “Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency”, Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Chinese Office Action dated Feb. 19, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 18, 2012 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 23, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Jul. 9, 2015 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Chinese Office Action dated Apr. 5, 2016 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;ClinicalTrails.gov; William Lee, Med. Uni. S.C.; “Safety Study of Ornithine Phenylacetate to Treat Patients with Acute Liver Failure (STOP-ALF)”, ID #NCT01548690; Feb. 2012; 7 pages.;;Darmaun et al., “Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism”, Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;DERWENT 1 January 1900 Derwent World Patents Index; AN 2003-314385, XP002364873, ""Composition used for preventing and treating hepatosis and hepatic encephalopathy comprises ornithine and asparagic acid"";;Davies, et al., “L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats”, Hepatology (Jul. 2009) 50(1): 155-164.;;Dejong et al., “Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia”, Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al., Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011 in International Application No. PCT/US2010/029708.;;Desjardins et al., “Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle”, Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dunitz et al., “Disappearing Polymorphs”, Acc Chem Res. (1995) 28: 193-200.;;Enns et al., “Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,”, N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;Eurasian Office Action dated May 24, 2016 for Application No. 201500650 filed Jul. 16, 2015.;;European Extended Search Report dated Nov. 30, 2012 for Application No. 10759442.6.;;Fabbri, Andrea et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology, 1993, vol. 18, No. 1, pp. 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., “Prediction of outcome following acute variceal haemorrhage”, Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., “Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels”, J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., “Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,”, Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, “Ornithine transcarbamylase deficiency: a urea cycle defect”, European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., “Prevention of initial variceal hemorrhage”, Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Grant, D.J.W., “Theory and Origin of Polymorphism” Chapter 1 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., (1999) pp. 1-11.;;Greenstein et al., Studies on the Metabolism of Amino Acids and Related Compounds in Vivo. III. Prevention of Ammonia Toxicity by Arginine and Related Compounds, Arch Biochem Biophys, 1956, vol. 64, Issue (2):, pp. 342-354.;;Grossi et al., “Amino acids mixtures in prevention of acute ammonia intoxication in dogs”, Arch Surg, 1967, vol. 94, pp. 261-266.;;Guillory, J.K., “Generation of Polymorphs, Hydrates, Solvates, and Amorphous” Chapter 5 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., (1999) pp. 183-226.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, vol. 129; pp. 1430-1433 w/English Machine translation.;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urea Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., “Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)”, Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., “Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?”, J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., “The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy”, Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Hirayama et al., [Eds], “Organic compound crystal produced handbook—Principles and know-how”, Maruzen Co., Ltd., Japan; (Jul. 2008), pp. 17-23, 37-40, 45-51 and 57-65; 31 pages.;;Honda et al., “Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy”, Biol. Pharm. Bull., Sep. 2002, 25(9): 1244-1246.;;Hopkins Medicine (http://www.hopkinsmedicine.org/gastroenterology_hepatology/_pdfs/liver/portal_hypertension.pdf; accessed Jun. 22, 2016); 13 pages.;;Hursthouse et al., “Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?”, Organic Process Research & Development, (2009) 13:1231-1240.;;Igarashi et al., “Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography”, Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., “Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria”, Biochim Biopys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;International Search Report and Written Opinion dated Jun. 3, 2010 for PCT/US2010/029708, filed Apr. 1, 2010.;;International Preliminary Report on Patentability dated Jun. 2, 2011 for Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;Israel Office Action dated Sep. 30, 2014 for Application No. 215449, filed Apr. 1, 2010.;;Iyer et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., “Acute-on-chronic liver failure: pathophysiological basis of therapeutic options”, Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., “Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,”, Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., “The molecular pathogenesis of hepatic encephalopathy”, The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses (2007) 69(5): 1064-1069, Elsevier Ltd.;;Jalan et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Jalan,, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publisheres, Inc., New York, NY, USA.;;James et al., “The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species”, Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Japanese Office Action dated May 13, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Oct. 21, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Jun. 7, 2016 for Application No. 2012-503725, filed Apr. 1, 2010.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure,, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Jiang et al., “L-Ornithine-I-aspartate in the management of hepatic encephalopathy: a meta-analysis”, J Gastroenterol Hepatol. (2009) 24(1): 9-14; available online: Sep. 28, 2008.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., “New secondary metabolites of phenylbutyrate in humans and rats”, Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, “Ammonia metabolism and hepatic encephalopathy”, Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan et al.,, Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Ciprofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., “Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,”, Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Kojima et al., “Effective Solid Form Selection for the Pharmaceutical Development”, J Pharma Science Tech. (Sep. 2008) 68(5): 344-349.;;Korean Office Action dated Jun. 8, 2016 for Application No. 10-2011-7026256, filed Apr. 1, 2010.;;Larsen et al., “Alternative Pathway Therapy for Hyperammonemia in Liver Failure”; Hepatolory (Jul. 2009), 50(1): 3-5.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Linderoth et al., “Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,”, Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lopez-Talavera et al., “Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats”, Hepatology (1996) 23(6): 1616-1621.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, (Jul. 2003), 52(7): 935-938.;;MacArthur et al., “Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., “Long-term treatment of girls with ornithine transcarbamylase deficiency”, N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., “Prospective treatment of urea cycle disorders”, J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maev I.V. Application of L-ornitine-L-aspartate in complex therapy of hepatic encephalopathy in liver cirrhosis patients (Engl. Title) koloproktologii, 2002, No. 6, pp. 60-66.;;Maier et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Maier, “Therapie der hepatischen Enzephalopathie”, Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Matsuoka et al., “Advanced Crystallization Technology of Organic Materials—Control of Size, Morphology, Polymorph and Purity”, Pharm Tech, Japan (May 2003) 19(6): 91(955)-101(965).;;Meijer et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., “A new therapy for portal systemic encephalopathy”, The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mexican Office Action dated Dec. 10, 2013 for Application No. MX/a/2012/013961, filed Nov. 30, 2012.;;Mihm et al., “Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)”, Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., “Septic Encephalopathy—Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy”, Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;Mizutani et al., “Hyperargininemia: Clinical course and treatment with sodium benzoate and phenylacetic acid”, Brain Dev., 1983, vol. 5, Issue 6, pp. 555-563.;;Moinard et al.,, “Effects of Ornithine 2-Oxoglutarate on Neutrophils in Stressed Rates: Evidence for the Involvement of Nitric Oxide and Polyamines”, Clin Sci, 2002, vol. 102, Issue 3, pp. 287-295, London, England.;;Mookerjee et al., “Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome,”, Hepatology, 2007, vol. 3, Issue 46, pp. 831-840.;;Mouille et al., Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion, Am J Gastrointest Liver Physiol., 2004, vol. 287, pp. 344-351.;;Nance et al., “Ammonia production in germ-free Eck fistula dogs”, Surgery, 1971, vol. 70, Issue 2, pp. 169-174.;;Navasa et al., “Bacterial infections in liver cirrhosis,”, Ital J Gastroenterol Hepatol., 1999, vol. 7, Issue 31, pp. 616-625.;;New Zealand Office Action dated Jan. 8, 2014 for Application No. 619235, filed Dec. 20, 2013.;;Newsholme et al., “Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease,”, J Nutr Biochem., 1999, vol. 6, Issue 10, pp. 316-324.;;Newsholme, “Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?”, J Nutr., 2001, vol. 9 Suppl, Issue 131, pp. 2515S-2522S.;;Olde Damink et al., “Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats”, Gut, 1997, vol. 40, pp. 418-424.;;Olde Damink et al., “Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS”, Hepatology, 2002, vol. 36, Issue 5, pp. 1163-1171.;;Olde Damink et al., “Interorgan ammonia metabolism in liver failure”, [not known], 2002, vol. 41, pp. 177-188.;;Olde Damink et al., “The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis”, [not known], 2003, vol. 37, pp. 1277-1285.;;Olde Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Pauwels et al., “Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection”, Hepatology, 1996, vol. 24, Issue 4, pp. 802-806.;;Petrowski et al., “Pharmacologic amino acid acylation in the acute hyperammonemia of propionic acidemia”, Journal of Neurogenetics, 1987, vol. 4, pp. 87-96.;;Plecko et al., “Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate”, Eur J Pediatr., 1998, vol. 157, pp. 996-998.;;Praphanphoj et al., “Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonemia”, J Inherit Metab Dis., 2000, vol. 23, pp. 129-136.;;Rajkovic et al., “Mechanisms of abnormalities in host defences against bacterial infection in liver disease,”, Clin Sci. (Lond.), 1985, vol. 3, Issue 68, pp. 247-253, London.;;Ramaswamy et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., Jul. 2002, vol. 22, Issue 13, pp. 4491-4498.;;Rees et al., “Effect of L-Ornithine-L-Aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial”, Gut, 2000, vol. 47, pp. 571-574.;;Riordan et al., “Treatment of hepatic encephalopathy”, Curr Concepts, 1997, vol. 337, Issue 7, pp. 473-479.;;Rogers, Q. R. et al., Deficiency of Pyrroline-5-Carboxylate Synthase in the Intestinal Mucosa of the Cat, The Journal of Nutrition, 1985, pp. 146-150, vol. 115, No. 1, American Institution of Nutrition.;;Romero-Gómez et al., “Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy”, Journal of Hepatology, 2004, vol. 41, pp. 49-54.;;Rose et al., “L-Ornithine-L-Aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action”, Metabolic Brain Disease, 1998, vol. 13, Issue 2, pp. 147-157.;;Rose et al., “L-Ornithine-L-Aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure”, Hepatology, 1999, vol. 30, Issue 3, pp. 636-640.;;Rudman et al., Maximal Rates of Excretion and Synthesis of Urea in Normal and Cirrhotic Subjects, The Journal of Clinical Investigation, Sep. 1973, vol. 52, pp. 2241-2249.;;Rukmini et al., “Region-specific changes in CNS muscarinic acetylcholine receptors in a rat model of hyperammonemia”, Biochem Pharmacol., 1998, vol. 56, Issue 2, pp. 237-241.;;Sanyal et al., Portosystemic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Results of a Prospective Controlled Study, Hepatology, 1994, p. 46-55, vol. 20, No. 1, Pt. 1, The American Association for the Study of Liver Diseases.;;Sanyal, A. J., Prediction of Variceal Hemorrhage in Patients with Cirrhosis, UpToDate, Inc., Website (www.uptodate.com), Jan. 2010, UpToDate.;;Sarhan et al., “Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy”, Neurochem Res., 1993, vol. 18, Issue 4, pp. 539-549.;;Scaglia et al., “Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients”, Mol Genet Metabolism, 2004, vol. 81, pp. S79-S85.;;Sears et al., “Disruption of the blood-brain barrier in hyperammonaemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine”, J Neurosci Res., 1985, vol. 14, Issue 2, pp. 255-261.;;Seiler et al., “Ornithine aminotransferase activity, liver ornithine concentration and acute ammonia intoxication”, Life Sciences, 1989, vol. 45, Issue 11, pp. 1009-1020.;;Seiler, “Ornithine aminotransferase, a potential target for the treatment of hyperammonemias”, 'Curr Drug Targets., Sep. 2000, vol. 1, Issue 2, pp. 119-153.;;Sen et al., “The pathophysiological basis of acute-on-chronic liver failure”, Liver, 2002, vol. 22, Issue Suppl. 2, pp. 5-13.;;Shangraw, Robert E. et al., Effect of Liver Disease and Transplantation on Urea Synthesis in Humans: Relationship to Acid-Base Status, AM J Physiol Gastrointest Liver Physiol, 1999, vol. 276, pp. 1145-1152.;;Shawcross et al., “Ammonia impairs neutrophil phagocytic function in liver disease,”, Hepatology, 2008, vol. 4, Issue 48, pp. 1202-1212.;;Shawcross et al., “Dispelling myths in the treatment of hepatic encephalopathy,”, Lancet, 2005, vol. 9457, Issue 365, pp. 431-433.;;Shawcross et al., “Hyperammonemia impairs neutrophil function”, Hepatology, 2005, vol. 42, pp. 537A.;;Shriner et al., “Recrystallization”, Chapter 3.5 Preliminary Examination in The Systematic Identification of Organic Compounds, John Wiley & Sons, Inc. New York, (1998), Chapter 3, pp. 78-81.;;Simell et al., “Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance”, Pediatric Research, 1986, vol. 20, Issue 11, pp. 1117-1121.;;Singapore Examination Report dated Sep. 27, 2013 for Application No. 201107116-4, filed Apr. 1, 2010.;;Singh, et al., Changing Epidemiology and Predictors of Mortality in Patients With Spontaneous Bacterial Peritonitis at a Liver Transplant Unit, Clinical Microbiology and Infection, Jun. 2003, p. 531-537, vol. 9, No. 6., European Society of Clinical Microbiology and Infectious Diseases.;;Smith et al., “The treatment of inborn errors of the urea cycle”, Nature, 1981, vol. 291, Issue 5814, pp. 378-380.;;Soláini et al., “Variations in the plasma concentration of ornithine, citrulline and arginine in acute experimental liver failure” [Article in Italian], Boll Soc Ital Biol Sper., 1981, vol. 57, Issue 7, pp. 705-710.;;Stedman's Medical Dictionary; “Encephalopathy”, 27th Edition (2002); 1 page.;;Stewart, P. M., et al., Effects of Arginine-Free Meals on Ureagenesis in Cats, American Journal of Physiological, 1981, pp. E310-E315, vol. 241, No. 4, The American Physiological Society.;;Stravitz, MD, et al., Intensive Care of Patients with Acute Liver Failure: Recommendations of the U.S. Acute Liver Failure Study Group, Critical Care Medicine, 2007, p. 2498-2508, vol. 35, No. 11, Lippincott Williams & Wilkins.;;Suchy et al., Clinical Manifestations and Complications—Typical Clinical Presentation;, Liver Disease in Children, 2nd Edition, 2001, pp. 74-77.;;Sugarbaker et al., “The role of the small intestine in ammonia production after gastric blood administration”, Ann Surg., 1987, vol. 206, Issue 1, pp. 5-17.;;Sukhotnik et al., “Oral glutamine prevents gut mucosal injury and improves mucosal recovery following lipopolysaccharide endotoxemia in a rat,”, J Surg Res., 2007, vol. 2, Issue 143, pp. 379-384.;;Svanberg et al., “Effects of amino acids on synthesis and degradation of skeletal muscle proteins in humans”, Am J Physiol., 1996, vol. 271, Issue 4 Pt1, pp. E718-E724.;;TDRdata.com, results from query of “Spontaneous Bacterial Peritonitis” in the epidemiological and references databases at www.tdrdata.com, retrieved on Jul. 27, 2010, pp. 1-7.;;Teran et al., “Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis”, Gastroenter., 1997, vol. 112, Issue 2, pp. 473-482.;;Trebicka et al., Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Roh-kinase and activation of endothelial nitric oxide synthase, Hepatology, (2007) 46(1): 242-253.;;Tuchman, M., et al., Management of Inherited Disorders of Ureagenesis, The Endocrinologist, 2002, vol. 12, No. 2, p. 99-109.;;Tuchman, MD et al., “Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome”, Arch Neurol., 1990, vol. 47, pp. 1134-1137.;;UK Search Report dated Feb. 21, 2005 for GB priority application No. 0426141.8.;;Van Berlo et al., “Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of isoleucine in hemoglobin? A study in pigs”, Hepatology, 1989, vol. 10, Issue 3, pp. 315-323.;;Van Den Berg et al., “The effect of glutamine-enriched enteral nutrition on intestinal microflora in very low birth weight infants: a randomized controlled trial,”, Clin Nutr., 2007, vol. 4, Issue 26, pp. 430-439.;;Vilstrup, H. et al., Elimination of Infused Amino Acids From Plasma of Control Subjects and of Patients With Cirrhosis of the Liver, European Journal of Clinical Investigation, 1982, vol. 12, pp. 197-202, Blackwell Scientific Publications.;;Vogels et al., “L-ornithine vs L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats”, J Hepatology, 1997, vol. 26, Issue 1, pp. 174-182.;;Wasmuth et al., “Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis,”, J Hepatol., 2005, vol. 2, Issue 42, pp. 195-201.;;Wright et al., “Reduction in Ammonia with L-Ornithine, Phenylacetate (OP) but not Anti-TNF Prevents LPS Induced Brain Edema in Bile-duct Ligated Cirrhotic Rats”, Abstract 773; J Hepatology (2009) 50: S283.;;Ytreb{acute over (ø)}et al., “Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure,”, Am J Physiol Gastrointest Liver Physiol., 2006, vol. 3, Issue 291, pp. G373-G381.;;Ytreb{acute over (ø)}et al., “L-Ornithine Phenylacetate Attenuates Increased Arterial and Extracellular Brain Ammonia and Prevents Intracranial Hypertension in Pigs with Acute Liver Failure”, Hepatology (Jul. 2009) 50(1): 165-174.;;Yudkoff et al., “In Vivo Nitrogen Metabolism in Ornithine Transcarbamylase Deficiency”, J Clin. Invest., Nov. 1996, 98(9): 2167-2173.;;Zetterman, Rowen K., MD, “Complications of Portal Hypertension: Hepatic Encephalopathy”, Medscape (Jun. 2011) available online at www.medscape.com/viewarticle/744392; downloaded Dec. 3, 2014; 6 pages.;;Zieve et al., “Ammonia toxicity: comparative protective effect of various arginine and ornithine derivatives, aspartate, benzoate, and carbamyl glutamate”, Metabo Brain Dis., 1986, vol. 1, Issue 1, pp. 25-35.;;Zieve et al., “Conditional deficiencies of ornithine or ornithine or arginine”, J Am Coll Nutr., 1986, vol. 5, Issue 2, pp. 167-176.;;Bosoi C.R. et al., Long term oral treatment of ornithine phenylacetate increases lean mass and attenuates brain edema in bile-duct ligated rats. Hepatology (Oct. 2015) 62(Suppl 1):953A; Abstract 1523.;;Jover-Cobos et al., Ornithine phenylacetate revisited; Metabolic Brain Disease (2013) 28(2): 327-331.;;Lukkarinen, M. et al., Effect of Lysine Infusion on Urea Cycle in Lysinuric Protein Intolerance, Metabolism, (May 2000), 49(5): 621-625.;;Ocera Therapeutics, Inc., News Release: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy; Globe Newswire; Apr. 1, 2015, 2 pages.;;Ocera Therapeutics, Inc., News Release: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Acute Hepatic Encephalopathy; Globe Newswire; Nov. 16, 2015, 2 pages. et al.",ACTIVE
270,KR,A,KR 20240004997 A,126-090-352-710-366,2024-01-11,2024,KR 20237041974 A,2022-05-06,US 202117313059 A;;US 2022/0027989 W,2021-05-06,에어로졸 생성 디바이스를 위한 디바이스 상태 전이의 유효화 및 수정을 위한 방법,"에어로졸 제공 디바이스의 기능적 시험을 위한 방법은 전력 유닛의 기능적 상태 전이 시험을 수행하는 단계를 포함할 수 있다. 전력 유닛의 기능적 상태 전이 시험은 시험 고정체에의 전력 유닛의 동작가능 커플링에 응답하여 에어로졸 제공 디바이스의 전력 유닛으로부터 고유 식별자를 추출하는 것과, 고유 식별자에 기반하여 전이 코드를 판정하는 것과, 전력 유닛을 초기 상태로부터 전이된 상태로 전이시키기 위해 시험 고정체를 통해 전력 유닛에 전이 코드를 제공하는 것과, 전력 유닛을 초기 상태로 전이시키는 것을 포함할 수 있다.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,,https://lens.org/126-090-352-710-366,Patent Application,no,0,0,4,4,0,A24F40/80;;A61M15/06;;A61M2205/6018;;A61M2205/70;;A61M11/042;;A61M11/005;;A61M15/0085;;A61M2205/6063;;A61M2205/43;;A61M2205/44;;A61M2205/3592;;A61M2205/3553;;A61M2205/3569;;A24F40/80;;A24F40/53;;A61M2205/70;;A61M15/06;;A61M2205/6018;;G01N27/00,A24F40/80;;A24F40/50;;A24F40/53;;A61M15/06,,0,0,,,,PENDING
271,MX,A,MX 2013003764 A,165-574-651-270-909,2013-05-20,2013,MX 2013003764 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE.,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA;;ANDERSON KEITH H,,https://lens.org/165-574-651-270-909,Patent Application,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,A61K31/192;;C07C227/18;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
272,US,B2,US 11641885 B2,004-637-890-246-479,2023-05-09,2023,US 202117313051 A,2021-05-06,US 202117313051 A,2021-05-06,Device and system for validation and modification of device state transitions for an aerosol generation device,"A test fixture for testing aerosol provision devices may include a housing, a plurality of testing modules disposed at the housing where each of the testing modules includes a cavity configured to receive a portion of an aerosol provision device, and processing circuitry operably coupled to the testing modules. Each of the testing modules may be configured to interface with an assembly of a respective one of the aerosol provision devices to transition the assembly between an initial state and a transitioned state during a functional test controlled by the processing circuitry. The processing circuitry may be configured to conduct the functional test of at least two of the testing modules simultaneously.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,RAI STRATEGIC HOLDINGS INC (2021-05-04),https://lens.org/004-637-890-246-479,Granted Patent,yes,10,2,6,6,0,A24F40/53;;A24F40/80;;A61M15/06;;G01M99/005;;A61M2205/3306;;A61M2205/3375;;A61M2205/8206;;A61M11/042;;A61M2205/276;;A61M2205/60;;A61M2016/0024;;A61M2016/0021;;A61M2016/0027;;A61M2205/505;;A61M2205/581;;A61M2205/582;;A61M2205/583;;A61M11/005;;A61M11/06;;A61M2205/3653;;A61M15/0003;;A61M2205/75;;A61M2016/0033;;A61M2205/3553;;A61M2205/3592;;A61M2205/3561;;A61M2205/70;;A61M2205/3584;;G01M99/008;;A24F40/80;;A24F40/53;;A61M15/06;;G01M99/005;;G06F11/26,A24F40/80;;A24F40/53;;A61M15/06;;G01M99/00;;G06F11/26,,1,0,,,"International Search Report and Written Opinion of corresponding International Application No. PCT/US2022/027981 dated Sep. 13, 2022, all pages cited in its entirety.",ACTIVE
273,WO,A1,WO 2018/045089 A1,034-280-241-725-903,2018-03-08,2018,US 2017/0049470 W,2017-08-30,US 201662381440 P,2016-08-30,MULTI-LAYER DEPOSITION SYSTEM AND PROCESS,"A modular multilayer deposition system includes a plurality of modular deposition chambers, including at least one parylene deposition chamber and at least one ALD deposition chamber. The parylene deposition chamber is connected in series with the ALD deposition chamber. Substrates are automatically moved from within the parylene deposition chamber to within the ALD deposition chamber or from within the ALD deposition chamber to the parylene deposition chamber.",HZO INC,YUN YANG;;SORENSEN MAX;;HSUEH CHIEN-LAN;;SU TINING;;DEMPSTER JIM;;ANDERSON ALEX;;BAKER LAYTON,,https://lens.org/034-280-241-725-903,Patent Application,yes,4,0,3,3,0,H01L21/67161;;H01L21/67173;;H01L21/67207;;H01L21/6776;;H01L21/022;;C23C16/54;;C23C28/00;;C23C16/26;;C23C16/52;;C23C16/45525;;H01L21/67173;;H01L21/67207;;H01L21/6776;;C23C16/44;;H01L21/67161;;C23C16/00;;C23C16/455;;H01L21/022;;C23C16/45544;;C23C16/45525;;C23C16/52,C23C16/455;;C23C16/00;;C23C16/44;;H01L21/00;;H01L21/02,,0,0,,,,PENDING
274,WO,A3,WO 2020/102424 A3,043-898-063-598-120,2020-07-23,2020,US 2019/0061280 W,2019-11-13,US 201862760457 P,2018-11-13,IMPROVED SAMPLE GRINDER,"A bead beater homogenizer (100) includes a shaft having a main body (30) extending along a main axis (32) and a distal connection body (34) extending along a connection axis (36) that is acutely angled with respect to the main axis (32), a motor (20) configured to rotate the shaft about the main axis (32), a head (60) rotatably connected to the distal connection body (34) of the shaft, and a clamp (62, 64, 66) secured to the head (60) and configured to secure a sample vial holder (70, 170, 270, 370, 470) configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis (32) is translated into motion of the head (60) in directions normal to the main axis (32). A sample vial holder (470) having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/043-898-063-598-120,Search Report,yes,1,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06;;G01N1/28,,1,1,127-110-826-073-277,10.1016/0168-583x(90)90459-8,"VAN DE WAL R S W ET AL: ""PROGRESS IN 14C DATING OF ICE AT UTRECHT"", NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH. SECTION B: BEAM INTERACTIONS WITH MATERIALS AND ATOMS, ELSEVIER BV, NL, vol. B52, no. 3 / 04, 2 December 1990 (1990-12-02), pages 469 - 472, XP000178412, ISSN: 0168-583X, DOI: 10.1016/0168-583X(90)90459-8",PENDING
275,BR,B1,BR 112013008054 B1,181-554-636-057-642,2019-04-09,2019,BR 112013008054 A,2011-10-05,US 2011/0054983 W;;US 39058510 P,2010-10-06,composição e processo para produção de sal de acetato de fenil l-ornitina,"composição e processo para produção de sal de acetato de fenil l-ornitina são aqui descritos processos para a produção de acetato de fenil l-ornitina. o processo pode incluir, por exemplo, misturar um sal de halogeneto de l-ornitina com acetato de fenil prata. o processo pode também incluir a formação de um sal de acetato de fenila in situ. o presente pedido também se refere a várias composições obtidas a partir destes processos, incluindo formas cristalinas.",OCERA THERAPEUTICS INC,ATTILIA FIGINI;;CHRISTINE HENDERSON DOUGAN;;JIM BEHLING;;KEITH H ANDERSON;;PETER MANINI;;STEPHEN WILLIAM WATT,,https://lens.org/181-554-636-057-642,Granted Patent,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
276,NZ,A,NZ 609191 A,074-423-210-027-340,2015-06-26,2015,NZ 60919111 A,2011-10-05,US 2011/0054983 W;;US 39058510 P,2010-10-06,Methods of making l-ornithine phenyl acetate,"Disclosed is a process for making L-ornithine phenyl acetate salt (V) comprising: preparing a solution of phenyl acetate salt by mixing a phenyl acetic acid and a base in a solvent; intermixing L-ornithine benzoate with the above solution; isolating a composition comprising L-ornithine phenyl acetate. The process may include forming an L-ornithine benzoate salt intermediate. The process may also include intermixing a halide salt of L-ornithine with silver phenyl acetate. The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/074-423-210-027-340,Patent Application,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,A61K31/192;;C07C227/18;;A61K31/198;;A61P1/16;;C01G5/00;;C07C57/32;;C07C57/46;;C07C229/26,,0,0,,,,PENDING
277,KR,A,KR 20240005011 A,035-057-963-553-167,2024-01-11,2024,KR 20237042024 A,2022-05-06,US 202117313051 A;;US 2022/0027981 W,2021-05-06,에어로졸 생성 디바이스를 위한 디바이스 상태 전이의 유효화 및 수정을 위한 디바이스 및 시스템,"에어로졸 제공 디바이스를 시험하는 시험 고정체는, 하우징과, 하우징에 배치된 복수의 시험 모듈 - 시험 모듈 각각은 에어로졸 제공 디바이스의 일부를 수용하도록 구성된 공동을 포함함 - 과, 시험 모듈에 동작 가능하게 결합된 처리 회로부를 포함한다. 시험 모듈 각각은 에어로졸 제공 디바이스 중 각각의 에어로졸 제공 디바이스의 조립체와 인터페이스하여 처리 회로부에 의해 제어되는 기능적 시험 동안 조립체를 초기 상태와 전이된 상태 간에 전이하도록 구성될 수 있다. 처리 회로부는 시험 모듈 중 적어도 2개의 시험 모듈의 기능적 시험을 동시에 수행하도록 구성될 수 있다.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,,https://lens.org/035-057-963-553-167,Patent Application,no,0,0,6,6,0,A24F40/53;;A24F40/80;;A61M15/06;;G01M99/005;;A61M2205/3306;;A61M2205/3375;;A61M2205/8206;;A61M11/042;;A61M2205/276;;A61M2205/60;;A61M2016/0024;;A61M2016/0021;;A61M2016/0027;;A61M2205/505;;A61M2205/581;;A61M2205/582;;A61M2205/583;;A61M11/005;;A61M11/06;;A61M2205/3653;;A61M15/0003;;A61M2205/75;;A61M2016/0033;;A61M2205/3553;;A61M2205/3592;;A61M2205/3561;;A61M2205/70;;A61M2205/3584;;G01M99/008;;A24F40/80;;A24F40/53;;A61M15/06;;G01M99/005;;G06F11/26,A24F40/80;;A24F40/53,,0,0,,,,PENDING
278,WO,A1,WO 2012/048043 A1,084-465-417-164-404,2012-04-12,2012,US 2011/0054983 W,2011-10-05,US 39058510 P,2010-10-06,METHODS OF MAKING L-ORNITHINE PHENYL ACETATE,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ . The present application also relates to various compositions obtained from these processes, including crystalline forms.",OCERA THERAPEUTICS INC;;ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/084-465-417-164-404,Patent Application,yes,13,27,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,2,0,,,"BIGHLEY L.D. ET AL.: ""Encyclopedia of pharmaceutical technology"", vol. 12, MARCEL DEKKER, INC., article ""Salt forms of drugs and absorption"", pages: 425 - 499;;See also references of EP 2625162A4",PENDING
279,US,A1,US 2022/0354186 A1,004-219-167-796-189,2022-11-10,2022,US 202117313059 A,2021-05-06,US 202117313059 A,2021-05-06,METHOD FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A method for functional testing of aerosol provision devices may include performing a functional state transition test of a power unit. The functional state transition test of the power unit may include extracting a unique identifier from the power unit of an aerosol provision device responsive to operable coupling of the power unit to a test fixture, determining a transition code based on the unique identifier, providing the transition code to the power unit via the test fixture to transition the power unit from an initial state to a transitioned state, and transitioning the power unit to the initial state.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,RAI STRATEGIC HOLDINGS INC (2021-05-04),https://lens.org/004-219-167-796-189,Patent Application,yes,11,2,4,4,0,A24F40/80;;A61M15/06;;A61M2205/6018;;A61M2205/70;;A61M11/042;;A61M11/005;;A61M15/0085;;A61M2205/6063;;A61M2205/43;;A61M2205/44;;A61M2205/3592;;A61M2205/3553;;A61M2205/3569;;A24F40/80;;A24F40/53;;A61M2205/70;;A61M15/06;;A61M2205/6018;;G01N27/00,A24F40/80;;A24F40/53;;G01N27/00,,0,0,,,,PENDING
280,AU,A1,AU 2011/312042 A1,076-080-967-337-595,2013-05-02,2013,AU 2011/312042 A,2011-10-05,US 39058510 P;;US 2011/0054983 W,2010-10-06,Methods of making L-ornithine phenyl acetate,"Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt",OCERA THERAPEUTICS INC,ANDERSON KEITH H;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,,https://lens.org/076-080-967-337-595,Patent Application,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C227/18;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26,,0,0,,,,ACTIVE
281,BR,A2,BR 112013008054 A2,103-251-137-956-806,2016-06-14,2016,BR 112013008054 A,2011-10-05,US 2011/0054983 W;;US 39058510 P,2010-10-06,composição e processo para produção de sal de acetato de fenil l-ornitina,,OCERA THERAPEUTICS INC,FIGINI ATTILIA;;DOUGAN CHRISTINE HENDERSON;;BEHLING JIM;;ANDERSON KEITH H;;MANINI PETER;;WATT STEPHEN WILLIAM,,https://lens.org/103-251-137-956-806,Patent Application,no,0,0,30,30,0,A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18;;A61P1/16;;C07C227/18;;C07C229/26;;C07C57/32;;A61K31/192;;A61K31/198;;C07C51/412;;C07C227/18,C07C57/46;;A61K31/192;;A61K31/198;;A61P1/16;;C07C227/18;;C07C229/26,,0,0,,,,ACTIVE
282,US,A,US 6157926 A,116-835-985-073-29X,2000-12-05,2000,US 18562598 A,1998-11-04,US 18562598 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,System and method for training and managing Internet guides,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA,ABOUT INC (2002-01-31),https://lens.org/116-835-985-073-29X,Granted Patent,yes,15,61,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,707/102;;707/513,8,1,041-858-749-543-336,10.17487/rfc1945,"Berners Lee, T., et al.; Hypertext Transfer Protocol HTTP/1.0; University of California, Irvine; http:/www.ics.uci.edu/pub/ietf/http/rfc1945.html; May 1996.;;Burke, J.; Web Databases with Cold Fusion 3; McGraw Hill; 1997.;;Dallas, A.; Using Collabra Share 2; Que; 1995.;;Graves, S.; FrontPage 97 Web Sites; The Coriolis Group, Inc.; 1997.;;HTML; w3, http://www.w3.org/History/19921103 . . . t/hypertext/WWW/MarkUp/MarkUp.html.;;HTML Quick Reference; The University of Kansas; http://www.cc.ukans.edu/ acs/docs/other/HTML quick.shtml.;;HTML Reference Manual; Sandia National Laboratories, http://www.sandia.gov/sci compute/html ref.html; Jan. 2, 1996.;;Miller, K., et al.; Inside Microsoft Visual InterDev; Microsoft Press; 1997.",EXPIRED
283,US,B2,US 10550069 B2,165-606-977-932-486,2020-02-04,2020,US 201816037655 A,2018-07-17,US 201816037655 A;;US 201715469359 A;;US 201514715481 A;;US 201414299940 A;;US 201313937107 A;;US 201213436642 A;;US 75376310 A;;US 16667609 P,2009-04-03,L-ornithine phenyl acetate and methods of making thereof,"Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.",OCERA THERAPEUTICS INC,ANDERSON KEITH E;;BEHLING JIM;;DOUGAN CHRISTINE HENDERSON;;WATT STEPHEN WILLIAM;;MANINI PETER;;FIGINI ATTILIA,HELSINN ADVANCED SYNTHESIS SA (2012-08-29);;OCERA THERAPEUTICS INC. C/O MALLINCKRODT PHARMACEUTICALS (2010-06-16);;SOLID FORM SOLUTIONS LTD (2013-04-10),https://lens.org/165-606-977-932-486,Granted Patent,yes,89,4,104,104,0,C07C51/412;;C07C51/43;;C07C57/32;;C07C227/18;;C07C227/42;;C07C229/26;;C07B2200/13;;A61K31/192;;A61K31/198;;A61P1/16;;C07C57/46;;C07C229/26;;C07C57/32;;C07C229/26;;C07C227/18;;C07C227/42;;C07C51/412;;C07C51/43;;A61K31/192;;C07C229/26;;C07C227/16;;C07C227/42;;A61P1/16;;A61K31/192;;C07C57/32;;C07C229/26;;A61K31/198;;A61K31/205;;C07C227/42;;C07C227/40;;C07C51/42,C07C227/40;;A61K31/192;;A61K31/198;;A61K31/205;;C07C51/42;;C07C57/32;;C07C227/42;;C07C229/26,,230,165,015-750-440-523-292;;005-617-134-437-163;;026-294-638-279-89X;;021-575-246-585-985;;151-697-969-723-439;;013-238-882-635-851;;109-586-006-962-328;;085-339-541-354-722;;184-275-615-368-06X;;055-496-964-700-755;;049-686-055-900-872;;061-918-386-524-538;;129-618-522-217-657;;030-434-965-040-524;;023-591-152-002-307;;007-364-858-655-289;;043-146-150-003-306;;067-100-980-739-280;;047-596-152-914-086;;024-489-496-639-593;;087-003-294-580-08X;;005-411-405-905-202;;041-810-317-989-147;;026-391-772-304-384;;012-623-150-017-390;;032-659-403-636-916;;052-791-998-865-147;;037-307-523-122-787;;009-214-187-079-899;;104-949-654-022-72X;;006-389-848-693-948;;089-860-122-860-623;;018-517-179-545-882;;092-886-233-497-138;;013-381-039-504-948;;144-424-389-607-020;;038-873-808-172-211;;054-839-265-626-125;;102-974-082-963-445;;005-702-234-567-017;;072-976-603-582-975;;178-262-138-140-918;;009-191-521-945-483;;073-092-236-316-538;;012-776-602-401-260;;053-694-799-361-597;;020-511-080-470-811;;001-920-859-754-787;;009-406-231-715-546;;073-163-690-157-915;;121-158-891-536-578;;014-876-067-358-029;;033-842-245-951-890;;105-074-384-452-347;;007-781-883-133-017;;073-911-883-028-838;;072-386-245-581-55X;;101-278-850-557-816;;146-807-588-852-994;;005-396-092-018-940;;015-116-765-849-444;;046-377-535-715-555;;106-060-037-182-062;;098-424-890-714-27X;;036-903-424-040-422;;107-486-946-957-376;;052-067-038-116-555;;052-684-471-190-493;;004-568-483-555-796;;063-040-386-072-391;;001-333-743-768-03X;;003-328-576-973-971;;008-176-274-719-662;;095-162-518-949-738;;024-348-963-372-076;;076-693-303-335-038;;007-084-720-458-198;;064-055-337-562-368;;069-739-648-979-821;;013-841-799-915-103;;032-748-625-290-265;;062-099-863-837-757;;079-593-245-841-055;;054-995-005-467-222;;041-329-570-173-079;;099-035-739-735-534;;072-547-628-364-928;;093-200-165-594-194;;008-274-826-287-829;;004-764-740-901-871;;037-674-594-420-743;;105-362-591-350-630;;036-013-168-609-901;;031-758-280-989-128;;064-981-485-159-530;;049-796-115-905-999;;008-841-018-283-529;;105-624-360-809-755;;060-965-237-325-653;;106-478-902-619-715;;020-191-827-595-592;;026-684-980-375-813;;155-746-121-945-548;;014-585-057-157-928;;016-245-934-364-075;;017-040-741-145-623;;027-296-352-845-29X;;118-190-784-711-854;;028-094-130-639-491;;052-664-611-823-937;;041-763-726-091-611;;105-215-652-900-713;;046-377-535-715-555;;075-927-681-372-170;;073-180-972-519-149;;044-485-594-222-465;;046-328-577-402-919;;091-010-477-383-601;;111-311-443-070-933;;012-261-100-493-035;;124-467-405-728-071;;010-208-513-979-628;;029-419-591-846-994;;003-526-763-484-740;;032-516-727-018-702;;094-400-537-780-40X;;084-881-256-943-396;;029-624-106-758-273;;052-308-695-243-647;;035-155-644-148-657;;093-350-008-802-15X;;001-436-299-870-282;;083-831-280-762-833;;038-642-776-927-940;;002-992-545-486-58X;;018-419-048-897-547;;172-105-260-241-360;;021-594-673-656-876;;129-174-137-700-680;;036-430-862-175-32X;;006-979-616-832-902;;004-086-526-654-013;;093-159-361-636-556;;012-247-665-964-294;;076-070-224-505-210;;016-249-747-580-90X;;022-980-060-535-387;;007-319-763-778-558;;041-883-471-681-172;;034-978-591-029-435;;006-945-361-671-311;;064-348-611-021-409;;013-520-813-294-749;;121-778-149-592-003;;012-164-908-969-046;;015-634-309-364-793;;035-230-669-274-593;;107-535-256-780-313;;011-803-647-630-475;;019-378-000-546-279;;161-575-194-317-861;;022-940-770-633-516;;028-944-494-543-501;;008-372-723-096-05X;;102-962-063-447-172,10.1053/jhep.2003.50133;;12668985;;10.1378/chest.119.5.1489;;11348958;;10.1007/bf02237960;;8869943;;10.1097/00001756-199402000-00002;;8199335;;10.1023/a:1024048118294;;12872849;;19707277;;10.2147/tcrm.s4443;;pmc2724191;;10.1136/bmj.38048.506134.ee;;pmc403844;;15054035;;10.1067/mpd.2001.109792;;11148526;;8941257;;10.1016/j.ymgme.2003.10.014;;15050974;;12668989;;10.1053/jhep.2003.50156;;11148549;;10.1067/mpd.2001.111836;;10.1203/00006450-198804000-00006;;3374991;;18007263;;10.1097/01.ccm.0000297954.45251.a9;;11391852;;10.1007/s002800000256;;10.1002/jps.2600660104;;833720;;10.1067/mpd.2001.111837;;11148550;;10551405;;10.1016/s0168-8278(99)80361-4;;3489499;;10.1002/bjs.1800730916;;17713407;;1008850;;pmc1164223;;10.1042/bj1600205;;17101577;;10.1080/00365520600780403;;10.1177/088307389901400810;;10456765;;6243418;;10.1126/science.6243418;;10.1056/nejm198406213102503;;6427608;;10.1006/mgme.2001.3156;;11286510;;10.1023/a:1021989230535;;12602499;;10.1007/s11011-007-9072-3;;17851742;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.1007/s005350200006;;11871762;;pmc231773;;8972229;;10.1128/mcb.17.1.482;;602619;;11104170;;10.1081/jdi-100101968;;10051463;;10.1002/hep.510290309;;9612237;;10.1152/ajpendo.1998.274.5.e801;;10.1002/hep.22897;;19437490;;1347032;;10.1016/0016-5085(92)90180-7;;10.1097/00004836-199712000-00026;;9451687;;10.1023/a:1020741226752;;10850554;;10.1128/aem.65.8.3287-3292.1999;;10427008;;pmc91493;;10.1021/ar00052a005;;17538087;;10.1056/nejmoa066596;;10.1016/0270-9139(93)90502-e;;10.1002/hep.1840180106;;8325618;;10.1038/ajg.2009.191;;19455106;;10.1002/bjs.1800720205;;3871650;;9336301;;10.4321/s1130-01082007001000007;;18052664;;12788037;;10.1016/s1090-3798(03)00040-0;;1349004;;10.1016/s0889-8553(21)00182-5;;10.1016/0003-9861(56)90278-8;;13363442;;10.1001/archsurg.1967.01330080099025;;6016275;;10.1055/s-2004-826885;;15213875;;1500687;;10.1016/0168-8278(92)90164-k;;15830303;;10.1055/s-2004-813917;;10898326;;10.1016/s0168-8278(00)80110-5;;10.7326/0003-4819-93-4-545;;7001971;;12230130;;10.1248/bpb.25.1244;;10.1021/op900169b;;10.1248/cpb.40.2196;;1423780;;10.1016/0304-4165(88)90071-2;;3334877;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10.1159/000047017;;11867872;;15521003;;10.1053/j.gastro.2004.08.005;;12757755;;10.1016/s1357-2725(02)00396-5;;10.1016/j.mehy.2006.12.061;;17467190;;19409290;;10.1053/j.gastro.2009.04.016;;10.1055/s-2003-42645;;14523680;;4403084;;10.1098/rspb.1972.0064;;15176533;;18823442;;10.1111/j.1440-1746.2008.05582.x;;10.1007/s11011-013-9391-5;;23456516;;3147907;;10.1111/j.1365-2362.1988.tb01053.x;;14709615;;10.1124/dmd.32.1.10;;10.1016/j.hepres.2004.08.013;;15607143;;9185752;;10.1002/hep.510250609;;10.1002/hep.23037;;19441099;;10.1002/hep.22177;;pmc3381946;;18318440;;10.1111/j.1872-034x.2008.00419.x;;19125949;;20382058;;pmc2905228;;10.1016/j.ymgme.2010.03.014;;10.1111/j.1530-0277.2006.00074.x;;16573581;;8675185;;10.1002/hep.510230644;;10.1053/jhep.1996.v23.pm0008675185;;10831173;;10.1016/s0026-0495(00)80038-4;;10.1016/s0026-0495(03)00089-1;;12870174;;10.1016/j.ymgme.2003.12.011;;15050977;;8778603;;10.1056/nejm199609193351204;;1720458;;10.1016/s0022-3476(05)83044-6;;10.1007/bf01477666;;225605;;3058448;;10.1055/s-2008-1067908;;2194222;;10.1152/physrev.1990.70.3.701;;3717115;;2302019;;10.1001/archinte.1990.00390140139029;;10.1001/archinte.150.2.443;;10.1016/s0899-9007(98)00191-9;;10198918;;10.1016/s0387-7604(83)80059-x;;6670711;;10.1042/cs1020287;;10.1042/cs20010162;;11869169;;10.1002/hep.21737;;17680644;;10.1053/j.gastro.2006.12.035;;17570224;;10.1152/ajpgi.00445.2003;;15064231;;4997833;;10604106;;10.1016/s0955-2863(99)00022-4;;15539305;;11533304;;10.1093/jn/131.9.2515s;;10.1136/gut.40.3.418;;9135535;;pmc1027096;;12395326;;10.1053/jhep.2002.36497;;12020618;;10.1016/s0197-0186(02)00040-2;;12774005;;10.1053/jhep.2003.50221;;10.1053/jhep.1996.v24.pm0008855179;;8855179;;10.1002/hep.510240408;;10.3109/01677068709167220;;3598771;;10.1007/s004310050985;;9877039;;9846074;;10801054;;10.1023/a:1005661631281;;2982530;;10.1042/cs0680247;;12052859;;pmc133904;;10.1128/mcb.22.13.4491-4498.2002;;10986219;;pmc1728090;;10.1136/gut.47.4.571;;9250851;;10.1056/nejm199708143370707;;pmc4237123;;23847109;;10.1002/hep.26611;;3965666;;10.1093/jn/115.1.146;;15246207;;10.1016/j.jhep.2004.03.021;;10.1016/s0168-8278(98)80479-0;;10462368;;10.1002/hep.510300311;;4727456;;pmc333026;;10.1172/jci107410;;9698078;;10.1016/s0006-2952(98)00112-9;;10.1002/hep.1840200109;;8020904;;10.1016/0270-9139(94)90133-3;;8474573;;10.1007/bf00967259;;10.1016/j.ymgme.2003.11.017;;15050979;;3930757;;10.1002/jnr.490140210;;2507845;;10.1016/0024-3205(89)90155-0;;11465067;;10.2174/1389450003349254;;12220296;;10.1034/j.1600-0676.2002.00001.x;;10330005;;10.1152/ajpgi.1999.276.5.g1145;;10.1002/hep.22474;;18697192;;15680459;;10.1016/s0140-6736(05)70239-7;;10.1016/s0140-6736(05)17832-5;;3099249;;10.1203/00006450-198611000-00011;;12848729;;10.1046/j.1469-0691.2003.00691.x;;7242660;;10.1038/291378a0;;7272044;;10.1152/ajpendo.1981.241.4.e310;;10.1097/01.ccm.0000287592.94554.5f;;17901832;;10.1097/00000658-198707000-00002;;pmc1492937;;3496861;;10.1016/j.jss.2007.02.002;;17574581;;10.1152/ajpendo.1996.271.4.e718;;8897860;;10.1053/gast.1997.v112.pm9024301;;9024301;;10.1002/hep.21673;;17596891;;10.1097/00019616-200203000-00008;;10.1001/archneur.1990.00530100104022;;2222247;;10.1002/hep.1840100311;;2788117;;17499398;;10.1016/j.clnu.2007.03.002;;23751856;;10.1097/mcg.0b013e318299c789;;10.1111/j.1365-2362.1982.tb00993.x;;6809468;;9148009;;10.1016/s0168-8278(97)80024-4;;15664244;;10.1016/j.jhep.2004.10.019;;10.1016/s0168-8278(09)60775-3;;10.1152/ajpgi.00440.2005;;16782695;;19554542;;10.1002/hep.22917;;pmc507662;;10.1172/jci119023;;8903337;;3508233;;10.1007/bf00998474;;10.1080/07315724.1986.10720123;;3088083;;10.1016/j.jceh.2017.01.025;;pmc6416231;;10.1007/s40265-018-1020-5;;30706422;;10.1111/j.1572-0241.2000.03295.x;;11151894;;10.1016/j.nutres.2007.04.019;;pmc508470;;9389730;;10.1172/jci119812;;10.1016/s1569-1993(07)60026-5;;4411934;;10.1016/j.surg.2005.04.019;;16153446,"Abraldes et al., “Hemodynamic Response to Pharmacological Treatment of Portal Hypertension and Long-Term Prognosis of Cirrhosis”, Hepatol. 2003, 37:902-908.;;Aggarwal et al., “Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU”, Chest, 2001, vol. 119, Issue 5, pp. 1489-1497.;;Albrecht et al., “Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate”, Metab Brain Dis., 1996, vol. 11, Issue 3, pp. 229-237.;;Albrecht et al., “Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy”, Neuroreport., 1994, vol. 5, Issue 6, pp. 671-673.;;Al-Hassnan et al., “The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia”, J. Inherit. Metab. Dis., 2003, vol. 26, pp. 89-91.;;Al Sibae et al., “Current Trends in the Treatment of Hepatic Encephalopathy”, Ther Clin Risk Manag. Jun. 2009, 5(3): 617-626.;;Als-Nielsen et al.,, Non-Absorbable Disaccharides for Hepatic Encephalopathy: Systematic Review of Randomised Trials, BMJ, 2004, p. 1-6.;;Anadiotis et al., “Ornithine transcarbamylase deficiency and pancreatitis”, J Pediatr, 2001, vol. 138, pp. 123-124.;;Anonymous,, “Sodium phenylbutyrate for urea cycle enzyme deficiencies.” [No authors listed], Med Lett Drugs Ther., Nov. 22, 1996, vol. 38, Issue 988, pp. 105-106.;;Australian Examination Report dated Jun. 11, 2014 from Application No. 2010232521, filed Apr. 1, 2010.;;Bachmann et al., “Ammonia toxicity to the brain and creatine”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S52-S57.;;Balata et al., “Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis,”, Hepatology, 2003, vol. 4, Issue 37, pp. 931-939.;;Batshaw et al., “Alternative pathway therapy for urea cycle disorders: twenty years later”, J Pediatr. 2001, 138(1 Suppl): S46-S55.;;Batshaw et al., “Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the Ornithine transcarbamylase-deficient sparse-fur mouse”, Pediatric Research, 1988, vol. 23, Issue 4, pp. 368-374.;;Beale et al., “Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double blind trial,”, Crit Care Med., 2008, vol. 1, Issue 36, pp. 131-144.;;Berg et al., “Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the non-human primate”, Cancer Chemother Pharmacol. May 2001, 47(5): 385-390. Abstract Only.;;Berge et al., “Pharmaceutical Salts”, J Pharm Sci, 1977, vol. 66, pp. 1-19.;;Berry et al., “Long-term management of patients with urea cycle disorders”, J Pediatri, 2001, vol. 138, Issue 1, pp. S56-S61.;;Bighley et al., “Salt Forms of Drugs and Absorption” in Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. New York, 1996, pp. 453-499.;;Blei et al., Pathophysiology of Cerebral Edema in Fulminant Hepatic Failure, Journal of Hepatology, 1999, p. 771-776, vol. 31, Denmark.;;Bleichner, et al., “Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage”, British Journal of Surgery, 1986, vol. 73, Issue 9, pp. 724-726.;;Bongers et al., “Exogenous glutamine: the clinical evidence,”, Crit Care Med., 2007, vol. 9 Suppl, Issue 35, pp. S545-S552.;;Bosoi et al., Long term oral treatment of ornithine phenylacetate increases lean mass and attenuates brain edema in bile-duct ligated rats. Hepatology Oct. 2015, 62(Suppl 1):953A; Abstract 1523.;;Braga et al., “Crystal Polymorphism and Multiple Crystal Forms”, Struct Bond, 2009, 132: 25-50 [pub online Feb. 25, 2009].;;Briggs et al., “Effect of Ornithine and Lactate on Urea Synthesis in Isolated Hepatocytes”, Biochem J, 1976, vol. 160, pp. 205-209.;;Bruha et al., “Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes”, Scand J Gastroenter. 2006, 41: 1454-1463.;;Brunquell et al., “Electroencephalographic findings in ornithine transcarbamylase deficiency”, J Child Neurol, 1999, vol. 14, Issue 8, pp. 533-536.;;Brusilow et al., “Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis”, Science, 1980, vol. 207, pp. 659-661.;;Brusilow et al., “Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis”, The New England Journal of Medicine, 1984, vol. 310, Issue 25, pp. 1630-1634.;;Burlina et al., “Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients”, Molecular Genetics and Metabolism, 2001, vol. 72, pp. 351-355.;;Butterworth, “Pathophysiology of hepatic encephalopathy: a new look at ammonia”, Metab Brain Dis., 2002, vol. 17, Issue 4, pp. 221-227.;;Butterworth, “Neuronal cell death in hepatic encephalopathy”, Metab Brain Dis. Dec. 2007, 22(3-4): 309-320.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, Pharma Res. 1995, 12(7): 945-954.;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds”, Topic in Current Chemistry 1998, 198: 163-208.;;Callado França, et al., Five Days of Ceftriaxone to Treat Spontaneous Bacterial Peritonitis in Cirrhotic Patients, Journal of Gastroenterology, Feb. 2002, p. 119-122 vol. 37, No. 2, Springer, Japan.;;Cavarec et al., “Molecular cloning and characterization of a transcription factor for the copia retrotransposon with homology to the BTB-Containing Lola Neurogenic Factor”, Mol. Cell. Biol., 1997, vol. 17, Issue 1, pp. 482-494.;;Chainuvati et al., “Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease”, Acta Hepatogastro., 1977, vol. 24, Issue 6, pp. 434-439.;;Chawla et al., “Challenges in Polymorphism of Pharmaeuticals”, CRIPS Mar. 2004, 5(1): 9-12.;;Chen et al., “Continuous arteriovenous hemodiafiltration in the acute treatment of hyperammonaemia due to ornithine transcarbamylase deficiency”, Renal Failure, 2000, vol. 22, Issue 6, pp. 823-836.;;Chinese Office Action dated Feb. 19, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 18, 2012 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Sep. 23, 2013 in Application No. 201080021311.6, filed Apr. 1, 2010.;;Chinese Office Action dated Jul. 9, 2015 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Chinese Office Action dated Apr. 5, 2016 for Application No. 201410392027.X, filed Aug. 11, 2014.;;Chung et al., “Cirrhosis and its Complications”, Harrison's Principles of Internal Medicine (16th Edition) (2005) 289, pp. 1858-1869.;;Clemmesen, et al., Cerebral Herniation in Patients With Acute Liver Failure is Correlated with Arterial Ammonia Concentration, Hepatology, Mar. 1999, p. 648-653, Vo. 29, No. 3, American Association for the Study of Liver Diseases.;;ClinicalTrails.gov; William Lee, Med. Uni. S.C.; “Safety Study of Ornithine Phenylacetate to Treat Patients with Acute Liver Failure (STOP-ALF)”, ID #NCT01548690; Feb. 2012; 7 pages.;;Darmaun et al., “Phenylbutyrate-induced glutamine depletion in humans; effect on leucine metabolism”, Am J Physiol Endocrinol Metab., 1998, vol. 274, pp. E801-E807.;;DERWENT 1 January 1900 Derwent World Patents Index; AN 2003-314385, XP002364873, ""Composition used for preventing and treating hepatosis and hepatic encephalopathy comprises ornithine and asparagic acid"";;Davies, et al., “L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats”, Hepatology Jul. 2009, 50(1): 155-164.;;DeJong et al., “Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia”, Gastroenterology, 1992, vol. 103, Issue 3, pp. 936-948.;;Del Rosario et al., Hyperammonemic encephalopathy, J Clin Gastroenterol, 1997, vol. 25, Issue 4, pp. 682-684.;;Demand with Article 34 amendments, filed Feb. 3, 2011 in International Application No. PCT/US2010/029708.;;Desjardins et al., “Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle”, Metab Brain Dis., 1999, vol. 14, Issue 4, pp. 273-280.;;Dewhirst et al., “Phylogeny of the defined murine microbiota: Altered Schaedler Flora”, Appl. Environ Microbiol. 1999, 65(8): 3287-3292.;;Dunitz et al., “Disappearing Polymorphs”, Acc Chem Res. 1995, 28: 193-200.;;Enns et al., “Survival after treatment with phenylacetate and benzoate for urea-cycle disorders,”, N Engl J Med., 2007, vol. 22, Issue 356, pp. 2282-2292.;;Eurasian Office Action dated May 24, 2016 for Application No. 201500650 filed Jul. 16, 2015.;;European Extended Search Report dated Nov. 30, 2012 for Application No. 10759442.6.;;European Extended Search Report dated Nov. 9, 2017 for Application No. 17185173.6, filed Aug. 7, 2017.;;Fabbri et al., Unresponsiveness of Hepatic Nitrogen Metabolism to Glucagon Infusion in Patients with Cirrhosis: Dependence on Liver Cell Failure, Hepatology 1993, 18(1): 28-35.;;Garcia-Tsao, MD, et al., Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program, Am J Gastroenterol, 2009, p. 1802-1829, Vo. 104.;;Garden et al., “Prediction of outcome following acute variceal haemorrhage”, Br J Surg., 1985, vol. 72, pp. 91-95.;;Gebhardt et al., “Treatment of cirrhotic rats with L-Ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels”, J Pharm Exp Thera., 1997, vol. 283, Issue 1, pp. 1-6.;;Gonzalez-Navajas et al., “Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool,”, Rev Esp Enferm Dig., 2007, vol. 10, Issue 99, pp. 599-603.;;Gordon, “Ornithine transcarbamylase deficiency: a urea cycle defect”, European Journal of Paediatric Neurology, 2003, vol. 7, pp. 115-121.;;Grace et al., “Prevention of initial variceal hemorrhage”, Gastroenter Clin North Am., 1992, vol. 21, Issue 1, pp. 149-161.;;Grant, D.J.W., “Theory and Origin of Polymorphism” Chapter 1 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., 1999; pp. 1-11.;;Greenstein et al., Studies on the Metabolism of Amino Acids and Related Compounds in Vivo. III. Prevention of Ammonia Toxicity by Arginine and Related Compounds, Arch Biochem Biophys, 1956, vol. 64, Issue (2):, pp. 342-354.;;Grossi et al., “Amino acids mixtures in prevention of acute ammonia intoxication in dogs”, Arch Surg, 1967, vol. 94, pp. 261-266.;;Guillory, J.K., “Generation of Polymorphs, Hydrates, Solvates, and Amorphous” Chapter 5 from Polymorphism in Pharmaceutical Solids, Brittain, Harry G. [Ed.]; Marcel Dekker, Inc., 1999, pp. 183-226.;;Häberle et al., Hyperammonämie: Ursachen, Diagnostik, Therapie, Dtsch Med Wochenschr, 2004, vol. 129; pp. 1430-1433.;;Hamberg, Ole et al., Effects of an Increase in Protein Intake on Hepatic Efficacy for Urea Synthesis in Healthy Subjects and in Patients with Cirrhosis, Journal of Hepatology, 1992, pp. 237-243, Elsevier Science Publishers B.V.;;Hass et al., “Detection of subclinical and overt hepatic encephalopathy and treatment control after L-Ornithine-L-Aspartate medication by magnetic resonance spectroscopy (1H-MRS)”, Z Gastroenterol, 2005, vol. 43, pp. 373-378.;;Häussinger et al., “Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?”, J Hepatol., 2000, vol. 32, Issue 6, pp. 1035-1038.;;Herlong et al., “The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy”, Ann Intern Med., 1980, vol. 93, Issue 4, pp. 545-550.;;Hirayama et al., [Eds], “Organic compound crystal produced handbook—Principles and know-how”, Maruzen Co., Ltd., Japan; (Jul. 2008), pp. 17-23, 37-40, 45-51 and 57-65; 31 pages.;;Honda et al., “Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy”, Biol. Pharm. Bull., Sep. 2002, 25(9): 1244-1246.;;Hopkins Medicine (http://www.hopkinsmedicine.org/gastroenterology_hepatology/_pdfs/liver/portal_hypertension.pdf; accessed Jun. 22, 2016); 13 pages.;;Hursthouse et al., “Why Do Organic Compounds Crystallise Well or Badly or Ever so Slowly? Why is Crystallisation Nevertheless Such a Good Purification Technique?”, Organic Process Research & Development, 2009, 13:1231-1240.;;Igarashi et al., “Determination of ornithine conjugates of some carboxylic acids in birds by high-performance liquid chromatography”, Chem Pharm Bull, 1992, vol. 40, Issue 8, pp. 2196-2198.;;Inoue et al., “Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria”, Biochim Biophys Acta., 1988, vol. 964, Issue 1, pp. 90-95.;;International Preliminary Report on Patentability dated Jun. 2, 2011 for Application No. PCT/US2010/029708, filed Apr. 1, 2010.;;International Search Report and Written Opinion dated Jun. 3, 2010 for PCT/US2010/029708, filed Apr. 1, 2010.;;Israel Office Action dated Sep. 30, 2014 for Application No. 215449, filed Apr. 1, 2010.;;Iyer et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., 2002, vol. 22, Issue 13, pp. 4491-4498.;;Jalan et al., “Acute-on-chronic liver failure: pathophysiological basis of therapeutic options”, Blood Purif, 2002, vol. 20, pp. 252-261.;;Jalan et al., “Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension,”, Gastroenterology, 2004, vol. 5, Issue 127, pp. 1338-1346.;;Jalan et al., “The molecular pathogenesis of hepatic encephalopathy”, The International Journal of Biochemistry & Cell Biology, 2003, vol. 35, pp. 1175-1181.;;Jalan et al., L-Ornithine Phenylacetate (OP): A Novel Treatment for Hyperammonemia and Hepatic Encephalopathy, Medical Hypotheses, 2007, 69(5): 1064-1069, Elsevier Ltd.;;Jalan et al., Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, p. 2048-2051, vol. 1236.;;Jalan, Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management, Seminars in Liver Disease, 2003, p. 271-282, vol. 23, No. 3, Thieme Medical Publisheres, Inc., New York, NY, USA.;;James et al., “The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species”, Proc R Soc Lond B., 1972, vol. 182, pp. 25-35.;;Japanese Office Action dated May 13, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Oct. 21, 2014 for Application No. 2012-503725, filed Apr. 1, 2010.;;Japanese Office Action dated Jun. 7, 2016 for Application No. 2012-503725, filed Apr. 1, 2010.;;Jeyamani et al., Hepatitis E virus and acute-on-chronic liver failure,, Indian J Gastroentero., 2004, vol. 23, Issue 2, pp. 45-46.;;Jiang et al., “L-Ornithine-I-aspartate in the management of hepatic encephalopathy: a meta-analysis”, J Gastroenterol Hepatol. 2009, 24(1): 9-14; available online: Sep. 28, 2008.;;Jover-Cobos et al., Ornithine phenylacetate revisited; Metabolic Brain Disease 2013, 28(2): 327-331.;;Kaiser, S. et al., Ammonia and Glutamine Metabolism in Human Liver Slices: New Aspects on the Pathogenesis of Hyperammonaemia in Chronic Liver Disease, European journal of Clinical Investigation , 1988, vol. 18, pp. 535-542.;;Kasumov et al., “New secondary metabolites of phenylbutyrate in humans and rats”, Drug Metab Dispos., 2004, vol. 32, Issue 1, pp. 10-19.;;Katayama, “Ammonia metabolism and hepatic encephalopathy”, Hep. Research, 2004, vol. 30, Issue 1, pp. S71-S78.;;Khan et al.,, Frequency of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Due to Hepatitis C Virus and Efficacy of Ciprofloxacin in its Treatment, Gomal Journal of Medical Sciences, Jul.-Dec. 2009, p. 149-154, vol. 7, No. 2.;;Kircheis et al., “Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study,”, Hepatology, 1997, vol. 6, Issue 25, pp. 1351-1360.;;Kojima et al., “Effective Solid Form Selection for the Pharmaceutical Development”, J Pharma Science Tech. Sep. 2008, 68(5): 344-349.;;Korean Office Action dated Jun. 8, 2016 for Application No. 10-2011-7026256, filed Apr. 1, 2010.;;Korean Office Action dated Mar. 30, 2017 for Application No. 10-2011-7026256, filed Apr. 1, 2010.;;Larsen et al., “Alternative Pathway Therapy for Hyperammonemia in Liver Failure”; Hepatolory, Jul. 2009, 50(1): 3-5.;;Lee et al., Acute Liver Failure: Summary of a Workshop, Hepatology, Apr. 2008, p. 1401-1415, vol. 47, No. 4.;;Lee, W. M., Acetaminophen-Related Acute Liver Failure in the United States, Hepatology Research, 2008, p. S3-S8, vol. 38, Suppl. 1, The Japan Society of Hepatology.;;Lee et al., “Phase 2 Comparison of a Novel Ammonia Scavenging Agent with Sodium Phenylbutyrate in Patients with Urea Cycle Disorders: Safety, Pharmacokinetics and Ammonia Control”, Mol Genet Metab. Mar. 2010, 100(3): 221-228.;;Linderoth et al., “Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study,”, Alcohol Clin Exp Res., 2006, Issue 30, pp. 636-641.;;Lopez-Talavera et al., “Thalidomide Inhibits Tumor Necrosis Factor alpha, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats”, Hepatology, 1996, 23(6): 1616-1621.;;Lukkarinen, M. et al., Effect of Lysine Infusion on Urea Cycle in Lysinuric Protein Intolerance, Metabolism, May 2000, 49(5): 621-625.;;Lukkarinen, M. et al., Oral Supplementation Corrects Plasma Lysine Concentrations in Lysinuric Protein Intolerance, Metabolism, Jul. 2003, 52(7): 935-938.;;MacArthur et al., “Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers”, Molecular Genetics and Metabolism, 2004, vol. 81, pp. S67-S73.;;Maestri et al., “Long-term treatment of girls with ornithine transcarbamylase deficiency”, N Engl J Med., 1996, vol. 335, Issue 12, pp. 855-859.;;Maestri et al., “Prospective treatment of urea cycle disorders”, J Pediatr., 1991, vol. 119, Issue 6, pp. 923-928.;;Maev I.V. Application of L-ornitine-L-aspartate in complex therapy of hepatic encephalopathy in liver cirrhosis patients (Engl. Title) koloproktologii, 2002, No. 6, pp. 60-66.;;Maier et al., Originalien Activities of Urea-Cycle Enzymes in Chronic Liver Disease, Klinische-Wochenschrift, 1979, vol. 67, pp. 661-665, Springer-Verlag.;;Maier, “Therapie der hepatischen Enzephalopathie”, Dtsch med Wschr., 1988, vol. 113, pp. 1886-1889.;;Matsuoka et al., “Advanced Crystallization Technology of Organic Materials—Control of Size, Morphology, Polymorph and Purity”, Pharm Tech, Japan (May 2003) 19(6): 91(955)-101(965).;;Meijer et al., Nitrogen Metabolism and Ornithine Cycle Function, Physiological Reviews, Jul. 1990, vol. 70, No. 3, pp. 701-748, The American Physiological Society.;;Mendenhall et al., “A new therapy for portal systemic encephalopathy”, The American Journal of Gastroenterology, 1986, vol. 81, Issue 7, pp. 540-543.;;Mexican Office Action dated Dec. 10, 2013 for Application No. MX/a/2012/013961, filed Nov. 30, 2012.;;Mihm et al., “Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE)”, Hepatology, 2001, vol. 34, Issue 4, pp. 543A.;;Mizock et al., “Septic Encephalopathy—Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy”, Arch Intern Med, 1990, vol. 150, pp. 443-449.;;Mizock, Nutritional Support in Hepatic Encephalopathy, Nutrition, 1999, pp. 220-228, vol. 15, No. 3, Elsevier Science Inc.;;Mizutani et al., “Hyperargininemia: Clinical course and treatment with sodium benzoate and phenylacetic acid”, Brain Dev., 1983, vol. 5, Issue 6, pp. 555-563.;;Moinard et al.,, “Effects of Ornithine 2-Oxoglutarate on Neutrophils in Stressed Rates: Evidence for the Involvement of Nitric Oxide and Polyamines”, Clin Sci, 2002, vol. 102, Issue 3, pp. 287-295, London, England.;;Mookerjee et al., “Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome,”, Hepatology, 2007, vol. 3, Issue 46, pp. 831-840.;;Mookerjee et al., “Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis”, Gastroenterology Jun. 2007, 132(7): 2533-2541.;;Mouille et al., “Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion”, Am J Gastrointest Liver Physiol., 2004, 287(2), G344-G351.;;Nance et al., “Ammonia production in germ-free Eck fistula dogs”, Surgery, 1971, vol. 70, Issue 2, pp. 169-174.;;Navasa et al., “Bacterial infections in liver cirrhosis,”, Ital J Gastroenterol Hepatol., 1999, vol. 7, Issue 31, pp. 616-625.;;New Zealand Office Action dated Jan. 8, 2014 for Application No. 619235, filed Dec. 20, 2013.;;Newsholme et al., “Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease,”, J Nutr Biochem., 1999, vol. 6, Issue 10, pp. 316-324.;;Newsholme, “Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?”, J Nutr., 2001, vol. 9 Suppl, Issue 131, pp. 2515S-2522S.;;Ocera Therapeutics, Inc., News Release: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy; Globe Newswire; Apr. 1, 2015, 2 pages.;;Ocera Therapeutics, Inc., News Release: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Acute Hepatic Encephalopathy; Globe Newswire; Nov. 16, 2015, 2 pages.;;Ocera Therapeutics, Inc., News Release: Ocera Completes Plasma Data from Pilot Phase 1 Study for Orally-available OCR-002 in Development for the Prevention of Acute Hepatic Encephalopathy; Globe Newswire; Jan. 8, 2016, 3 pages.;;Olde Damink et al., “Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats”, Gut, 1997, vol. 40, pp. 418-424.;;Olde Damink et al., “Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS”, Hepatology, 2002, vol. 36, Issue 5, pp. 1163-1171.;;Olde Damink et al., “Interorgan ammonia metabolism in liver failure”, Neurochemistry International, 2002, vol. 41, pp. 177-188.;;Olde Damink et al., “The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis”, Hepatology, 2003, vol. 37, pp. 1277-1285.;;Olde Damink et al., Stimulated Liver and Muscle Protein Synthesis by Intravenous Isoleucine Supplementation During a Simulated Variceal Bleed in Patients with Cirrhosis of the Liver, Hepatology, Oct. 2001, AASLD Abstracts #50.;;Pauwels et al., “Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection”, Hepatology, 1996, vol. 24, Issue 4, pp. 802-806.;;Petrowski et al., “Pharmacologic amino acid acylation in the acute hyperammonemia of propionic acidemia”, Journal of Neurogenetics, 1987, vol. 4, pp. 87-96.;;Plecko et al., “Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate”, Eur J Pediatr., 1998, vol. 157, pp. 996-998.;;Powell et al., “Compendium of Excipients for Parenteral Formulations”, PDA J Pharm Sci Technol. 1998, 52(5): 238-311.;;Praphanphoj et al., “Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonemia”, J Inherit Metab Dis., 2000, vol. 23, pp. 129-136.;;Rajkovic et al., “Mechanisms of abnormalities in host defences against bacterial infection in liver disease,”, Clin Sci. (Lond.), 1985, vol. 3, Issue 68, pp. 247-253, London.;;Ramaswamy et al., “Mouse model for human arginase deficiency”, Mol Cell Biol., Jul. 2002, vol. 22, Issue 13, pp. 4491-4498.;;Rees et al., “Effect of L-Ornithine-L-Aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial”, Gut, 2000, vol. 47, pp. 571-574.;;Riordan et al., “Treatment of hepatic encephalopathy”, Curr Concepts, 1997, vol. 337, Issue 7, pp. 473-479.;;Rockey et al., “Randomized, Double-Blind, Controlled Study of Glycerol Phenylbutyrate in Hepatic Encephalopathy,” Hepatology (2014) 59(3): 1073-1083.;;Rogers, Q. R. et al., Deficiency of Pyrroline-5-Carboxylate Synthase in the Intestinal Mucosa of the Cat, J Nutrition, 1985, 115(1): 146-150.;;Romero-Gómez et al., “Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy”, J Hepatol. 2004, 41: 49-54.;;Rose et al., “L-Ornithine-L-Aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action”, Metabolic Brain Disease, 1998, vol. 13, Issue 2, pp. 147-157.;;Rose et al., “L-Ornithine-L-Aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure”, Hepatology, 1999, vol. 30, Issue 3, pp. 636-640.;;Rudman et al., Maximal Rates of Excretion and Synthesis of Urea in Normal and Cirrhotic Subjects, The Journal of Clinical Investigation, Sep. 1973, vol. 52, pp. 2241-2249.;;Rukmini et al., “Region-specific changes in CNS muscarinic acetylcholine receptors in a rat model of hyperammonemia”, Biochem Pharmacol., 1998, vol. 56, Issue 2, pp. 237-241.;;Sanyal et al., Portosystemic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Results of a Prospective Controlled Study, Hepatology, 1994, p. 46-55, vol. 20, No. 1, Pt. 1, The American Association for the Study of Liver Diseases.;;Sanyal, A. J., Prediction of Variceal Hemorrhage in Patients with Cirrhosis, UpToDate, Inc., Website (www.uptodate.com), Jan. 2010, UpToDate.;;Sarhan et al., “Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy”, Neurochem Res., 1993, vol. 18, Issue 4, pp. 539-549.;;Scaglia et al., “Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients”, Mol Genet Metabolism, 2004, vol. 81, pp. S79-S85.;;Sears et al., “Disruption of the blood-brain barrier in hyperammonaemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine”, J Neurosci Res., 1985, vol. 14, Issue 2, pp. 255-261.;;Seiler et al., “Ornithine aminotransferase activity, liver ornithine concentration and acute ammonia intoxication”, Life Sciences, 1989, vol. 45, Issue 11, pp. 1009-1020.;;Seiler, “Ornithine aminotransferase, a potential target for the treatment of hyperammonemias”, Curr Drug Targets., Sep. 2000, vol. 1, Issue 2, pp. 119-153.;;Sen et al., “The pathophysiological basis of acute-on-chronic liver failure”, Liver, 2002, vol. 22, Issue Suppl. 2, pp. 5-13.;;Shangraw et al., Effect of Liver Disease and Transplantation on Urea Synthesis in Humans: Relationship to Acid-Base Status, AM J Physiol Gastrointest Liver Physiol, 1999, vol. 276, pp. 1145-1152.;;Shawcross et al., “Ammonia impairs neutrophil phagocytic function in liver disease,”, Hepatology, 2008, vol. 4, Issue 48, pp. 1202-1212.;;Shawcross et al., “Dispelling myths in the treatment of hepatic encephalopathy,”, Lancet, 2005, vol. 9457, Issue 365, pp. 431-433.;;Shawcross et al., “Hyperammonemia impairs neutrophil function”, Hepatology, 2005, vol. 42, pp. 537A.;;Shriner et al., “Recrystallization”, Chapter 3.5 Preliminary Examination in the Systematic Identification of Organic Compounds, John Wiley & Sons, Inc. New York, 1998, Chapter 3, pp. 78-81.;;Simell et al., “Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance”, Pediatric Research, 1986, vol. 20, Issue 11, pp. 1117-1121.;;Singapore Examination Report dated Sep. 27, 2013 for Application No. 201107116-4, filed Apr. 1, 2010.;;Singapore Search Report and Written Opinion dated Jul. 11, 2014 from Application No. 2013024559, filed Apr. 2, 2013.;;Singaporean Search and Written Opinion dated Mar. 1, 2013 for Application No. 201108982-8, filed Jun. 8, 2010.;;Singaporean Search & Examination Report dated Nov. 5, 2013 for Application No. 201108982-8, filed Jun. 8, 2010.;;Singh, et al., Changing Epidemiology and Predictors of Mortality in Patients With Spontaneous Bacterial Peritonitis at a Liver Transplant Unit, Clinical Microbiology and Infection, Jun. 2003, p. 531-537, vol. 9, No. 6., European Society of Clinical Microbiology and Infectious Diseases.;;Smith et al., “The treatment of inborn errors of the urea cycle”, Nature, 1981, vol. 291, Issue 5814, pp. 378-380.;;Soláini et al., “Variations in the plasma concentration of ornithine, citrulline and arginine in acute experimental liver failure” [Article in Italian], Boll Soc Ital Biol Sper., 1981, vol. 57, Issue 7, pp. 705-710.;;Stedman's Medical Dictionary; “Encephalopathy”, 27th Edition, 2002; 1 page.;;Stewart, P. M., et al., Effects of Arginine-Free Meals on Ureagenesis in Cats, American Journal of Physiological, 1981, pp. E310-E315, vol. 241, No. 4, The American Physiological Society.;;Stravitz, MD, et al., Intensive Care of Patients with Acute Liver Failure: Recommendations of the U.S. Acute Liver Failure Study Group, Critical Care Medicine, 2007, p. 2498-2508, vol. 35, No. 11, Lippincott Williams & Wilkins.;;Suchy et al., Clinical Manifestations and Complications—Typical Clinical Presentation;, Liver Disease in Children, 2nd Edition, 2001, pp. 74-77.;;Sugarbaker et al., “The role of the small intestine in ammonia production after gastric blood administration”, Ann Surg., 1987, vol. 206, Issue 1, pp. 5-17.;;Sukhotnik et al., “Oral glutamine prevents gut mucosal injury and improves mucosal recovery following lipopolysaccharide endotoxemia in a rat,”, J Surg Res., 2007, vol. 2, Issue 143, pp. 379-384.;;Svanberg et al., “Effects of amino acids on synthesis and degradation of skeletal muscle proteins in humans”, Am J Physiol., 1996, vol. 271, Issue 4 Pt1, pp. E718-E724.;;Timely Data Resource (TDR), IPD Printable Search Results, “Incidence and Prevalence Database, ICD-9 Code: 567. Peritonitis,” <URL:http://www.tdrdata.com/IPD/ipd_searchresultsdataprinter.aspx?SessionGUID=ac0c91d8-7 . . . , 7□27-2010, 7 pages.;;Teran et al., “Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis”, Gastroenter., 1997, vol. 112, Issue 2, pp. 473-482.;;Trebicka et al., Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Roh-kinase and activation of endothelial nitric oxide synthase, Hepatology, 2007, 46(1): 242-253.;;Tuchman, M., et al., Management of Inherited Disorders of Ureagenesis, The Endocrinologist, 2002, vol. 12, No. 2, p. 99-109.;;Tuchman, MD et al., “Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome”, Arch Neurol., 1990, vol. 47, pp. 1134-1137.;;UK Search Report dated Feb. 21, 2005 for GB priority application No. 0426141.8.;;Van Berlo et al., “Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of isoleucine in hemoglobin? A study in pigs”, Hepatology, 1989, vol. 10, Issue 3, pp. 315-323.;;Van Den Berg et al., “The effect of glutamine-enriched enteral nutrition on intestinal microflora in very low birth weight infants: a randomized controlled trial,”, Clin Nutr., 2007, vol. 4, Issue 26, pp. 430-439.;;Ventura-Cots et al., Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study; J Clin Gastroenter. (2013) 47(10): 881-887. et al.",ACTIVE
284,WO,A1,WO 2022/235995 A1,171-919-327-470-181,2022-11-10,2022,US 2022/0027989 W,2022-05-06,US 202117313059 A,2021-05-06,METHOD FOR VALIDATION AND MODIFICATION OF DEVICE STATE TRANSITIONS FOR AN AEROSOL GENERATION DEVICE,"A method for functional testing of aerosol provision devices may include performing a functional state transition test of a power unit. The functional state transition test of the power unit may include extracting a unique identifier from the power unit of an aerosol provision device responsive to operable coupling of the power unit to a test fixture, determining a transition code based on the unique identifier, providing the transition code to the power unit via the test fixture to transition the power unit from an initial state to a transitioned state, and transitioning the power unit to the initial state.",RAI STRATEGIC HOLDINGS INC,GARRIS ROBERT LOGAN;;LUKAN SEAN;;MARTING JIM;;DAUGHERTY SEAN;;CARPENTER AUSTIN;;MOUGEY SPENCER;;ANDERSON KEITH,,https://lens.org/171-919-327-470-181,Patent Application,yes,3,0,4,4,0,A24F40/80;;A61M15/06;;A61M2205/6018;;A61M2205/70;;A61M11/042;;A61M11/005;;A61M15/0085;;A61M2205/6063;;A61M2205/43;;A61M2205/44;;A61M2205/3592;;A61M2205/3553;;A61M2205/3569;;A24F40/80;;A24F40/53;;A61M2205/70;;A61M15/06;;A61M2205/6018;;G01N27/00,A24F40/80;;A24F40/49;;A24F40/50;;A24F40/53;;A61M15/06;;G06F21/31;;G06Q10/00;;G06Q20/20,,0,0,,,,PENDING
285,AU,A1,AU 2019/381713 A1,023-199-125-078-932,2021-06-10,2021,AU 2019/381713 A,2019-11-13,US 201862760457 P;;US 2019/0061280 W,2018-11-13,Improved sample grinder,"A bead beater homogenizer (100) includes a shaft having a main body (30) extending along a main axis (32) and a distal connection body (34) extending along a connection axis (36) that is acutely angled with respect to the main axis (32), a motor (20) configured to rotate the shaft about the main axis (32), a head (60) rotatably connected to the distal connection body (34) of the shaft, and a clamp (62, 64, 66) secured to the head (60) and configured to secure a sample vial holder (70, 170, 270, 370, 470) configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis (32) is translated into motion of the head (60) in directions normal to the main axis (32). A sample vial holder (470) having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/023-199-125-078-932,Patent Application,no,0,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06;;G01N1/28,,0,0,,,,PENDING
286,EP,A2,EP 3880790 A2,064-376-585-733-354,2021-09-22,2021,EP 19829710 A,2019-11-13,US 201862760457 P;;US 2019/0061280 W,2018-11-13,IMPROVED SAMPLE GRINDER,,SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/064-376-585-733-354,Patent Application,yes,0,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06;;G01N1/28,,0,0,,,,ACTIVE
287,CA,A1,CA 3119162 A1,071-733-243-873-724,2020-05-22,2020,CA 3119162 A,2019-11-13,US 201862760457 P;;US 2019/0061280 W,2018-11-13,IMPROVED SAMPLE GRINDER,"A bead beater homogenizer (100) includes a shaft having a main body (30) extending along a main axis (32) and a distal connection body (34) extending along a connection axis (36) that is acutely angled with respect to the main axis (32), a motor (20) configured to rotate the shaft about the main axis (32), a head (60) rotatably connected to the distal connection body (34) of the shaft, and a clamp (62, 64, 66) secured to the head (60) and configured to secure a sample vial holder (70, 170, 270, 370, 470) configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis (32) is translated into motion of the head (60) in directions normal to the main axis (32). A sample vial holder (470) having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/071-733-243-873-724,Patent Application,no,0,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06;;G01N1/28,,0,0,,,,PENDING
288,US,B1,US 11724632 B1,008-712-091-738-277,2023-08-15,2023,US 202217959413 A,2022-10-04,US 202217959413 A;;US 202017130141 A;;US 201962952781 P,2019-12-23,Material collection and transfer cart,"An apparatus includes a base frame, first and second bins, first and second hydraulic assemblies, and a computer controller. The first hydraulic assembly is configured to selectively raise and lower the first bin relative to the base frame. The second hydraulic assembly is configured to selectively raise and lower the second bin relative to the base frame. The first and second hydraulic assemblies are individually actuable, and their actuation is coordinated by the controller. In another aspect, a method for transferring product using an apparatus includes inputting to a computer controller a first threshold rate of change in weight signals of a weight sensor; relaying a plurality of weight signals from the weight sensor to the controller; calculating a determination by the controller at least in part on whether the threshold rate of change has been exceeded; and automating actuation of a hydraulic assembly based on the determination.",AMITY TECH LLC,MEYER BRADLEY;;ANDERSON MICHAEL;;GUST JAKE;;FEHR LLOYD;;KNOBLOCH DAMON;;WULF DENNIS;;NIELAND JIM;;FEHR BRAD,,https://lens.org/008-712-091-738-277,Granted Patent,yes,7,0,2,2,0,B62D63/06;;B62D59/00;;B62D55/06;;B60P1/283;;B60P1/165;;B60P1/162;;B60P1/286;;B62D63/06;;B66F9/22;;B62D55/08;;B66F9/0655,B60P1/62;;B60P1/16;;B60P1/28;;B62D55/08;;B62D63/06;;B66F9/065;;B66F9/22,,0,0,,,,ACTIVE
289,US,A1,US 2020/0150005 A1,029-964-462-736-004,2020-05-14,2020,US 201916682969 A,2019-11-13,US 201916682969 A;;US 201862760457 P,2018-11-13,Sample Grinder,"A bead beater homogenizer includes a shaft having a main body extending along a main axis and a distal connection body extending along a connection axis that is acutely angled with respect to the main axis, a motor configured to rotate the shaft about the main axis, a head rotatably connected to the distal connection body of the shaft, and a clamp secured to the head and configured to secure a sample vial holder configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis is translated into motion of the head in directions normal to the main axis. A sample vial holder having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/029-964-462-736-004,Patent Application,yes,0,7,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,G01N1/28;;C12M1/33,,0,0,,,,ACTIVE
290,US,B1,US 8892648 B1,057-807-941-635-899,2014-11-18,2014,US 201113173494 A,2011-06-30,US 201113173494 A,2011-06-30,Media player social network integration,"A media player user interface on behalf of a user associated with a user account is generated that has a social network module that includes media updates associated with other users to which the user is linked. Media player actions associated with the user occurring in the media player user interface are also captured, updates are generated and provided to social network modules in a media player user interface associated with other linked users.",DURHAM SCOTT;;PAPE CRAIG;;MEAKER SCOTT K;;ANDERSON ERIN O;;ROBERTS PAUL WILLIAM;;DANTZLER JIM L;;AMAZON TECH INC,DURHAM SCOTT;;PAPE CRAIG;;MEAKER SCOTT K;;ANDERSON ERIN O;;ROBERTS PAUL WILLIAM;;DANTZLER JIM L,AMAZON TECHNOLOGIES INC (2011-07-06),https://lens.org/057-807-941-635-899,Granted Patent,yes,18,58,1,1,0,G06Q50/01;;G06Q50/01,G06F15/16,709/204;;709/205;;709/226,2,1,081-145-505-641-838,10.1109/p2p.2010.5569963,"Sehr, Andres. ""Spotify-The Next Generation."" Apr. 27, 2010. pp. 1-2. Retrieved from https://www.spotify.com/us/blog/archives/2010/04/27/the-next-generation/.;;Kreitz et. al. ""Spotify-Large Scale, Low Latency, P2P Music-on-Demand Streaming."" Aug. 27, 2010. 2010 IEEE Tenth International Conference on Peer-to-Peer Computing. pp. 1-10.",INACTIVE
291,US,B1,US 11491904 B1,069-195-805-237-395,2022-11-08,2022,US 202017130141 A,2020-12-22,US 202017130141 A;;US 201962952781 P,2019-12-23,Material collection and transfer cart,"An apparatus includes a base frame, first and second bins, first and second hydraulic assemblies, and a computer controller. The first hydraulic assembly is configured to selectively raise and lower the first bin relative to the base frame. The second hydraulic assembly is configured to selectively raise and lower the second bin relative to the base frame. The first and second hydraulic assemblies are individually actuable, and their actuation is coordinated by the controller. In another aspect, a method for transferring product using an apparatus includes inputting to a computer controller a first threshold rate of change in weight signals of a weight sensor; relaying a plurality of weight signals from the weight sensor to the controller; calculating a determination by the controller at least in part on whether the threshold rate of change has been exceeded; and automating actuation of a hydraulic assembly based on the determination.",AMITY TECH LLC,MEYER BRADLEY;;ANDERSON MICHAEL;;GUST JAKE;;FEHR LLOYD;;KNOBLOCH DAMON;;WULF DENNIS;;NIELAND JIM;;FEHR BRAD,,https://lens.org/069-195-805-237-395,Granted Patent,yes,27,0,2,2,0,B62D63/06;;B62D59/00;;B62D55/06;;B60P1/283;;B60P1/165;;B60P1/162;;B60P1/286;;B62D63/06;;B66F9/22;;B62D55/08;;B66F9/0655,B60P1/16;;B60P1/28;;B62D55/08;;B62D63/06;;B66F9/065;;B66F9/22,,7,0,,,"“Dump Carts” brochure, Aulick Industries, 4 pages, Jan. 2020.;;“Hydraulic Dump Cart,” Web page <http://www.kelleymfg.com/products/peanut/dumpcart.aspx>, 2 pages, Mar. 1, 2009, retrieved from Internet Archive Wayback Machine <http://web.archive.org/ http://www.kelleymfg.com> on Oct. 14, 2020.;;Kelley Double Dump Cart, photo, publicly available at least as of Sep. 30, 2020.;;Kelley Double Dump Cart 2, photo, publicly available at least as of Sep. 30, 2020.;;“Dump Cart,” KMC (Kelley Mfg. Co.), 4 pages, publicly available at least as of Sep. 30, 2020.;;https://www.facebook.com/MilkSource/videos/362753992038111, Milk Source, LLC, 1 minute 46 second video, uploaded Sep. 14, 2021, downloaded Dec. 13, 2021, 2 pages.;;http://www.hsmfgco.com/wbctz-product/hi-dump-box/, H&S Manufacturing Company, Inc., Hi-Dump Box, Copyright© 2021, downloaded Dec. 13, 2021, 2 pages.",ACTIVE
292,US,B1,US 8826135 B1,106-715-334-539-659,2014-09-02,2014,US 201113173523 A,2011-06-30,US 201113173523 A,2011-06-30,Media player social network integration,"A media player user interface on behalf of a user associated with a user account is generated that has a social network module that includes music updates associated with other users to which the user is linked. Media player actions associated with the user occurring in the media player user interface are also captured, updates are generated and provided to social network modules in a media player user interface associated with other linked users.",DURHAM SCOTT;;PAPE CRAIG;;MEAKER SCOTT K;;ANDERSON ERIN O;;ROBERTS PAUL WILLIAM;;DANTZLER JIM L;;AMAZON TECH INC,DURHAM SCOTT;;PAPE CRAIG;;MEAKER SCOTT K;;ANDERSON ERIN O;;ROBERTS PAUL WILLIAM;;DANTZLER JIM L,AMAZON TECHNOLOGIES INC (2011-07-06),https://lens.org/106-715-334-539-659,Granted Patent,yes,17,40,2,2,0,G06Q30/00;;H04N21/26258;;H04N21/4667;;H04N21/4788;;H04N21/8113;;H04N21/8133;;G06Q50/01;;H04N21/4788;;H04N21/8113;;G06Q30/00;;H04N21/26258;;G06Q50/01;;H04N21/4667;;H04N21/8133;;H04L67/535;;G06F3/0484,G06F3/00;;G06F3/01,715/716;;715/719;;715/727;;715/747;;715/758;;715/810,2,1,081-145-505-641-838,10.1109/p2p.2010.5569963,"Sehr, Andres. ""Spotify-The Next Generation."" Apr. 27, 2010. pp. 1-2. Retrieved from http://www.spotify.com/us/blog/archives/2010/04/27/the-next-generation/.;;Kreitz, et al. ""Spotify-Large Scale, Low Latency, P2P Music-on-Demand Streaming."" Aug. 27, 2010. 2010 IEEE Tenth International Conference on Peer-to-Peer Computing. pp. 1-10.",INACTIVE
293,CN,A,CN 113227347 A,176-672-332-185-65X,2021-08-06,2021,CN 201980085266 A,2019-11-13,US 201862760457 P;;US 2019/0061280 W,2018-11-13,IMPROVED SAMPLE GRINDER,"A bead beater homogenizer (100) includes a shaft having a main body (30) extending along a main axis (32) and a distal connection body (34) extending along a connection axis (36) that is acutely angled with respect to the main axis (32), a motor (20) configured to rotate the shaft about the main axis (32), a head (60) rotatably connected to the distal connection body (34) of the shaft, and a clamp (62, 64, 66) secured to the head (60) and configured to secure a sample vial holder (70, 170, 270, 370, 470) configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis (32) is translated into motion of the head (60) in directions normal to the main axis (32). A sample vial holder (470) having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREGORY;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GILAD;;BECK ANDREAS,,https://lens.org/176-672-332-185-65X,Patent Application,no,6,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06;;G01N1/28,,1,0,,,"杜雅静;王宇意;章丹婷;郭丽微;方杰;高梦炜;何文涓;钟晓春;: ""研磨珠均质仪提取增生性瘢痕组织蛋白质的方法"", 医学信息, no. 15, pages 59 - 62",PENDING
294,US,B2,US 11460381 B2,030-183-595-656-642,2022-10-04,2022,US 201916682969 A,2019-11-13,US 201916682969 A;;US 201862760457 P,2018-11-13,Sample grinder,"A bead beater homogenizer includes a shaft having a main body extending along a main axis and a distal connection body extending along a connection axis that is acutely angled with respect to the main axis, a motor configured to rotate the shaft about the main axis, a head rotatably connected to the distal connection body of the shaft, and a clamp secured to the head and configured to secure a sample vial holder configured to hold one or more sample vials therein, wherein rotational motion of the shaft about the main axis is translated into motion of the head in directions normal to the main axis. A sample vial holder having an internal network of channels defined within the housing through which a coolant can be passed to control a temperature of a vial disposed therein is also provided.",SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,SPEX SAMPLEPREP LLC (2019-11-13),https://lens.org/030-183-595-656-642,Granted Patent,yes,2,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,G01N1/00;;B01L3/00;;C12M1/33;;C12N15/10;;G01N1/28,,2,1,127-110-826-073-277,10.1016/0168-583x(90)90459-8,"International Search Report and Written Opinion, issued by International Searching Authority in corresponding International Application No. PCT/US2019/061280, dated Jun. 26, 2020.;;R. S. W. van de Wal et al., “Progress in 14C Dating of Ice at Utrecht”, 2107b Nuclear Instruments & Methods in Physics Research B, Elsevier BV, Amsterdam, NL, vol. B52, Nos. 3/4, pp. 469-472, (1990).",ACTIVE
295,EP,B1,EP 3880790 B1,157-799-769-964-620,2023-10-04,2023,EP 19829710 A,2019-11-13,US 201862760457 P;;US 2019/0061280 W,2018-11-13,IMPROVED SAMPLE GRINDER,,SPEX SAMPLEPREP LLC,SLUTTER WARREN STEPHEN;;KING GREG;;SMITH ERIC;;ANDERSON-SMITH LEA;;DISTABILE JIM;;COHEN GEOFF;;BECK ANDREW,,https://lens.org/157-799-769-964-620,Granted Patent,yes,1,0,9,9,0,G01N2001/2866;;G01N1/286;;C12M47/06;;B02C17/14;;B01L3/508;;C12M45/02;;C12N15/1003;;G01N1/286;;G01N2001/2866,C12M1/33;;B02C17/14;;C12M1/00;;C12N1/06;;G01N1/28,,1,0,,,"VAN DE WAL R S W ET AL: ""PROGRESS IN 14C DATING OF ICE AT UTRECHT"", NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH. SECTION B: BEAM INTERACTIONS WITH MATERIALS AND ATOMS, ELSEVIER BV, NL, vol. B52, no. 3 / 04, 2 December 1990 (1990-12-02), pages 469-472, XP000178412, ISSN: 0168-583X, DOI: 10.1016/0168-583X(90)90459-8",ACTIVE
296,US,A1,US 2001/0026806 A1,195-709-595-457-448,2001-10-04,2001,US 83835101 A,2001-04-19,US 83835101 A;;US 3560298 A,1998-03-05,Antibacterial phosphoinositides technical field,"
    It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: 

    wherein R ₁ and R ₂ are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C ₆ to C ₂₀ and R ₁ and R ₂ can be the same or different; and R ₃ to R ₇ are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R ₃ to R ₇ being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof. 
",HWANG SHIE-MING;;HUANG YUNG-SHENG;;LIU JIM-WEN;;MUKERJI PRADIP;;ANDERSON STEVEN NEAL;;MEULBROEK JONATHAN A.,HWANG SHIE-MING;;HUANG YUNG-SHENG;;LIU JIM-WEN;;MUKERJI PRADIP;;ANDERSON STEVEN NEAL;;MEULBROEK JONATHAN A,,https://lens.org/195-709-595-457-448,Patent Application,yes,0,0,3,3,0,A23L33/10;;A23L33/10,A23L1/30;;A61K9/22,424/439;;514/103,0,0,,,,EXPIRED
297,WO,A1,WO 2005/062010 A1,191-329-269-440-309,2005-07-07,2005,US 2004/0040686 W,2004-12-02,US 73691303 A,2003-12-15,THERMALLY STABILIZED RADIATION DETECTOR UTILIZING TEMPERATURE CONTROLLED RADIATION FILTER,"A radiation detector (10) has a base (12) and a window (16) that define a vacuum chamber (20). Within the vacuum chamber (20) is a temperature controlled filter (32) and a focal plane array (FPA) (22) defining a gap h therebetween. The filter (32) is heat sunk to a readout integrated circuit (ROIC) (24) and thermoelectric elements (28) to inhibit heat transfer from non-scene sources (38, 40) to the FPA (22). The temperature controlled filter (32) may also incorporate a bandpass filter to reflect all sources of radiation not within the desired wavelength region of interest. The temperature controlled filter (32) is maintained at substantially the same temperature as the FPA (22).",RAYTHEON CO,KENNEDY ADAM M;;SESSLER TODD;;DODDS ROBERT K;;VANLUE DAVID;;SHMOYS DMITRY;;ANDERSON JOHN STEVEN;;ANDREW JIM,,https://lens.org/191-329-269-440-309,Patent Application,yes,2,3,7,7,0,G01J5/20;;G01J5/20;;G01J5/061;;G01J5/061,G01J5/06;;G01J5/20,,0,0,,,,PENDING
298,US,B1,US 9516122 B1,012-773-009-862-636,2016-12-06,2016,US 201414465398 A,2014-08-21,US 201414465398 A;;US 201113173523 A,2011-06-30,Media player social network integration,"A media player user interface on behalf of a user associated with a user account is generated that has a social network module that includes music updates associated with other users to which the user is linked. Media player actions associated with the user occurring in the media player user interface are also captured, updates are generated and provided to social network modules in a media player user interface associated with other linked users.",AMAZON TECH INC,DURHAM BRANDON SCOTT;;PAPE CRAIG;;MEAKER SCOTT K;;ANDERSON ERIN O;;ROBERTS PAUL WILLIAM;;DANTZLER JIM L,AMAZON TECHNOLOGIES INC (2011-07-06),https://lens.org/012-773-009-862-636,Granted Patent,yes,18,0,2,2,0,G06Q30/00;;H04N21/26258;;H04N21/4667;;H04N21/4788;;H04N21/8113;;H04N21/8133;;G06Q50/01;;H04N21/4788;;H04N21/8113;;G06Q30/00;;H04N21/26258;;G06Q50/01;;H04N21/4667;;H04N21/8133;;H04L67/535;;G06F3/0484,G06F3/00;;G06F3/01;;G06F3/0484;;H04L29/08,,2,1,081-145-505-641-838,10.1109/p2p.2010.5569963,"Sehr, Andres. ""Spotify-The Next Generation."" Apr. 27, 2010. pp. 1-2. Retrieved from http://www.spotify.com/us/blog/archives/2010/04/27/the-next-generation/.;;Kreitz, et al. ""Spotify-Large Scale, Low Latency, P2P Music-on-Demand Streaming."" Aug. 27, 2010. 2010 IEEE Tenth International Conference on Peer-to-Peer Computing. pp. 1-10.",ACTIVE
299,US,B1,US 7105821 B1,110-068-316-529-189,2006-09-12,2006,US 73691303 A,2003-12-15,US 73691303 A,2003-12-15,Thermally stabilized radiation detector utilizing temperature controlled radiation filter,"A radiation detector 10 has a base 12 and a window 16 that define a vacuum chamber 20 . Within the vacuum chamber 20 is a temperature controlled filter 32 and a focal plane array (FPA) 22 defining a gap h therebetween. The filter 32 is heat sunk to a readout integrated circuit (ROIC) 24 and thermoelectric elements 28 to inhibit heat transfer from non-scene sources 38, 40 to the FPA 22 . The temperature controlled filter 32 may also incorporate a bandpass filter to reflect all sources of radiation not within the desired wavelength region of interest. The temperature controlled filter 32 is maintained at substantially the same temperature as the FPA 22.",RAYTHEON CO,KENNEDY ADAM M;;SESSLER TODD;;DODDS ROBERT K;;VANLUE DAVID;;SHMOYS DMITRY;;ANDERSON JOHN STEVEN;;ANDREW JIM,RAYTHEON COMPANY (2003-10-30),https://lens.org/110-068-316-529-189,Granted Patent,yes,14,17,7,7,0,G01J5/20;;G01J5/20;;G01J5/061;;G01J5/061,G01J3/50;;G01J5/06;;G01J5/20,250/339.07,2,0,,,"""Infrared System Engineering"", Hudson, Jr., Richard D., JOhn Wiley & Sons, New York, pp. 351-354.;;""Optical system for a wide field of view staring infrared sensor having improved optical symmetry"", Wellman, William H. et al., U.S. Appl. No. 10/423,504, filed Apr. 25, 2003.",ACTIVE
300,US,B1,US 6248372 B1,157-830-944-432-73X,2001-06-19,2001,US 42807699 A,1999-10-27,US 42807699 A;;US 3560398 A,1998-03-05,Bioactive rice flour extract useful for treatment of haemophilus influenzae infections,"The present invention is directed to a rice flour extract (RFE) which can be used in the prophylaxis and treatment of bacterial infections, particularly bacterial infections caused by Haemophilus influenzae and to a method of preparing and using such an antibacterial rice flour extract. The anti-Haemophilus influenzae rice flour extract of the present invention can be prepared from commercial food grade rice flours or non-commercial food grade rice flours.",ABBOTT LAB,MUKERJI PRADIP;;HWANG SHIE-MING;;HUANG YUNG-SHENG;;LIU JIM-WEN;;ANDERSON STEVEN NEAL;;MEULBROEK JONATHAN A,,https://lens.org/157-830-944-432-73X,Granted Patent,yes,3,2,1,1,0,A61K36/899;;A61K36/899,A01N65/00;;A61K36/899,424/750,8,5,010-977-129-818-412;;028-004-960-223-354;;047-450-088-880-966;;074-358-935-527-707;;094-271-871-434-192,10.1042/bj2900145;;8382475;;pmc1132394;;8135730;;pmc1137935;;10.1042/bj2980269;;1567374;;10.1042/bj2830255;;pmc1131022;;2176203;;10.1016/s0021-9258(18)45672-4;;10.1016/s0021-9258(17)45429-9;;2174051,"Martha Windholz, Ssan Budavari, Edis., The Merek Index, 10th Ed., Merck Company, Inc., 6922 (1983).;;Abstract of Japanese Patent 05139983 A, Jun. 08, 1993.;;Brearley, C.A. and Hanke, D.E., ""Pathways of synthesis of 3, 4-and 4, 5-phosphorlated phosphatidylinositols in the duckweed Spirodela polyrhiza L.,"" Biochem. J. (1993) 290, pp. 145-150.;;Munnik , T., Irvine, R. and Musgrave, A., ""Rapid turnover of phosphatidylinositol 3-phosphate in the green alga Chlamydomonas eugametos. signs of a phosphatidylinositide 3-kinase signaling pathway in lower plants?"". Biochem. J. (1994) 298, pp. 269-273.;;Brearley, C.A., and Hanke, D.E., ""3-and 4-phosphorylated phosphatidylinositols in the aquatic plant Spirodela polyrhiza L.,"" Biochem. J. (1992) 283, pp. 255-260.;;Yamamoto, K., Graziani, A., Carpenter, C., Cantley, L.C.., Lapetina, E.G., Medline Abstract, 1990, ""A Novel Pathway for the Formation of Phosphatidylinositol 3, 4-bisphosphate. Phosphorylation of phosphatidylinositol 3-monophosphate by phosphatidylinositol-3-monophosphate 4-kinase,"" J. Biol. Chem., 1990, 265(36), pp. 22086-22089.;;Carpenter, C.L., Duckworth, B.C., Auger, K.R., Cohen, B., Schaffhausen, B.S., Cantley, L.C., MedLine Abstract, 1990, ""Purification and Characterization of Phosphoinositide 3-Kinase from Rat Liver,"" J. Biol. Chem., 1990, 265(32), pp. 19704-19711.;;Food and Nutrition Bulletin, vol. 17, No. 2., Jun. 1996.",EXPIRED
301,US,B2,US 6447797 B2,040-931-699-064-59X,2002-09-10,2002,US 83835101 A,2001-04-19,US 83835101 A;;US 3560298 A,1998-03-05,Antibacterial phosphoinositides,"
    It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: 

    wherein R _{ 1 } and R _{ 2 } are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C _{ 6 } to C _{ 20 } and R _{ 1 } and R _{ 2 } can be the same or different; and R _{ 3 } to R _{ 7 } are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R _{ 3 } to R _{ 7 } being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof. 
",ABBOTT LAB,HWANG SHIE-MING;;HUANG YUNG-SHENG;;LIU JIM-WEN;;MUKERJI PRADIP;;ANDERSON STEVEN NEAL;;MEULBROEK JONATHAN A,,https://lens.org/040-931-699-064-59X,Granted Patent,yes,3,0,3,3,0,A23L33/10;;A23L33/10,A23L1/30;;A61K9/22,424/439;;424/464;;424/468;;424/474;;424/475;;424/479;;424/481;;424/489;;424/490;;424/493;;424/496,0,0,,,,EXPIRED
302,US,B1,US 6258375 B1,038-134-737-703-126,2001-07-10,2001,US 3560298 A,1998-03-05,US 3560298 A,1998-03-05,Antibacterial phosphoinositides,"It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: ##STR1## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C.sub.6 to C.sub.20 and R.sub.1 and R.sub.2 can be the same or different; and R.sub.3 to R.sub.7 are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R.sub.3 to R.sub.7 being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof.",ABBOTT LAB,HWANG SHIE-MING;;HUANG YUNG-SHENG;;LIU JIM-WEN;;MUKERJI PRADIP;;ANDERSON STEVEN NEAL;;MEULBROEK JONATHAN A,ABBOTT LABORATORIES (1998-02-23),https://lens.org/038-134-737-703-126,Granted Patent,yes,3,4,3,3,0,A23L33/10;;A23L33/10,A23L1/30;;A61K9/22,424/439;;424/489;;514/773;;514/777;;514/784;;514/888,8,5,010-977-129-818-412;;028-004-960-223-354;;047-450-088-880-966;;074-358-935-527-707;;094-271-871-434-192,10.1042/bj2900145;;8382475;;pmc1132394;;8135730;;pmc1137935;;10.1042/bj2980269;;1567374;;10.1042/bj2830255;;pmc1131022;;2176203;;10.1016/s0021-9258(18)45672-4;;10.1016/s0021-9258(17)45429-9;;2174051,"Abstract of US Patent No. 5498408 Mar. 1996.;;Abstract of Japanese Patent 05139983 A Jun. 1993.;;Brearley, C.A. and Hanke, D.E., ""Pathways of synthesis of 3,4-and 4,5-phosphorylated phosphatidylinositols in the duckweed Spirodela polyrhiza L.,"" Biochem. J. (1993) 290, pp. 145-150.;;Munnik, T., Irvine, R. and Musgrave, A., ""Rapid turnover of phosphatidylinositol 3-phosphate in the green alga Chlamydomonas eugametos: signs of a phosphatidylinositide 3-kinase signalling pathway in lower plants?"", Biochem. J. (1994) 298, pp. 269-273.;;Brearley, C.A., and Hanke, D.E., ""3-and 4-phosphorylated phosphatidylinositols in the aquatic plant Spirodela polyrhize L.,"" Biochem. J. (1992) 283, pp. 255-260.;;Yamamoto, K., Graziani, A. Carpenter, C., Cantley, L.C., Lapetina, E.G., MedLine Abstract, 1990, ""A Novel Pathway for the Formation of Phosphatidylinositol 3,4-bisphosphate. Phosphorylation of phosphatidylinositol 3-monophosphate by phosphatidylinositol-3-monophosphate 4-kinase,"" J. Biol. Chem., 1990, 265(36), pp. 22086-22089.;;Carpenter, C.L., Duckworth, B.C., Auger, K.R., Cohen, B., Schaffhausen, B.S., Cantley, L.C., MedLine Abstract, 1990, ""Purification and Characterization of Phosphoinositide 3-Kinase from Rat Liver,"" J. Biol. Chem., 1990, 265(32), pp. 19704-19711.;;Food and Nutrition Bulletin, vol. 17, No. 2., Jun., 1996.",EXPIRED
303,EP,A1,EP 1709406 A1,074-881-884-326-759,2006-10-11,2006,EP 04817960 A,2004-12-02,US 2004/0040686 W;;US 73691303 A,2003-12-15,THERMALLY STABILIZED RADIATION DETECTOR UTILIZING TEMPERATURE CONTROLLED RADIATION FILTER,,RAYTHEON CO,KENNEDY ADAM M;;SESSLER TODD;;DODDS ROBERT K;;VANLUE DAVID;;SHMOYS DMITRY;;ANDERSON JOHN STEVEN;;ANDREW JIM,,https://lens.org/074-881-884-326-759,Patent Application,yes,0,0,7,7,0,G01J5/20;;G01J5/20;;G01J5/061;;G01J5/061,G01J5/06;;G01J5/20,,1,0,,,See references of WO 2005062010A1,ACTIVE
304,EP,B1,EP 1709406 B1,011-834-495-796-952,2019-01-23,2019,EP 04817960 A,2004-12-02,US 2004/0040686 W;;US 73691303 A,2003-12-15,THERMALLY STABILIZED RADIATION DETECTOR UTILIZING TEMPERATURE CONTROLLED RADIATION FILTER,,RAYTHEON CO,KENNEDY ADAM M;;SESSLER TODD;;DODDS ROBERT K;;VANLUE DAVID;;SHMOYS DMITRY;;ANDERSON JOHN STEVEN;;ANDREW JIM,,https://lens.org/011-834-495-796-952,Granted Patent,yes,1,1,7,7,0,G01J5/20;;G01J5/20;;G01J5/061;;G01J5/061,G01J5/06;;G01J5/20,,0,0,,,,ACTIVE
305,SE,D0,SE 9601390 D0,059-189-177-525-869,1996-04-12,1996,SE 9601390 A,1996-04-12,SE 9601390 A,1996-04-12,Förbränningsanläggning och förfarande för förbränning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSSON HANS;;ANDERSON JIM;;ANDERSSON KARL-ERIK;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;SKEPPE HAAKAN;;WEATHERBY JOHN,,https://lens.org/059-189-177-525-869,Patent Application,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,PENDING
306,US,B1,US 9195770 B1,076-939-449-862-532,2015-11-24,2015,US 201414258309 A,2014-04-22,US 201414258309 A;;US 92175904 A;;US 46191703 A;;US 3339201 A;;US 75636501 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,System and method for identifying content using content templates for distribution to internet users,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/076-939-449-862-532,Granted Patent,yes,28,0,4,4,0,G06Q10/10;;G06F16/958;;G06F16/954;;G06F16/955;;G06F16/986;;G06F16/954;;G06F16/955;;G06F16/986;;G06Q10/10;;G06F16/958,G06F13/00;;G06F17/30;;G06Q10/10,,18,0,,,"Bernes-Lee, T., ""Hypertext Transfer Protocol-HTTP/1.0""; University of California, Irvine; http://www.ics.uci.edu/pub/ietf/http/rfc1945.html; May 1996.;;Burke, J., ""Web Databases with Cold Fusion 3"", McGraww-Hill, 1997.;;Dallas, A., ""Using Collabra Share 2"", Que, 1995.;;Graves, S., ""FrontPage 97 Web Sites"", The Coriolis Group, Inc., 1997.;;""HTML"", w3, http://www.w3.org/History/19921103...t/.hypertext/WWW/MarkUp/MarkUp.html.-undated.;;""HTML Quick Reference"", The University of Kansas, http://www.cc.ukans.edu/~acs/docs/other/HTML-quick.shtml.-undated.;;""HTML Reference Manual"", Sandia National Laboratories, http://www.sandia.gov/sci-compute/html-ref.html; Jan. 2, 1996.;;Miller, K., et al., ""Inside Microsoft Visual InterDev"", Microsoft Press, 1997.;;Kurnit's Startup: Mining for Ad Deals and Intrigue, by Robert Silverman, dated Feb. 12-25, 1997.;;About.com-Our Story: http://ourstory.com/index.htm?COB=home&PID, 1999.;;LookSmart's Beseen: http://www.beseen.com, 1999.;;Yahoo! GeoCities-Yosemite; http://www.geocities.com/Yosemite, 1994-99.;;GeoCities-Pages That Pay-About PTP; http://geocities.yahoo.com/pagesthatpay/ptp-overview.htm, 1994-99.;;Document Count Them In; http://proquest.umi.com/pqdweb?TS=...&Sid=3&Idx=28&Deli=1&RQT=309&D-undated.;;A Beginner's Guide to HTML, NCSA, ncsa.uiuc.edu, revised Apr. 1996, edits: Jul. 1996; Sep. 1996; Jan. 1997.;;Shelton, D., Yahoo goes local with Bay Area Guide, Jun. 24, 1996, CNET.com-News-Entertainment & Media; http://news.cnet.com/news/0-1005-200-311623.html.;;Yahoo Scores Big-Name Financing, Nov. 29, 1995, CNET.com-News-Communications-YahooScores Big-Name Financing, http://news.cnet.com/news/0-1004-200-310097.html?tag=.;;Aguilar, R., Yahoo loves New York, Sep. 8, 1996, CNET.com-News-Enterprise Computing-Yahoo loves New York, http://aolcom.cnet.com/news/0-1003-200-312489.html.",EXPIRED
307,SE,L,SE 9601390 L,152-058-668-077-977,1997-10-13,1997,SE 9601390 A,1996-04-12,SE 9601390 A,1996-04-12,Förbränningsanläggning och förfarande för förbränning,,ABB CARBON AB,ADAMS CHRISTOPHER;;ANDERSSON HANS;;ANDERSON JIM;;ANDERSSON KARL-ERIK;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;SKEPPE HAAKAN;;WEATHERBY JOHN,,https://lens.org/152-058-668-077-977,Abstract,no,0,0,6,6,0,F23C10/10;;F23C10/16,F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,PENDING
308,CA,A1,CA 2306331 A1,025-600-829-089-649,1998-08-27,1998,CA 2306331 A,1998-02-06,CA 2268571 A;;US 3785297 P,1997-02-07,COLLABORATIVE INTERNET DATA MINING SYSTEM,"A collaborative Internet data training system which automatically processes information provided by a plurality of guides to create web sites and thereby provide a branded or uniform look and feel to the web sites. The apparatus for collaborative mass production of a web publication comprises a server computer; a storage device storing global data files; and a collaborative web page generator for combining global data files with an HTML template file to create completed web pages wherein the HTML global data interacts with the template to form a combined response. The method for collaborative processing comprises the steps of providing web site construction information at the server level; building into pages instructions to look for missing web site construction information at the server level; and constructing web sites without the need to edit code at all the web sites. The method also includes a quality control process that checks a site for dead links that no longer reference active web pages, and checks when a site was last updated to assure that the guide responsible for the site is actively participating in the network.",GEN INTERNET INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;ANDERSON JIM;;KURNIT SCOTT PHILIP;;TALLER OLGA;;DAY WILLIAM,,https://lens.org/025-600-829-089-649,Patent Application,no,0,0,1,19,0,,H04L12/16,,0,0,,,,DISCONTINUED
309,US,A1,US 2002/0062343 A1,109-227-207-223-260,2002-05-23,2002,US 3339201 A,2001-12-28,US 3339201 A;;US 75636501 A;;US 3785297 P,1997-02-07,Collaborative internet data mining system,"
   A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides. 
",APPLEMAN KENNETH H.;;MAIER ELIZABETH A.;;GERMAISE SCOTT C.;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/109-227-207-223-260,Patent Application,yes,0,27,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,709/203;;709/218,0,0,,,,DISCONTINUED
310,US,B2,US 6336132 B2,055-798-837-109-552,2002-01-01,2002,US 75636501 A,2001-01-09,US 75636501 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,Internet resource location system with identified and approved human guides assigned to specific topics to provide content related to the topic,"
    A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides. 
",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/055-798-837-109-552,Granted Patent,yes,27,157,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,709/203,18,0,,,"Bernes-Lee, T., ""Hypertext Transfer Protocol-HTTP/1.0""; University of California, Irvine; http://www.ics.uci.edu/pub/ietf/http/rfc1945.html; May 1996.;;Burke, J., ""Web Databases with Cold Fusion 3""; McGraw-Hill, 1997.;;Dallas, A., ""Using Collabra Share 2,"" Que, 1995.;;Graves, S., ""FrontPage 97 Web Sites,"" The Coriolis Group, Inc., 1997.;;""HTML,"" w3, http://www.w3.org/History/19921103 . . . t/.hypertext/WWW/MarkUp/MarkUp.html.;;""HTML Quick Reference,"" The University of Kansas, http://www.cc.ukans.edu/~acs/docs/other/HTML_quick/shtml.;;""HTML Reference Manual,"" Sandia National Laboratories, http://www.sandia.gov/sci_compute/html_ref.html; Jan. 2, 1996.;;Miller, K., et al., ""Inside Microsoft Visual InterDev,"" Microsoft Press, 1997.;;Kurnit's Startup: Mining for Ad Deals and Intrigue, by Robert Silverman, dated Feb. 12-25, 1997.;;About.com-Our Story: http://ourstory.com/index.htm?COB=home&PID, 1999.;;LookSmart's Beseen: http://www.beseen.com, 1999.;;Yahoo!GeoCities-Yosemite; http://www.geocites.com/Yosemite, 1994-99.;;GeoCities-Pages That Pay-About PTP; http://geocities.yahoo.com/pagesthatpay/ptp_overview.htm, 1994-99.;;Document Count Them In; http://proquest.umi.com/pqdweb?TS= . . . &Sid=3&Idx=28&Deli=1&RQT=309&D.;;A Beginner's Guide to HTML, NCSA, ncsa.uiuc.edu, revised Apr. 1996, edits: 7/96; 9/96; 1/97.;;Shelton, D., Yahoo goes local with Bay Area guide, Jun. 24, 1996, CNET.com-News-Entertainment & Media; http://news.cnet.com/news/0-1005-200-311623.html.;;Yahoo Scores Big-Name Financing, Nov. 29, 1995, CNET.com-News-Communications-YahooScores Big-Name Financing, http://news.cnet.com/news/0-1004-200-310097.html?tag=.;;Aguilar, R., Yahoo loves New York, Sep. 8, 1996, CNET.com-News-Enterprise Computing-Yahoo loves New York, http://aolcom.cnet.com/news/0-1003-200-312489.html.",EXPIRED
311,US,A,US 6081788 A,178-924-933-116-79X,2000-06-27,2000,US 18555298 A,1998-11-04,US 18555298 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,Collaborative internet data mining system,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/178-924-933-116-79X,Granted Patent,yes,14,171,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,705/14;;395/200.33;;370/429;;705/27,9,1,041-858-749-543-336,10.17487/rfc1945,"About.com Our story: http://ourstory.com/index.htm COB home&PID, 1999.;;LookSmart s Beseen; http://www.beseen.com, 1999.;;Yahoo GeoCities Yosemite; http://www.geocities.com/Yosemite, 1994 1999.;;GeoCities Pages That Pay About PTP; http://geocities.yahoo.com/pagesthatpay/ptp overview.htm, 1994 1999.;;Document Count them in ; http://proquest.umi.com/pqdweb TS . . . &Sid 3&Idx 28&Deli 1&RQT 309&D, Feb. 03, 1997.;;Berners Lee, T., et al.; Hypertext Transfer Protocol HTTP/1.0; University of California, Irvine ; http://www.ics.uci.edu/pub/ietf/http/rfc 1945.html; May 1996.;;HTML; w3, http://www.w3.org/History/19921103 . . . t/hypertext/WWW/MarkUp/MarkUp.html.;;HTML Quick Reference; The University of Kansas ; http://www.cc.ukans.edu/ acs/docs/other/HTML quick.shtml.;;HTML Reference Manual; Sandia National Laboratories , http://www.sandia.gov/sci compute/html ref.html; Jan. 2, 1996.",EXPIRED
312,CA,C,CA 2268571 C,186-931-441-124-932,2010-04-06,2010,CA 2268571 A,1998-02-06,US 3785297 P;;US 9802087 W,1997-02-07,COLLABORATIVE INTERNET DATA MINING SYSTEM,"A collaborative Internet data mining system which automatically processes information provided by a plurality of guides to create web sites and thereby provide a branded or uniform look and feel to the web sites. The apparatus for collaborative mass production of a web publication comprises a server computer; a storage device storing global data files; and a collaborative web page generator for combining global data files with an HTML template file to create completed web pages wherein the HTML global data interacts with the template to form a combined response. The method for collaborative processing comprises the steps of providing web site construction information at the server level; building into pages instructions to look for missing web site construction information at the server level; and constructing web sites without the need to edit code at all the web sites. The method also includes a quality control process that checks a site for dead links that no longer reference active web pages, and checks when a site was last updated to assure that the guide responsible for the site is actively participating in the network.",GEN INTERNET INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,,https://lens.org/186-931-441-124-932,Granted Patent,no,0,0,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06F3/14;;G06F9/44;;G06Q10/00;;G06Q10/10;;G06Q30/02,,0,0,,,,EXPIRED
313,CA,A1,CA 2692298 A1,079-562-322-033-624,1998-08-27,1998,CA 2692298 A,1998-02-06,US 3785297 P;;CA 2268571 A,1997-02-07,COLLABORATIVE INTERNET DATA MINING SYSTEM,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,,https://lens.org/079-562-322-033-624,Patent Application,no,0,0,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02;;H04L12/16;;H04L12/26,,0,0,,,,EXPIRED
314,US,B1,US 6195681 B1,096-934-321-071-259,2001-02-27,2001,US 12984398 A,1998-08-06,US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,Guide-based internet directory system and method,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/096-934-321-071-259,Granted Patent,yes,7,80,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,709/203,9,1,041-858-749-543-336,10.17487/rfc1945,"Kurnit's Startup: Mining for Ad Deals and Intrigue, by Robert Silverman, dated Feb. 12-25, 1997.;;Berners-Lee, T., et al.; ""Hypertext Transfer Protocol-HTTP/1.0;"" University of California, Irvine; http;//www.ics.uci.edu/pub/ietf/http/rfc1945.html; May 1996.;;Burke, J.; ""Web Databases with Cold Fusion 3;"" McGraw-Hill; 1997.;;Dallas, A.; ""Using Collabra Share 2;"" McGraw-Hill; 1997.;;Graves, S.; ""FrontPage 97 Web Sites,"" The Coriolis Group, Inc.; 1997.;;""HTML;"" w3, http://www.w3.org/History/19921103 . . . t/hypertext/WWW/MarkUp/MarkUp.html. undated.;;""HTML Quick Reference;"" The University of Kansas; http://www.cc.ukans.edu/~acs/docs/other/HTML-quick,shtml, undated.;;""HTML Reference Manual;"" Sandia National Laboratories, http://www.sandia.gov/sci-compute/html-ref.html; Jan 2, 1996.;;Miller, K., et al., ""Inside Microsoft Visual InterDev;"" Microsoft Press; 1997.",EXPIRED
315,US,A1,US 2003/0208535 A1,116-096-762-868-363,2003-11-06,2003,US 46191703 A,2003-06-12,US 46191703 A;;US 3339201 A,2001-12-28,Collaborative internet data mining system,"
   A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides. 
",APPLEMAN KENNETH H.;;MAIER ELIZABETH A.;;GERMAISE SCOTT C.;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/116-096-762-868-363,Patent Application,yes,9,28,4,4,0,G06Q10/10;;G06F16/958;;G06F16/954;;G06F16/955;;G06F16/986;;G06F16/954;;G06F16/955;;G06F16/986;;G06Q10/10;;G06F16/958,G06F17/30;;G06Q10/10,709/203;;709/218,0,0,,,,DISCONTINUED
316,WO,A2,WO 2008/144375 A2,121-626-803-082-938,2008-11-27,2008,US 2008/0063675 W,2008-05-15,US 93803407 P,2007-05-15,METHODS AND SYSTEMS FOR MANAGING FACILITY POWER AND COOLING,"Systems and methods are provided for determining data center resource requirements, such as cooling and power requirements, and for monitoring performance of data center resource systems, such as cooling and power systems, in data centers. At least one aspect provides a system and method that enables a data center operator to determine available data center resources, such as power and cooling, at specific areas and enclosures in a data center to assist in locating new equipment in the data center.",AMERICAN POWER CONV CORP;;ANDERSON MIKKEL;;DALGAS MIKKEL;;HAMMOND BRAD T;;IVES TED;;GIAQUINTO TODD J;;MORGAN JANE;;RASMUSSEN NEIL;;VANGILDER JIM,ANDERSON MIKKEL;;DALGAS MIKKEL;;HAMMOND BRAD T;;IVES TED;;GIAQUINTO TODD J;;MORGAN JANE;;RASMUSSEN NEIL;;VANGILDER JIM,,https://lens.org/121-626-803-082-938,Patent Application,yes,0,30,21,38,0,G06Q10/06;;G06Q10/06313;;H05K7/20836;;H01H21/24;;Y02P90/82;;H05K7/2079;;G06Q10/06;;G06Q10/06313;;H05K7/20836;;H01H21/24;;H05K7/2079,H05K7/20,,0,0,,,,PENDING
317,WO,A3,WO 2008/144375 A3,020-279-205-595-754,2009-04-09,2009,US 2008/0063675 W,2008-05-15,US 93803407 P,2007-05-15,METHODS AND SYSTEMS FOR MANAGING FACILITY POWER AND COOLING,"Systems and methods are provided for determining data center resource requirements, such as cooling and power requirements, and for monitoring performance of data center resource systems, such as cooling and power systems, in data centers. At least one aspect provides a system and method that enables a data center operator to determine available data center resources, such as power and cooling, at specific areas and enclosures in a data center to assist in locating new equipment in the data center.",AMERICAN POWER CONV CORP;;ANDERSON MIKKEL;;DALGAS MIKKEL;;HAMMOND BRAD T;;IVES TED;;GIAQUINTO TODD J;;MORGAN JANE;;RASMUSSEN NEIL;;VANGILDER JIM,ANDERSON MIKKEL;;DALGAS MIKKEL;;HAMMOND BRAD T;;IVES TED;;GIAQUINTO TODD J;;MORGAN JANE;;RASMUSSEN NEIL;;VANGILDER JIM,,https://lens.org/020-279-205-595-754,Search Report,yes,3,0,21,38,0,G06Q10/06;;G06Q10/06313;;H05K7/20836;;H01H21/24;;Y02P90/82;;H05K7/2079;;G06Q10/06;;G06Q10/06313;;H05K7/20836;;H01H21/24;;H05K7/2079,H05K7/20;;G06F17/50;;G06Q10/00,,0,0,,,,PENDING
318,CA,C,CA 2692298 C,045-959-137-794-458,2014-10-28,2014,CA 2692298 A,1998-02-06,US 3785297 P;;CA 2268571 A,1997-02-07,COLLABORATIVE INTERNET DATA MINING SYSTEM,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,,https://lens.org/045-959-137-794-458,Granted Patent,no,0,0,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06Q30/02;;G06F17/30;;G06Q10/00;;G06Q10/10;;H04L12/16;;H04L12/26,,0,0,,,,EXPIRED
319,US,A1,US 2005/0198116 A1,075-219-221-426-169,2005-09-08,2005,US 92175904 A,2004-08-19,US 92175904 A;;US 46191703 A;;US 3339201 A;;US 75636501 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,Collaborative internet data mining system,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT P,ABOUT INC (2002-01-31),https://lens.org/075-219-221-426-169,Patent Application,yes,27,42,4,4,0,G06Q10/10;;G06F16/958;;G06F16/954;;G06F16/955;;G06F16/986;;G06F16/954;;G06F16/955;;G06F16/986;;G06Q10/10;;G06F16/958,G06F17/30;;G06Q10/10,709/203;;709/218,0,0,,,,EXPIRED
320,WO,A1,WO 1997/039278 A1,133-703-602-053-26X,1997-10-23,1997,SE 9700595 W,1997-04-10,SE 9601390 A,1996-04-12,A METHOD AND A COMBUSTION PLANT FOR PRESSURIZED FLUIDISED BED COMBUSTION WITH RECIRCULATION OF SOLID MATERIAL,"A combustion plant comprises a combustion chamber (1) which is provided to enclose a pressurized, fluidized bed (4). Furthermore, the plant comprises a purification device (9, 10, 11) for purifying the combustion gases. The purification device comprises a separating member (9) and a device for recirculating the separated particulate material to the combustion chamber (1). The recirculation device comprises a channel (23) connecting the separating member and combustion chamber, and passive means (25) configured in such a manner that during the operation of the combustion plant a column of material is formed in the channel (23). The passive means forms a passage having a constant flow area in a lower part of the channel (23) and permits that the weight of the column (24) of material in a continuous flow discharges the material therethrough. The invention also relates to a method of operating the combustion plant.",ABB CARBON AB;;ADAMS CHRISTOPHER;;ANDERSSON HANS;;ANDERSON JIM;;ANDERSSON KARL ERIK;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;SKEPPE HAAKAN;;WEATHERBY JOHN,ADAMS CHRISTOPHER;;ANDERSSON HANS;;ANDERSON JIM;;ANDERSSON KARL-ERIK;;ANDERSSON MATS C;;BRAENNSTROEM ROINE;;SKEPPE HAAKAN;;WEATHERBY JOHN,,https://lens.org/133-703-602-053-26X,Patent Application,yes,7,0,6,6,0,F23C10/10;;F23C10/16,F23C10/02;;F23C10/10;;F23C10/16,,0,0,,,,PENDING
321,US,B2,US 8719333 B2,176-743-502-320-793,2014-05-06,2014,US 92175904 A,2004-08-19,US 92175904 A;;US 46191703 A;;US 3339201 A;;US 75636501 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,System and method for collecting content using templates for distribution to internet users,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP;;ABOUT INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/176-743-502-320-793,Granted Patent,yes,28,0,4,4,0,G06Q10/10;;G06F16/958;;G06F16/954;;G06F16/955;;G06F16/986;;G06F16/954;;G06F16/955;;G06F16/986;;G06Q10/10;;G06F16/958,G06F17/30;;G06F13/00;;G06Q10/10,709/203,18,0,,,"Bemes-Lee, T., ""Hypertext Transfer Protocol-HTTP/1.0""; University of California, Irvine; http://www.ics.uci.edu/pub/ietf/http/rfc1945.html; May 1996.;;Burke, J., ""Web Databases with Cold Fusion 3"", McGraww-Hill, 1997.;;Dallas, A., ""Using Collabra Share 2"", Que, 1995.;;Graves, S., ""FrontPage 97 Web Sites"", The Coriolis Group, Inc., 1997.;;""HTML"", w3, http://www.w3.org/History/19921103...t/hypertext/WWW/MarkUp/MarkUp.html.;;""HTML Quick Reference"", The University of Kansas, http://www.cc.ukans.edu/~acs/docs/other/HTML-quick.shtml.;;""HTML Reference Manual"", Sandia National Laboratories, http://www.sandia.gov/sci-compute/html-ref.html; Jan. 2, 1996.;;Miller, K., et al., ""Inside Microsoft Visual InterDev"", Microsoft Press, 1997.;;Kurnit's Startup: Mining for Ad Deals and Intrigue, by Robert Silverman, dated Feb. 12-25, 1997.;;About.com-Our Story: http://ourstory.com/index.htm?COB.home&PID, 1999.;;LookSmart's Beseen: http://www.beseen.com, 1999.;;Yahoo! GeoCities-Yosemite; http://www.geocities.com/Yosemite, 1994-99.;;GeoCities-Pages That Pay-About PTP; http://geocities.yahoo.com/pagesthatpay/ptp-overview.htm, 1994-99.;;Document Count Them In; http://proquest.umi.com/pqdweb?TS=...& Sid=3&Idx=28&Deli=1&RQT=309&D.;;A Beginner's Guide to HTML, NCSA, ncsa.uiuc.edu, revised Apr. 1996, edits: Jul. 1996; Sep. 1996; Jan. 1997.;;Shelton, D., Yahoo goes local with Bay Area Guide, Jun. 24, 1996, CNET.com-News-Entertainment & Media; http://news.cnet.com/news/0-1005-200-311623.html.;;Yahoo Scores Big-Name Financing, Nov. 29, 1995, CNET.com-News-Communications-YahooScores Big-Name Financing, http://news.cnet.com/news/0-1004-200-310097.html?tag=.;;Aguilar, R., Yahoo loves New York, Sep. 8, 1996, CNET.com-News-Enterprise Computing-Yahoo loves New York, http://aolcom.cnet.com/news/0-1003-200-312489.html.",EXPIRED
322,US,A1,US 2001/0009013 A1,090-277-425-408-009,2001-07-19,2001,US 75636501 A,2001-01-09,US 75636501 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,Internet resource location system with identified and approved human guides assigned to specific topics to provide content related to the topic,"
   A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides. 
",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/090-277-425-408-009,Patent Application,yes,0,24,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,709/203;;707/513,0,0,,,,EXPIRED
323,US,B1,US 6226648 B1,092-041-940-591-305,2001-05-01,2001,US 18562498 A,1998-11-04,US 18562498 A;;US 12984398 A;;US 1992498 A;;US 3785297 P,1997-02-07,System and method for modification of included files used in a automatic web page generation system,"A collaborative Internet data mining system for facilitating a group effort from a plurality of guides to the Internet, by automatically processing the information provided by the guides and thereby create a branded or uniform look and feel to the web sites supported by the plurality of guides.",ABOUT COM INC,APPLEMAN KENNETH H;;MAIER ELIZABETH A;;GERMAISE SCOTT C;;DAY WILLIAM;;ANDERSON JIM;;TALLER OLGA;;KURNIT SCOTT PHILIP,ABOUT INC (2002-01-31),https://lens.org/092-041-940-591-305,Granted Patent,yes,10,138,18,19,0,G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;G06F16/954;;G06Q10/10;;G06Q30/0247;;G06Q30/0272;;G06Q30/0277;;Y10S707/99943;;G06F16/954,G06F17/30;;G06Q10/00;;G06Q10/10;;G06Q30/02,707/102;;707/513;;707/517,8,1,041-858-749-543-336,10.17487/rfc1945,"Berners-Lee, T., et al.; ""Hypertext Transfer Protocol-HTTP/1.0;"" University of California, Irvine; http://www.ics.uci.edu/pub/ietf/http/rfc1945.html; May 1996.;;Burke, J.; ""Web Databases with Cold Fusion 3;"" McGraw-Hill; 1997.;;Dallas, A.; ""Using Collabra Share 2;"" Que; 1995.;;Graves, S.; ""FrontPage 97 Web Sites;"" The Coriolis Group, Inc.; 1997.;;""HTML;"" w3, http://www.w3.org/History/19921103 . . . t/hypertext/WWW/MarkUp/MarkUp.html.;;""HTML Quick Reference;"" The University of Kansas; http://www.cc.ukans.edu/~acs/docs/other/HTML_quick.shtml.;;""HTML Reference Manual;"" Sandia National Laboratories, http://www.sandia.gov/sci_compute/html_ref.html: Jan. 2, 1996.;;Miller, K., et al.; ""Inside Microsoft Visual InterDev;"" Microsoft Press; 1997.",EXPIRED
324,US,A1,US 2003/0181926 A1,072-453-265-313-998,2003-09-25,2003,US 32473002 A,2002-12-19,US 32473002 A;;US 481701 A;;US 2768101 A,2001-12-07,Suture trimmer,"
   A suture trimmer having a shaft with a groove formed in the side thereof, a cutting member movably disposed within the shaft, and a suture retainer slidably disposed within the shaft. The suture trimmer may be used to position knots formed within a suture loop prior to trimming the free end(s) of the suture loop, and to deliver an agent near the location where the suture is severed. 
",DANA MICHAEL;;GROSS T. DANIEL;;MARTHALER MAURICE;;MA DAWN;;ANDERSON STEVEN C.;;TERWILLIGER MARC;;SWETT JIM;;FRIEDMAN MITCHELL B.,DANA MICHAEL;;GROSS T DANIEL;;MARTHALER MAURICE;;MA DAWN;;ANDERSON STEVEN C;;TERWILLIGER MARC;;SWETT JIM;;FRIEDMAN MITCHELL B,ABBOTT LABORATORIES (2003-05-23),https://lens.org/072-453-265-313-998,Patent Application,yes,36,132,7,38,0,A61B17/0467;;A61B17/0485;;A61B17/0467;;A61B17/0485,A61B17/04,606/148,0,0,,,,EXPIRED
325,US,B2,US 7918867 B2,125-807-057-664-933,2011-04-05,2011,US 32473002 A,2002-12-19,US 32473002 A;;US 481701 A;;US 2768101 A,2001-12-07,Suture trimmer,"A suture trimmer having a shaft with a groove formed in the side thereof, a cutting member movably disposed within the shaft, and a suture retainer slidably disposed within the shaft. The suture trimmer may be used to position knots formed within a suture loop prior to trimming the free end(s) of the suture loop, and to deliver an agent near the location where the suture is severed.",ABBOTT LAB,DANA MICHAEL;;GROSS T DANIEL;;MARTHALER MAURICE;;MA DAWN;;ANDERSON STEVEN C;;TERWILLIGER MARC;;SWETT JIM;;FRIEDMAN MITCHELL B,ABBOTT LABORATORIES (2003-05-23),https://lens.org/125-807-057-664-933,Granted Patent,yes,77,1109,7,38,0,A61B17/0467;;A61B17/0485;;A61B17/0467;;A61B17/0485,A61B17/04;;A61B17/12,606/144;;606/139;;606/145;;606/148,28,0,,,"PCT/US02/39151 International Search Report.;;Patent No. 6,746,457, Office Action, mailed Dec. 18, 2002.;;Patent No. 6,746,457, Notice of Allowance, mailed Jul. 28, 2003.;;Patent No. 6,746,457, Notice of Allowance, mailed Feb. 4, 2004.;;Patent No. 6,746,457, Issue Notification, mailed May 20, 2004.;;Patent No. 7,094,246, Office Action, mailed Aug. 31, 2005.;;Patent No. 7,094,246, Notice of Allowance, mailed Feb. 23, 2006.;;Patent No. 7,094,246, Issue Notification, mailed Aug. 2, 2006.;;Patent No. 7,147,646, Office Action, mailed May 17, 2006.;;Patent No. 7,147,646, Notice of Allowance, mailed Oct. 2, 2006.;;Patent No. 7,147,646, Issue Notification, mailed Nov. 22, 2006.;;Patent No. 2003/0120287, Office Action, mailed Jun. 2, 2003.;;Patent No. 2003/0120287, Office Action, mailed Dec. 8, 2003.;;Patent No. 2003/0120287, Office Action, mailed May 28, 2004.;;Patent No. 2003/0120287, Office Action, mailed Oct. 23, 2006.;;Patent No. 2003/0120287, Office Action, mailed Apr. 17, 2007.;;U.S. Appl. No. 10/027,681, mailed May 27, 2008, Office Action.;;U.S. Appl. No. 10/027,681, mailed Dec. 23, 2008, Office Action.;;U.S. Appl. No. 10/027,681, mailed Jul. 8, 2009, Office Action.;;U.S. Appl. No. 11/461,243, mailed Apr. 29, 2009, Office Action.;;U.S. Appl. No. 11/461,243, mailed Oct. 21, 2009, Office Action.;;U.S. Appl. No. 11/465,035, mailed Nov. 28, 2008, Office Action.;;U.S. Appl. No. 10/027,681, mailed Feb. 17, 2010, Office Action.;;U.S. Appl. No. 11/465,035, mailed Mar. 4, 2010, Office Action.;;U.S. Appl. No. 11/461,243, mailed Mar. 15, 2010, Office Action.;;U.S. Appl. No. 11/461,243, mailed Jul. 28, 2010, Notice of Allowance.;;U.S. Appl. No. 11/465,035, mailed Jun. 22, 2010, Office Action.;;U.S. Appl. No. 10/027,681, mailed Aug. 16, 2010, Office Action.",INACTIVE
326,US,B2,US 7992571 B2,043-610-541-921-952,2011-08-09,2011,US 46503506 A,2006-08-16,US 46503506 A;;US 32473002 A;;US 2768101 A;;US 481701 A,2001-12-07,Suture trimmer,"A suture trimmer having a shaft with a groove formed in the side thereof, a cutting member movably disposed within the shaft, and a suture retainer slidably disposed within the shaft. The suture trimmer may be used to position knots formed within a suture loop prior to trimming the free end(s) of the suture loop, and to deliver an agent near the location where the suture is severed.",ABBOTT LAB,GROSS T DANIEL;;MARTHALER MAURICE;;DANA MICHAEL;;MA DAWN;;ANDERSON STEVEN C;;TERWILLIGER MARC;;SWETT JIM;;FRIEDMAN MITCHELL B,,https://lens.org/043-610-541-921-952,Granted Patent,yes,76,20,7,38,0,A61B17/0467;;A61B17/0485;;A61B17/0467;;A61B17/0485,A61B19/00;;A61B17/04,128/898;;606/148;;289/17,37,0,,,"U.S. Appl. No. 10/027,681, Mail Date Jul. 8, 2009, Office Action.;;U.S. Appl. No. 10/027,681, Mail Date Feb. 17, 2010, Office Action.;;U.S. Appl. No. 10/324,730, Mail Date Oct. 30, 2009, Notice of Allowance.;;U.S. Appl. No. 10/324,730, Mail Date Mar. 23, 2010, Notice of Allowance.;;U.S. Appl. No. 11/461,243, Mail Date Apr. 29, 2009, Office Action.;;U.S. Appl. No. 11/461,243, Mail Date Oct. 21, 2009, Office Action.;;PCT/US02/39151 International Search Report.;;6,746,457, Office Action, Mail Date Dec. 18, 2002.;;6,746,457, Notice of Allowance, Mail Date Jul. 28, 2003.;;6,746,457, Notice of Allowance, Mail Date Feb. 4, 2004.;;6,746,457, Issue Notification, Mail Date May 20, 2004.;;7,094,246, Office Action, Mail Date Aug. 31, 2005.;;7,094,246, Notice of Allowance, Mail Date Feb. 23, 2006.;;7,094,246, Issue Notification, Mail Date Aug. 2, 2006.;;7,147,646, Office Action, Mail Date May 17, 2006.;;7,147,646, Notice of Allowance, Mail Date Oct. 2, 2006.;;7,147,646, Issue Notification, Mail Date Nov. 22, 2006.;;2003/0120287, Office Action, Mail Date Jun. 2, 2003.;;2003/0120287, Office Action, Mail Date Dec. 8, 2003.;;2003/0120287, Office Action, Mail Date May 28, 2004.;;2003/0120287, Office Action, Mail Date Oct. 23, 2006.;;2003/0120287, Office Action, Mail Date Apr. 17, 2007.;;2003/0181926, Office Action, Mail Date Mar. 27, 2006.;;2003/0181926, Office Action, Mail Date Aug. 8, 2006.;;2003/0181926, Office Action, Mail Date Jan. 29, 2007.;;2003/0181926, Notice of Allowance, Mail Date Aug. 30, 2007.;;U.S. Appl. No. 10/027,681, Mail Date May 27, 2008, Office Action.;;U.S. Appl. No. 10/027,681, Mail Date Dec. 23, 2008, Office Action.;;U.S. Appl. No. 10/324,730, Mail Date Aug. 19, 2008, Office Action.;;U.S. Appl. No. 12/914,658, filed Oct. 28, 2010, Dana, et al.;;U.S. Appl. No. 10/324,730, Mail Date Sep. 22, 2010, Notice of Allowance.;;U.S. Appl. No. 10/027,681, Mail Date Jan. 19, 2011, Office Action.;;U.S. Appl. No. 10/324,730, Mail Date Mar. 16, 2011, Issue Notification.;;U.S. Appl. No. 11/461,243, Mail Date Nov. 10, 2010, Issue Notification.;;U.S. Appl. No. 10/027,681, Mail Date Aug. 16, 2010, Office Action.;;U.S. Appl. No. 11/461,243, Mail Date Mar. 15, 2010, Office Action.;;U.S. Appl. No. 11/461,243, Mail Date Jul. 28, 2010, Notice of Allowance.",EXPIRED
327,US,A1,US 2006/0293700 A1,196-755-908-754-093,2006-12-28,2006,US 46503506 A,2006-08-16,US 46503506 A;;US 32473002 A;;US 2768101 A;;US 481701 A,2001-12-07,Suture Trimmer,"A suture trimmer having a shaft with a groove formed in the side thereof, a cutting member movably disposed within the shaft, and a suture retainer slidably disposed within the shaft. The suture trimmer may be used to position knots formed within a suture loop prior to trimming the free end(s) of the suture loop, and to deliver an agent near the location where the suture is severed.",ABBOTT LAB,DANA MICHAEL;;GROSS T D;;MARTHALER MAURICE;;MA DAWN;;ANDERSON STEVEN C;;TERWILLIGER MARC;;SWETT JIM;;FRIEDMAN MITCHELL B,,https://lens.org/196-755-908-754-093,Patent Application,yes,9,23,7,38,0,A61B17/0467;;A61B17/0485;;A61B17/0467;;A61B17/0485,A61B17/04,606/148,0,0,,,,EXPIRED
328,US,B1,US 8954448 B1,072-329-259-883-531,2015-02-10,2015,US 201113222480 A,2011-08-31,US 201113222480 A,2011-08-31,Presenting content related to current media consumption,Disclosed are various embodiments for presenting content items that are related to media items that are currently being consumed by a user. A media item in a stream of media items being presented to a user is identified. A content item that is relevant to the media item is determined. An entry is added to the entries of a relevant content listing. The entry includes a link to the content item. The entries in the relevant content listing are chronologically correlated to the stream that is being presented to the user. The relevant content listing is updated in a user interface that is being presented to the user.,DURHAM SCOTT;;ROBERTS PAUL WILLIAM;;MEAKER SCOTT K;;DANTZLER JIM L;;MOSS RANDALL E;;ANDERSON ERIN O;;SHEPHERD BENJAMIN J;;AMAZON TECH INC,DURHAM SCOTT;;ROBERTS PAUL WILLIAM;;MEAKER SCOTT K;;DANTZLER JIM L;;MOSS RANDALL E;;ANDERSON ERIN O;;SHEPHERD BENJAMIN J,AMAZON TECHNOLOGIES INC (2011-09-09),https://lens.org/072-329-259-883-531,Granted Patent,yes,14,16,3,3,0,G06Q30/0621;;G06F16/435;;G06F16/435;;G06Q30/0621;;G06Q30/02;;G06F3/0482;;H04L65/60,G06F17/30,707/748;;707/723;;707/752;;707/754,5,0,,,"U.S. Appl. No. 13/036,539 entitled ""Metadata-Based File System,"" which was filed Feb. 28, 2011.;;U.S. Appl. No. 13/173,782 entitled ""Media Recommendations Based on Media Consumption,"" which was filed Jun. 30, 2011.;;U.S. Appl. No. 13/173,539 entitled ""Media Recommendations Based on Playlists,"" which was filed Jun. 30, 2011.;;U.S. Appl. No. 13/173,494 entitled ""Media Player Social Network Integration,"" which was filed Jun. 30, 2011.;;U.S. Appl. No. 13/197,479 entitled ""Media Recommendations,"" which was filed Aug. 3, 2011.",ACTIVE
329,US,A1,US 2015/0106717 A1,195-939-835-973-251,2015-04-16,2015,US 201414577646 A,2014-12-19,US 201414577646 A;;US 201113222480 A,2011-08-31,PRESENTING CONTENT RELATED TO CURRENT MEDIA CONSUMPTION,Disclosed are various embodiments for presenting content items that are related to media items that are currently being consumed by a user. A media item in a stream of media items being presented to a client is identified. A content item that is relevant to the media item is determined. An entry is added to the entries of a relevant content listing. The entry includes a link to the content item. The entries in the relevant content listing are arranged in a time-based sequence such that the at least one entry correlates to a sequence of playback in the client of a plurality of media files. The relevant content listing is updated in a user interface that is being presented to the user.,AMAZON TECH INC,DURHAM BRANDON SCOTT;;ROBERTS PAUL WILLIAM;;MEAKER SCOTT K;;DANTZLER JIM L;;MOSS RANDALL E;;ANDERSON ERIN O;;SHEPHERD BENJAMIN J,AMAZON TECHNOLOGIES INC (2011-09-09),https://lens.org/195-939-835-973-251,Patent Application,yes,0,1,3,3,0,G06Q30/0621;;G06F16/435;;G06F16/435;;G06Q30/0621;;G06Q30/02;;G06F3/0482;;H04L65/60,H04L29/06;;G06F3/0482,715/716,0,0,,,,ACTIVE
330,US,B2,US 9170712 B2,120-140-758-565-247,2015-10-27,2015,US 201414577646 A,2014-12-19,US 201414577646 A;;US 201113222480 A,2011-08-31,Presenting content related to current media consumption,Disclosed are various embodiments for presenting content items that are related to media items that are currently being consumed by a user. A media item in a stream of media items being presented to a client is identified. A content item that is relevant to the media item is determined. An entry is added to the entries of a relevant content listing. The entry includes a link to the content item. The entries in the relevant content listing are arranged in a time-based sequence such that the at least one entry correlates to a sequence of playback in the client of a plurality of media files. The relevant content listing is updated in a user interface that is being presented to the user.,AMAZON TECH INC,DURHAM BRANDON SCOTT;;ROBERTS PAUL WILLIAM;;MEAKER SCOTT K;;DANTZLER JIM L;;MOSS RANDALL E;;ANDERSON ERIN O;;SHEPHERD BENJAMIN J,AMAZON TECHNOLOGIES INC (2011-09-09),https://lens.org/120-140-758-565-247,Granted Patent,yes,67,1,3,3,0,G06Q30/0621;;G06F16/435;;G06F16/435;;G06Q30/0621;;G06Q30/02;;G06F3/0482;;H04L65/60,G06F17/30;;G06F3/0482;;G06Q30/02;;H04L29/06,,11,1,081-145-505-641-838,10.1109/p2p.2010.5569963,"U.S. Appl. No. 13/036,539 entitled ""Metadata-Based File System,"" filed Feb. 28, 2011.;;U.S. Appl. No. 13/173,782 entitled ""Media Recommendations Based on Media Consumption,"" filed Jun. 30, 2011.;;U.S. Appl. No. 13/173,539 entitled ""Media Recommendations Based on Playlists,"" filed Jun. 30, 2011.;;U.S. Appl. No. 13/173,494 entitled ""Media Player Social Network Integration,"" filed Jun. 30, 2011.;;U.S. Appl. No. 13/197,479 entitled ""Media Recommendations,"" filed Aug. 3, 2011.;;Ioannis Konstas, et al., ""On Social Networks and Collaborative Recommendation"", AMC SIGR '09, Jul. 19-23, 2009.;;Henry Kautz, et al., ""Combining Social Networks and Collaborative Filtering"", Commuinications of the ACM Mar. 1997/vol. 40, No. 3.;;Sehr, Andres. ""Spotify-The Next Generation."" Apr. 27, 2010. pp. 1-2. Retrieved from https://www.spotify.com/us/blog/archives/201 0/04/27/the-next-generation/.;;Kreitz et al. ""Spotify-Large Scale, Low Latency, P2P Music-on-Demand Streaming."" Aug. 27, 2010. 2010 IEEE Tenth International Conference on Peer-to-Peer Computing. pp. 1-10.;;U.S. Appl. No. 13/049,251, entitled ""File System Merchandising,"" filed Mar. 16, 2011.;;U.S. Appl. No. 13/161,176, entitled ""Recommendations Based on File Activity in a Networked Storage System,"" filed Jun. 15, 2011.",ACTIVE
331,US,A1,US 2019/0143034 A1,071-446-459-567-038,2019-05-16,2019,US 201916243662 A,2019-01-09,US 201916243662 A;;US 201414586927 A;;US 201462054134 P;;US 201361922709 P,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY","Device for delivering a beneficial agent to a user includes a cassette including a cassette housing with a fluid reservoir, the cassette housing having a cassette base region, and a delivery tube. The device also includes a pump having a pump housing containing a pump assembly and having a receiving region to receive the cassette base region. The pump assembly includes a fluid drive component, a display, a plurality of input buttons. The pump assembly also includes a first processor coupled to the fluid drive component and the display and configured to reduce power to the fluid drive component and the display when the pump is in an inactive state, and a second processor coupled to the first processor and the plurality of input buttons, the second processor configured to provide an activation signal to the first processor when one or more of the plurality of input buttons is deployed.",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/071-446-459-567-038,Patent Application,yes,3,1,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/168;;A61M5/142;;F04B43/08;;F04B43/12,,0,0,,,,PENDING
332,US,A1,US 2022/0027816 A1,195-981-165-870-534,2022-01-27,2022,US 202117382248 A,2021-07-21,US 202117382248 A;;US 202063054690 P,2020-07-21,WORKPLACE DISRUPTION DATA AND PROTOCOLS,"This disclosure describes systems, methods, and devices related to customizing the presentation of data indicative of disruptive events relative to workplaces. A device may determine a geographical area comprising one or more geographical sub-areas, and a disruptive event is taking place at the geographical area. The device may determine one or more metrics associated with the disruptive event. The device may determine, based on the one or more metrics, a first disruption score indicative of a future severity condition caused by the disruptive event that will take place at a first geographical sub-area of the one or more geographical sub-areas. The device may generate a first user interface to present a geographical map associated with the geographical area, and the first geographical area is marked by the first disruption score.",COX AUTOMOTIVE INC,RITTER DUANE;;KIRK CHRIS;;SHORTAL JIM;;LACKS JESSIE;;SMOKE JONATHAN;;STRAND MARK;;HORTON TAYLOR;;ANDERSON RUSSELL;;TAFT SPENCER;;JOHNSON RUSS;;WRONOWSKI VIKTOR,COX AUTOMOTIVE INC (2021-08-24),https://lens.org/195-981-165-870-534,Patent Application,yes,14,2,1,1,0,G06Q10/063116;;G06Q10/0633;;G06Q10/06312;;G16H50/80;;G06N20/00;;G06N7/01;;G06Q10/06312;;G06Q10/0633;;G16H50/80;;G06Q10/063116;;G06N7/01,G06Q10/06;;G06N7/00;;G16H50/80,,1,0,,,"Nguyen, D. X. (2016). Iterated filtering and smoothing with application to infectious disease models (Order No. 10153054). Available from ProQuest Dissertations and Theses Professional. (1817403881). (Year: 2016)",PENDING
333,AU,A,AU 2000/066693 A,050-057-956-194-614,2002-01-03,2002,AU 2000/066693 A,2000-10-24,US 59745500 A,2000-06-20,Method of forming and inserting filter elements in cup-shaped containers,,KEURIG GREEN MOUNTAIN INC,GORDAN STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRETCH MIKE,"KEURIG, INCORPORATED (2001-08-09)",https://lens.org/050-057-956-194-614,Patent Application,no,0,0,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;A47J31/08;;B01D29/00;;B01D35/02;;B01D35/30;;B65B29/02,,0,0,,,,EXPIRED
334,JP,A,JP 2002018213 A,052-930-516-086-640,2002-01-22,2002,JP 2000373887 A,2000-12-08,US 59745500 A,2000-06-20,METHOD FOR PREPARATION AND INSERTION OF FILTER ELEMENT TO BE INSERTED INTO CUP TYPE CONTAINER,"PROBLEM TO BE SOLVED: To provide a method for surely fixing a filter element by preparing effectively the filter element to be inserted into a cup type container to be accurately inserted therein. SOLUTION: A filter material is folded in two adjacent layers which are connected to each other along a folded line of a bottom part while separable upper ends are provided. The adjacent layers are cut by pressure, the upper end is formed in a scalloped type pattern, and a carrier mandrel is inserted between the adjacent layers. The adjacent layers are bonded to each other along a joint running in a direction crossing the folded line of the bottom part to be connected to each other by a scrap part. Further, they are formed in a filter element F of a series of folded shaped truncated cone shape the inside of which is supported by the carrier mandrel. The filter elements F are separated from each other by pressure cutting and removing the scrap part. The separated filter element F is transferred into a cup type container C arranged below from the carrier mandrel, and the inserted filter element F is fixed to an inner surface of the cup type container C.",KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,,https://lens.org/052-930-516-086-640,Patent Application,no,0,13,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;A47J31/08;;B01D29/00;;B01D35/02;;B01D35/30;;B65B29/02,,0,0,,,,EXPIRED
335,AU,B2,AU 784244 B2,007-182-134-396-990,2006-02-23,2006,AU 2000/066693 A,2000-10-24,US 59745500 A,2000-06-20,Method of forming and inserting filter elements in cup-shaped containers,"A method of forming and inserting filter elements (F) into cup-shaped (C) containers comprises the steps of: a) folding a continuous web of filter material (30) into two adjacent plies (30') which have separable upper edges and are joined one to the other along a bottom fold line(30""); b) blanking the upper edges of the adjacent (30') plies into a scalloped pattern; c) inserting carrier mandrels (36) between the adjacent plies (30'); d) joining the adjacent plies (30') along seams extending transversely with respect to the bottom fold line (30"") to form a series of collapsed frustoconical filter elements interconnected by scrap segments (42) and supported internally by the carrier mandrels (36); e) separating the filter elements (F) one from the other by blanking and removing the said scrap segments (42); f) transferring the filter elements (F) from the carrier mandrels into underlying cup-shaped containers (C) and g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers (C). <IMAGE> <IMAGE>",KEURIG INC,GORDAN STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,"KEURIG, INCORPORATED (2001-08-09)",https://lens.org/007-182-134-396-990,Granted Patent,no,2,0,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;B01D27/04;;A47J31/08;;B01D29/00;;B01D29/25;;B01D35/02;;B01D35/30;;B65B29/02,,0,0,,,,EXPIRED
336,NZ,A,NZ 508350 A,197-143-193-084-653,2002-08-28,2002,NZ 50835000 A,2000-11-23,US 59745500 A,2000-06-20,Method of forming and inserting filter elements in cup-shaped containers by forming from continuous web,A method of forming and inserting filter elements (F) into cup-shaped (C) containers comprises the steps of: a) folding a continuous web of filter material into two adjacent plies which have separable upper edges and are joined one to the other along a bottom fold line; b) blanking the upper edges of the adjacent plies into a scalloped pattern; c) inserting carrier mandrels (not shown) between the adjacent plies; d) joining the adjacent plies along seams extending transversely with respect to the bottom fold line to form a series of collapsed frustoconical filter elements interconnected by scrap segments (not shown) and supported internally by the carrier mandrels (not shown); e) separating the filter elements (F) one from the other by blanking and removing the said scrap segments (not shown); f) transferring the filter elements (F) from the carrier mandrels into underlying cup-shaped containers (C) and g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers.,KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,"KEURIG, US (2001-10-26);;GREEN MOUNTAIN COFFEE ROASTERS, INC., US (2014-11-13)",https://lens.org/197-143-193-084-653,Patent Application,no,0,0,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/08;;B01D29/00;;B01D35/02;;A47J31/06;;B01D35/30;;B65B29/02,,0,0,,,,DISCONTINUED
337,EP,B1,EP 1167204 B1,147-985-355-671-648,2006-07-12,2006,EP 00310662 A,2000-11-30,US 59745500 A,2000-06-20,Method of forming and inserting filter elements in cup-shaped containers,"A method of forming and inserting filter elements (F) into cup-shaped (C) containers comprises the steps of: a) folding a continuous web of filter material (30) into two adjacent plies (30') which have separable upper edges and are joined one to the other along a bottom fold line(30""); b) blanking the upper edges of the adjacent (30') plies into a scalloped pattern; c) inserting carrier mandrels (36) between the adjacent plies (30'); d) joining the adjacent plies (30') along seams extending transversely with respect to the bottom fold line (30"") to form a series of collapsed frustoconical filter elements interconnected by scrap segments (42) and supported internally by the carrier mandrels (36); e) separating the filter elements (F) one from the other by blanking and removing the said scrap segments (42); f) transferring the filter elements (F) from the carrier mandrels into underlying cup-shaped containers (C) and g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers (C). <IMAGE> <IMAGE>",KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,,https://lens.org/147-985-355-671-648,Granted Patent,yes,3,0,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;B65B29/02;;A47J31/08;;B01D29/00;;B01D35/02;;B01D35/30,,0,0,,,,EXPIRED
338,US,B1,US 6440256 B1,137-767-911-548-328,2002-08-27,2002,US 59745500 A,2000-06-20,US 59745500 A,2000-06-20,Method of forming and inserting filter elements in cup-shaped containers,"
    A method of forming and inserting filter elements into cup-shaped containers comprises the steps of: 

    a) folding a continuous web of filter material into two adjacent plies which have separable upper edges and are joined one to the other along a bottom fold line; 

    b) blanking the adjacent plies to form their upper edges into a scalloped pattern; 

    c) inserting carrier mandrels between the adjacent plies; 

    d) joining the adjacent plies along seams extending transversely with respect to the bottom fold line to form a series of collapsed frustoconical filter elements interconnected by scrap segments and supported internally by the carrier mandrels; 

    e) separating the filter elements one from the other by blanking and removing the scrap segments; 

    f) transferring the filter elements from the carrier mandrels into cup-shaped containers arranged therebeneath; and 

    g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers. 
",KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVID;;WOLF JIM;;HELMBRECHT MIKE,KEURIG INCORPORATED ( A DELAWARE CORPORATION) (1998-02-25);;KEURIG GREEN MOUNTAIN INC (2013-12-23);;KEURIG INC (2000-11-20),https://lens.org/137-767-911-548-328,Granted Patent,yes,6,202,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/08;;B01D29/00;;A47J31/06;;B01D35/02;;B01D35/30;;B65B29/02,156/293;;156/201;;156/204;;156/217;;156/227;;156/267;;156/270;;156/308.4,0,0,,,,EXPIRED
339,EP,A1,EP 1167204 A1,137-546-434-436-534,2002-01-02,2002,EP 00310662 A,2000-11-30,US 59745500 A,2000-06-20,Method of forming and inserting filter elements in cup-shaped containers,"A method of forming and inserting filter elements (F) into cup-shaped (C) containers comprises the steps of:
 a) folding a continuous web of filter material (30) into two adjacent plies (30') which have separable upper edges and are joined one to the other along a bottom fold line(30""); b) blanking the upper edges of the adjacent (30') plies into a scalloped pattern; c) inserting carrier mandrels (36) between the adjacent plies (30'); d) joining the adjacent plies (30') along seams extending transversely with respect to the bottom fold line (30"") to form a series of collapsed frustoconical filter elements interconnected by scrap segments (42) and supported internally by the carrier mandrels (36); e) separating the filter elements (F) one from the other by blanking and removing the said scrap segments (42); f) transferring the filter elements (F) from the carrier mandrels into underlying cup-shaped containers (C) and g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers (C).",KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,,https://lens.org/137-546-434-436-534,Patent Application,yes,3,20,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;A47J31/08;;B01D29/00;;B01D35/02;;B01D35/30;;B65B29/02,,0,0,,,,EXPIRED
340,AT,T1,AT E332842 T1,199-643-599-313-712,2006-08-15,2006,AT 00310662 T,2000-11-30,US 59745500 A,2000-06-20,VERFAHREN ZUM HERSTELLEN UND EINFÜHREN VON FILTERELEMENTEN IN BECHERFÖRMIGE BEHÄLTER,"A method of forming and inserting filter elements (F) into cup-shaped (C) containers comprises the steps of: a) folding a continuous web of filter material (30) into two adjacent plies (30') which have separable upper edges and are joined one to the other along a bottom fold line(30""); b) blanking the upper edges of the adjacent (30') plies into a scalloped pattern; c) inserting carrier mandrels (36) between the adjacent plies (30'); d) joining the adjacent plies (30') along seams extending transversely with respect to the bottom fold line (30"") to form a series of collapsed frustoconical filter elements interconnected by scrap segments (42) and supported internally by the carrier mandrels (36); e) separating the filter elements (F) one from the other by blanking and removing the said scrap segments (42); f) transferring the filter elements (F) from the carrier mandrels into underlying cup-shaped containers (C) and g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers (C). <IMAGE> <IMAGE>",KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,,https://lens.org/199-643-599-313-712,Granted Patent,no,0,0,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;A47J31/08;;B01D29/00;;B01D35/02;;B01D35/30;;B65B29/02,,0,0,,,,EXPIRED
341,DE,D1,DE 60029316 D1,038-234-923-246-094,2006-08-24,2006,DE 60029316 T,2000-11-30,US 59745500 A,2000-06-20,Verfahren zum Herstellen und Einführen von Filterelementen in becherförmige Behälter,"A method of forming and inserting filter elements (F) into cup-shaped (C) containers comprises the steps of: a) folding a continuous web of filter material (30) into two adjacent plies (30') which have separable upper edges and are joined one to the other along a bottom fold line(30""); b) blanking the upper edges of the adjacent (30') plies into a scalloped pattern; c) inserting carrier mandrels (36) between the adjacent plies (30'); d) joining the adjacent plies (30') along seams extending transversely with respect to the bottom fold line (30"") to form a series of collapsed frustoconical filter elements interconnected by scrap segments (42) and supported internally by the carrier mandrels (36); e) separating the filter elements (F) one from the other by blanking and removing the said scrap segments (42); f) transferring the filter elements (F) from the carrier mandrels into underlying cup-shaped containers (C) and g) securing the thus inserted filter elements to interior surfaces of the cup-shaped containers (C). <IMAGE> <IMAGE>",KEURIG INC,GORDON STEVEN J;;SWEENEY RICHARD P;;CHRISTOPHER ANTHONY J;;ANDERSON BRETT;;BOCCUTI A DAVID;;WALSH KEVIN;;SALLUM HANI;;RAMLER DAVE;;WOLF JIM;;HELMBRECHT MIKE,,https://lens.org/038-234-923-246-094,Granted Patent,no,0,0,12,12,0,A47J31/08;;B65B29/022;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;B65B29/02;;B65B29/06;;B65B43/10;;B65B43/18;;B65B43/46;;Y10T156/108;;Y10T156/1051;;Y10T156/1015;;Y10T156/101;;Y10T156/1085;;Y10T156/1036;;A47J31/08;;B65B29/022,A47J31/06;;B65B29/02;;A47J31/08;;B01D29/00;;B01D35/02;;B01D35/30,,0,0,,,,EXPIRED
342,WO,A3,WO 2015/103377 A3,066-551-272-788-416,2015-08-27,2015,US 2014/0072964 W,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY","Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially- outward projection defining a helical engagement portion disposed along a length of the cam shaft, and a plurality of finger plates disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. Systems and techniques for delivering a beneficial agent to a user are also provided.",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/066-551-272-788-416,Search Report,yes,5,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,PENDING
343,AU,A1,AU 2014/373703 A1,154-359-374-509-019,2016-07-28,2016,AU 2014/373703 A,2014-12-31,US 201414586927 A;;US 201414586930 A;;US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 2014/0072964 W,2013-12-31,"Pump, motor and assembly for beneficial agent delivery","Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially- outward projection defining a helical engagement portion disposed along a length of the cam shaft, and a plurality of finger plates disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. Systems and techniques for delivering a beneficial agent to a user are also provided.",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/154-359-374-509-019,Patent Application,no,0,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,ACTIVE
344,WO,A2,WO 2015/103377 A2,149-589-016-587-546,2015-07-09,2015,US 2014/0072964 W,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY","Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially- outward projection defining a helical engagement portion disposed along a length of the cam shaft, and a plurality of finger plates disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. Systems and techniques for delivering a beneficial agent to a user are also provided.",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/149-589-016-587-546,Patent Application,yes,2,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,PENDING
345,BR,A2,BR 112016015410 A2,011-245-766-079-440,2017-08-08,2017,BR 112016015410 A,2014-12-31,US 2014/0072964 W;;US 201462054134 P;;US 201414586923 A;;US 201414586930 A;;US 201414586927 A;;US 201361922709 P,2013-12-31,BOMBA PERISTÁLTICA E DISPOSITIVO PARA A ENTREGA DE UM AGENTE BENÉFICO PARA UM USUÁRIO,"BOMBA, MOTOR E CONJUNTO PARA A ENTREGA DE AGENTE BENÉFICO. A presente invenção refere-se a uma bomba que inclui um motor, um eixo de cames acoplado no motor para rotação ao redor de um eixo geométrico longitudinal do eixo de cames, o eixo de cames tendo pelo menos uma projeção radialmente para fora definindo uma porção de engate helicoidal disposta ao longo de um comprimento do eixo de cames e uma pluralidade de chapas de palhetas dispostas ao longo do comprimento do eixo de cames, cada chapa de palhetas montada para movimento em uma direção transversal em relação ao eixo geométrico longitudinal do eixo de cames, cada chapa de palhetas tendo uma abertura definida nela para receber o eixo de cames através dela, cada abertura tendo uma região de borda substancialmente reta e uma região de borda oposta. O engate da porção de engate helicoidal com a região de borda substancialmente plana durante a rotação do eixo de cames impele a chapa de palhetas transversalmente para uma posição estendida. Sistemas e técnicas para a entrega de um agente benéfico para um usuário também são apresentados.",ABBVIE INC,PHIL D ANDERSON;;RAJKUMAR CONJEEVARAM;;JI ZHOU;;SEAN MACKEY;;TED HANAGAN;;GURJINDER DHAMI;;KEVIN NOVAK;;SCOTT SMIEJA;;MARK PANZER;;BENJAMIN GREUEL;;JIM HOCH;;RYAN THOMPSON,,https://lens.org/011-245-766-079-440,Patent Application,no,0,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,PENDING
346,EP,A2,EP 3089772 A2,076-870-995-464-432,2016-11-09,2016,EP 14827699 A,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A;;US 2014/0072964 W,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY",,ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/076-870-995-464-432,Patent Application,yes,0,1,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,ACTIVE
347,CA,A1,CA 2935686 A1,140-823-344-252-150,2015-07-09,2015,CA 2935686 A,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A;;US 2014/0072964 W,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY","Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially- outward projection defining a helical engagement portion disposed along a length of the cam shaft, and a plurality of finger plates disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. Systems and techniques for delivering a beneficial agent to a user are also provided.",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/140-823-344-252-150,Patent Application,no,0,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,DISCONTINUED
348,ES,T3,ES 2668987 T3,182-065-494-310-188,2018-05-23,2018,ES 14827699 T,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A;;US 2014/0072964 W,2013-12-31,"Bomba, motor y conjunto para el suministro de un agente beneficioso","Una bomba peristáltica (1030) adecuada para el suministro de un agente beneficioso a un usuario, que comprende: un motor (3); un árbol de levas (2) acoplado al motor para una rotación sobre un eje longitudinal del árbol de levas, teniendo el árbol de levas al menos un saliente radialmente hacia fuera (21) que define una parte de acoplamiento helicoidal dispuesta a lo largo de una longitud del árbol de levas; y una pluralidad de placas de dedo (4) dispuestas a lo largo de la longitud del árbol de levas, estando montada cada placa de dedo para su movimiento en una dirección transversal con respecto al eje longitudinal del árbol de levas, teniendo cada placa de dedo una abertura (41) definida en la misma para recibir el árbol de levas a través de la misma, teniendo cada abertura una región de borde sustancialmente recta (44) y una región de borde opuesta (45); en la que el acoplamiento de la parte de acoplamiento helicoidal (21) con la región de borde sustancialmente plana (44) durante la rotación del árbol de levas empuja la placa de dedo transversalmente hacia una posición extendida, caracterizada por que la región de borde opuesta comprende un borde arqueado (45).",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/182-065-494-310-188,Granted Patent,no,0,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,ACTIVE
349,AU,B2,AU 2014/373703 B2,075-240-854-579-444,2019-08-22,2019,AU 2014/373703 A,2014-12-31,US 201414586927 A;;US 201414586930 A;;US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 2014/0072964 W,2013-12-31,"Pump, motor and assembly for beneficial agent delivery","Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially- outward projection defining a helical engagement portion disposed along a length of the cam shaft, and a plurality of finger plates disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. Systems and techniques for delivering a beneficial agent to a user are also provided.",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/075-240-854-579-444,Granted Patent,no,3,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,ACTIVE
350,JP,A,JP 2020110605 A,038-120-670-638-835,2020-07-27,2020,JP 2020031258 A,2020-02-27,JP 2016543591 A;;US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A,2013-12-31,"PUMP, MOTOR, AND ASSEMBLY FOR DELIVERY OF BENEFICIAL AGENT","To provide portable infusion pumps having improved energy consumption and battery life, improved pump efficiency and control, improved comfort and ergonomics, and improved cassette configuration.SOLUTION: A pump 1030 includes: a motor; a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially-outward projection defining a helical engagement portion disposed along a length of the cam shaft; and a plurality of finger plates disposed along the length of the cam shaft, each finger plate being mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position.SELECTED DRAWING: Figure 1A",ABBVIE INC,PHIL D ANDERSON;;RAJKUMAR CONJEEVARAM;;ZHOU ZHI;;SEAN MACKEY;;KEVIN NOVAK;;TED HANAGAN;;GURJINDER DHAMI;;SCOTT SMIEJA;;MARK PANZER;;BENJAMIN GREUEL;;JIM HOCH;;RYAN THOMPSON,,https://lens.org/038-120-670-638-835,Patent Application,no,15,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,ACTIVE
351,EP,B1,EP 3089772 B1,078-851-361-574-305,2018-01-17,2018,EP 14827699 A,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A;;US 2014/0072964 W,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY",,ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/078-851-361-574-305,Granted Patent,yes,5,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,ACTIVE
352,EP,A1,EP 3308811 A1,115-541-095-141-350,2018-04-18,2018,EP 17203875 A,2014-12-31,US 201361922709 P;;US 201462054134 P;;US 201414586923 A;;US 201414586927 A;;US 201414586930 A;;EP 14827699 A,2013-12-31,"PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY","Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially-outward projection defining a helical engagement portion disposed along a length of the cam shaft, and a plurality of finger plates disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft, each finger plate having an aperture defined therein to receive the cam shaft therethrough, each aperture having a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. Systems and techniques for delivering a beneficial agent to a user are also provided.
",ABBVIE INC,ANDERSON PHIL D;;CONJEEVARAM RAJKUMAR;;ZHOU JI;;MACKEY SEAN;;NOVAK KEVIN;;HANAGAN TED;;DHAMI GURJINDER;;SMIEJA SCOTT;;PANZER MARK;;GREUEL BENJAMIN;;HOCH JIM;;THOMPSON RYAN,,https://lens.org/115-541-095-141-350,Patent Application,yes,5,0,19,19,0,A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;F04B43/12;;A61M5/16831;;A61M5/14228;;A61M5/14244;;A61M2005/16863;;A61M2205/12;;A61M2205/50;;A61M2205/6054;;F04B43/082;;A61M2205/14;;A61M2205/16;;A61M5/142;;A61M2205/502;;F04B43/12;;F04B43/1223,A61M5/142,,0,0,,,,PENDING
353,GB,A,GB 2562410 A,010-647-802-915-748,2018-11-14,2018,GB 201811838 A,2017-10-20,US 2017/0057665 W;;US 201662411292 P;;US 201662411312 P;;US 201662411351 P,2016-10-21,"Substrate shape, geometry, positioning, and/or cell density to improve aftertreatment performance","An aftertreatment component's shape, entrance geometry, and/or position within an aftertreatment assembly can be modified for local and/or bulk exhaust flow control. In some implementations, a body of the aftertreatment component has a non-circular cross-section, a non-circular opening, and/or a variable face geometry. The non-circular cross-section and/or opening can be of a variety of different shapes.",CUMMINS EMISSION SOLUTIONS INC,JOHN G BUECHLER;;RANDOLPH G ZORAN;;RYAN M JOHNSON;;STEPHEN M HOLL;;TAREN DEHART;;JIM ALONZO;;MATTHEW L ANDERSON;;APOORV KALYANKAR;;GEORGE E MAVROUDIS;;GAURAV HEMANT PANDIT,,https://lens.org/010-647-802-915-748,Patent Application,no,5,0,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/28;;F01N3/022,,0,0,,,,DISCONTINUED
354,WO,A1,WO 2018/075931 A1,048-737-648-820-625,2018-04-26,2018,US 2017/0057665 W,2017-10-20,US 201662411292 P;;US 201662411312 P;;US 201662411351 P,2016-10-21,"SUBSTRATE SHAPE, GEOMETRY, POSITIONING, AND/OR CELL DENSITY TO IMPROVE AFTERTREATMENT PERFORMANCE","An aftertreatment component's shape, entrance geometry, and/or position within an aftertreatment assembly can be modified for local and/or bulk exhaust flow control. In some implementations, a body of the aftertreatment component has a non-circular cross-section, a non-circular opening, and/or a variable face geometry. The non-circular cross-section and/or opening can be of a variety of different shapes.",CUMMINS EMISSION SOLUTIONS INC,BUECHLER JOHN G;;ZORAN RANDOLPH G;;JOHNSON RYAN M;;HOLL STEPHEN M;;DEHART TAREN;;ALONZO JIM L;;ANDERSON MATTHEW L;;KALYANKAR APOORV;;MAVROUDIS GEORGE EUGENE;;PANDIT GAURAV HEMANT,,https://lens.org/048-737-648-820-625,Patent Application,yes,5,3,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/022,,0,0,,,,PENDING
355,US,B2,US 10865681 B2,004-465-755-716-660,2020-12-15,2020,US 201715781433 A,2017-10-20,US 201715781433 A;;US 201662411292 P;;US 201662411312 P;;US 201662411351 P;;US 2017/0057665 W,2016-10-21,"Substrate shape, geometry, positioning, and/or cell density to improve aftertreatment performance","An aftertreatment component's shape, entrance geometry, and/or position within an aftertreatment assembly can be modified for local and/or bulk exhaust flow control. In some implementations, a body of the aftertreatment component has a non-circular cross-section, a non-circular opening, and/or a variable face geometry. The non-circular cross-section and/or opening can be of a variety of different shapes.",CUMMINS EMISSION SOLUTIONS INC,BUECHLER JOHN G;;ZORAN RANDOLPH G;;JOHNSON RYAN M;;HOLL STEPHEN M;;DEHART TAREN;;ALONZO JIM L;;ANDERSON MATTHEW L;;KALYANKAR APOORV;;MAVROUDIS GEORGE EUGENE;;PANDIT GAURAV HEMANT,CUMMINS EMISSION SOLUTIONS INC (2017-10-31),https://lens.org/004-465-755-716-660,Granted Patent,yes,13,2,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/022;;B01D53/94;;F01N3/021;;F01N3/20;;F01N3/28,,2,0,,,"International Search Report from corresponding published PCT Application No. WO 2018/075931, dated Mar. 5, 2018, pp. 1-3.;;Written Opinion from corresponding published PCT Application No. WO 2018/075931, dated Mar. 5, 2018, pp. 1-4.",ACTIVE
356,DE,T5,DE 112017005323 T5,046-651-860-872-705,2019-08-01,2019,DE 112017005323 T,2017-10-20,US 201662411351 P;;US 201662411312 P;;US 201662411292 P;;US 2017/0057665 W,2016-10-21,"Substratform, Geometrie, Positionierung und/oder Zelldichte zur Verbesserung der Nachbehandlungsleistung","Die Form einer Nachbehandlungskomponente, die Eintrittsgeometrie und/oder die Position innerhalb einer Nachbehandlungsbaugruppe können für die Regulierung eines lokalen Abgasstromes und/oder Massenabgasstromes geändert werden. In manchen Implementierungen hat ein Körper der Nachbehandlungskomponente einen nicht-kreisförmigen Querschnitt, eine nicht-kreisförmige Öffnung und/oder eine variable Oberflächengeometrie. Der nicht-kreisförmige Querschnitt und/oder die Öffnung können eine Vielzahl unterschiedlicher Formen aufweisen.",CUMMINS EMISSION SOLUTIONS INC,BUECHLER JOHN G;;ZORAN RANDOLPH G;;JOHNSON RYAN M;;HOLL STEPHEN M;;DEHART TAREN;;ALONZO JIM L;;ANDERSON MATTHEW L;;KALYANKAR APOORV;;MAVROUDIS GEORGE EUGENE;;PANDIT GAURAV HEMANT,,https://lens.org/046-651-860-872-705,Patent Application,no,0,1,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/022,,0,0,,,,PENDING
357,GB,A,GB 2594874 A,098-284-321-603-324,2021-11-10,2021,GB 202110545 A,2017-10-20,US 201662411351 P;;US 201662411292 P;;US 201662411312 P;;GB 201811838 A,2016-10-21,"Substrate shape, geometry, positioning, and/or cell density to improve aftertreatment performance","A radial aftertreatment component 1200 comprising: a substrate having a radial exterior surface 1202, and a radial interior surface 1204 defining a central axial inlet or outlet, the substrate including a channel 1210 formed therethrough from a first end at the radial exterior surface to a second end at the radial interior surface, wherein, in a cross-section of the substrate, the channel has an S-shape.",CUMMINS EMISSION SOLUTIONS INC,JOHN G BUECHLER;;RANDOLPH G ZORAN;;RYAN M JOHNSON;;STEPHEN M HOLL;;TAREN DEHART;;JIM L ALONZO;;MATTEW L ANDERSON;;APOORV KALYANKAR;;GEORGE EUGENE MAVROUDIS;;GAURAV HEMANT PANDIT,,https://lens.org/098-284-321-603-324,Patent Application,no,2,0,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/28;;F01N3/021;;F01N3/022,,0,0,,,,ACTIVE
358,GB,B,GB 2594874 B,193-193-947-948-025,2022-05-04,2022,GB 202110545 A,2017-10-20,US 201662411351 P;;US 201662411292 P;;US 201662411312 P;;GB 201811838 A,2016-10-21,"Substrate shape, geometry, positioning, and/or cell density to improve aftertreatment performance",,CUMMINS EMISSION SOLUTIONS INC,JOHN G BUECHLER;;RANDOLPH G ZORAN;;RYAN M JOHNSON;;STEPHEN M HOLL;;TAREN DEHART;;JIM L ALONZO;;MATTEW L ANDERSON;;APOORV KALYANKAR;;GEORGE EUGENE MAVROUDIS;;GAURAV HEMANT PANDIT,,https://lens.org/193-193-947-948-025,Granted Patent,no,2,0,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/28;;F01N3/021;;F01N3/022,,0,0,,,,ACTIVE
359,GB,B8,GB 2594874 B8,093-958-352-493-531,2022-10-12,2022,GB 202110545 A,2017-10-20,US 201662411351 P;;US 201662411292 P;;US 201662411312 P;;GB 201811838 A,2016-10-21,"Substrate shape, geometry, positioning, and/or cell density to improve aftertreatment performance",,CUMMINS EMISSION SOLUTIONS INC,JOHN G BUECHLER;;RANDOLPH G ZORAN;;RYAN M JOHNSON;;STEPHEN M HOLL;;TAREN DEHART;;JIM L ALONZO;;MATTHEW L ANDERSON;;APOORV KALYANKAR;;GEORGE EUGENE MAVROUDIS;;GAURAV HEMANT PANDIT,,https://lens.org/093-958-352-493-531,Amended Patent,no,0,0,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/28;;F01N3/021;;F01N3/022,,0,0,,,,ACTIVE
360,US,A1,US 2019/0234270 A1,019-596-432-913-218,2019-08-01,2019,US 201715781433 A,2017-10-20,US 201715781433 A;;US 201662411292 P;;US 201662411312 P;;US 201662411351 P;;US 2017/0057665 W,2016-10-21,"SUBSTRATE SHAPE, GEOMETRY, POSITIONING, AND/OR CELL DENSITY TO IMPROVE AFTERTREATMENT PERFORMANCE","An aftertreatment component's shape, entrance geometry, and/or position within an aftertreatment assembly can be modified for local and/or bulk exhaust flow control. In some implementations, a body of the aftertreatment component has a non-circular cross-section, a non-circular opening, and/or a variable face geometry. The non-circular cross-section and/or opening can be a variety of different shapes.",CUMMINS EMISSION SOLUTIONS INC,BUECHLER JOHN G;;ZORAN RANDOLPH G;;JOHNSON RYAN M;;HOLL STEPHEN M;;DEHART TAREN;;ALONZO JIM L;;ANDERSON MATTHEW L;;KALYANKAR APOORV;;MAVROUDIS GEORGE EUGENE;;PANDIT GAURAV HEMANT,CUMMINS EMISSION SOLUTIONS INC (2017-10-31),https://lens.org/019-596-432-913-218,Patent Application,yes,8,0,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/20;;F01N3/021;;F01N3/28,,0,0,,,,ACTIVE
361,CN,A,CN 108603428 A,029-539-903-830-278,2018-09-28,2018,CN 201780010143 A,2017-10-20,US 201662411292 P;;US 201662411312 P;;US 201662411351 P;;US 2017/0057665 W,2016-10-21,"SUBSTRATE SHAPE, GEOMETRY, POSITIONING, AND/OR CELL DENSITY TO IMPROVE AFTERTREATMENT PERFORMANCE","An aftertreatment component's shape, entrance geometry, and/or position within an aftertreatment assembly can be modified for local and/or bulk exhaust flow control. In some implementations, a body ofthe aftertreatment component has a non-circular cross-section, a non-circular opening, and/or a variable face geometry. The non-circular cross-section and/or opening can be of a variety of differentshapes.",CUMMINS EMISSION SOLUTIONS INC,BUECHLER JOHN G;;ZORAN RANDOLPH G;;JOHNSON RYAN M;;HOLL STEPHEN M;;DEHART TAREN;;ALONZO JIM L;;ANDERSON MATTHEW L;;KALYANKAR APOORV;;MAVROUDIS GEORGE EUGENE;;PANDIT GAURAV HEMANT,,https://lens.org/029-539-903-830-278,Patent Application,no,8,1,11,11,0,F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;F01N3/022;;F01N3/2803;;F01N2330/60;;F01N2330/30;;F01N3/0217;;F01N3/2803;;F01N3/022;;F01N2330/30;;F01N2330/60;;Y02T10/12;;B01D53/9418;;B01D53/944;;F01N3/0215;;F01N3/2066;;F01N3/208;;F01N3/2882,F01N3/022,,0,0,,,,PENDING
362,EP,A1,EP 2262566 A1,096-976-554-598-460,2010-12-22,2010,EP 09716422 A,2009-03-06,US 2009/0036354 W;;US 3432808 P,2008-03-06,Balloon catheter devices with folded balloons,,BOSTON SCIENT SCIMED INC,KNAPP DAVID;;MICKLEY TIMOTHY;;CHEN JOHN;;SUTERMEISTER DEREK;;FREYMAN TOBY;;KOCUR GORDON;;HORN DANIEL;;ANDERSON JIM;;ARCAND BEN;;RASSAT JAY;;RIZQ RAED;;NAZAROVA IRINA;;QUILLIN DAN;;WEBER JAN;;SCHEUERMANN TORSTEN,,https://lens.org/096-976-554-598-460,Patent Application,yes,0,0,19,19,0,A61L29/085;;A61L29/16;;A61L2300/416;;A61M25/0045;;A61M25/10;;A61M25/1029;;A61M2025/0056;;A61M2025/1031;;A61M2025/105;;B29L2009/005;;A61M25/1029;;A61L29/085;;A61M2025/0056;;B29L2009/005;;A61M2025/105;;A61M25/10;;A61M2025/1031;;A61L2300/416;;A61M25/0045;;A61L29/16,A61F2/958;;A61L29/00;;A61M25/10;;A61L29/08;;A61L29/16;;A61M25/00;;B29L9/00,,0,0,,,,DISCONTINUED
363,WO,A1,WO 2009/111712 A1,066-407-546-476-713,2009-09-11,2009,US 2009/0036354 W,2009-03-06,US 3432808 P,2008-03-06,BALLOON CATHETER DEVICES WITH FOLDED BALLOONS,"Catheter devices (10) having an expandable balloon (14) for delivering a therapeutic agent to a body site. The balloon has one or more folds (16) which serve as a reservoir for containing the therapeutic agent. The fold may have any of various configurations to hold the therapeutic agent. In some cases, the balloon comprises one or more lobes that forms the fold(s). The therapeutic agent may be provided in various ways. For example, the therapeutic agent may be contained in packets that rupture upon expansion of the balloon, or as a plurality of discrete bulk masses, or sealed within compartments.",BOSTON SCIENT SCIMED INC;;KNAPP DAVID;;MICKLEY TIMOTHY;;CHEN JOHN;;SUTERMEISTER DEREK;;FREYMAN TOBY;;KOCUR GORDON;;HORN DANIEL;;ANDERSON JIM;;ARCAND BEN;;RASSAT JAY;;RIZQ RAED;;NAZAROVA IRINA;;QUILLIN DAN;;WEBER JAN;;SCHEUERMANN TORSTEN,KNAPP DAVID;;MICKLEY TIMOTHY;;CHEN JOHN;;SUTERMEISTER DEREK;;FREYMAN TOBY;;KOCUR GORDON;;HORN DANIEL;;ANDERSON JIM;;ARCAND BEN;;RASSAT JAY;;RIZQ RAED;;NAZAROVA IRINA;;QUILLIN DAN;;WEBER JAN;;SCHEUERMANN TORSTEN,,https://lens.org/066-407-546-476-713,Patent Application,yes,13,6,19,19,0,A61L29/085;;A61L29/16;;A61L2300/416;;A61M25/0045;;A61M25/10;;A61M25/1029;;A61M2025/0056;;A61M2025/1031;;A61M2025/105;;B29L2009/005;;A61M25/1029;;A61L29/085;;A61M2025/0056;;B29L2009/005;;A61M2025/105;;A61M25/10;;A61M2025/1031;;A61L2300/416;;A61M25/0045;;A61L29/16,A61F2/958;;A61L29/00,,0,0,,,,PENDING
364,US,A1,US 2009/0250597 A1,132-808-240-763-903,2009-10-08,2009,US 86942307 A,2007-10-09,US 86942307 A;;US 24356205 A,2005-10-05,OPTICAL FIBER ASSEMBLY WRAPPED ACROSS ROLL-NOD GIMBAL AXES IN A DIRCM SYSTEM,"A control mechanism pins an optical fiber assembly on and off gimbal and between gimbals to route the assembly from an off-gimbal optical source across the gimbal axis/axes to an on-gimbal optical element so that the fiber assembly moves with the rotation of the gimbals. To accommodate a relatively large range of motion, the control mechanism is suitably configured to route the fiber assembly in a “U-shaped” loop with one end pinned off-gimbal in a stationary guide track and the other end pinned on-gimbal point in a rotating guide track so that the loose fiber assembly is constrained in the concentric tracks on and off gimbal. As the gimbal rotates, the loop seats onto one guiding track and peels off of the other guiding track while always maintaining its U shape. To accommodate a relatively small range of motion in other gimbal configurations, the control mechanism is suitably configured to pin one end of the fiber assembly off-gimbal and pass the fiber assembly directly over the gimbal where it is pinned on the other side of the gimbal. In a multi-gimbal pointer, the fiber assembly preferably exhibits different mechanical stresses as it crosses the different gimbals.",RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH III FRANK E;;HICKS JIM R,RAYTHEON COMPANY (2005-12-15),https://lens.org/132-808-240-763-903,Patent Application,yes,7,1,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,F41G7/00,250/227.11,0,0,,,,ACTIVE
365,EP,A2,EP 1946350 A2,034-493-298-894-344,2008-07-23,2008,EP 06816560 A,2006-10-05,US 2006/0039426 W;;US 24356205 A,2005-10-05,OPTICAL FIBER ASSEMBLY WRAPPED ACROSS GIMBAL AXES,,RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,,https://lens.org/034-493-298-894-344,Patent Application,yes,0,0,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,F41G7/22;;F41H13/00;;G01S7/481;;G01S7/495,,0,0,,,,ACTIVE
366,WO,A2,WO 2007/044684 A2,117-752-045-160-644,2007-04-19,2007,US 2006/0039426 W,2006-10-05,US 24356205 A,2005-10-05,OPTICAL FIBER ASSEMBLY WRAPPED ACROSS GIMBAL AXES,"A control mechanism pins an optical fiber assembly on and off gimbal and between gimbals to route the assembly from an off-gimbal optical source across the gimbal axis/axes to an on-gimbal optical element so that the fiber assembly moves with the rotation of the gimbals. To accommodate a relatively large range of motion, the control mechanism is suitably configured to route the fiber assembly in a “U-shaped” loop with one end pinned off-gimbal in a stationary guide track and the other end pinned on-gimbal point in a rotating guide track so that the loose fiber assembly is constrained in the concentric tracks on and off gimbal. As the gimbal rotates, the loop seats onto one guiding track and peels off of the other guiding track while always maintaining its U-shape. To accommodate a relatively small range of motion in other gimbal configurations, the control mechanism is suitably configured to pin one end of the fiber assembly off-gimbal and pass the fiber assembly directly over the gimbal where it is pinned on the other side of the gimbal. In a multi-gimbal pointer, the fiber assembly preferably exhibits different mechanical stresses as it crosses the different gimbals.",RAYTHEON CO;;MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,,https://lens.org/117-752-045-160-644,Patent Application,yes,2,3,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,H01J5/02;;H01J40/14,,1,0,,,See also references of EP 1946350A4,PENDING
367,EP,A4,EP 1946350 A4,085-484-885-877-042,2012-10-31,2012,EP 06816560 A,2006-10-05,US 2006/0039426 W;;US 24356205 A,2005-10-05,OPTICAL FIBER ASSEMBLY WRAPPED ACROSS GIMBAL AXES,,RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,,https://lens.org/085-484-885-877-042,Search Report,no,2,0,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,F41G7/22;;F41H13/00;;G01S7/481;;G01S7/495,,1,0,,,See also references of WO 2007044684A2,ACTIVE
368,EP,B1,EP 1946350 B1,079-810-540-716-87X,2013-11-27,2013,EP 06816560 A,2006-10-05,US 2006/0039426 W;;US 24356205 A,2005-10-05,OPTICAL FIBER ASSEMBLY WRAPPED ACROSS GIMBAL AXES,,RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,,https://lens.org/079-810-540-716-87X,Granted Patent,yes,1,2,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,F41G7/22;;F41H13/00;;G01S7/481;;G01S7/495,,0,0,,,,ACTIVE
369,US,B2,US 7667190 B2,142-917-300-056-270,2010-02-23,2010,US 86942307 A,2007-10-09,US 86942307 A;;US 24356205 A,2005-10-05,Optical fiber assembly wrapped across roll-nod gimbal axes in a DIRCM system,"A control mechanism pins an optical fiber assembly on and off gimbal and between gimbals to route the assembly from an off-gimbal optical source across the gimbal axis/axes to an on-gimbal optical element so that the fiber assembly moves with the rotation of the gimbals. To accommodate a relatively large range of motion, the control mechanism is suitably configured to route the fiber assembly in a “U-shaped” loop with one end pinned off-gimbal in a stationary guide track and the other end pinned on-gimbal point in a rotating guide track so that the loose fiber assembly is constrained in the concentric tracks on and off gimbal. As the gimbal rotates, the loop seats onto one guiding track and peels off of the other guiding track while always maintaining its U shape. To accommodate a relatively small range of motion in other gimbal configurations, the control mechanism is suitably configured to pin one end of the fiber assembly off-gimbal and pass the fiber assembly directly over the gimbal where it is pinned on the other side of the gimbal. In a multi-gimbal pointer, the fiber assembly preferably exhibits different mechanical stresses as it crosses the different gimbals.",RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH III FRANK E;;HICKS JIM R,RAYTHEON COMPANY (2005-12-15),https://lens.org/142-917-300-056-270,Granted Patent,yes,7,23,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,F41G7/00,250/239;;250/234;;250/227.11;;244/3.16,1,0,,,"Bae Systems, Infrared-Transmitting Fibers for Advanced IRCM Demonstrations, IRIS Paper 2001CMC02x, May 2001, Nashua, New Hampshire.",ACTIVE
370,US,A1,US 2009/0227949 A1,151-232-605-352-198,2009-09-10,2009,US 39954809 A,2009-03-06,US 39954809 A;;US 3432808 P,2008-03-06,BALLOON CATHETER DEVICES WITH FOLDED BALLOONS,"Catheter devices having an expandable balloon for delivering a therapeutic agent to a body site. The balloon has one or more folds which serve as a reservoir for containing the therapeutic agent. The fold may have any of various configurations to hold the therapeutic agent. In some cases, the balloon comprises one or more lobes that forms the fold(s). The therapeutic agent may be provided in various ways. For example, the therapeutic agent may be contained in packets that rupture upon expansion of the balloon, or as a plurality of discrete bulk masses, or sealed within compartments.",BOSTON SCIENT SCIMED INC,KNAPP DAVID;;MICKLEY TIMOTHY J;;CHEN JOHN;;SUTERMEISTER DEREK;;FREYMAN TOBY;;KOCUR GORDON;;HORN DANIEL;;ANDERSON JIM;;ARCAND BEN;;RASSAT JAY;;RIZQ RAED;;NAZAROVA IRINA;;QUILLIN DAN;;WEBER JAN;;SCHEUERMANN TORSTEN,BOSTON SCIENTIFIC SCIMED INC (2009-03-11),https://lens.org/151-232-605-352-198,Patent Application,yes,98,145,19,19,0,A61L29/085;;A61L29/16;;A61L2300/416;;A61M25/0045;;A61M25/10;;A61M25/1029;;A61M2025/0056;;A61M2025/1031;;A61M2025/105;;B29L2009/005;;A61M25/1029;;A61L29/085;;A61M2025/0056;;B29L2009/005;;A61M2025/105;;A61M25/10;;A61M2025/1031;;A61L2300/416;;A61M25/0045;;A61L29/16,A61F2/958,604/103.02,0,0,,,,ACTIVE
371,US,B2,US 7304296 B2,156-277-181-595-030,2007-12-04,2007,US 24356205 A,2005-10-05,US 24356205 A,2005-10-05,Optical fiber assembly wrapped across gimbal axes,"A control mechanism pins an optical fiber assembly on and off gimbal and between gimbals to route the assembly from an off-gimbal optical source across the gimbal axis/axes to an on-gimbal optical element so that the fiber assembly moves with the rotation of the gimbals. To accommodate a relatively large range of motion, the control mechanism is suitably configured to route the fiber assembly in a “U-shaped” loop with one end pinned off-gimbal in a stationary guide track and the other end pinned on-gimbal point in a rotating guide track so that the loose fiber assembly is constrained in the concentric tracks on and off gimbal. As the gimbal rotates, the loop seats onto one guiding track and peels off of the other guiding track while always maintaining its U shape. To accommodate a relatively small range of motion in other gimbal configurations, the control mechanism is suitably configured to pin one end of the fiber assembly off-gimbal and pass the fiber assembly directly over the gimbal where it is pinned on the other side of the gimbal. In a multi-gimbal pointer, the fiber assembly preferably exhibits different mechanical stresses as it crosses the different gimbals.",RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH III FRANK E;;HICKS JIM R,RAYTHEON COMPANY (2006-01-09),https://lens.org/156-277-181-595-030,Granted Patent,yes,5,36,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,F41G7/00,250/239;;250/234;;244/3.16,1,0,,,"Bae Systems, Infrared-Transmitting Fibers for Advanced IRCM Demonstrations, IRIS Paper 2001CMC02x, May, 2001, Nashua, New Hampshire.",ACTIVE
372,WO,A3,WO 2007/044684 A3,144-931-154-763-287,2008-12-11,2008,US 2006/0039426 W,2006-10-05,US 24356205 A,2005-10-05,OPTICAL FIBER ASSEMBLY WRAPPED ACROSS GIMBAL AXES,"A control mechanism pins an optical fiber assembly on and off gimbal and between gimbals to route the assembly from an off-gimbal optical source across the gimbal axis/axes to an on-gimbal optical element so that the fiber assembly moves with the rotation of the gimbals. To accommodate a relatively large range of motion, the control mechanism is suitably configured to route the fiber assembly in a “U-shaped” loop with one end pinned off-gimbal in a stationary guide track and the other end pinned on-gimbal point in a rotating guide track so that the loose fiber assembly is constrained in the concentric tracks on and off gimbal. As the gimbal rotates, the loop seats onto one guiding track and peels off of the other guiding track while always maintaining its U-shape. To accommodate a relatively small range of motion in other gimbal configurations, the control mechanism is suitably configured to pin one end of the fiber assembly off-gimbal and pass the fiber assembly directly over the gimbal where it is pinned on the other side of the gimbal. In a multi-gimbal pointer, the fiber assembly preferably exhibits different mechanical stresses as it crosses the different gimbals.",RAYTHEON CO;;MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,,https://lens.org/144-931-154-763-287,Search Report,yes,4,0,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,G01D13/22,,0,0,,,,PENDING
373,US,A1,US 2007/0075237 A1,107-817-204-669-619,2007-04-05,2007,US 24356205 A,2005-10-05,US 24356205 A,2005-10-05,Optical fiber assembly wrapped across gimbal axes,"A control mechanism pins an optical fiber assembly on and off gimbal and between gimbals to route the assembly from an off-gimbal optical source across the gimbal axis/axes to an on-gimbal optical element so that the fiber assembly moves with the rotation of the gimbals. To accommodate a relatively large range of motion, the control mechanism is suitably configured to route the fiber assembly in a “U-shaped” loop with one end pinned off-gimbal in a stationary guide track and the other end pinned on-gimbal point in a rotating guide track so that the loose fiber assembly is constrained in the concentric tracks on and off gimbal. As the gimbal rotates, the loop seats onto one guiding track and peels off of the other guiding track while always maintaining its U shape. To accommodate a relatively small range of motion in other gimbal configurations, the control mechanism is suitably configured to pin one end of the fiber assembly off-gimbal and pass the fiber assembly directly over the gimbal where it is pinned on the other side of the gimbal. In a multi-gimbal pointer, the fiber assembly preferably exhibits different mechanical stresses as it crosses the different gimbals.",RAYTHEON CO,MILLS JAMES P;;GARRETT DAVID G;;SUNNE WAYNE L;;KNAPP DAVID J;;BRUNTON DANIEL W;;ANTHONY DAVID G;;ANDERSON EMMET R;;HARRISON DANIEL C;;SMITH FRANK E III;;HICKS JIM R,RAYTHEON COMPANY (2006-01-09),https://lens.org/107-817-204-669-619,Patent Application,yes,5,27,12,12,0,F41G7/224;;F41H13/0056;;G01S7/4818;;G01S7/495;;F41G7/224;;G01S7/495;;G01S7/4818;;F41H13/0056,H01J5/02;;H01J40/14,250/239,0,0,,,,ACTIVE
374,EP,A1,EP 4225215 A1,113-828-663-021-070,2023-08-16,2023,EP 21802868 A,2021-10-07,US 202063089253 P;;US 202163239550 P;;US 202163239563 P;;US 2021/0053942 W,2020-10-08,BALLOON EXPANDABLE TRANSCATHETER VALVE DELIVERY DEVICE SHAFT REINFORCEMENT DEVICES,,MEDTRONIC INC,CONNOLLY REISS;;DUFFY NIALL;;PHELAN JIM;;CIOBANU CONSTANTIN;;ANDERSON MARC;;TWOHIG EOGHAN;;MOORE GAVIN;;O'CONNOR MICHAEL;;MONTGOMERY STEPHEN;;COONEY GERARD;;FALLON MICHEAL;;KHILJI HUDA;;LYDON DAVID;;MCGUINN ALAN;;MCGUINNESS CIARAN;;MULLEN CONLETH;;NORGROVE MATTHEW;;KITT TOMAS,,https://lens.org/113-828-663-021-070,Patent Application,yes,0,0,3,3,0,A61F2/2433;;A61F2002/9583;;A61F2/2433,A61F2/24;;A61F2/958,,0,0,,,,PENDING
375,WO,A1,WO 2022/076667 A1,021-611-373-735-216,2022-04-14,2022,US 2021/0053942 W,2021-10-07,US 202063089253 P;;US 202163239550 P;;US 202163239563 P,2020-10-08,BALLOON EXPANDABLE TRANSCATHETER VALVE DELIVERY DEVICE SHAFT REINFORCEMENT DEVICES,"A balloon catheter configured for delivery of a prosthetic heart valve is provided. The balloon catheter is configured to deploy a prosthetic heart valve through inflation. The balloon catheter is provided with a reinforcing member configured to increase the rigidity of the balloon catheter over an operational portion of the device. The increased rigidity serves to prevent damage to an introducer sheath, patient anatomy, or the prosthetic heart valve during delivery of the prosthetic heart valve.",MEDTRONIC INC,CONNOLLY REISS;;DUFFY NIALL;;PHELAN JIM;;CIOBANU CONSTANTIN;;ANDERSON MARC;;TWOHIG EOGHAN;;MOORE GAVIN;;O'CONNOR MICHAEL;;MONTGOMERY STEPHEN;;COONEY GERARD;;FALLON MICHEAL;;KHILJI HUDA;;LYDON DAVID;;MCGUINN ALAN;;MCGUINNESS CIARAN;;MULLEN CONLETH;;NORGROVE MATTHEW;;KITT TOMAS,,https://lens.org/021-611-373-735-216,Patent Application,yes,9,1,3,3,0,A61F2/2433;;A61F2002/9583;;A61F2/2433,A61F2/24;;A61F2/958,,0,0,,,,PENDING
376,US,A1,US 2023/0372095 A1,148-631-908-196-284,2023-11-23,2023,US 202118248277 A,2021-10-07,US 202118248277 A;;US 202163239563 P;;US 202163239550 P;;US 202063089253 P;;US 2021/0053942 W,2020-10-08,BALLOON EXPANDABLE TRANSCATHETER VALVE DELIVERY DEVICE SHAFT REINFORCEMENT DEVICES,"A balloon catheter configured for delivery of a prosthetic heart valve is provided. The balloon catheter is configured to deploy a prosthetic heart valve through inflation. The balloon catheter is provided with a reinforcing member configured to increase the rigidity of the balloon catheter over an operational portion of the device. The increased rigidity serves to prevent damage to an introducer sheath, patient anatomy, or the prosthetic heart valve during delivery of the prosthetic heart valve.",MEDTRONIC INC,CONNOLLY REISS;;DUFFY NIALL;;PHELAN JIM;;CIOBANU CONSTANTIN;;ANDERSON MARC;;TWOHIG EOGHAN;;MOORE GAVIN;;O'CONNOR MICHAEL;;MONTGOMERY STEPHEN;;COONEY GERARD;;FALLON MICHEAL;;KHILJI HUDA;;LYDON DAVID;;MCGUINN ALAN;;MCGUINNESS CIARAN;;MULLEN CONLETH;;NORGROVE MATTHEW;;KITT TOMAS,MEDTRONIC INC (2021-09-01),https://lens.org/148-631-908-196-284,Patent Application,yes,0,0,3,3,0,A61F2/2433;;A61F2002/9583;;A61F2/2433,A61F2/24,,0,0,,,,PENDING
377,WO,A1,WO 2021/183844 A1,018-344-477-416-189,2021-09-16,2021,US 2021/0022048 W,2021-03-12,US 202016818424 A;;US 202117249706 A,2020-03-13,"SYSTEMS FOR ACCESSING, PROCESSING, AND OUTPUTTING INVENTORY, SERVICE, AND SUPPLY CHAIN PARAMETER DATA","A computing system may receive an indication of a selected item facility that represents a particular supply chain item processed at a particular facility, render, for display, a first view of a user interface pertaining to the selected item facility, that includes an item flow map that shows a flow of the particular supply chain item represented by the selected item facility between at least two facilities, receive a selection of a user interface element shown within the first view of the user interface; and in response to receipt of the selection of the user interface element, render, for display on the screen, a second view of the user interface that shows additional information pertaining to the selected item facility or the particular facility represented by the selected item facility, where the additional information is not shown in the first view of the user interface.",3M INNOVATIVE PROPERTIES CO,PHANIRAJ VIRURU;;BLOEDORN KARL W;;ANDERSON SAMUEL J;;LOVELL MICHAEL J;;HOCKEY PETER A;;AUSTIN JENNIFER L;;RANCH JEFFREY L;;PUNG ANDREW J;;BORCHARD DAVID C;;HART II DONALD S D;;JACOB JIM D;;SOULE KIRK R;;SIEMER MATTHEW J;;JILEK SCOTT R,,https://lens.org/018-344-477-416-189,Patent Application,yes,5,0,3,4,0,G06Q10/087;;G06F3/04842;;G06Q10/087,G06Q10/08;;G06Q10/06;;G06Q10/10,,0,0,,,,PENDING
378,US,A1,US 2021/0287149 A1,187-229-267-446-624,2021-09-16,2021,US 202016818424 A,2020-03-13,US 202016818424 A,2020-03-13,EFFICIENTLY ACCESSING AND VISUALIZING SUPPLY CHAIN DATA,"Systems, methods, and devices for accessing and visualizing supply chain data. A computing system can receive an indication of a selected facility item. The selected facility item can represent a particular supply chain item that is processed at a particular facility of a set of facilities in an organization. The system can render a first view of a user interface pertaining to the selected facility item. The computing system can receive a selection of a first user interface element within the first view of the user interface, and in response, transition from the first view of the user interface that includes the item flow map to a second view of the user interface that shows additional information pertaining to the selected facility item or the particular facility represented by the selected facility item that is not shown in the first view.",3M INNOVATIVE PROPERTIES CO,PHANIRAJ VIRURU;;BLOEDORN KARL W;;ANDERSON SAMUEL J;;LOVELL MICHAEL J;;HOCKEY PETER A;;AUSTIN JENNIFER L;;RANCH JEFFREY L;;PUNG ANDREW J;;BORCHARD DAVID C;;HART II DONALD S D;;JACOB JIM D;;SOULE KIRK R;;SIEMER MATTHEW J;;JILEK SCOTT R,3M INNOVATIVE PROPERTIES COMPANY (2021-02-15),https://lens.org/187-229-267-446-624,Patent Application,yes,4,0,1,4,0,G06Q10/067;;G06Q10/08;;G06Q10/067;;G06F3/04842;;G06Q10/08,G06Q10/06;;G06F3/0484;;G06Q50/28,,0,0,,,,PENDING
379,US,A1,US 2021/0287161 A1,084-508-966-834-009,2021-09-16,2021,US 202117249706 A,2021-03-10,US 202117249706 A;;US 202016818424 A,2020-03-13,"SYSTEMS FOR ACCESSING, PROCESSING, AND OUTPUTTING INVENTORY, SERVICE, AND SUPPLY CHAIN PARAMETER DATA","A computing system may receive an indication of a selected facility item that represents a particular supply chain item processed at a particular facility, render, for display, a first view of a user interface pertaining to the selected facility item, that includes an item flow map that shows a flow of the particular supply chain item represented by the selected facility item between at least two facilities, receive a selection of a user interface element shown within the first view of the user interface; and in response to receipt of the selection of the user interface element, render, for display on the screen, a second view of the user interface that shows additional information pertaining to the selected facility item or the particular facility represented by the selected facility item, where the additional information is not shown in the first view of the user interface.",3M INNOVATIVE PROPERTIES CO,PHANIRAJ VIRURU;;BLOEDORN KARL W;;ANDERSON SAMUEL J;;LOVELL MICHAEL J;;HOCKEY PETER H;;AUSTIN JENNIFER L;;RANCH JEFFREY L;;PUNG ANDREW J;;BORCHARD DAVID C;;HART II DONALD S D;;JACOB JIM D;;SOULE KIRK R;;SIEMER MATTHEW J;;JILEK SCOTT R,,https://lens.org/084-508-966-834-009,Patent Application,yes,8,1,3,4,0,G06Q10/087;;G06F3/04842;;G06Q10/087,G06Q10/08;;G06F3/0484,,0,0,,,,PENDING
380,EP,A1,EP 4118602 A1,152-420-576-973-44X,2023-01-18,2023,EP 21766976 A,2021-03-12,US 202016818424 A;;US 202117249706 A;;US 2021/0022048 W,2020-03-13,"SYSTEMS FOR ACCESSING, PROCESSING, AND OUTPUTTING INVENTORY, SERVICE, AND SUPPLY CHAIN PARAMETER DATA",,3M INNOVATIVE PROPERTIES COMPANY,PHANIRAJ VIRURU;;BLOEDORN KARL W;;ANDERSON SAMUEL J;;LOVELL MICHAEL J;;HOCKEY PETER A;;AUSTIN JENNIFER L;;RANCH JEFFREY L;;PUNG ANDREW J;;BORCHARD DAVID C;;HART II DONALD S D;;JACOB JIM D;;SOULE KIRK R;;SIEMER MATTHEW J;;JILEK SCOTT R,,https://lens.org/152-420-576-973-44X,Patent Application,yes,0,0,3,4,0,G06Q10/087;;G06F3/04842;;G06Q10/087,G06Q10/08;;G06Q10/06;;G06Q10/10,,0,0,,,,DISCONTINUED
